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Resumo 
A multirresistencia bacteriana é unha ameaza para a humanidade debido á falta de 
opcións terapéuticas; o desenvolvemento de vacinas para prever as enfermidades 
bacterianas é unha prioridade na saúde pública e veterinaria.     
As vacinas vivas son eficientes, inducindo respostas inmunes de tipo humoral e 
celular. Con todo, só unhas poucas están licenciadas debido a inexistencia de mecanismos 
universais de atenuación da virulencia.     
A síntese de D-glutamato é un mecanismo conservado nas bacterias e é esencial 
para a formación do peptidoglicano.  
Aquí se describe unha plataforma tecnolóxica para a produción de vacinas 
bacterianas vivas auxótrofas para D-glutamato, o cal foi aplicado con éxito contra os 
patóxenos multirresistentes Acinetobacter baumannii, Pseudomonas aeruginosa e 
Staphylococcus aureus. 
Cando foron administradas in vivo, as cepas das vacinas presentaron atenuación da 
virulencia e un crecemento auto-limitado, sen causar enfermidade. Ademais, 
desencadearon a produción de anticorpos específicos e con reactividades cruzadas e a 
liberación de citocinas. 
Estas vacinas demostraron unha eficacia protectora nos ratos de 80-100% contra 
clons multirresistentes, virulentos e de alto risco, como A. baumannii AbH12O-A2, Ab307-
0294, P. aeruginosa PA14 y S. aureus USA300LAC. 
Esta estratexia innovadora pode resolver os problemas de atenuación da virulencia 
bacteriana, representando unha nova xeración de vacinas eficaces e seguras.  
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Resumen 
La multirresistencia bacteriana constituye una amenaza para la humanidad debido 
a la falta de opciones terapéuticas; el desarrollo de vacunas para prevenir las enfermedades 
bacterianas es una prioridad en salud pública y veterinaria.  
Las vacunas vivas son eficientes, induciendo una respuesta inmunitaria humoral y 
celular. Sin embargo, pocas están licenciadas debido a la inexistencia de mecanismos 
universales de atenuación de la virulencia.  
La síntesis de D-glutamato es un mecanismo conservado en las bacterias y esencial 
para la formación del peptidoglicano.  
Aquí se describe una plataforma tecnológica para la obtención de vacunas 
bacterianas vivas auxótrofas para D-glutamato, que se aplicó con éxito contra los 
patógenos multirresistentes Acinetobacter baumannii, Pseudomonas aeruginosa y 
Staphylococcus aureus. 
Cuando administradas in vivo, las cepas vacunales mostraron atenuación de la 
virulencia y un crecimiento autolimitado, sin causar enfermedad. Además, desencadenaron 
la producción de anticuerpos con reactividades específicas y cruzadas y la liberación de 
citoquinas.  
Estas vacunas demostraron una eficacia protectora en ratones de 80-100% frente a 
clones multirresistentes, virulentos y de alto riesgo, como A. baumannii AbH12O-A2, 
Ab307-0294, P. aeruginosa PA14 y S. aureus USA300LAC. 
Esta estrategia innovadora puede solucionar las dificultades de atenuación de la 
virulencia bacteriana, representando una nueva generación de vacunas eficaces y seguras.  
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Abstract 
Multidrug resistance in bacteria is a major threat to humanity due to the lack of 
therapeutic options; thus, vaccine development is a priority for global human and animal 
health.  
Bacterial live vaccines induce antibody- and cell-mediated immunity and result in 
efficient immunizations, however, only few are licensed and there is no universal strategy 
for attenuation.  
D-glutamate synthesis is a universal key step in bacterial cell wall formation. 
Here we present a strategic platform for generating effective bacterial whole-cell 
vaccines auxotrophic for D-glutamate. This strategy was successfully applied to generate 
three independent vaccines against the major multidrug-resistant pathogens, Acinetobacter 
baumannii, Pseudomonas aeruginosa and Staphylococcus aureus. 
 These vaccine strains showed virulence attenuation and self-limited growth in vivo 
without risk of disease. Immunization with these whole-cell vaccines elicited high levels of 
specific and cross-reactive antibodies and stimulated cytokine secretion. Furthermore, 
immune responses correlated with 80-100% mice protection against the genetically 
unrelated, multidrug-resistant, virulent and high-risk clones A. baumannii AbH12O-A2, 
Ab307-0294, P. aeruginosa PA14, and S. aureus USA300LAC using an acute lethal infection 
model.  
This innovative approach overcomes the classical difficulties so far encountered in 
obtaining virulence attenuation and represents a new generation of effective, safe and 
universal bacterial vaccines for the future.  
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Preface 
D-glutamate (D-Glu) is an essential component of the bacterial cell wall. Glutamate 
racemase (MurI), enzyme that converts L-glutamate (L-Glu) to D-Glu is present in all species 
of bacteria and its essential role in peptidoglycan biosynthesis has been confirmed in 
species spanning the bacterial kingdom, including Gram-positive bacteria that encode the 
D-amino acid transaminases (Dat) for D-Glu production.  
Here it is described a novel platform for the generation of effective live attenuated 
bacterial vaccines composed of D-Glu auxotrophic strains, which can be obtained through 
the inactivation of the gene (or genes) encoding MurI and also the gene (or genes) coding 
for Dat, capable of catalysing the interconversion of D-alanine (D-Ala) to D-Glu.  
Hence, we took advantage of this technology to create three prototypes of 
experimental vaccines against Acinetobacter baumannii, Pseudomonas aeruginosa and 
Staphylococcus aureus, composed of D-Glu auxotrophic strains. Once obtained, we 
demonstrated their reliable efficacy as live vaccines in a mouse model of acute lethal 
infection. More importantly, this strategy has potential application to any bacterial 
pathogen, overcoming the classical difficulties in obtaining virulence attenuation and 
represents a new generation of effective bacterial vaccines for the future. 
In this Doctoral Thesis, the following objectives were established: 
• Obtain MurI– mutants of A. baumannii and P. aeruginosa, auxotrophic for 
D-Glu; 
• Obtain a MurI–Dat– mutant of S. aureus, auxotrophic for D-Glu; 
• Characterize MurI– or MurI–Dat– mutants of A. baumannii, P. aeruginosa 
and S. aureus at the phenotypic and ultrastructural level; 
• Optimize and implement models of acute lethal infection for testing wild-
type A. baumannii, P. aeruginosa and S. aureus strains, in BALB/c and 
C57BL/6 mice; 
• Estimate the level of attenuation of MurI– or MurI–Dat– mutants using the 
previously optimized model of acute lethal infection; 
viii 
 
• Determine the immunogenic potential of MurI– or MurI–Dat– mutants used 
as vaccines, by measuring IgM and IgG immunoglobulins and exploring the 
nature of T cell responses generated in the vaccinated individuals;  
• Examine the cross-reactivity of IgG antibodies produced against 
heterologous strains not included in the vaccine compositions; 
• Determine anti-A. baumannii, -P. aeruginosa and -S. aureus vaccine efficacy 
against acute lethal infection by challenging vaccinated mice with several 
genetically and epidemiologically unrelated bacterial isolates, including 
multidrug-resistant, virulent and high-risk clones such as S. aureus 
USA300LAC; 
• Evaluate the protection conferred by the passive transfer of antibodies to 
naïve mice, obtained from mice administered these vaccines;   
• Exploit alternative routes of vaccine administration;  
• Assess in vivo safety of D-Glu auxotrophic bacterial vaccines through   
monitoring blood clearance of MurI– or MurI–Dat– mutants once 
administered to mice; 
• Assess environmental safety of D-Glu auxotrophic bacterial vaccines 
through evaluation of phenotypic stability and persistence of MurI– or 
MurI–Dat– mutants, when compared to their wild-type homologues. 
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ACRONYMS 
Ala: Alanine 
APC: antigen-presenting cell 
Asp: Aspartate 
Ata: Trimeric autotransporter protein 
ATCC: American Type Culture Collection 
BAP: Biofilm-associated protein  
Bbp: Bone-binding protein 
BCG: Bacille Calmette-Guérin 
BCR: B cell receptor 
BP: Bordetella pertussis 
bp: Base pairs 
CD: Cluster of differentiation 
CECT: Spanish Type Culture Collection 
CF: Cystic fibrosis 
CFU: Colony-forming units 
CHIPS: Chemotaxis inhibitory protein of Staphylococcus aureus 
Clf: Clumping factor 
Cna: Collagen-binding protein 
CoA: Coagulase 
CP: Capsular polysaccharide 
CT: Cholera toxin 
Dat: D-amino acid transaminase 
DCs: Dendritic cells 
DIM: Dimycocerosates 
DNA: Deoxyribonucleic acid 
DNECs: Desquamated nasal epithelial cells 
DTPw: Diphtheria-tetanus-pertussis vaccine, killed whole-cells of the pertussis component 
(Pw). 
Eap: Extracellular adherence proteins 
EbpS: Elastin-binding protein 
Efb: Extracellular fibrinogen-binding protein 
Emp: Extracellular matrix-binding protein 
Eno: Enolase (laminin-binding protein) 
ESKAPE: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species 
Fab: Fragment antigen binding region 
FBS: Fetal bovine serum 
Fc: Fragment crystallizable region 
Fep: Cefepime 
FnBP: Fibronectin-binding protein 
FPR: Formyl peptide receptor 
G-CSF: Granulocyte-colony stimulating factor 
Gln: Glutamine 
Glu: Glutamate 
Gly: Glycine 
GMO: Genetically modified organism 
hHb: Human hemoglobin 
His: Histidine 
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HIV: Human immunodeficiency virus 
HLA: Human leukocyte antigens 
HNECs: Human nasal epithelial cells 
ICU: Intensive care unit 
IDSA: Infectious Disease Society of America 
IFN-γ: Interferon-gamma 
Ig: Immunoglobulin 
IL: Interleukin 
IM: Inner membrane 
IM: Intramuscular 
IP: Intraperitoneal 
Isd: Iron-regulated surface determinant 
JTTR: Joint Theater Trauma Registry 
KLH: Keyhole limpet hemocyanin 
LB: Luria-Bertani broth 
LD: Lethal dose 
LPS: Lipopolysaccharide 
M: Cytoplasmic membrane 
mAb: Monoclonal antibody 
MCS: Multiple cloning site 
MDR: Multidrug-resistant 
MEM: Meropenem 
MEP: Mucoid exopolysaccharide 
MH: Mueller Hinton 
MHC: Major histocompatibility complex 
MRSA: Methicillin-resistant-Staphylococcus aureus 
MSCRAMMs: Microbial surface component recognizing adhesive matrix molecules 
MTBVAC: Mycobacterium tuberculosis vaccine 
MurI: Glutamate racemase 
MV: Mechanical ventilation 
NK: Natural killer 
OM: Outer membrane 
Omp: Outer membrane protein  
oriT: Origin of transfer 
Pa: Pertussis acellular 
PAMPs: pathogen-associated molecular patterns 
PCR:  Polymerase chain reaction 
PDIM: Phthiocerol dimycocerosate 
PG: Peptidoglycan 
PGE2: Prostaglandin E2 
PGL: Phenol glycolipid 
Phe: Phenylalanine 
PMA: Polymannuronic acid 
PMNs: Polymorphonuclear leukocytes  
PNAG: Poly-N-acetyl-glucosamine 
Pro: Proline 
PRRs: Pattern recognition receptors 
PSM: Phenol soluble modulin 
PT: Pertussis toxin 
PVL: Panton-Valentine leucocidin 
Pw: Whole-cell pertussis vaccine 
qRT-PCR: Quantitative real-time reverse transcription PCR 
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RD: Region of Difference 
RNA: Ribonucleic acid 
RNS: Reactive nitrogen species 
ROS: Reactive oxygen species 
SAK: Staphylokinase 
SasG: Staphylococcus aureus surface protein G 
Sbi: Second immunoglobulin-binding protein of S. aureus 
SCID: Severe combined immunodeficiency 
SCIN: Staphylococcal complement inhibitor 
Sdr: Serine-aspartic acid repeat protein 
SE: Staphylococcal enterotoxin 
SEA: Staphylococcal enterotoxin A 
SEB: Staphylococcal enterotoxin B 
SEM: Scanning electron microscopy  
SER: Serine 
SNP: Single nucleotide polymorphism 
SOD: Superoxide dismutase 
Spa: Protein A 
SPF: Specific pathogen-free 
SPURR: Spurr’s epoxy embedding medium 
TB: Tuberculosis 
TCR: T cell receptor 
TEM: Transmission electron microscopy 
Tfh: Follicular T helper cells 
Th cells: helper T cells 
Thr: Threonine 
TLR: Toll-like receptor  
TMB: Tetramethylbenzidine 
TNF: Tumour necrosis factor 
TSB: Tryptic Soy Broth 
TSST: Toxic shock syndrome toxin 
Ty: Typhoid 
T3SS: Type III secretion system 
UDP-GlcNAc: UDP-N-acetylglucosamine 
UDP-MurNAc: UDP-N-acetyl muramic acid 
Val: Valine 
VAP: Ventilator-associated pneumonia 
vWF: Von willebrand factor adhesion 
WHO: World Health Organization 
WTA: Wall teichoic acids 
XDR: Extensively drug-resistant 
X-Gal: 5-bromo-4-chloro-3-indolyl β-D-galactopyranoside 
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1. BACKGROUND 
1.1. Immune response to bacterial pathogens and vaccinology 
1.1.1. The innate immune system 
Invading pathogens are detected by the innate immune system through molecular-
sensing surveillance mechanisms. These mechanisms include detection of pathogens via 
pattern recognition receptors (PRRs), expressed by cells of the innate immune system, 
which can be secreted, or expressed on the cell surface, or are present in intracellular 
compartments (e.g. DNA/RNA sensors). Examples of PRRs are the transmembrane Toll-like 
receptors (TLRs). Examples of mammalian TLRs that act as bacterial receptors are TLR1, 
TLR2, TLR4, TLR5, and TLR9. PRRs are able to bind to molecules (such as bacterial 
membrane components) that are shared by several pathogens (e.g. all Gram-negative 
bacteria express lipopolysaccharide [LPS]), enabling the innate immune system to sense the 
occurrence of an infectious event. Recently, dendritic cells (DCs) and macrophages have 
been shown to react to signals released by damaged cells, indicating that the immune 
system can react to both the presence of infectious microbes (via pathogen-associated 
molecular patterns [PAMPs]) and to the consequences of an infectious event. Specialized 
chemical messengers, including cytokines and chemokines, are secreted by 
stressed/damaged cells and innate immune cells to attract other resident and circulating 
innate cells to the site of infection. Cells dying due to infection also release other small 
molecules, such as urea, which alert DCs. 
Signalling through PRRs triggers intracellular signalling pathways to tailor the profile 
of gene expression. Redundancy exists in pathogens detection systems, as multiple 
receptors may recognize the same pathogenic structure and, conversely, a single receptor 
may be capable of delivering more than one signal to the host cell. Overall, the integration 
of these signals by antigen-presenting cells (APCs) leads to their activation. This enables 
them to act as messengers to precisely define the nature of the perceived danger and 
convey this information to the secondary lymphoid organs, where they interact with, and 
specifically activate, the relevant adaptive immune response.   
Under some circumstances, pathogen clearance may be achieved by innate 
immune effectors without activation of an adaptive immune response. Activated innate 
cells act as phagocytes, engulfing and destroying the pathogen within intracellular vesicles 
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containing digestive enzymes. To be efficient, this response requires both the recruitment 
and activation of phagocytes at the site of infection, a process often referred to as the 
inflammatory response. Cells residing in proximity to the infection site are activated upon 
recognition of PAMPs, and secrete a large array of soluble mediators, including chemokines 
and cytokines. Chemokines behave as chemoattractants, favouring the recruitment of 
innate immune cells to the site of infection, while cytokines (including tumour necrosis 
factor and interferons) act by increasing the phagocytic activity of cells. Innate immune cells 
also produce a series of soluble chemical factors (such as peptides) that are able to directly 
target the invading microbes. Additionally, antigens are taken up by innate cells, with 
immature DCs the most specialized among them. The antigen is subsequently processed 
and the DC differentiates into an APC. Antigen-carrying APCs then migrate to the draining 
lymph node and provide the link between the innate and adaptive immune responses.      
Another component of the innate immune system is the complement system. The 
complement system consists of approximately 25 proteins that work together to 
“complement” the action of the adaptive immune response in destroying bacteria. 
Complement proteins circulate in the blood in an inactive form. Once activated, 
complement components serve several effector roles including the recruitment of 
phagocytes, the opsonization of pathogens to promote phagocytosis, the removal of 
antibody-antigen complexes and the lysis of antibody-coated cells.  
1.1.2. The adaptive immune system 
 Innate immune system alerts the adaptive immune system, whereby lymphocytes 
with antigen-specific receptors are activated and proliferate to fight the pathogen. Their 
antigen receptors evolved in response to the selection pressure of different pathogens and 
therefore have very diverse characteristics. Lymphocytes can be found circulating in the 
blood/lymph and residing within secondary lymphoid organs, such as the lymph nodes and 
spleen. There are two main subsets of lymphocytes involved in adaptive immune 
responses, whose nomenclature reflects the site of their development – B cells develop in 
the bone marrow and T cells develop in the thymus. The adaptive immune system 
essentially functions via the production of three key types of effector: antibodies (produced 
from B cells), cytokines and cytolytic molecules (produced by T cells).  
Professional APCs, typified by DCs, can ingest pathogen-derived proteins, partially 
digest, process and transport the peptide products to the cell surface, rather than targeting 
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them for complete destruction. These pathogen-derived peptide antigens are bound by a 
specialized set of receptors known as human leukocyte antigens (HLA) that act as “antigen-
presenting” molecules. These molecules are encoded by a gene family called the major 
histocompatibility complex (MHC). DCs displaying pathogen-derived antigen on the cell 
surface leave the infected site and migrate towards the nearest lymph node, where they 
are destined to activate pathogen-specific T cells. T cells do not directly recognize whole 
pathogens, but are only specifically activated by DCs transformed into APCs which present 
molecular fragments in association with MHC molecules at the cell surface. Naïve 
lymphocytes are therefore “blind” to live microorganisms and need the help of APCs to 
adequately react to an invading pathogen. Cells activated by antigen-bearing DCs express 
the cluster of differentiation (CD)4 cell-surface protein, and are referred to as CD4+ T cells. 
These cells acts primarily by secreting soluble factors (cytokines) that are able to exert 
direct antimicrobial properties and affect the behaviour of other immune cells. In most 
cases, CD4+ cells help other immune cells perform their task and are, therefore, referred to 
as helper T cells (Th).  
Activation of CD4+ cells represents a key step in setting in motion an adaptive 
immune response. The adaptive immune response is frequently characterized by two 
effector cell populations, the CD8-expressing cytolytic T cells and the antibody-secreting B 
cells. CD8+ T cells exploit the TCR (T cell receptor)/MHC interaction around pathogen-
derived peptides to detect and fight intracellular pathogens. In contrast to classically 
defined APCs, which display antigenic fragments in association with MHC class II molecules, 
non-immune cells use a closely related set of molecules to display peptides derived from 
the cytoplasm – the MHC class I molecules. This complex mechanism of antigen 
presentation allows CD8+ T cells to scan proteins from within the cell, while preserving the 
integrity of the membrane. CD8+ T cells have the ability to secrete cytotoxic factors in 
addition to cytokines. These factors enable these cells to kill cells displaying pathogen-
derived peptides presented by MHC class I molecules. Optimal proliferation of CD8+ T cells 
and acquisition of full cytolytic potential is best achieved in the presence of cytokines 
produced by CD4+ T helper cells.      
Antibodies represent a highly diverse set of soluble proteins secreted by the subset 
of lymphocytes referred to as B cells. B cells develop in the bone marrow before 
undergoing a process of differentiation and maturation in the spleen. As with T 
lymphocytes, each B lymphocyte expresses a unique antigen receptor (B cell receptor 
[BCR]) enabling the cells to react to a specific antigen. In marked contrast to TCRs, BCRs can 
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directly bind to molecules expressed by pathogens, with no need for previous 
internalization and presentation by APCs or other innate immune cells. Upon antigen 
encounter, B cells expressing the cognate BCR are induced to proliferate and differentiate 
into plasma cells, which can secrete large amounts of a soluble form of the BCR that we 
know as an antibody. This soluble protein is thus released in the blood and other body 
fluids enabling them to fight infections at distant sites.  
Antibodies consist of a fragment crystallizable region (Fc), a structural feature 
common to all antibodies of a given isotype, and a fragment antigen binding region (Fab), 
which includes the portion that gives the antigen specificity (or antigen-binding 
characteristics) of the antibody. The variable region of the antibody can exist in a huge 
number of molecular configurations, and an individual’s BCR repertoire is generated to 
maximize capability to produce antibodies that are useful against diverse potential 
pathogenic threats. The constant part of the molecule exists in five different forms 
(isotypes) (Immunoglobulin [Ig]A, IgD, IgE, IgG and IgM) that determine the ability of an 
antibody class to localize to particular body sites and target specific types of infection, and 
to recruit the optimal local effector cells. IgG is the most abundant antibody in normal 
human serum and consists of four human subclasses (IgG1, IgG2, IgG3 and IgG4) each 
containing a different Fc region. As a result, the different subclasses have different effector 
functions, both in terms of triggering IgG-Fc receptor-expressing cells, resulting in 
phagocytosis or antibody-dependent cell-mediated cytotoxicity, and activating complement 
[1]. In mice, the IgG isotype is divided into five subclasses (IgG1, IgG2a, IgG2b, IgG2c and 
IgG3). Subclass nomenclature has arisen independently for each species and so there is no 
general relationship between the subclasses from each species. 
In most cases, direct activation of B cells by an antigen is observed in response to 
repetitive antigenic structures, such as carbohydrates found in bacterial walls. These T cell-
independent responses are characterized by the secretion of low-affinity antibodies of the 
IgM type. This type of response is often stereotyped in nature, lacking the typical memory 
response upon re-exposure to the same antigen. In most cases, optimal B cell activation 
and differentiation into antibody-secreting plasma cells is only observed when both B and T 
cells are simultaneously activated by the same pathogen. In these instances, CD4+ T cells 
differentiate into follicular T helper cells (Tfh) that are able to provide a helper signal to B 
cells. Tfh cells have been defined by secretion of IL-21, a cytokine though to favour the 
secretion of antibodies by antigen-specific B cells. T cell-dependent B cell responses are 
characterized by the secretion of high-affinity antibodies and a large spectrum of isotypes 
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(in particular IgG), and are typical associated with immunity resulting from natural 
exposure.       
Th1 cells and IFN-γ  
One subset of Th cells, the Th1 cells, appear to secrete mainly interferon-gamma 
(IFN-γ), an important immunoregulatory cytokine known to limit pathogen survival and 
spreading. It is also known to promote the differentiation of cytolytic cells that are able to 
destroy cells infected with intracellular pathogens. Indeed, IFN-γ was originally identified 
through its anti-viral activity [2]. It plays key roles in host defense by exerting anti-viral, 
anti-proliferative and immunoregulatory activities [3-5]. IFN-γ induces the production of 
cytokines and upregulates the expression of various membrane proteins including class I 
and II MHC antigens. IFN-γ is a potent activator of macrophage effector functions. It 
potentiates the secretion of immunoglobulins by B cells and affects isotype switching. IFN-γ 
also influences T helper cell phenotype determination by inhibiting Th2 differentiation and 
stabilizing Th1 cells [3-5]. IFN-γ is produced primarily by activated natural killer (NK) cells, 
activated Th1 cells and activated CD8+ cytotoxic cells [3-5]. Additional cell types that 
produce IFN-γ include macrophages [6], DCs [7,8] and mast cells [9]. Mouse IFN-γ shares 
approximately 40% amino acid (aa) sequence identity with human IFN-γ and does not have 
cross-species activity [3-5]. Th1 cells are therefore, considered important for inducing 
immune responses involved in the clearance of intracellular pathogens.  
Th2 cells and IL-4 
Another subset of T helper cells, the Th2 cells, are key in organizing host defense 
against extracellular pathogens and in helping B cells to produce antibodies. These cells 
produce cytokines (interleukins [IL] IL-4, IL-5, IL-13) that appear particularly important at 
activating innate cells (eosinophils, mast cells). IL-4 was originally described in 1982 as a B 
cell stimulatory factor [10] and is now known to regulate a myriad of immune functions 
including Ig isotype switching, class II MHC expression by B cells, and the differentiation fate 
of certain T cell subsets [11]. Mouse IL-4 is a 20 kDa single chain glycoprotein that shares 
56% and 61% aa identity with mature human and rat IL-4, respectively [12-15]. Mouse IL-4 
is species specific and is inactive on both human and rat cells [16,17]. Mouse cells known to 
express IL-4 following activation include CD4+ Th2 cells [18,19], CD4+ NK1.1+ and NK1.1- T 
cells [20], DCs [21], mast cells [22], eosinophils [23], and basophils [24]. In mice, IL-4 
promotes the synthesis of IgE plus the anaphylactic form of IgG1 [25,26]. On monocytes, IL-
4 inhibits the LPS-induced production of tumour necrosis factor (TNF)-α, IL-1β, IL-6, and 
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prostaglandin E2 (PGE2), thus suppressing the creation of a proinflammatory environment 
[11,27]. IL-4 also blocks IFN-γ production during T cell differentiation, driving CD4+ T cells 
towards a Th2 phenotype [28].  
Th17 cells and IL-17 
A third subset of effector T helper cells, called Th17, produce IL-17 and are 
important in clearing pathogens during host defense reactions [29]. Functionally, IL-17 is 
best known for its participation in the recruitment and survival of neutrophils [30-32]. Its 
induction is believed to be the result of antigen stimulation of DCs, resulting in IL-23 
secretion. In a TCR-independent event, IL-23 can induce T cell production of IL-17 [30]. In 
the tissues, IL-17 appears to promote neutrophil extravasation, principally through its 
effects on macrophages and endothelial cells. On macrophages, IL-17 induces TNF-α, IL-1β 
and IL-6 production [33]. TNF-α and IL-1β then act on local endothelial cells to induce 
granulocyte-colony stimulating factor (G-CSF) secretion, an effect that is potentiated by IL-
17 [34]. IL-17 further contributes to polymorphonuclear leukocyte influx by inducing 
endothelial cells to release chemokines and nitric oxide production, which may increase 
vascular permeability [30,35]. Several groups have now also demonstrated the formation of 
Th17 memory in response to vaccination in mice. Generation of immunity to the pulmonary 
pathogen Klebsiella pneumoniae by mucosal vaccination with heat-killed Klebsiella bacteria 
required Th17 cells [36]. The memory response generated afforded protection against 
multiple different clades of the K. pneumoniae species, including much more virulent or 
multidrug-resistant strains. In a Mycobacterium tuberculosis vaccine model, protection was 
also found to be dependent on Th17 cells acting as a first-line of defense in the lung before 
Th1 cells arrived [37,38]. Mouse IL-17 is a 30-35 kDa variably glycosylated homodimeric 
protein that belongs to a unique family of cysteine-knot related proteins [30,39,40]. Mature 
mouse IL-17 shares 61% and 89% aa sequence identity to human and rat IL-17, respectively 
[41,42]. While rodent and human mature sequences show modest aa sequence identity, 
human IL-17 is active on both mouse and rat cells [35,43]. Th17 cells also produce IL-22, an 
interleukin that acts cooperatively with IL-17 to enhance expression of antimicrobial 
peptides associated with host defense [44]. Recently, Th17 cells were also shown to 
function as B cell helpers, triggering antibody production in vivo [45].   
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Figure 1 summarizes the main aspects of the human immune response to 
pathogens. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 | An overview of the human immune response. Innate immune cells begin to 
mature and differentiate after detection of invading pathogens, while migrating to the 
lymph nodes. APCs induce the adaptive immune response including activation of T cells into 
effector cells and differentiation of T cells into memory cells. CD8+ T cells can directly kill 
infected tissue/cells via molecular and chemical signaling and induce infected 
cells/phagocytes to kill intracellular pathogens, or inhibit pathogen replication. Naïve B cells 
differentiate into antibody-secreting plasma cells and memory B cells following activation 
by IL-4-secreting Th2 cells. IFN-γ-secreting-Th1 cells activate tissue-resident macrophages. 
Antibodies can enhance the effector functions of innate cells and neutralize pathogens 
directly. IL-17 produced by Th17 cells acts by recruiting neutrophils to the site of infection. 
IL-22 enhances expression of antimicrobial peptides. Partially adapted from [46]. 
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Immunological memory 
Upon differentiation, naïve T and B cells, each expressing a unique TCR and BCR, 
migrate to the blood and peripheral lymphoid organs. Some of these cells will differentiate 
into effector cells (such as cytokine-producing T cells or antibody-secreting plasma cells), 
while others will become memory cells, able to survive for a long period of time within the 
host. Exposure to an antigen (pathogen or vaccine) therefore leads to a long-term (and 
sometimes permanent) modification of the cellular repertoire, such that the relative 
frequency of T and B cells specific for an individual antigen is increased in antigen-exposed 
individuals compared with naïve individuals (Fig. 2). 
In addition to their increased frequency, memory T and B lymphocytes also display 
novel functional properties, enabling them to develop secondary (recall) responses on re-
encounter with their specific antigen, or a closely related antigen. The adaptive response on 
secondary exposure leads to a rapid expansion and differentiation of memory T and B cells 
into effector cells, and the production of high levels of antibodies. A higher proportion of 
IgG and other isotypes of antibodies compared with the level of IgM characterizes memory 
antibody responses.  
By definition, all effective vaccines lead to the development of immune memory, by 
mimicking the threat of an infection and providing antigens derived from the specific 
pathogen. The ability to generate immune memory is the key attribute of the adaptive 
immune system, which is crucial for the long-term protection of individuals and 
populations. Generating immune memory depends on a high degree of interaction among 
many different cell types, which maintains higher numbers of T and B cells that were 
selected as the most useful in the primary immune response. However, while the relative 
contribution of clonal memory cells to protection can be inferred from the molecules they 
express and their functional behaviour, the presence of memory cells per se is not 
indicative of absolute protection against disease.   
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Figure 2 | The kinetics of primary and recall (memory) immune responses. On first 
exposure to a pathogen or antigen (referred to as “priming” in vaccination), the innate 
immune system must detect, process and translate the threat into a form that can be 
understood by the adaptive immune system. This occurs via the bridging actions of APCs 
and takes days/weeks. Following resolution of the challenge, a specialized “memory” cell 
population remains, and is maintained for a long time (months/years), remaining within the 
host for the rest of its life. On subsequent exposure to the same antigen (referred to as 
“boosting” in vaccination), the innate immune response is triggered as before but now the 
memory cell populations are able to mount a greater and more rapid response as they do 
not need to undergo the same activation process as naïve cells. From [46].  
 
1.1.3. Immunological requirements of a vaccine and vaccine 
development challenges 
Vaccines aim to prevent the disease symptoms that are the consequences of a 
pathogenic infection. In most cases, this does not occur by completely preventing infection 
but by limiting the consequences of the infection. Vaccines developed from pathogens can 
vary in the complexity of the pathogen-derived material they contain. The requirement for 
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more than the presence of a “foreign” antigen to elicit an immune response must always be 
considered in vaccine design. Highly refined subunit antigen formulations, and some 
inactivated whole pathogens, do not contain many of the molecular features and defensive 
triggers that are required to alert the innate immune system. These type of antigen are 
designed to minimize excessive inflammatory responses but, as a result, may be sub- 
optimally immunogenic. Under these circumstances, adjuvants are often added to the 
vaccines compositions. The induction of CD4+ T cells is essentially controlled by the nature 
of this inflammatory response.   
The dominant immune response to a given pathogen or antigen may not 
necessarily be the optimum response for inducing protection. Antibody titers are often 
considered to represent adequate indicators of immune protection but may not be the 
actual mechanism by which optimal protection is achieved. Useful specific so-called 
immune correlates of immunity/protection may be unknown or incompletely characterized. 
Therefore, modern vaccine design still looks to clinical trials to provide information about 
clinical efficacy and, if possible, the immunological profiles of protected individuals.  
Immunogenicity is assessed by laboratory measurements of immune effectors, 
typically antibodies. Increasingly, however, specific T cell activation is included in the 
parameters assessed, as adequate T cell immunity may be essential for recovery from some 
infections. Other important consideration in vaccine immunology include the phenomena 
of immune tolerance and immunological/antigenic interference, which can supress or 
prevent development of adequate immune responses following vaccination. Immune 
tolerance refers to the induction of immunological non-responsiveness by repeated 
exposure to similar antigens, such as polysaccharide antigens; this effect is dose-dependent 
and may be limited in time as increasing the interval between subsequent doses can 
partially restore responsiveness.  
This text was partially adapted from [46].  
 
1.2. Bacterial vaccines 
Vaccines are attenuated, inactivated organisms or purified products derived from 
them. There are several types of bacterial vaccines in use and actually licensed worldwide 
(Fig. 3). 
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Figure 3 | Major classification of bacterial vaccines licensed for immunization and 
distribution worldwide. 
 
These vaccines represent different strategies used to try to reduce risk of illness, 
while retaining the ability to induce a beneficial immune response. Some of these vaccines 
contain inactivated, but previously virulent bacteria that have been inactivated, or its 
components. The whole-cell pertussis vaccine (Pw) is a suspension of the entire Bordetella 
pertussis organism that has been inactivated, usually with formalin. Examples of toxoid-
based vaccines include Clostridium tetani and Corynebacterium diphtheria. Conjugated 
vaccines include Haemophilus influenzae b, Neisseria meningitidis and Streptococcus 
pneumoniae and are composed of polysaccharides linked to more immunogenic proteins. 
Live, attenuated bacterial vaccines include Salmonella Typhi, Mycobacterium bovis and 
Vibrio cholerae and will be discussed in detail. 
 
1.3. Live vaccines and mechanisms of virulence attenuation 
Bacterial live vaccines are highly efficient because they are harmless versions of 
disease causing pathogenic bacteria and mimic the natural infection. These live attenuated 
vaccines that use the complete pathogen induce both cell-mediated and antibody-
mediated immunity, resulting in efficient immunizations and a lessened need for booster 
injections. This typically provokes more durable immunological responses, being the 
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preferred vaccine type for healthy adults. These vaccines have been used extensively for 
decades to prevent respiratory or enteric pathogens that cause severe disease and 
epidemics in humans [47-49], and the most frequent infections of herd animals [50-57]. 
Advantages of live bacterial vaccines include their mimicry of a natural infection, intrinsic 
adjuvant properties and their possibility to be administered orally. 
However, pathogenic bacteria demands for attenuation to weaken its virulence. 
Traditionally, attenuation of virulence was achieved through natural selection by multiple 
passages of the microorganism on growth medium, random mutagenesis or more recently, 
genetic modification of target genes particularly suited to inducing virulence attenuation. 
Moreover, they may not be safe for use in immunocompromised individuals, and may 
rarely revert to a virulent form and cause disease.   
With the increased knowledge of mucosal immunity and the availability of genetic 
tools for heterologous gene expression, the concept of live vaccine vehicles gains renewed 
interest. Indeed, the use of live bacteria to induce an immune response to itself or to a 
carried vaccine component is an attractive vaccine strategy. The actual use of genetic 
modified bacteria as vaccines and vaccine delivery vehicles implies construction of 
recombinant strains that contains the gene cassette encoding the antigen. However, 
vaccination using recombinant bacteria require particular attention regarding their safety 
as they may propagate in the host and be released into the environment by the vaccines 
[58]. This places these vaccines in the debate on application of genetically modified 
organisms.  
1.3.1. Typhoid fever (oral)  
 Typhoid infections, caused by Salmonella enterica serovar Typhi, are major killers 
responsible for over 200,000 deaths yearly [59]. This organism can infect humans and other 
higher primates but no other animal reservoir has been recognized. This suggests that it 
may be possible to eliminate typhoid through the use of vaccination and other public health 
measures. The death toll from typhoid would be higher except for the availability of 
vaccines. The two well-tolerated vaccines in use in humans provide partial and temporally 
limited protection and are quite distinct [60-62].  
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Ty21a live attenuated oral vaccine 
One of the two well-tolerated vaccines is the live-attenuated typhoid bacterium-
strain Ty21a. Ty21a is safe and protective as live oral vaccine and was developed in the 
early 1970s by chemical mutagenesis of a pathogenic S. Typhi strain [63]. The characteristic 
mutations in this strain include an inactivation of the galE gene, so Ty21a has an impaired 
capacity to synthetize LPS O-chain, and also inability to express the capsular polysaccharide 
(CP) Vi antigen, both considered major targets of protective antibody [63]. However, 
approximately two dozen additional mutations are also present in Ty21a [63] (Table 1).  
Table 1| Mutations identified in strain Ty21a compared to Ty2. Adapted from [64]. 
 
Gene Genotype Phenotype 
galE 
Base change at pos. 367 TCC → CCC leads 
to Ser → Pro 
 
No galactose epimerase activity [63]  
Base deletion at pos. 444 leads to frame 
shift 
No production of smooth type LPS without 
galactose. Only possible in presence of 
galactose in nutrient medium. 
Lysis if galactose is in excess in the nutrient 
medium. Blue when growing on a galactose 
containing brom-thymol-blue indicator agar 
(Fig. 4) [65]  
galT No mutation 
Reduced activity: 35%, independent from 
the nutrient medium [63]  
alK 
Base change at pos. 86 GTC → GCC leads 
to Val → Ala 
Reduced activity: 15%, independent from 
the nutrient medium [63]  
galP No mutation Activity depends on the nutrient medium 
rpoS 
Insertion of G at pos. 933 in Ty2 and Ty21a 
compared to S. typhimurium strains → 
frame shift that modifies the amino acid 
sequence of the C-terminal part of σS 
Mutated stress response 
ilvD 
Base exchange at pos. 1525 GCG → ACG 
leads to Ala → Thr  
Isoleucine and valine auxotrophy test in 
minimal medium: no growth without these 
two amino acids 
Base exchange at pos. 1607 GGC → GAC 
leads to Gly → Asp  
 
rcsC 
Base exchange at pos. 1541 TCC → TTC 
leads to Ser → Phe 
 
tviC 
Base exchange at pos. 996 CAG → CAA 
leads to Gln → Gln 
 
tviE 
Base exchange at pos. 803 GGC → GAC 
leads to Gly → Asp 
 
tviE 
Base exchange at pos. 1699 GGA → AGA 
leads to Gly → Arg 
 
vexD 
Base exchange at pos. 1205 CGC → CAC 
leads to Arg → His 
No Vi polysaccharide synthesized: no 
agglutination with Vi antiserum 
vexE 
Base exchange at pos. 893 GGT → GAT 
leads to Gly → Asp 
 
Base exchange at pos. 1111 GCG → ACG 
leads to Ala → Thr 
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Table 1 (cont.)| Mutations identified in strain Ty21a compared to Ty2. Adapted from [64]. 
 
Gene Genotype Phenotype 
vexE 
Base exchange at pos. 1552 GGC → AGC 
leads to Gly → Ser 
 
 
Figure 4 | Growth of S. Typhi Ty21a and Ty2 on 
agar medium containing galactose. Ty21a 
bacteria produce small grey-bluish colonies, and 
the wild-type strain Ty2 generates large yellow 
colonies (From R. Germanier).    
 
 
 
Ty21a is the main constituent of Vivotif [66], the only licensed oral vaccine against 
typhoid fever. Although Ty21a has proven to be remarkably well tolerated in placebo-
controlled clinical trials [67], it is not clear precisely what mutations in addition to 
inactivation of galE and of Vi synthesis are most responsible for the stable, impressive 
attenuation of this vaccine, thus, how this attenuated bacterium confers protection is not 
fully understood. The importance of antibody to Vi is evidenced by the use of purified Vi 
antigen as a stand-alone vaccine. Vi antigen is made of repeating units (1-4)-2-deoxy-2-N-
acetyl galacturonic acid encoded within the viaB locus from S. Typhi [68]. Immunization 
provides protection against typhoid at levels comparable to Ty21a in adults and older 
children in the first two years post-immunization [60,61]. The protection conferred by 
immunization with Vi antigen is likely to be mediated via systemic antibody as it has not 
been found to induce pronounced mucosal antibody responses, nor have a requirement for 
T cell involvement [69,70]. Therefore, understanding the nature of antibody responses to Vi 
antigen and other vaccines based on CP is likely to be important in understanding the basis 
of immunity to many pathogens and improving vaccines that target them.  
1.3.2. Cholera (oral) 
Vibrio cholerae is a Gram-negative bacillus that causes cholera, a severe, 
dehydrating diarrheal illness of humans. Two O serogroups of V. cholerae, O1 and O139, 
can cause epidemics of cholera gravis. V. cholerae O1 is by far the more important as O139 
infections are found in just a few areas of Asia (where they are responsible for only a few 
percent of cases) and O139 has not been reported from Africa. Two biotypes of V. cholerae 
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O1 exist, El Tor and classical, although presently only El Tor strains are prevalent. Recently, 
highly virulent El Tor strains have emerged that produce classical biotype cholera 
enterotoxin. Within each biotype of O1 are found two main serotypes, Inaba and Ogawa.  
For a cholera vaccine to be a useful public health tool, it must protect against both 
serotypes and biotypes. Live, orally administered, attenuated vaccine strains of V. cholerae 
have many theoretical advantages over killed vaccines. A single oral inoculation could result 
in intestinal colonization, obviating the need for repetitive dosing. Live V. cholerae 
organisms can also respond to the intestinal environment and immunological exposure to 
in vivo-expressed bacterial products could result in better immunological protection against 
wild-type V. cholerae infection. Attenuated V. cholerae have been developed using 
recombinant molecular biology techniques [71]. Attempts were made to further lessen 
reactogenicity of obtained strains, by decreasing the ability of attenuated V. cholerae 
vaccine strains to colonize the intestinal surface and by further attenuating vaccine strains 
by removing various purported toxic elements.   
CVD 103-HgR 
A σctxA derivative of classical strain V. cholerae 569B (CVD 103) was found to be 
immunogenic and minimally reactogenic [47]. To facilitate identification of the vaccine 
strain, a mercury-resistance gene (hgR) was inserted into the hemolysis A gene (hlyA) to 
generate CVD 103-HgR [47,72]. In North American adults, a single oral dose of about 5×108 
CFU of CVD 103-HgR elicits significant (four-fold or greater) rises in serum vibriocidal 
antibody (that is, seroconversion) in over 90% of those vaccinated, and vaccine organisms 
are excreted by about 25% [73]. A single dose of CVD 103-HgR significantly protects North 
Americans against cholera caused by V. cholerae O1 of either classical or El Tor biotype and 
either Inaba or Ogawa serotype [47,74,75].  
Peru-15 
A live, oral, attenuated V. cholerae O1 El Tor Inaba C6709 cholera vaccine strain 
was constructed in the 1990s by deleting the entire cholera toxin (CT) genetic element and 
attRS1 sites, inserting the gene for the B subunit of CT into recA, and screening for a non-
motile derivative, to derive the vaccine strain Peru-15 [76]. Peru-15 is well tolerated and 
immunogenic (90-100% vibriocidal seroconversion rate) as a single dose in volunteer 
studies [76,77]. Peru-15 was studied in a staged double-blind, randomized, placebo-
controlled Phase I/II field trial in Bangladesh. The vaccine was safe and well tolerated. 
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Vibriocidal antibody responses were seen in 30 out of 40 (75%) vaccine recipients [78]. 
Studies in toddlers and infants demonstrated 84 and 70% vibriocidal response rates, 
respectively, with an overall vibriocidal response rate of 77% in children less than 5 years of 
age [79].  
V. cholerae vaccine 638 
In the 1990s, a live, oral, attenuated El Tor Ogawa cholera vaccine was constructed 
by deleting the entire CT genetic element, CTXΦ, from V. cholerae O1 El Tor Ogawa strain 
C7258 and by insertion of the Clostridium thermocellum endoglucanase A gene (celA) into 
the hemagglutinin/protease hapA gene. The celA::hapA modification does not affect 
immunogenicity or colonization of the vaccine strain in animals [80]; but does permit rapid 
identification of the strain through assessment of β-(1–4) endoglucanase activity encoded 
by celA in carboxymethylcellulose indicator agar stained with Congo red, in which the 
vaccine strain appears as a red colony [80]. In a double-blind, placebo-controlled study in 
Cuba, V. cholerae 638 was examined preliminary for safety and immunogenicity [80] and no 
significant adverse reactions were observed in volunteers immunized. V. cholerae 638 was 
further evaluated for protective efficacy in a randomized, double-blind, placebo-controlled 
in a trial also in Cuba [81]. Among 24 of the vaccinees, 96% developed vibriocidal 
responses, and 50% developed an anti-LPS IgA response in serum [81]. At 1 month after 
vaccination, 12 vaccinees and 9 placebo recipients were challenged with 7 × 105 CFU  of 
virulent strain V. cholerae 3008 [81]. None of the 12 vaccinees, but 7 volunteers from the 
placebo group, had diarrhea; two of the latter developed severe cholera [81].    
Other live oral cholera vaccines 
Other live oral attenuated V. cholerae O1 strains have been developed, including 
VA1.3 in India [82] and IEM108 in China [83]. These strains have been immunogenic in 
animals, but no human studies have yet been reported.   
This text was adapted from [84].  
1.3.3. BCG and MTBVAC 
BCG 
Tuberculosis (TB) caused by Mycobacterium tuberculosis, remains a global health 
emergency. Additional threats to TB control include the spread of multidrug-resistant TB 
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(MDR-TB), the appearance of extensively drug-resistant TB (XDR-TB), and the destructive 
impact of TB/HIV coinfection. Bacille Calmette-Guérin (BCG), an attenuated strain of 
Mycobacterium bovis, is currently the only available vaccine against TB. Since 1974, BCG 
vaccination has been included in the WHO Expanded Program of Immunization [85]. It is 
estimated that more than 3 billion individuals have been immunized with BCG and over 100 
million doses of BCG are administered annually, making it the most widely used vaccine in 
humans [85]. Meta-analysis studies have confirmed that BCG protects children, providing 
>80% efficacy against severe forms of TB, including tuberculous meningitis and military TB. 
In contrast, evidence for protection against pulmonary TB in adolescents and adults 
remains contentious as efficacy estimates from clinical trials, observational case control 
studies and contact studies range from 0 to 80% [49]. Although it is generally considered 
safe and has been used as a human vaccine since the 1920s, the mechanisms of BCG 
attenuation remain largely unknown. Moreover, BCG strains also exhibit differences in 
residual virulence level. Recent studies have provided direct evidence that the distribution 
of major mycobacterial virulence factors varies among BCG lineages [86,87], and suggests 
that different BCG substrains have different mechanisms of attenuation.  
BCG originated with “lait Nocard”, a virulent strain of M. bovis isolated from the 
milk of a cow suffering from tuberculosis mastitis. Around 1901, this strain was brought to 
the Institute Pasteur in France, and used by Albert Calmette and Camille Guérin for studies 
of bovine tuberculosis. Calmette added ox bile to the glycerol-soaked potato slices on 
which the M. bovis was cultured in order to minimize bacterial clumping and optimize 
animal infection experiments. Within a few months, an isolate with unusual colony 
morphology and reduced virulence in guinea pigs appeared. After 13 years of serial in vitro 
passaging of this M. bovis strain (1908-1921) and different animal models experiments, the 
first human trial occurred. In July 1921, an infant was given three doses (∼2.4×108 CFU in 
total) by the oral route [88]. This child did not develop TB even though the infant’s mother 
had died of TB shortly after giving birth. As early as 1924, cultures of BCG were distributed 
to laboratories around the world and dozens of distinct daughter strains emerged, including 
four that are currently in major use: BCG-Pasteur (1173P2), BCG-Japan (Tokyo-172), BCG-
Danish (Copenhagen-1331) and BCG-Glaxo (1077).  
Mechanisms of BCG attenuation 
BCG strains have undergone two phases of attenuation. The initial phase (1908-
1921) comprises the 230 in vitro passages conducted by Calmette and Guérin to produce 
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the original vaccine. The second phase starts circa 1924 with widespread use and 
distribution of BCG. It ends several decades, and hundreds of passages, later with the 
establishment of frozen seed lots. Due to the initial phase, it is expected that BCG strains 
should share a set of common attenuating mutations, whereas the second phase should 
give rise to additional mutations, specific to individual BCG strains and lineages. A 
molecular phylogeny based on various studies has been established (Fig. 5) and is generally 
consistent with the historical records of BCG dissemination.  
 
 
 
Ç 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 | Genealogy of BCG vaccines. Polymorphisms that affect known virulence genes 
are highlighted. From [49].  
 
Attenuation of BCG between 1908-1921 
A Region of Difference-1 (RD1) that is deleted in all BCG strains but present in 
virulent strains of M. tuberculosis and M. bovis was identified [89,90]. RD1 encodes the ESX-
1 protein secretion system, which is one of the five type-VII secretion systems found in the 
M. tuberculosis genome [91]. Since it is common to all BCG strains, the loss of RD1 likely 
occurred in the initial stage of BCG attenuation. However, reintroduction of ESX-1 into BCG 
does not restore full virulence [92] and the RD1 deletion mutant of M. tuberculosis is still 
more virulent than BCG in long-term murine infections experiments [93]. Posterior studies 
indicate additional single nucleotide polymorphisms (SNPs) between different BCG strains 
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[94]. This suggests that loss of virulence during the initial 230 in vitro passages of BCG 
involved both the loss of RD1 and the accumulation of attenuating SNPs.    
Attenuation of BCG after 1924 
The dissemination of BCG to various parts of the world began in 1924. With 
different methods of propagation of the vaccine strains, BCG substrains emerged. Not until 
1966, with the introduction of the “seed-lot system”, was lyophilization of BCG strains 
started and the process of in vitro evolution halted. The deletion of RD2, accounts for the 
lack of MPB64 in the strains acquired after 1927.  
The direct evidence that BCG strains differ in established virulence factors first 
came from the comparative biochemical analysis of phthiocerol dimycocerosates (PDIMs) 
and phenol glycolipids (PGLs) [87]. PDIMs and PGLs are structurally related, methyl-
branched fatty acid-containing complex lipids of mycobacterial cell wall and are considered 
exclusive to pathogenic mycobacteria. Analysis of 12 BCG strains reveals that BCG-Japan, 
BCG-Moreau and BCG-Glaxo do not produce PDIMs and PGLs, whereas the other BCG 
strains do [87]. In BCG-Moreau, the PDIM and PGL defect is likely due to a 975 bp deletion 
that affects fadD26 and ppsA [86], which are part of the biosynthetic locus of PDIMs and 
PGLs [86,95].  
Furthermore, strains with defects in the PhoP regulon, such as phoP mutant in M. 
tuberculosis, are more attenuated than BCG-Pasteur in SCID mice infections [96]. Other 
studies have also demonstrated that the PhoP-PhoR system, particularly PhoP, plays an 
essential role in M. tuberculosis virulence [97-99]. A frame-shift mutation whitin the phoP 
gene of BCG-Prague makes this strain a natural phoP mutant [86]. The PhoP-PhoR system is 
one of 11 two component systems found in the M. tuberculosis genome [100]. The PhoR 
protein is a transmembrane histidine kinase that transmits signals from the environment. 
Autophosphorylation of PhoR is followed by transfer of the phosphoryl group to PhoP, a 
response regulator that mediates expression of multiple genes [97].  
BCG-Sweden and BCG-Birkhaug contain deletions in whiB3 and trcR, that are not 
present on other BCG strains [86]. Evidence obtained thus far suggest that WhiB proteins 
are transcriptional factors involved in the regulation of important mycobacterial cellular 
processes, including cell division, pathogenesis, oxidative stress responses and antibiotic 
resistance [101-103]. Specifically, deletion of whiB3 attenuates in vivo growth of M. bovis in 
guinea pigs [104] and WhiB3 is known to maintain the redox homeostasis to modulate 
1. BACKGROUND     
30 
 
macrophage response [105]. TrcR is the response regulator of the TcrR-TrcS two-
component system. Deletion of trcS from M. tuberculosis generates a hypervirulent 
phenotype such that the strains exhibits increased lethality in SCID mice [106]. 
Deletions affecting other genes with potential impact on virulence have also been 
found in certain BCG strains. The M. tuberculosis genome contains four mce operons, each 
containing 9-12 genes that encode membrane permease subunits of ABC transporters and 
putative secreted or cell-surface proteins [107]. The mce4C and mce4D genes are deleted in 
BCG-Frappier [108]. Recently, it was shown that the mce4 operon of M. tuberculosis 
encodes a cholesterol import system, which appears to be important for persistence 
infection [109,110].  
Finally, BCG strains can be viewed as two major groups that differ significantly in 
virulence level, the more virulent ones represented by BCG-Russia, -Sweden, -Danish and –
Pasteur, and the less virulent group including BCG-Japan, -Moreau, -Glaxo and –Prague. 
Deletions identified in some of these strains that affect vaccine properties as manifested in 
animal and clinical studies are listed in Table 2.    
Table 2 | Deletions identified in BCG strains that affect currently known virulence factors.  
 
Deletions BCG strains affected 
fadD26-ppsA BCG-Moreau 
whiB3, trcR BCG-Birkhaug, BCG-Sweden 
phoP BCG-Prague 
phoR BCG-Sweden, -Birkhaug, -Danish, -Glaxo, -Frappier 
mce4 BCG-Frappier 
All BCG strains contain the RD1 deletion, which contribute partially their attenuation. Additional 
deletions that may affect virulence levels of specific BCG strains are listed here. Adapted from [49].  
 
This text was adapted from [49].  
MTBVAC 
BCG confers protection against severe forms of TB (meningitis and miliary TB) in 
children but lacks consistency in preventing pulmonary disease, the most common form 
responsible for transmission by respiratory route [111]. Thus, very substantial efforts have 
been made over the past decade to develop new vaccines against TB. MTBVAC, a live 
attenuated M. tuberculosis vaccine, is based on the prototype SO2 (which has a safety and 
efficacy profile) and is genetically engineered to fulfil the Geneva consensus requirements 
for progressing new live mycobacterial vaccines into Phase 1 clinical trials, demanding the 
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presence of two stable independent mutations without antibiotic resistance markers for M. 
tuberculosis-based candidates. Indeed, this vaccine has two independent stable deletion 
mutations without antibiotic resistance markers in the virulence genes phoP, coding for a 
transcription factor key for the regulation of M. tuberculosis virulence, and fadD26, 
essential for the synthesis of DIM, one of the major mycobacterial virulence factors (Fig. 6).  
 
 
 
 
 
 
 
Figure 6 | Step-by-step construction of MTBVAC from SO2. Deletions in fadD26 and phoP 
genes were genetically engineered in SO2 strain. The final strain MTBVAC is a DIM-deficient 
phoP mutant which provides better assurance of genetic stability and has no antibiotic-
resistace markers. phoP and fadD26 genes are represented as grey arrows, white rectangles 
illustrate antibiotic-resistance markers and black arrow-heads depicts res sites [112]. 
Vertical discontinuous lines indicate the position of restriction sites used for strain 
construction and horizontal discontinuous lines depict DNA regions that are not to scale. 
From [113].              
 
MTBVAC exhibits equivalent safety and biodistribution profiles (Fig. 7) as the 
reference licensed strain BCG Danish 1331, used in the clinic, and confers superior 
protection with mouse model (Fig. 8) and other preclinical studies. As a result, MTBVAC is 
the first vaccine of this kind to enter human clinical trials, in January 2013 [113]. 
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  Figure 7 | MTBVAC biodistribution 
profile. BALB/c mice were 
intradermally inoculated with 
MTBVAC (black diamonds) or BGC 
Danish 1331 (white circles) and 
bacterial load in lymph nodes was 
determined. A similar clearance 
profile was obtained for both strains 
(mean ± s.e.m.). *P<0.05 **P<0.01, 
unpaired Student’s t test. From [113].       
 
 
 
 
        
 
 
 
 
 
 
 
Figure 8 | Protective efficacy of MTBVAC in mice. C57BL/6 mice received a subcutaneous 
administration of MTBVAC (black diamonds) or BCG Danish 1331 (white circles), or were 
not vaccinated (white squares), followed by an intranasal challenge with virulent H37Rv. At 
4 weeks post-challenge, bacterial burden (mean ± s.e.m.) was assessed in A, lungs and B, 
spleen. Significant CFU reduction was observed in MTBVAC vaccinated animals compared to 
BCG. *P<0.05, **P<0.01, ***P<0.001, unpaired Student’s t test. From [113].              
 
1.3.4. Bordetella pertussis BPZE1 
Since the 1940s and 1950s, Pw’s have been combined with diphtheria and tetanus 
toxoids in formulations called diphtheria-tetanus-pertussis (DTPw) vaccines and are now 
sometimes combined in addition with hepatitis B, inactivated polio and/or H. influenzae b 
vaccines. These were produced and used in many countries and are today still the most 
widely childhood formulations to protect simultaneously against diphtheria, tetanus and 
pertussis. There is little difference between production procedures of Pw vaccines. All 
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contain whole B. pertussis bacteria that have been inactivated by heat, formaldehyde 
treatment or other chemical procedures. 
The effectiveness of Pw vaccination to prevent pertussis in children has been 
documented through numerous efficacy trials, starting with those conducted by the British 
Medical Council in the 1940s, and long-term epidemiological studies. However, not all Pw 
vaccines showed equal efficacy, leading to substantial differences in quality between the 
manufacturers. Although Pw vaccines have been administered to millions of children 
worldwide and have prevented hundreds of thousands of deaths, adverse events have 
resulted in decreased confidence in Pw vaccines during the 1970s and 1980s.  
The first attempts to develop live attenuated B. pertussis vaccines date back to the 
1980s, when [114] developed an aroA mutant of B. pertussis. This mutant strain was highly 
attenuated, but it failed to efficiently colonize the respiratory tract of mice. Therefore, 
repeated nasal immunizations of high doses were required to obtain significant protective 
effects using this strain. More recently, [115] have developed an attenuated vaccine strain, 
based on the knowledge of the specific molecular mechanisms of pertussis pathogenesis. 
This vaccine strain, BPZE1, contains genetic alterations that eliminate or inactivate three 
different B. pertussis toxins. The dermonecrotic toxin gene was deleted, and the PT 
(pertussis toxin) gene was genetically modified by altering two different codons, so that the 
enzymatic ADP-ribosyltransferase activity of the toxin was abolished, yielding a fully 
inactive protein. Finally, the B. pertussis ampG gene was replaced by E. coli ampG, which 
resulted in virtual absence of the tracheal cytotoxin. This strain was found to be 
nonpathogenic in mouse models and caused no pulmonary inflammation, yet it is able to 
colonize the mouse respiratory tract nearly as long as the virulent parent strain. A single 
nasal administration of BPZE1 induces full protection against challenge with virulent B. 
pertussis in mice [116]. Protection against challenge is dose dependent and is directly 
related to the ability of the vaccine strain to colonize the respiratory tract and to induce 
both anti-B. pertussis antibodies and IFN-γ-secreting cells. Moreover, in preclinical mouse 
studies, BPZE1 induced long-lasting protection [117]. For up to at least 1 year, a single nasal 
administration of BPZE1 to adult or infant mice provided total protection against nasal 
challenge with virulent B. pertussis, whereas immunity induced by two administrations of 
Pa (pertussis acellular) vaccine started to wane at 6 months after the last immunization. In 
addition to B. pertussis, BPZE1 vaccination also protects mice against B. parapertussis [115-
117] and B. bronchiseptica infection [118].  
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The excellent safety profile of BPZE1 has allowed it to be classified from a safety 
level 2 to a safety level 1 organism in several countries. Together with its immunoprotective 
properties in preclinical models, this has allowed BPZE1 to be tested in phase I clinical 
safety trials in human volunteers. A placebo-controlled, double-blind, dose-escalating 
safety trial was performed and volunteers were followed up for safety and immunogenicity 
for 6 months [119]. Twelve subjects per dose received ×103, ×105 or ×107 CFU as droplets 
with half of the dose in each nostril. Twelve controls received the diluent. Nasopharyngeal 
colonization with BPZE1 of five subjects were seen in the high dose group. Significant 
increases in immune responses against pertussis antigens were seen in all colonized 
subjects. Adverse events occurred with similar frequency in the placebo and vaccine groups 
and were considered trivial. It was concluded that BPZE1 is safe in healthy adults and able 
to transiently colonize the nasopharynx and can thus undergo further clinical development 
(Trial Registration: ClinicalTrials.gov, NCT01188512). Similar to the Bacille Calmette-Guérin, 
the only available vaccine against tuberculosis, the target population of this vaccine is the 
newborns in order to provide earlier protection against the most severe forms of the 
disease and to prime anti-pertussis immunity to be boosted later in life by Pa vaccines 
[120].  
 
1.4. The background for vaccines against “ESKAPE” bacteria 
Further, the emergence of MDR or even pandrug-resistant bacteria, such as MDR-
Acinetobacter baumannii, MDR-Pseudomonas aeruginosa and methicillin-resistant-
Staphylococcus aureus (MRSA) and the lack of licensed vaccines against these pathogens 
has resulted in significantly increased mortality rates with limited or no options for 
therapeutic interventions, especially for Gram-negative bacilli. Moreover, the Infectious 
Disease Society of America (IDSA) reported the emergence and spread of six highly 
dangerous pathogens named “ESKAPE” [121]: Enterococcus faecium, Staphylococcus 
aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and 
Enterobacter species, for which therapeutic options are so extremely limited. IDSA issued a 
“Call to Action for the Medical Community” in the hope of raising awareness [122]. Despite 
ongoing efforts by governments and some successes, only few new antimicrobial drugs had 
been approved in recent years and novel strategies for controlling “ESKAPE” bacteria are 
urgently needed.    
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1.4.1. The background for a vaccine against A. baumannii 
 A. baumannii is a Gram-negative, strictly aerobic, catalase-positive, oxidase-
negative, nonfermenting, nonfastidious, rod-shaped (coccobacillus) bacterium. Bacteria of 
this genus lacks flagella, but exhibit twitching or swarming motility. This bacterium grows 
well on solid media that is used routinely in microbiology laboratories, such as sheep blood 
agar or tryptic soy agar, at a 37 ºC incubation temperature. These organisms form smooth, 
sometime mucoid, grayish white colonies; these present a colony diameter of 1.5 to 3 mm 
after overnight culture [123]. 
Nosocomial infections caused by A. baumannii have become a serious public health 
problem. This has become especially apparent due to the global emergence of MDR strains 
of A. baumannii. MDR A. baumannii is resistant to antibiotics from multiple classes, making 
the clinical management of infections caused by these strains increasingly difficult 
[124,125]. Moreover, the ability of A. baumannii to cause infections in various anatomic 
sites, ranging from the central nervous system and urinary tracts in hospitalized patients 
with invasive devices, to severe respiratory and skin and soft tissues infections, suggests the 
presence of diverse virulence factors [126,127].  
In this context, the implementation of prophylactic vaccination, both active and 
passive, for the prevention of infections caused by A. baumannii may represent a cost-
effective approach for reducing the clinical and economic burden of infectious caused by 
this pathogen. Moreover, using this approach, the emergence of new resistance 
phenotypes would be avoided, since this strategy does not rely on the use of antibiotics. 
Although community-acquired infections have been reported, infections caused by A. 
baumannii are mostly acquired in the hospital setting. This is a critical point when 
considering which populations would benefit from prophylaxis, as the targeted vaccination 
of hospitalized patients or patients at risk of being hospitalized who have risk factors for 
acquiring infections by A. baumannii would likely be the most cost-effective approach. 
Based on this idea, four patient populations at-risk for the acquisition of A. baumannii 
infection are proposed for targeted vaccination (Fig. 9).  
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Figure 9 | Proposed high-risk population for targeted vaccination against A. baumannii. 
From [128].  
 
 As A. baumannii is a frequent cause of ventilator-associated pneumonia (VAP), 
patients who require mechanical ventilation (MV) at the time of the presentation and 
patients who have a high likelihood of needing MV during their clinical course are potential 
targets for vaccination. This includes patients who undergo programmed surgical 
procedures, such as cardiac, neurologic and pulmonary operations, for which MV is a part 
of routine post-operative care. In addition, individuals admitted urgently who may require 
mechanical ventilation are also at-risk for A. baumannii VAP. A second group of patients 
that may benefit form vaccination are those at risk for acquiring nosocomial skin and soft 
tissue infections caused by A. baumannii. Individuals at risk for this type of infection include 
patients that have sustained extensive burn injury, patients undergoing complex abdominal 
surgical procedures, and military personnel sustaining war-related trauma and 
hospitalization. 
Extensive surgery, severe trauma, burn injury and war have been associated with A. 
baumannii infection, making patients with these conditions candidates for a vaccine against 
A. baumannii. After severe trauma and burn injury the immune system suffers profound 
alterations with simultaneous increased expression of classical inflammatory, anti-
inflammatory and adaptive immunity genes [129]. Additionally, physical injury related to 
these events may increase the expression of Th2 lymphocytes which cause impaired cell 
mediated immunity and may disable critical components of protection against A. baumannii 
[130]. Macrophage activation may suffer, impairing the host defense against A. baumannii 
infection through decreased phagocytosis and secretion of cytokines, which in turn may 
limit the recruitment of neutrophils to the site of infection and impair the clearance of A. 
baumannii [131,132].  
A third target population for immunization is patients who are at risk for A. 
baumannii meningitis. These infections are primarily associated with neurosurgical 
At risk-groups for vaccination 
against A. baumannii 
Patients with 
programmed  
or emergency MV 
Individuals at-risk 
for skin and soft 
tissue infections 
Neurosurgical 
operations with risk 
of meningitis  
Patients admitted  
to ICU during an 
outbreak  
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operations, raising the possibility that patients with undergoing both programmed and 
emergent neurosurgical procedures in situations where A. baumannii infection could occur 
may benefit from vaccination. A final possibility is the vaccination of patients admitted to 
an intensive care unit in the context of an outbreak of a difficult-to-treat clone of A. 
baumannii.    
Once at-risk patient populations have been identified, it must be determined when 
and how these patients should be vaccinated. A key factor is whether an active or passive 
immunization schedule would be more appropriate given the clinical scenario. Individuals 
for whom the risk of acquiring an infection caused by A. baumannii can be foreseen could 
be actively immunized with enough time to allow for a protective immune response to be 
elicited before that individual is exposed to A. baumannii. This would include patients 
undergoing programmed surgical procedures and military personnel. Patients for whom the 
risk of exposure cannot be foreseen, such as patients sustaining traumatic injuries or 
patients undergoing emergent surgery, the use of passive immunization is a more logical 
approach. Although passive immunization has the potential to provide almost 
instantaneous protective immunity, its ability to prevent bacterial diseases in the clinical 
setting has yet to be determined.     
Experimental vaccines against A. baumannii  
Due to the fact that some of the target populations for vaccination include critically 
ill patients with weakened immune systems, a crucial issue will be the ability of a vaccine to 
elicit an effective response in this context. Patients vulnerable to A. baumannii are often 
elderly, suffer multiple comorbidities, and are functionally impaired. Chronic inflammation 
and putative deficiencies in antigen presentation, humoral and cellular immunity may lead 
to poor vaccine responses [133]. Also, as A. baumannii produces a diversity of infection 
types, an ideal vaccine would be capable of protecting against all A. baumannii infections. 
Given the infections described above, this may require that the vaccine produces both a 
systemic and a mucosal response. In addition, the contributions of the cellular and humoral 
arms of the immune response have yet to be fully characterized. Studies performed in 
experimental models of A. baumannii infections has shown that the passive transfer of 
serum raised against A. baumannii antigens is sufficient for providing protection against 
infection [134-139]. Moreover, since in many cases the risk for exposure to A. baumannii 
cannot be foreseen, an ideal vaccine would induce protective immunity shortly after a 
single administration. This may be less problematic when passive immunization approaches 
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are employed, however for active vaccination a vaccine that requires a lengthy 
administration regimen or is slow to induce protective immunity may not be effective in 
cases that require the rapid elicitation of protective immunity.  
Another consideration is the selection of an appropriate strategy for the design of a 
vaccine for active or passive immunizations. An ideal vaccine should contain antigens that 
are present on the bacterial cell surface, expressed during human infection, present in the 
majority of the A. baumannii strains and highly conserved at the amino acid level, if the 
antigen is a protein. The experimental vaccines against A. baumannii produced and studied 
so far are summarized in Table 3.     
Table 3| Experimental vaccines against A. baumannii. 
 
Antigen Results References 
Purified antigens 
Trimeric 
autotransport
er protein 
(Ata) 
Passive intravenous immunization, opsonophagocytosis 
of A. baumannii with antisera, complement-dependent 
bactericidal activity of antisera, reduction in tissue 
bacterial loads after passive immunization in a mouse 
model of pneumonia 
[134]  
K1 capsular 
polysaccharid
e 
Subcutaneous passive immunization in a mouse soft 
tissue infection model, decrease in tissue bacterial loads 
[138]  
Outer 
membrane 
protein A 
(OmpA) 
Subcutaneous vaccination with an aluminium hydroxide 
adjuvant, protection in a diabetic mouse model of 
sepsis, opsonophagocytosis of A. baumannii with 
antisera, protection after passive immunization 
[140]  
Poly-N-acetyl-
β-(1-6)-
glucosamine 
(PNAG) 
Passive intranasal/intravenous immunization, 
opsonophagocytosis of A. baumannii with antisera, 
reduction in tissue bacterial loads after passive 
immunization in a mouse model of pneumonia  
[134]  
Biofilm-
associated 
protein (Bap) 
Freund’s adjuvant, reduction in post-infection tissue 
bacterial loads, protection in a mouse model of sepsis 
[141]  
Outer 
membrane 
protein W 
(OmpW) 
Subcutaneous vaccination of fusion protein thioredoxin-
OmpW with aluminium-based adjuvant, reduction in 
post-infection tissue bacterial loads, protection in a 
mouse model of sepsis  
[142]  
Multicomponent 
Outer 
membrane 
vesicles 
Intramuscular vaccination with an aluminium-based 
adjuvant, reduction in post-infection tissue bacterial 
loads in mouse models of pneumonia and sepsis, 
protection in a mouse model of sepsis. 
[137,143] 
 
Outer 
membrane 
complexes 
Intramuscular vaccination with an aluminium-based 
adjuvant, reduction in post-infection tissue bacterial 
loads, protection in mouse model of sepsis, passive 
protection using antisera, treatment of infected mice 
with antisera 
[139]  
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Table 3 (cont.) | Experimental vaccines against A. baumannii. 
 
Antigen Results References 
Multicomponent 
Formalin-
inactivated 
whole-cells  
Intramuscular/intranasal vaccination with or without an 
aluminium-based adjuvant, reduction in post-infection 
tissue bacterial loads, protection in a mouse model of 
sepsis and pneumonia, passive protection using 
antisera. 
[136,144,145]  
 
Lipopolysacch
aride-
deficient 
whole-cells  
Formalin inactivated whole-cell vaccine, intramuscular 
vaccination with aluminium-based adjuvant, reduction 
in post-infection tissue bacterial loads, protection in a 
mouse model of sepsis 
[146]  
 
 
The experimental vaccines that have been described for A. baumannii can be 
classified into two broad groups, vaccines that consist of a single purified antigen, and 
multicomponent vaccines. Within the first group, the outer membrane protein OmpA [140], 
the biofilm-associated protein Bap [141], the membrane transporter Ata [135], the K1 
capsular polysaccharide [138], the membrane associated polysaccharide poly-N-acetylb-(1–
6)-glucosamine [134] and the outer membrane protein OmpW [142] have been reported as 
good candidates due to their ability to elicit specific immune response. However, survival 
experiments after active immunization have only been reported for OmpA, OmpW and Bap, 
whose expression in strains that do not form biofilms is unclear. These vaccines present the 
limitation of stimulating antibodies only against injected antigens, rather than whole-cells.  
The strategies employing multicomponent vaccines have included outer membrane 
complexes [139], outer membrane vesicles [137,143] and formalin-inactivated whole-cells 
[136,144,145]. Recently, a formalin-inactivated vaccine containing an LPS-deficient strain of 
A. baumannii was described [146]. This strain has a large deletion in lpxD and completely 
lacks lipopolysaccharide. LPS consists of the O-antigen, a core polysaccharide and lipid A, 
the moiety responsible for the endotoxin activity of LPS. Thus, this strain had extremely low 
levels of endotoxin activity. Multicomponent vaccines induced not only a potent immune 
response but also provided high levels of protection against A. baumannii infections in a 
murine model of acute lethal infection and pneumonia, some of each using both parental 
strains and clinical isolates.  
 Considering the presence of diverse virulence factors in A. baumannii, as well as the 
MDR phenotype, it is apparent that its genome readily participates in horizontal gene 
transfer [147]. Therefore, protection from a single component vaccine targeting resistance 
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or virulence determinants may be transient and elusive, and effectiveness may vary 
according to strain type and genotype. Nevertheless, a vaccine that targets even a limited 
number of A. baumannii strains may still prove useful.   
 In summary, vaccine development for A. baumannii has already begun, 
highlightening the importance of defining characteristics of the target patient populations 
and the desired immune response that can be used to guide effective vaccine design.   
This text was adapted from [128,148].  
1.4.2 The background for a vaccine against P. aeruginosa 
P. aeruginosa belongs to the Pseudomonadaceae family, members of the Gram-
negative γ-proteobacteria class, which also includes the Enterobacteriaceae and 
Vibrionaceae groups of bacteria. P. aeruginosa is a Gram-negative rod measuring 0.5-0.8 
µm by 1.5-3.0 µm and possesses a polar flagellum providing motility; interestingly, loss of 
this flagellum may be associated with increased virulence because the flagellum activates 
host immunity [149]. P. aeruginosa is a ubiquitous organism able to survive in inanimate 
and animate environments. It is commonly found in soil and water but has the ability to 
survive using a wide variety of nutrients. In humans, it is an opportunistic pathogen, rarely 
causing disease in healthy individuals but colonizing and then infecting patients with 
compromised immune system function. Knowledge of the structure and physiology of P. 
aeruginosa is important to understand its high virulence and intrinsic ability to develop 
resistance to antimicrobial agents and to help develop preventive treatments.  
 Despite the recognition of P. aeruginosa is an opportunistic pathogen, no vaccine 
against this bacteria have come to market. P. aeruginosa causes serious infections in 
humans, particularly in the critically ill [150], the immunocompromised [151,152], those 
with burn wounds, or combat-related wound infections [153,154], and those with cystic 
fibrosis (CF) [155]. It is also one of the most frequently isolated pathogens from contact 
lenses-associated bacterial keratitis [156]. The multitude of intrinsic and acquired 
resistance mechanisms contributes to the intractable nature of many of these infections. A 
recent population-based study of P. aeruginosa bacteremia in Canada shed light on the 
overall incidence of serious P. aeruginosa infections [157]. This study reported an 
exponential increased risk of bacteremia after age 60, with a remarkable high annual 
incidence (per 100,000) of 10 in ages 60-69, 20 in ages 70-79 and 35 in ages >80, and an 
overall mortality rate of 29%. About a third of these cases of bacteremia were classified as 
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having a pulmonary source. This incidence is on par with that of invasive MRSA infections in 
the US in 2011, which was recently estimated to be 26 per 100,000 [158].  
 Pulmonary infections caused by P. aeruginosa generally dichotomize between 
acute pneumonia, usually associated with mechanical ventilation (ventilator-associated 
pneumonia [VAP]) and the chronic pneumonia of CF. Based on the data from the National 
Healthcare Safety Network from 2009-2010 [159], P. aeruginosa was the most commonly 
isolated Gram-negative pathogen and the second most common pathogen overall in the 
setting of VAP, accounting for 11% of cases. Of the P. aeruginosa VAP isolates, 33% were 
fluoroquinolone-resistant, 30% were carbapenem-resistant, and 18% were multidrug-
resistant [159]. Notably, VAP due to P. aeruginosa has a particularly high attributable 
mortality [160].  
 P. aeruginosa is also a major cause of combat-related wound infections. A recent 
review of the Joint Theater Trauma Registry (JTTR) for infections among more than 16,000 
Iraq and Afghanistan combat casualties noted that infections were mostly due to Gram-
negative bacteria (48%), most commonly involving wounds (27%) or lungs (15%), and 25% 
of the Gram-negatives were P. aeruginosa [153]. In a review of all trauma casualties 
evacuated from the Iraqi theatre to a U.S. Navy hospital ship in 2003, there was high 
antibitioic resistance in P. aeruginosa strains causing infections, with 56% being 
tobramycin-resistant and 37% ceftazidime-resistant [154]. These and other similar studies 
suggest that P. aeruginosa is a major cause of combat-related wound infections that are 
difficult to treat due to high antibiotic resistance and also associated with high morbidity.  
 CF is an autosomal-recessive genetic disorder, with about 1,000 new cases 
diagnosed each year. Although there are approximately 30,000 patients suffering from its 
complications in the U.S. alone, chronic lung infection with P. aeruginosa accounts for most 
of the morbidity and mortality associated with the disease [161].  
Candidates to immunization with P. aeruginosa vaccine would be relatively easy to 
identify. While some obvious populations can be identified (preoperative patients 
schedules for major surgery, soldiers, police, firefighters, wearers of extended-use contact 
lenses, CF patients), it might be reasonable to consider clinical trials involving vaccination of 
everyone over 60. An effective vaccine given to individuals with an increased risk for 
hospitalization due merely to age, and vaccinating adults soon after admission to ICUs 
(which is predicated on rapid immune responses) could be very cost effective.  
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Overall, considering the problem of hospital-acquired infections, the prominent 
role of P. aeruginosa in this setting, the problem of antibiotic resistance, and an aging 
population, a vaccine against P. aeruginosa is urgently needed.  
Experimental vaccines against P. aeruginosa 
LPS-based vaccines 
 LPS, the major component of the outer membrane of P. aeruginosa, is composed of 
lipid A, relatively conserved inner and outer core oligosaccharides and highly variable 
peripheral long chain polysaccharides (O-antigen). The differences in chemical structure of 
O-antigens and hence the variation in immunological reactivity of P. aeruginosa isolates 
forms the basis of its classification into more than 20 heterogeneous serotypes, with each 
serotype possessing subtype strains having subtle variations, leading to over 30 subtypes 
[162]. It is well established from animal studies that antibodies to the LPS O antigen 
mediate high-level immunity to P. aeruginosa infections [163]. However, for many of the O 
antigens, protective epitopes are poorly immunogenic, while non-protective O antigen 
epitopes often elicit the best immune responses after active vaccination [164]. To counter 
the O-antigen heterogeneity, multivalent vaccines have been developed to target a broader 
range of clinically active P. aeruginosa serotypes. A heptavalent O antigen vaccine prepared 
from LPS of seven different serotypes called Pseudogen (Parke Davis and Co.) showed 
efficacy in nonrandomized trials among adult cancer and burn patients in preventing fatal 
P. aeruginosa infections [165,166], but this vaccine was limited by toxicity, and studies in 
patients with leukemia and CF showed no benefit [167,168]. An improved LPS-based 
polyvalent vaccine (16 strains) was investigated in CF patients prior to P. aeruginosa 
colonization [169]. However, the vaccine failed to reduce the rate of Pseudomonas 
colonization when compared with the non-vaccinated control group [170]. Despite these 
and other efforts for more than 40 years, realization of clinically applicable LPS or O-
polysaccharide-based vaccines remain elusive. Extensive serological heterogeneity, LPS-
associated toxicity, cost and complexity of development of lipid free multivalent-conjugates 
are the major obstacles in vaccine development.  Another concern for the usefulness of 
LPS-based vaccine is the observed inconsistency in immune responses in different species 
[171] that makes it difficult to predict the vaccine performance in humans. Furthermore, 
vaccination with a multivalent LPS O-antigen vaccine composed of antigens from 
serologically distinct strains within the same overall serogroup showed interference in the 
immunogenicity of the individual components [172].  
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MEP-based vaccines 
Chronic infection with P. aeruginosa in the respiratory tract of CF patients is 
characterized by the conversion of the non-mucoid to the mucoid phenotype due to 
overproduction of mucoid exopolysaccharide (MEP; also known as alginate).  The early, 
non-mucoid isolates are LPS-smooth and serologically typeable while the late, mucoid 
isolates are LPS-rough and non-typeable [173]. LPS-rough strains lack the O antigen 
polysaccharide (also known as O side chain) attached to the LPS core. Unlike LPS, MEP is 
relatively conserved between strains, which makes it an attractive vaccine antigen. The 
detection of higher levels of serum anti-MEP opsonophagocytic antibody titers in older CF 
patients that remained free of P. aeruginosa infection rationalized the development of 
MEP-based vaccines more than 20 years ago [174]. To improve immunogenicity, MEPs have 
been conjugated to various carrier proteins such as exotoxin A, tetanus toxoid or keyhole 
limpet hemocyanin (KLH) [175-177]. In mice and rabbits, these vaccine preparations 
successfully enhanced the MEP-specific immune responses and elicited opsonizing 
antibodies against heterologous MEPs. The preservation of O-acetyl groups and preventing 
depolymerization of MEP during the conjugate vaccine preparation resulted in broader 
cross-reactivity among heterologous strains [177]. Interestingly, an engineered human IgG1 
monoclonal antibody to the mannuronic acid epitopes of alginate was recently shown to 
protect mice against acute lethal pneumonia caused by non-mucoid, LPS-smooth strains 
[178]. It seems MEP-based vaccines may still hold potential, though, for the chronically 
infected CF population.  
Live attenuated vaccines 
P. aeruginosa mutants having a deletion of the aroA gene, PAO1ΔaroA and 
PA14ΔaroA, which is required for the synthesis of aromatic amino acids, have proven to be 
highly attenuated and immunogenic in animal models [179-181]. These mutants are unable 
to synthesize aromatic amino acids and cannot efficiently acquire them from the host and 
hence can survive at detectable levels only up to 3-4 days following administration. Nasal 
immunization of mice with live attenuated P. aeruginosa PAO1ΔaroA (aroA deletion) is 
highly protective against acute lethal pneumonia caused by P. aeruginosa strains having the 
same LPS O antigen as the vaccine (called serotype-homologous strains); passive transfer 
did not protect against a less virulent strain, while active immunization did, thus suggesting 
that cellular immunity also played a prominent role in protective immunity [180]. 
Interestingly, in a murine corneal infection model, active immunization with PAO1ΔaroA or 
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passive immunotherapy with rabbit antiserum raised against PAO1ΔaroA protected against 
corneal infections caused by heterologous serogroups of P. aeruginosa [182]. Outer 
membrane antigens, but not the LPS O-antigen, were the protective component of the 
vaccine in this setting. PA14ΔaroA vaccine strain protected mice against acute lethal 
pneumonia caused by LPS-heterologous P. aeruginosa strains in the absence of serum 
opsonic antibodies, suggesting a T cell effect. Depletion of IL-17 before challenge of 
immunized mice, or absence of the IL-17 receptor, abrogated the protective efficacy of the 
vaccine [181]. Mucosal vaccination with a multivalent vaccine composed of live-attenuated 
P. aeruginosa strains (ΔaroA) induced multifactorial immune responses against diverse 
bacterial antigens and protected against acute fatal lung infection [183]. Effector CD4+ T 
cells as well as opsonic antibodies directed not only against multiple O antigens but also 
against the more conserved LPS core and bacterial surface proteins, were generated. 
Furthermore, the use of multivalent live attenuated did not generate immunological 
interference in opsonic-antibody responses which had been observed with multivalent 
purified O-antigen vaccines. Thus, live attenuated vaccines provide an easy, safe and 
efficacious method to induce anti-P. aeruginosa immunity against broad range of antigens. 
Development of additional means to attenuated virulence while maintaining 
immunogenicity will further facilitate clinical realization of such vaccines. 
Live-attenuated Salmonella strains for P. aeruginosa antigen delivery  
Oral immunization of mice with attenuated Salmonella enterica serovar 
Typhimurium SL3261 expressing P. aeruginosa O11 O-antigen resulted in enhanced 
pulmonary bacterial clearance and increased survival time after intranasal challenge with 
homologous, but not heterologous, P. aeruginosa strains [184]. Intranasal administration of 
this vaccine was more effective against acute pneumonia and could also protect against P. 
aeruginosa infections after burns or eye injury [185] and against pneumonia in 
immunocompromised mice made leukopenic [186]. Strains in O11 serotype are common 
clinically and have a high prevalence of cytotoxicity so are associated with a high mortality 
rate [187]. Another Salmonella strain SL3261-based live attenuated vaccine that expressed 
pseudomonas outer membrane fusion protein OprF-OpRI, induced specific IgG and IgA 
antibodies in the respiratory mucosa after oral and systemic vaccination [188]. In a clinical 
trial enrolling healthy volunteers, systemic and mucosal immunization with this vaccine 
induced comparable levels of OprF-OprI-specific serum antibody titers. However, IgG and 
IgA in the lower airways were only induced following nasal or oral administration [189]. 
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Overall, the use of Salmonella vaccines may be an efficient means to generate mucosal 
immunity.  
Outer membrane proteins, flagella, pili, type III secretion system, extracellular toxins and 
proteases 
P. aeruginosa vaccine strategies have focused on the outer membrane proteins 
(OMPs) OprF and OprI, which are antigenically related among all serotypes, as well as 
OprF/I fusion proteins. Recombinant OprI [190,191] and an OprF/I fusion protein [192] have 
been shown to be well tolerated in human trials. The OprF/I fusion protein vaccine [193] is 
currently in phase II/III clinical trials (clinicaltrials.gov, NCT01563263) in which adults are 
vaccinated soon after admission to ICUs. This OprF/I vaccine induces opsonic antibodies 
[193] as well as antibodies that inhibit IFN-γ binding to P. aeruginosa [194] (interfering with 
a virulence mechanism).  
Among vaccines tested in patients with CF, there is a bivalent flagella vaccine, 
which showed a small but statistically significant (P=0.05) reduction in P. aeruginosa 
infection in a large randomized trial [195]. P. aeruginosa flagella is essential for motility, 
chemotaxis, invasiveness and adhesion [196-198]. The vaccine clearly seemed to work, as 
only strains with flagella types not included in the vaccine were isolated from patients after 
vaccination. It was therefore suggested that the inclusion of additional P. aeruginosa 
flagella types in future vaccine preparations may improve the efficacy of a flagella vaccine 
in CF patients. Unfortunately, the company involved in preparation of this vaccine 
(IMMUNO, Vienna, Austria) stopped production before the end of the trial [199]. A 
conjugate vaccine of flagellin coupled to polymannuronic acid (PMA, which contains an 
epitope recognized by the opsonic monoclonal antibody to alginate) elicited opsonic 
antibodies against mucoid but not nonmucoid strains of P. aeruginosa, and rabbit antisera 
to this PMA-flagellin vaccine showed improved clearance of both mucoid and nonmucoid 
strains in a murine respiratory model [200]. Importantly, antibodies elicited by the PMA-
flagellin vaccine did not neutralize the TLR5-activating activity of flagellin, an important part 
of innate immunity flagellated microbial pathogens.  
As other Gram-negative bacteria, P. aeruginosa expresses pili on their surface, 
which are polymeric assemblies of the pilin protein that assists in bacterial adhesion, 
biofilm formation and twitching motility. Pilin-based vaccines have shown variable 
efficacies to reduce bacterial adherence. Pilus antigens are serologically heterogeneous 
[201], and pillin alleles among CF and non-CF human isolates showed marked distinction in 
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allele distribution [202]. This serological heterogeneity and the hidden conserved binding 
site complicates the further development of pilin-based vaccines. So far there have been no 
human studies with pilin vaccines.  
P. aeruginosa employs the type III secretion system (T3SS) to deliver effector 
proteins responsible for virulence, tissue injury and cytotoxicity to the cytosol of host cells. 
PcrV protein, a component of T3SS is located on the bacterial surface and is required for 
translocation of these effector proteins. Immunization with a vaccine targeting PcrV 
induced protective immunity in mice, decreased lung inflammation and injury in a murine 
lung infection model [203] and a burn mouse model [204]. A multivalent T3SS-based 
protein vaccine, including P. aeruginosa PcrV and needle tip proteins for four other Gram-
negative bacteria also showed to be immunogenic [205]. 
Exotoxin A, an ADP-ribosyl transferase that inhibits host protein synthesis, is the 
most toxic virulence factor of P. aeruginosa. Immunization with a truncated exotoxin A 
subunit or DNA vaccine elicited specific antibodies and protected mice from the lethal 
challenge with lethal doses of wild-type exotoxin A [206-208].  
Elastase and alkaline proteases interfere with the host immune system by cleaving 
immunoglobulins [209,210] inhibiting cytokines [211,212] and interfering with the immune 
cell functions [213-215]. Immunization with elastase and alkaline protease toxoids were 
effective in P. aeruginosa infection models of hemorrhagic pneumonia in minks [216], 
corneal ulcers [217] and burns in mice [218]. In a mouse model of P. aeruginosa gut derived 
sepsis, immunization with alkaline protease, elastase and exotoxin A provided protection 
when all three were used combined, but failed when each component was used alone 
[219].   
Overall, immunization against PcrV and extracellular toxins seems efficient to block 
the inflammatory and cytotoxic effects induced by P. aeruginosa and they may thus be 
useful as part of multicomponent vaccines. However, none of these vaccines has yet been 
tested in humans.  
In summary, despite intense efforts over the past few decades a marketable 
vaccine against P. aeruginosa has not yet evolved. The medical community is still waiting a 
vaccine to delay or prevent initial pulmonary infection in individuals with CF, as this would 
have significant impact and may be accomplished in the future.  
This text was adapted from [220] and [221].  
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Passive immunotherapy with multifunctional bispecific antibodies  
 Increasing drug resistance to virtually all antibiotic classes, particularly within 
ESKAPE pathogens, is stimulating a renewed interest in pathogen-specific strategies 
including monoclonal antibody (mAb) technology for the most problematic 
microorganisms.  Although mAbs offer considerable potential, P. aeruginosa is a challenging 
target for a single mAb approach. Multifunctional bispecific antibodies targeting 
persistence factor PsI exopolysaccharide and the serotype-independent T3SS virulence 
factor PcrV, designated BiS4αPa, were recently constructed [222]. This new bispecific 
antibody platform exhibited superior synergistic protection against P. aeruginosa-induced 
murine pneumonia compared to parent mAb combinations or other available bispecific 
antibody structures and supported this molecule (designated MEDI3902) as a promising 
clinical candidate for the prophylaxis or adjunctive treatment of P. aeruginosa infections. 
MEDI3902 completed a Phase I trial in healthy volunteers for the prevention of nosocomial 
pneumonia in USA (NCT02255760) on April 2015. 
1.4.3 The background for a vaccine against S. aureus 
S. aureus is a Gram-positive, catalase-positive, oxidase-negative, facultative 
anaerobe, perfectly spherical bacterium about 1 µm in diameter that occur in microscopic 
clusters resembling grapes. It forms a fairly large yellow colony on rich medium and is often 
hemolytic on blood agar. S. aureus can grow at a temperature range of 15-45 ºC and at 
NaCl concentrations as high as 15%. The staphylococci grow in clusters because the cells 
divide successively in three perpendicular planes with the sister cells remaining attached to 
one another following each successive division. Since the exact point of attachment of 
sister cells may not be within the divisional plane, and the cells may change position slightly 
while remaining attached, the result is formation of an irregular cluster of cells [223].  
Many vaccinologists would place the need for a highly effective vaccine against S. 
aureus in the top 3-5 public health essentials. This organism is among the most frequent 
causes of infections in virtually all human and many animal tissues [224,225] causing 
considerable morbidity and mortality [226-229] and community-acquired infections in 
otherwise healthy people. Invasive disease is associated with 20% and higher mortality 
[230-233] due to a combination of rapidly evolving resistance to antibiotics [228,234-236] 
and multiple virulence factors (Fig. 10).  
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Figure 10 | Virulence factors of S. aureus potentially involved in the field of vaccination 
against S. aureus infections. Bbp: Bone-binding protein; CHIPS: Chemotaxis inhibitory 
protein of Staphylococcus aureus; Clf: Clumping factor; Cna: Collagen-binding protein; CoA: 
Coagulase; DNECs: Desquamated Nasal Epithelial Cells; Eap: Extracellular adherence 
proteins; EbpS: Elastin-bonding protein; Efb: Extracellular fibrinogen-binding protein; Emp: 
Extracellular matrix-binding protein; Eno: Enolase (laminin-binding protein); FnBP: 
Fibronectin-binding protein; FPR: Formyl peptide receptor; hHb: Human hemoglobin; 
HNECs: Human nasal epithelial cells; Isd: Iron-regulated surface determinant; MSCRAMMs: 
Microbial surface component recognizing adhesive matrix molecules; PVL: Panton-
Valentine leucocidin; SAK: Staphylokinase; SasG: Staphylococcus aureus surface protein G; 
SCIN: Staphylococcal complement inhibitor; Sdr: Serine-aspartic acid repeat protein; SEA: 
Staphylococcal enterotoxin A; SEs: Staphylococcal enterotoxins; TLR2: Toll-like receptor 2; 
vWF: Von willebrand factor adhesion; WTA: Wall teichoic acids. From [237].     
 
 
 S. aureus possesses a variety of means to both colonize the host (around 20% of 
adults are persistent carriers of this microorganism [238]) and evade the immune system by 
inhibiting phagocytic uptake and killing [239,240] (Fig. 11).  
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Figure 11 | S. aureus survival strategies during infection. CHIPS: Chemotaxis inhibitory 
protein of Staphylococcus aureus; Eap: Extracellular adherence proteins; Isd: Iron-regulated 
surface determinant; MSCRAMMs: Microbial surface component recognizing adhesive 
matrix molecules; ROS: Reactive oxygen species; SAK: Staphylokinase; SOD: Superoxide 
dismutase; PSM: Phenol soluble modulin; TSST: toxic shock syndrome toxin. Adapted from 
[239].  
 
This bacterium has developed a large armamentarium of virulence factors to enable 
it to adapt and survive in a variety of host niches and as a result, to cause a multitude of 
diverse infection pathologies (ranging from relative mild skin infections to life-threatening 
wound and bloodstream infections). These are some of its most important abilities: 
• Entry into the host by breaching the protective physical barriers to infection (skin, 
mucosa), or by entering a lesion. S. aureus adheres to extracellular matrix 
components and invades host epithelial cells using a variety of molecules that are 
collectively termed MSCRAMM (Microbial surface component recognizing adhesive 
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matrix molecules). These include fibronectin-binding proteins (FnBPA, FnBPB) [241-
242], fibrinogen-binding proteins also known as “Clumping factors” (ClfA, ClfB) 
[243-244] and collagen-binding protein (Cna) [245]. Two factors, ClfB and wall-
associated teichoic acids, have so far proven roles in nasal colonization of humans 
and rats [246,247].    
• Obtains the essential nutrients for growth that are restricted in the host, such as 
iron and manganese, by expressing iron acquisition receptors, such as Iron-
regulated surface determinant (IsdB) [248], and manganese uptake receptors, such 
as the ABC transporter MntABC [249].  
• S. aureus has been generally recognized to survive well both inside and outside of 
host cells. In the extracellular milieu, S. aureus must overcome opsonization by 
complement and antibodies, which directly or indirectly leads to killing of S. aureus 
or uptake by phagocytes through Fc or complement receptors. S. aureus avoids 
opsonophagocytosis by expressing on its surface an anti-phagocytic polysaccharide 
capsule (CP5 or CP8) [250], ClfA [251], protein A (Spa) [252,253], Sbi (second 
immunoglobulin-binding protein of S. aureus) [254] and a number of complement 
inhibitors, like SCIN (Staphylococcal complement inhibitor) [255], all of which 
inactivate or prevent host opsonins from binding or targeting the bacterium for 
destruction. Specifically, Spa is known to inhibit opsonophagocytosis by binding IgG 
by the Fc region, which prevents classical complement fixation and recognition by 
the neutrophil Fc receptor [253].  
• S. aureus can shelter within epithelial cells, endothelial cells, and even 
macrophages [256]. By contrast, neutrophils present a more formidable challenge 
to S. aureus. S. aureus deploys a number of strategies to resist neutrophil killing. 
First, it secretes two molecules, CHIP (Chemotaxis inhibitory protein) and Eap 
(Extracellular adherence protein), which respectively block neutrophil recognition 
of chemotactic factors [257] and neutrophil binding to endothelial adhesion 
molecule ICAM-1 [258]. Inhibition of ICAM-1 binding prevents leukocyte adhesion, 
diapedesis, and extravasation from the bloodstream to the site of infection. S. 
aureus also mediates defense against ROS (reactive oxygen species), RNS (reactive 
nitrogen species) and antimicrobial peptides that are unleash by neutrophils at the 
site of infection. S. aureus deploys a large number of antioxidant enzymes (e.g. 
catalase, pigment, superoxide dismutase) that neutralize ROS and RNS [253] and 
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antimicrobial peptides are degraded by aureolysin [259] and neutralized by SAK 
(staphylokinase) [260]. Also, S. aureus counters by secreting specific toxins [261], 
which lyse neutrophils. The phenol soluble modulin (PSM) is a group of bacterial 
peptides previously described in S. epidermidis, which induce inflammation and 
neutrophil cytolysis. The virulence role of PSM peptides has been confirmed in a 
CA-MRSA skin infection model [262].   
• In addition, S. aureus can evade immune killing by producing multiple toxins that 
are either lethal to immune cells, such as alpha toxin and Panton-Valentine 
leucocidin (PVL), or act as superantigens, such as toxic shock syndrome toxin (TSST) 
and staphylococcal enterotoxin B (SEB) [263-265]. The mechanism underlying 
evasion of adaptive immune response is poorly understood, however studies have 
shown that staphylococcal enterotoxins, TSST, and Eap (a MHC class II analog) could 
all alter T cell functions by targeting the T cell receptor activation pathway 
[266,267].  
• Spa has been shown to deplete splenic marginal zone B cells, which are precursor 
to B cells [268]. The results could be poor generation of specific B cell response. 
This mechanism, coupled with strategies described above to block effective 
antibody binding to bacterial surface and inactivation of T cell functions, could had 
been construed as a tactic devised by S. aureus to prevent development of long-
term memory and be important underlying reasons why this pathogen has the 
ability to infect the human host repeatedly throughout life.  
While several vaccines have shown efficacy in preclinical models, and despite of  
ongoing efforts, there is no licensed vaccine against S. aureus, because no human clinical 
trial has yet been well succeeded (see Table 4).  
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Table 4| Recent phase II and III clinical trials of passive and active immunization for S. 
aureus and coagulase negative staphylococci. 
 
Compound Product Phase Study design Results 
Active Immunization 
StaphVax 
(NABI 
Biopharmaceu
ticals) 
[269]  
Bivalent vaccine 
of capsular 
polysaccharide 
(CP) 5 & 8 
conjugated 
individually to 
recombinant 
exoprotein A 
Phase 
III 
Randomized, 
double-blind, 
placebo-controlled 
trial of StaphVax in 
prevention of S. 
aureus bacteremia 
in hemodialysis 
dependent adults (n 
= 1804)  
Efficacy in reduction of S. 
aureus bacteremia at 54 
weeks non-significant 
(P=0.23); post-hoc efficacy 
estimate at 40 weeks: 57% 
(P=0.02) 
V710 (Merck 
Sharp & 
Dohme Corp.) 
[230] 
IsdB 
Phase 
III 
Randomized, 
double-blind, 
placebo-controlled, 
event trial of 
efficacy of V710 to 
prevent major S. 
aureus infection in 
adults undergoing 
median sternotomy 
(n = 8031) 
Study stopped 
prematurely by data 
monitoring committee; no 
significant efficacy. 
Vaccine recipients who 
developed S. aureus 
infection were 5 times 
more likely to die than 
control recipients who 
developed S. aureus 
infection (23.0 vs 4.2 per 
100 person-years)  
Passive Immunization - Treatment 
Aurexis 
Tefibazumab 
(Bristol-Myers 
Squibb) [270] 
Humanized 
monoclonal 
anti-clumping 
factor A 
antibodies 
Phase 
II 
Randomized, 
double-blind, 
placebo-controlled 
trial of standard 
treatment plus 
either Aurexis or 
placebo (n = 63)   
No differences in adverse 
events or rate of death, 
relapse, or complications 
Altastaph 
(NABI 
Biopharmaceu
ticals) [271] 
Pooled human 
anti-capsular 
polysaccharide 
(CP) types 5 & 8 
antibodies 
Phase 
II 
Randomized, 
double-blind, 
placebo-controlled 
trial of standard 
treatment plus 
Altastaph or 
placebo for S. 
aureus bacteremia 
in adults (n = 40) 
No significant mortality 
difference; shorter length 
of stay in Altastaph vs 
placebo (9 days vs 14 days; 
P=0.03) 
Aurograb 
(NeuTec 
Pharma) (not 
published in 
peer-reviewed 
journal) 
Single-chain 
antibody 
variable 
fragment 
against ABC 
transporter 
component GrfA 
Phase 
III 
Unpublished by 
sponsor 
Addition of Aurograb to 
standard therapy for life-
threatening staphylococcal 
infections failed to show 
efficacy 
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Table 4 (cont.) | Recent phase II and III clinical trials of passive and active immunization 
for S. aureus and coagulase negative staphylococci. 
 
Compound Product Phase Study design Results 
Passive Immunization - Prevention 
MEDI4893, 
SAATELLITE 
(MedImmune 
LLC) [272]  
A human 
monoclonal 
antibody against 
S. aureus alpha 
toxin  
Phase 
II 
Randomized, 
double-blind, 
placebo-controlled, 
single-dose, dose-
ranging study of the 
efficacy and safety 
of MEDI4893 for 
prevention of 
pneumonia caused 
by S. aureus in 
mechanically 
ventilated adult 
subjects. 
(Recruiting) 
Altastaph 
(NABI 
Biopharmaceu
ticals) [273]  
Immune serum 
from subjects 
vaccinated with 
StaphVax 
Phase 
II 
Randomized, 
double-blind, 
placebo-controlled 
trial of Altastaph or 
placebo for 
prevention of 
nosocomial S. 
aureus infections in 
very low birth 
weight babies (n = 
206) 
High levels of antibodies; 
no difference in rate of 
invasive S. aureus 
Veronate 
(Bristol-Myers 
Squibb) 
[274]  
Pooled human 
IgG to ClfA (S. 
aureus) and 
SdrG (S. 
epidermidis) 
Phase 
III 
Double-blind, 
placebo-controlled 
trial of INH-21 vs 
placebo for 
prevention of 
staphylococcal late-
onset sepsis in 
infants with birth 
weights 500 to 
1,250 g (n = 1983) 
No difference in 
staphylococcal late-onset 
sepsis (5% INH-21 vs 6% 
placebo; P=0.34) 
Pagibaximab 
(Biosynexus 
Incorporated) 
[275]  
Humanized 
mouse chimeric 
mouse 
monoclonal 
antibody against 
lipoteichoic acid 
Phase 
II 
Randomized, 
double-blind, 
placebo-controlled 
dose ranging study 
for prevention of 
staphylococcal 
infection in patients 
with birth weights 
700 to 1,300 g (n = 
88) 
Definite staphylococcal 
sepsis occurred in 0% (90 
mg/kg), 20% (60 mg/kg), 
and 13% (placebo) 
(P=0.11). Findings not 
confirmed in Phase III trial  
 
While some studies have identified genes commonly found among a large majority 
of clinical isolates [276,277] no single essential virulence factor needed for infection in most 
settings that can be targeted as a vaccine is known, exceptions being diseases mediated 
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purely by toxins such as toxic-shock syndrome toxin [278,279], exfoliative dermatitis and 
mediators of staphylococcal food poisoning [280,281]. Extensive genetic [282] and hence 
antigenic variability in many potential antigens precludes their use as vaccines. Variability in 
the level of expression leading to a highly variable surface [283,284] provides an easy 
means for bacterial escape from immune effectors by merely reducing levels of antigens to 
below that needed for elimination or killing of bacteria. S. aureus is also notorious for 
causing frequent reinfections, indicating natural infection does not readily induce acquired 
immunity that can be defined and used to guide vaccine development.   
In many reviews [285-290], the major point made is that we have insufficient 
insight into the basis for virulence and immunity of this organism to rationally design 
vaccines targeting known protective immune effectors. The biological complexity based on 
redundant and wide variety of virulence factors, the undefined mechanisms of host 
immunity, the high recurrence rates seen in humans, particularly with MRSA infections 
[291-293] and evidence for inadequate immune responses following infection [294-297]  
may be insurmountable challenges to finding a broadly-effective vaccine for S. aureus.   
Because vaccine results obtained with mice, rats and rabbits do not predict human 
immunity, animal studies cannot be improved for vaccine development [298]. As all of the 
failed S. aureus vaccines tested to date in humans [230,299-301] have shown reductions in 
bacterial burdens and even protection from lethality [302,306] in many animal models, it is 
clear these models have no predictive capacity for effectiveness in humans. Therefore, 
animal and human susceptibility and the course of S. aureus infections are just too damn 
different from lab animals, and few other animals are routinely available to study vaccines.     
Overall, developing a universal vaccine for S. aureus is a top priority but to date we 
have only had failures in human clinical trials. Given the plethora of bacterial virulence 
factors, broad range of humans at-risk for infections, lack of any information regarding 
immune effectors mediating protection for any manifestation of S. aureus infection and 
overall competence of this organism as a colonizer, commensal and pathogen, it seems that 
getting a universal vaccine will be a very difficult task.  
This text was adapted from [239,285,286,307].  
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1.5. Glutamate racemase, D-amino acid transaminase and the 
mechanism of peptidoglycan formation 
The bacterial cell wall is a highly cross-linked polymeric structure consisting of 
repeating peptidoglycan units of disaccharides (joined in β1-4 linkage) which contain a 
novel pentapeptide substitution [308]. Cross-linking occurs through transpeptidation of the 
peptide linkages between adjacent glycan strands resulting a structural mesh that acts as a 
cellular skeleton that protects the cell from rupture due to the osmotic pressure gradient. 
Inhibition of cell wall production renders the bacteria susceptible to lysis by osmotic 
pressure and inhibitors that target this pathway are generally bactericidal.  
The conversion of glucosamine-1-phosphate to UDP-N-acetylglucosamine (UDP-
GlcNAc) is the first committed step to peptidoglycan synthesis and culminates with the 
production of UDP-N-acetyl muramic acid-pentapeptide (UDP-MurNAc-pentapeptide) (Fig. 
12). A key feature of the peptidoglycan is the incorporation of D-amino acids, D-glutamate 
(D-Glu) by the ligase MurD and D-alanine (D-Ala) as a dipeptide formed by D-Ala-D-Ala 
ligase, which is a substrate of the ligase MurF. It is presumed that these unusual residues 
provide a defense against hydrolysis of the bacterial capsule, as host proteases are unable 
to recognize sequences containing D-amino acid residues. While there is some variation in 
the peptide composition of the pentapeptide intermediate, incorporation of D-Glu as the 
second amino acid is strictly conserved across the bacterial kingdom [308]. 
Glutamate racemase (MurI), a member of the co-factor-independent, two-thiol-
based family of amino acid racemases that converts L-glutamate (L-Glu) to D-Glu, has been 
implicated in the production and maintenance of sufficient D-Glu pool levels required for 
the early phases of peptidoglycan biosynthesis. This enzyme was the subject of four 
decades of research, and it is now evident that it is conserved and essential for growth 
across the bacterial kingdom. 
Using the mutant strain WM355 of Escherichia coli [309], which requires D-Glu for 
growth, MurI activity was unambiguously assigned to an open reading frame encoding a 
protein of 289 amino acids in the 90 min region of the chromosome, near the murA and 
murB genes, but quite distant from the remaining Phase I peptidoglycan biosynthetic genes 
[310]. Disruption of this gene, denoted murI, was found to alter the peptidoglycan 
precursor pool distribution and ultimately lead to cellular lysis [311]. Subsequent studies 
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confirmed the essentiality of murI for cellular growth through more detailed genetic 
dissection of the WM335 mutant strain [312].  
D-amino acid transaminase (Dat) is the enzyme that catalyzes the conversion of D-
Ala to D-Glu. Dat activity is found in various Gram-positive bacteria, including Bacillus [313-
315], Staphylococcus [316] and Listeria [317].  
The dawn of the genomic era rapidly established the presence of MurI in all species 
of bacteria encoding a cell wall and its essential role in peptidoglycan biosynthesis has been 
confirmed in species spanning the bacterial kingdom, including Gram-positive bacteria that 
encode the Dat pathway for D-Glu production [318-321]. Furthermore, the Dat gene in S. 
aureus has shown to be non-essential based on a high frequency of transposon insertions 
mapped through the gene encoding this activity [318].   
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Figure 12 | Schematic of Phase I peptidoglycan biosynthesis. MurI and Dat are depicted in 
violet. Adapted from [308].  
 
 
 
 
1. BACKGROUND     
58 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
59 
 
 
 
 
 
 
2. HYPOTHESIS AND OBJECTIVES               
 
 
 
 
 
 
 
 
 
60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
61 
 
2. HYPOTHESIS AND OBJECTIVES 
D-Glu is an essential component of bacterial peptidoglycan and is found in the cell 
wall of virtually all bacteria [308]. Earlier work suggests that MurI, enzyme that converts L-
Glu to D-Glu for the synthesis of peptidoglycan, can be targeted for antibiotic development 
[322,323]. However, it is worth noting that none of the previous work proposed the 
usefulness of MurI mutants as live attenuated bacterial vaccines.  
Here it is proposed a novel platform for the generation of effective live attenuated 
bacterial vaccines composed of D-Glu auxotrophic strains, which can be obtained through 
the inactivation of the gene (or genes) encoding MurI and also the gene (or genes) coding 
for Dat capable of catalysing the interconversion of D-Ala to D-Glu (Fig. 13). It was 
hypothesized that the strict requirement of sufficient D-Glu pool levels impairs the correct 
replication of D-Glu auxotrophic bacteria in the mammal host, and this could result in a 
remarkable level of attenuation and high effectiveness of these strains as whole-cell 
vaccines.  
 
 
Figure 13 | D-Glu auxotrophy is achieved by inactivation of D-Glu producing enzymes. A, 
Sequence of metabolic processes culminating in the formation of D-Glu and the 
incorporation in the bacterial peptidoglycan. B, Cell wall structure of a Gram-negative 
bacterium (non-depicted lipopolysaccharides and proteins). C, Cell wall structure of a Gram-
positive bacterium (non-depicted teichoic acids and proteins). PG: peptidoglycan. OM: 
outer membrane. IM: inner membrane. M: cytoplasmic membrane. 
 
(A) 
(B) 
(C) 
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Further, the emergence of MDR-A. baumannii, MDR-P. aeruginosa and MRSA and 
the lack of licensed vaccines against these pathogens has resulted in significantly increased 
mortality rates with limited or no options for therapeutic interventions [121,285,286].  
Hence, by creating MurI– (and MurI–Dat–) mutants, we took advantage of this 
technology to create three prototypes of experimental vaccines against A. baumannii, P. 
aeruginosa and S. aureus using D-Glu auxotrophic strains. Once obtained, we demonstrated 
their reliable efficacy as live vaccines in a mouse model of acute lethal infection. More 
importantly, we demonstrated that this strategy has potential application to any bacterial 
pathogen.  
 
In this Doctoral Thesis, the following objectives were established: 
• Obtain MurI– mutants of A. baumannii and P. aeruginosa, auxotrophic for 
D-Glu; 
• Obtain a MurI–Dat– mutant of S. aureus, auxotrophic for D-Glu; 
• Characterize MurI– or MurI–Dat– mutants of A. baumannii, P. aeruginosa 
and S. aureus at the phenotypic and ultrastructural level; 
• Optimize and implement models of acute lethal infection for testing wild-
type A. baumannii, P. aeruginosa and S. aureus strains, in BALB/c and 
C57BL/6 mice; 
• Estimate the level of attenuation of MurI– or MurI–Dat– mutants using the 
previously optimized model of acute lethal infection; 
• Determine the immunogenic potential of MurI– or MurI–Dat– mutants used 
as vaccines, by measuring IgM and IgG immunoglobulins and exploring the 
nature of T cell responses generated in the vaccinated individuals;  
• Examine the cross-reactivity of IgG antibodies produced against 
heterologous strains not included in the vaccine compositions; 
• Determine anti-A. baumannii, -P. aeruginosa and -S. aureus vaccine efficacy 
against acute lethal infection by challenging vaccinated mice with several 
genetically and epidemiologically unrelated bacterial isolates, including 
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multidrug-resistant, virulent and high-risk clones such as S. aureus 
USA300LAC; 
• Evaluate the protection conferred by the passive transfer of antibodies to 
naïve mice, obtained from mice administered these vaccines;   
• Exploit alternative routes of vaccine administration;  
• Assess in vivo safety of D-Glu auxotrophic bacterial vaccines through   
monitoring blood clearance of MurI– or MurI–Dat– mutants once 
administered to mice; 
• Assess environmental safety of D-Glu auxotrophic bacterial vaccines 
through evaluation of phenotypic stability and persistence of MurI– or 
MurI–Dat– mutants, when compared to their wild-type homologues. 
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3. MATERIALS AND METHODS 
3.1. Bacterial strains, growth conditions and reagents 
All bacterial strains and plasmids used in this study are listed in Table 5. We 
selected A. baumannii ATCC 17978, P. aeruginosa PAO1 and S. aureus 132 for genetic 
manipulation to generate the indicated mutant strains, creating mutant derivatives with in-
frame deletions in MurI or MurI plus Dat coding genes. A. baumannii ATCC 17978 and P. 
aeruginosa PAO1 are reference strains. S. aureus 132 is an MRSA strain isolated from a 
patient at the Microbiology Department of the Clínica Universitaria de Navarra (Pamplona, 
Spain). This strain is able to produce alternative biofilm matrix depending on environmental 
conditions consisting of proteins or exopolysaccharides [324]. All E. coli, A. baumannii and 
P. aeruginosa strains were grown in Luria-Bertani broth (LB: 10 g/L tryptone, 5 g/L yeast 
extract, 10 g/L sodium chloride) or on LB agar at 37 ºC unless otherwise stated. S. aureus 
strains were grown in Tryptic Soy Broth (TSB) or in TSB agar at 37 ºC unless otherwise 
stated. Ampicillin, kanamycin, gentamycin and erythromycin, when appropriate for plasmid 
selection, were added at a concentration of 100, 50, 30 and 10 µg/mL, respectively. X-Gal 
(5-bromo-4-chloro-3-indolyl β-D-galactopyranoside) was used at a concentration of 150 
µg/mL. All primers and chemicals were purchased from Sigma-Aldrich, unless mentioned. 
 
Table 5 | Strains and plasmids used in the present work. 
 
Strain or plasmid Relevant features Source or reference 
A. baumannii strains   
ATCC 17978 Reference strain ATCC 
ATCC 17978 ΔmurI1 ATCC 17978 derivative, ΔA1S_0380 This study 
ATCC 17978 ΔmurI2 ATCC 17978 derivative, ΔA1S_3398 This study 
ATCC 17978 ΔmurI1 ΔmurI2 
ATCC 17978 derivative, ΔA1S_0380 
ΔA1S_3398  
This study 
ATCC 19606 Reference strain Laboratory collection 
AbH12O-A2 
Multidrug-resistant clinical isolate 
from an outbreak, Spain, 2006-2008 
[325]  
Ab307-0294 
Encapsulated clinical isolate from 
blood, Buffalo, NY, 1994 
[326] 
P. aeruginosa strains   
PAO1 Reference strain CECT 
PAO1 ΔmurI PAO1 derivative, ΔPA4662 This study 
PA14 
Hypervirulent strain from burn 
infection 
[327] 
PA21_ST175 Multidrug-resistant high-risk clone  [328] 
PA12142 
Liverpool epidemic strain isolate 
from a CF patient  
[329] 
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Table 5 (cont.) | Strains and plasmids used in the present work. 
 
Strain or plasmid Relevant features Source or reference 
P. aeruginosa strains   
PA51441321 
A Coruña Hospital isolate from 
bronchiectasis patient; MemR, FepR 
Laboratory collection 
PA51442390 
A Coruña Hospital isolate from a CF 
patient; mucoid phenotype; MemR 
Laboratory collection 
LES400 
Liverpool epidemic strain from a CF 
patient with chronic infection 
[330] 
LES431 
Liverpool epidemic strain from a 
non-CF parent with pneumonia 
[330] 
PA28562 
A Coruña Hospital isolate from 
bronchiectasis patient; mucoid 
phenotype; 
Laboratory collection 
E. coli strains   
S17-1 
recA–, thi–, pro–, hsdR– (RP4-2Tc::Mu 
Km::Tn7) 
[331] 
TG1 
supE thi-1 Δ(lac-proAB) Δ(mcrB-
hsdSM)5, (rK–mK–)[F’ traD36 proAB 
lacIqZΔM15] 
[332] 
DC10β 
Δdcm in the DH10B background  
[F- mcrA Δ(mrr-hsdRMS-mcrBC) 
Φ80dlacZΔM15 ΔlacX74 endA1 recA1 
deoR Δ(ara,leu)7697 araD139 galU 
galK nupG rpsL λ-] 
[333] 
S. aureus strains   
132 MRSA clinical isolate [324] 
132 ΔmurI  132 derivative, ΔmurI This study 
132 Δdat 132 derivative, Δdat This study 
132 ΔmurI Δdat  132 derivative, ΔmurI Δdat This study 
132 Δspa 
132 derivative, Δspa protein A-
deficient 
[324] 
RN4220 
restriction-deficient NCTC 8325 
derivative, rsbU-, agr- 
[334] 
FPR3757 (USA300LAC) 
Community-acquired MRSA strain 
from wrist abscess; USA300 epidemic 
clone 
[335] 
RF122 
ST151 and CC151 strain from bulk 
milk (Ireland) 
[336] 
ED133 (formerly 1174) 
ST133 and CC133 strain from ovine 
mastitis (France) 
[337] 
ED98 
ST5 and CC5 strain from broiler 
chicken (skeletal infection, United 
Kingdom) 
[338] 
Plasmids   
pMo130 
KmR; oriT+ sacB+ xylE+, gene 
replacement vector for allelic 
exchange in Burkholderia; ColE1 ori 
[339] 
pEX18Gm 
GmR; oriT+ sacB+, gene replacement 
vector with MCS from pUC18 
[340] 
pMAD 
AmpR; EryR, bgaB+, E. coli/S. aureus 
shuttle vector that is temperature –
sensitive in S. aureus 
[341] 
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3.2. Construction of A. baumannii MurI–, P. aeruginosa PAO1 MurI– and 
S. aureus MurI–Dat– mutants 
Mutant alleles, designated ΔmurI1 and ΔmurI2 in A. baumannii ATCC 17978, ΔmurI 
in P. aeruginosa PAO1, and ΔmurI and Δdat in S. aureus 132 with in-frame deletions 
corresponding to murI1, murI2, murI, murI and dat genes were constructed. These mutant 
alleles were replaced, either singly or together, by the corresponding wild-type alleles using 
the previously described allelic exchange systems with the pMo130, pEX18Gm and pMAD 
plasmids in A. baumannii, P. aeruginosa and S. aureus, respectively. Primers used are listed 
in Table 6. Restrictions enzymes, GoTaq DNA polymerase and T4 DNA Ligase were 
purchased from Promega (Biotech Ibérica, SL) and used as recommended by the supplier. 
The Expand High Fidelity PCR System was obtained from Roche (Roche Farma, S.A.). 
Plasmid DNA isolation from E. coli was achieved using the Wizard Plus SV Minipreps DNA 
Purification System, from Promega or the Plasmid Midi Kit, from Qiagen (IZASA, S.A.). 
Genomic DNA from A. baumannii and P. aeruginosa was obtained using the High Pure PCR 
Template Preparation Kit, from Roche. Genomic DNA from S. aureus was obtained using the 
Wizard Genomic DNA Purification Kit, from Promega. Electrotransformation of A. 
baumannii, E. coli, P. aeruginosa and S. aureus was performed according to the Gene Pulser 
Xcell Electroporation System instructions, Biorad (Bio-Rad Laboratories, S.A.) or protocols 
described elsewhere [333]. The GeneRuler 1 kb Plus DNA Ladder (Thermo Fisher Scientific) 
was used as molecular weight marker.   
 
Table 6 | Oligonucleotides designed for the present work. 
 
Analysis, 
gene or primer 
Orientation Primer sequence (5’-3’) 
  Unmarked deletion of A. baumannii murI1 and murI2 genes 
UP_murI1(NotI) Forward cccgcggccgcggggtcctgcacctacgatga 
UP_murI1(BamHI) Reverse cccggatccgggacctccaatacctgaatc 
DOWN_murI1(BamHI) Forward cccggatccggggctctgttgtaggcattc 
DOWN_murI1(SphI) Reverse cccgcatgcgggcatccttgtgattgcatt 
UP_murI2(NotI)II Forward cccgcggccgcgggttggtcaggtccttgttg 
UP_murI2(BamHI)II Reverse cccggatccgggtacagccgtcatggtgtt 
DOWN_murI2(BamHI) Forward cccggatccgggacgcgtttacctgtagaa 
DOWN_murI2(SphI) Reverse cccgcatgcgggagcggtacaactaattgg 
EXTfw_murI1 Forward gcaattaggcacttgagg 
EXTrv_murI1 Reverse atacgctcaggttgcatc 
INTfw_murI1 Forward agcctatgttccgtatgg 
INTrv_murI1 Reverse tcaaccagtgtgaattgg 
EXTfw_murI2 Forward ccgattggaatgattgac 
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Table 6 (cont.) | Oligonucleotides designed for the present work. 
 
Analysis, 
gene or primer 
Orientation Primer sequence (5’-3’) 
  Unmarked deletion of A. baumannii murI1 and murI2 genes 
EXTrv_murI2 Reverse agagcattctggtcgaag 
INTfw_murI2 Forward tagcaatagaaccagcgg 
INTrv_murI2 Reverse ttgtgccgttacagcttc 
  Unmarked deletion of P. aeruginosa murI gene 
UP_murI(HindIII)II Forward cccaagcttgggggcaatccgccgtatatc 
UP_murI(NotI) Reverse cccgcggccgcgggggcgttgcccgcagacgg 
DOWN_murI(NotI) Forward cccgcggccgcgggtcgttcctggcagacgtg 
DOWN_murI(XbaI) Reverse ccctctagagggtccgctctcgcagtccga 
EXTfw_murI Forward gtatcggcaaggtggagt 
EXTrv_murI Reverse gaatggcttgatcgagtc 
INTfw_murI Forward atccgaatcgttgctcta 
INTrv_murI Reverse acaatacgcgctccagct 
 Unmarked deletion of S. aureus murI and dat genes  
UP_murI(MluI) Forward cccacgcgtgggccgaaacaaaaaacagta 
UP_murI(NotI) Reverse cccgcggccgcgggattcggtcatccttactt 
DOWN_murI(NotI) Forward cccgcggccgcggggaggatttttaatgaaag 
DOWN_murI(BglII) Reverse cccagatctgggtttcttccattgaacttc 
UP_dat(MluI) Forward cccacgcgtgaaacgtattcatatgat 
UP_dat(NotI) Reverse cccgcggccgcatattattcctccacgca 
DOWN_dat(NotI) Forward cccgcggccgcaattctttcatcatattt 
DOWN_dat(BglII) Reverse cccagatctgcgaatctaaactcggta 
EXTfw_murI Forward gcttgccctaaaggtattcc 
EXTrv_murI Reverse gggccactcatacttatgac 
INTfw_murI Forward tgtcggaggtttgacagtag 
INTrv_murI Reverse ctaacttcacgagccgtttc 
EXTfw-seq-UP_murI Forward atgactgaacaatcagtgaa 
EXTrv-seq-DOWN_murI Reverse tgatggtgccatgtaaagtt 
EXTfw_dat Forward gtcatgggtgacgtgacaac 
EXTrv_dat Reverse gcaccacctgctgaatcaag 
INTfw_dat Forward tattcaagcaacgcgtggtg 
INTrv_dat Reverse agttgacgtgtaattgggcc 
EXTfw-seq-UP_dat Forward gccggttgtaacagaagatg 
EXTrv-seq-DOWN_dat Reverse caattgccgggtctgcaatc 
 
3.2.1. A. baumannii ATCC 17978 ΔmurI1, ATCC 17978 ΔmurI2 and 
ATCC 17978 ΔmurI1 ΔmurI2 mutants   
In detail, A. baumannii DNA fragments of about 1 kb corresponding to the 
upstream and downstream regions of murI1 and murI2 were amplified by PCR with the 
combination of primers UP_murI1(NotI)/UP_murI1(BamHI), 
DOWN_murI1(BamHI)/DOWN_murI1(SphI), UP_murI2(NotI)II/UP_murI2(BamHI)II and 
DOWN_murI2(BamHI)/DOWN_murI2(SphI). The upstream fragments obtained were 
digested with NotI and BamHI restriction enzymes; downstream fragments were digested 
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with BamHI and SphI. Digested products were ligated into pMo130 (Fig. 14), which was 
previously linearized with NotI and SphI and the recombinant plasmids 
pMo130_UP/DOWN_murI1 and pMo130_UP/DOWN_murI2 obtained were independently 
transformed in E. coli S17-1 by electroporation. S17-1 transformants were selected on LB 
containing kanamycin, sprayed with pyrocatechol, and only yellow colonies expressing the 
xylE reporter gene were analyzed by PCR to confirm the presence of the recombinant 
plasmids, that were then individually introduced in A. baumannii ATCC 17978 by 
electroporation. A. baumannii bright yellow and kanamycin-resistant colonies, representing 
the first crossover event, were grown on LB supplemented with 15% sucrose for 6 hours, 
and then plated on the same agar medium. The resulting white colonies (after spraying 
with pyrocatechol) were analyzed by PCR (using the combination of primers 
EXTfw_murI1/EXTrv_murI1, EXTfw_murI2/EXTrv_murI2, INTfw_murI1/INTrv_murI1, 
INTfw_murI2/INTrv_murI2) to confirm the second crossover event resulting in ΔmurI1 and 
ΔmurI2 genotypes, produced by the allelic exchange of plasmids 
pMo130_UP/DOWN_murI1 and pMo130_UP/DOWN_murI2 with the murI1 and murI2 
alleles, respectively (Fig. 15). The pMo130_UP/DOWN_murI2 plasmid was also introduced 
in the ATCC 17978 ΔmurI1 mutant previously obtained, by electroporation. Transformant 
bright yellow and kanamycin-resistant colonies, were then grown on LB containing 15% 
sucrose and supplemented with 10 mM D-Glu for 6 hours, and plated on the same agar 
medium. The resulting white colonies (after spraying with pyrocatechol) were picked from 
agar plates containing 10 mM D-Glu and inoculated in patches at comparable locations on 
LB agar plates with and without 10 mM D-Glu. Presumptive colonies with the ΔmurI1 
ΔmurI2 double mutant genotype that grew only on D-Glu containing plates, were analyzed 
by PCR using the primers EXTfw_murI2/EXTrv_murI2 and INTfw_murI2/INTrv_murI2 to 
confirm the second crossover event, produced by the allelic exchange of plasmid 
pMo130_UP/DOWN_murI2 with the murI2 allele.  
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Figure 14 | Map of the pMo130 gene replacement vector. The locations of genes, their 
transcriptional orientations and the restriction sites of the MCS1 and MCS2, in clockwise 
order, are shown. pMo130 carries a neomycin-kanamycin resistance cassette (NeoR/KmR), a 
sucrose counter-selectable marker (sacB), an origin of transfer (oriT) for conjugation-
mediated plasmid transfer, a pBR322 origin of replication from ColE1, MCS1, the reporter 
gene xylE and MCS2. MCS, multiple cloning site. Plasmid drawn to scale. Adapted from 
[339]. 
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Figure 15 | Allelic exchange of pMo130_UP/DOWN_murI1 with chromosomic DNA to 
construct a murI1 deletion in A. baumannii ATCC 17978. DNA fragments upstream and 
downstream the murI1 gene are cloned into pMo130 MCS2 to generate 
pMo13_UP/DOWN_murI1. pMo13_UP/DOWN_murI1 is introduced into A. baumannii 
through transformation and co-integrants are recovered by kanamycin selection and 
screening for xylE positive yellow colonies. Resolved co-integrants are recovered by sucrose 
counter-selection and screening for xylE negative white colonies. Colonies are analyzed by 
PCR to distinguish deletion mutants from wild-type isolates. Adapted from [339].       
              
3.2.2. P. aeruginosa PAO1 ΔmurI mutant   
For P. aeruginosa, DNA fragments of about 1 kb in length corresponding to the 
upstream and downstream regions of the murI gene were amplified by PCR with the 
combination of primers UP_murI(HindIII)II/UP_murI(NotI) and 
DOWN_murI(NotI)/DOWN_murI(XbaI). The upstream fragment obtained was digested with 
HindIII and NotI restriction enzymes; the downstream fragment was digested with NotI and 
XbaI. Digested products were ligated into pEX18Gm (Fig. 16), which was previously 
linearized with HindIII and XbaI and the recombinant plasmid pEX18Gm_UP/DOWN_murI 
obtained was transformed in E. coli S17-1 by electroporation. S17-1 transformants were 
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selected on LB containing gentamycin and were analyzed by PCR to confirm the presence of 
the recombinant plasmid, which was then introduced in P. aeruginosa PAO1 by 
electroporation. P. aeruginosa gentamycin-resistant colonies, representing the first 
crossover event, were grown on LB containing 15% sucrose and 10 mM D-Glu for 6 hours, 
and plated on the same agar medium. The resulting colonies were picked from agar plates 
containing 10 mM D-Glu and inoculated in patches at comparable locations on LB agar 
plates with and without 10 mM D-Glu. Presumptive colonies with the ΔmurI mutant 
genotype that grew only on D-Glu containing plates, were analyzed by PCR using the 
primers EXTfw_murI/EXTrv_murI and INTfw_murI/INTrv_murI to confirm the second 
crossover event, produced by the allelic exchange of plasmid pEX18Gm_UP/DOWN_murI 
with the murI allele (Fig. 17).  
 
 
 
Figure 16 | Map of the pEX18Gm gene replacement vector. The locations of genes, their 
transcriptional orientations and the restriction sites of the MCS, in clockwise order, are 
shown. pEX18Gm carries a gentamycin resistance cassette (GmR), a pUC origin of replication 
from ColE1, a MCS from pUC18, an origin of transfer (oriT) for conjugation-mediated 
plasmid transfer and a sucrose counter-selectable marker (sacB). MCS, multiple cloning site. 
Plasmid drawn to scale. Adapted from [340].      
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Figure 17 | Allelic exchange of pEX18Gm_UP/DOWN_murI with chromosomic DNA to 
construct a murI deletion in P. aeruginosa PAO1. DNA fragments upstream and 
downstream the murI gene are cloned into pEX18Gm MCS to generate 
pEX18Gm_UP/DOWN_murI. pEX18Gm_UP/DOWN_murI is introduced into P. aeruginosa 
through transformation and co-integrants are recovered by gentamycin selection. Resolved 
co-integrants are recovered by sucrose counter-selection. Colonies are analyzed by PCR to 
distinguish deletion mutants from wild-type isolates.  
 
3.2.3. S. aureus 132 ΔmurI, 132 Δdat and 132 ΔmurI Δdat mutants   
For S. aureus, DNA fragments of 1 kb corresponding to the upstream and 
downstream flanking regions of murI and dat genes were amplified by PCR using primers 
UP_murI(MluI)/UP_murI(NotI), DOWN_murI(NotI)/DOWN_murI(BglII), 
UP_dat(MluI)/UP_dat(NotI) and DOWN_dat(NotI)/DOWN_dat(BglII), and next digested by 
the restriction enzymes indicated within brackets. Digested products were ligated into 
pMAD (Fig. 18), previously linearized with MluI and BglII. The resulting 
pMAD_UP/DOWN_murI and pMAD_UP/DOWN_dat plasmids were confirmed by 
sequencing and independently transformed by electroporation into E. coli TG1 and DC10β, 
respectively. For the allelic exchange of pMAD_UP/DOWN_murI with the murI allele, the 
recombinant plasmid was transformed in S. aureus RN4220 and then in S. aureus 132 by 
electroporation. For the allelic exchange of pMAD_UP/DOWN_dat with the dat allele, the 
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recombinant plasmid was directly introduced into S. aureus 132 from E. coli DC10β. 
Homologous recombination experiments were performed as follows: one blue 
erythromycin-resistant colony of S. aureus containing pMAD_UP/DOWN_murI or 
pMAD_UP/DOWN_dat was grown in TSB with erythromycin at 30 ºC for 2 hours and then, 
at 43.5 ºC, a non-permissive temperature for pMAD replication. Resulting cultures were 
serially diluted and light blue erythromycin-resistant colonies, representing the first 
crossover event, were selected at 43.5 ºC in TSB plates with erythromycin and X-Gal. 
Several of these colonies were grown in TSB without antibiotic at 30 ºC for 18 hours, and 
then plated on the same agar medium. The resulting white colonies were analyzed by PCR 
and sequencing (using the combination of primers EXTfw_murI/EXTrv_murI, 
INTfw_murI/INTrv_murI, EXTfw-seq-UP_murI/EXTrv-seq-DOWN_murI, 
EXTfw_dat/EXTrv_dat, INTfw_dat/INTrv_dat and EXTfw-seq-UP_dat/EXTrv-seq-DOWN_dat, 
designed for S. aureus) to confirm the ΔmurI and Δdat genotypes produced by the allelic 
exchange of plasmids pMAD_UP/DOWN_murI (Fig. 19) and pMAD_UP/DOWN_dat with the 
murI and dat alleles, respectively. pMAD_UP/DOWN_dat plasmid was also introduced by 
electroporation in the 132 ΔmurI mutant. Transformant blue erythromycin-resistant 
colonies were firstly grown in TSB at 30 ºC and then, at 43.5 ºC to obtain colonies resulting 
from the first crossover. Several of these colonies were transferred to TSB with 10 mM D-
Glu, incubated at 30 ºC for 18 hours, and then plated on the same agar medium. The 
resulting white colonies were picked and inoculated in patches at comparable locations on 
TSB agar plates with and without 10 mM D-Glu. Presumptive colonies with the ΔmurI Δdat 
double mutant genotype that grew only with D-Glu were confirmed for the second 
crossover event, produced by the allelic exchange of the plasmid pMAD_UP/DOWN_dat 
with the dat allele, by PCR and sequencing using the primers EXTfw_dat/EXTrv_dat, 
INTfw_dat/INTrv_dat and EXTfw-seq-UP_dat/EXTrv-seq-DOWN_dat. 
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Figure 18 | Map of the pMAD gene replacement vector. The locations of genes, their 
transcriptional orientations and the restriction sites of the MCS, in clockwise order, are 
shown. pMAD carries a pE194ts::ermC thermosensitive pE194 replication origin with an 
erythromycin resistance gene (ermC), a MCS and a bgaB gene encoding a thermostable β-
galactosidase, allowing the easy screening of transformants on X-Gal. MCS, multiple cloning 
site. Plasmid drawn to scale. Adapted from [341]. 
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Figure 19 | Allelic exchange of pMAD_UP/DOWN_murI with chromosomic DNA to 
construct a murI deletion in S. aureus 132. DNA fragments upstream and downstream the 
murI gene are cloned into pMAD MCS to generate pMAD_UP/DOWN_murI. 
pMAD_UP/DOWN_murI is introduced into S. aureus through transformation and co-
integrants grown at 43.5 ºC, a non-permissive temperature for plasmid replication, are 
recovered by screening for light blue colonies, derived from bgaB expression on X-Gal agar 
plates, and erythromycin resistance, conferred by ermC. Resolved co-integrants are 
recovered by screening for white colonies grown on X-Gal agar plates at 30 ºC, a permissive 
temperature for plasmid replication which leads to plasmid excision. Colonies are analyzed 
by PCR to distinguish deletion mutants from wild-type isolates. Adapted from [341]. 
 
3.3. Growth and viability curves   
To determine the growth and viability of A. baumannii ATCC 17978, P. aeruginosa 
PAO1, and derived mutant strains, these bacterial strains were cultured overnight at 37 ºC 
and 180 rpm in 5 mL LB supplemented with 10 mM D-Glu. Bacterial cultures were 
centrifuged (4,000 g, 15 min) and the pellets were washed twice with LB. After pellet 
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suspension in 5 mL LB, 100 µL were used to inoculate 100 mL of LB with or without 10 mM 
D-Glu and left incubating at 37 ºC under agitation (180 rpm). For A. baumannii ATCC 17978 
and derived mutants, samples were taken every 60 min for 7 hours to determine the 
culture turbidity (OD600nm). In parallel, samples were taken every 2 hours up to 6 hours to 
determine CFU (colony-forming units) in LB agar with 10 mM D-Glu. For P. aeruginosa PAO1 
and PAO1 ΔmurI, samples were taken at 0, 60, 180, 300, 480 and 1,320 min to determine 
the culture turbidity (OD600nm). In parallel, samples were taken at 0, 180, 480 and 1,320 min 
to determine CFU in LB agar with 10 mM D-Glu. In the case of S. aureus, overnight cultures 
of S. aureus 132, 132 ΔmurI, 132 Δdat and 132 ΔmurI Δdat were centrifuged (3,900 g, 20 
min) and the pellets washed once with TSB. After pellet suspension, cultures adjusted to 
OD600nm = 2 were used to inoculate 100 mL of TSB with or without 20 mM D-Glu (×10-2 
dilution) and left incubating at 37 ºC under agitation (180 rpm). Samples were taken at 0 
and every 60 min up to 8 hours to determine the culture turbidity (OD600nm). In parallel, 
samples were taken at 0, 120, 240, 360 and 480 min to determine CFU in TSB agar with 10 
mM D-Glu for 132 ΔmurI Δdat or without D-Glu for the remaining strains. All cultures were 
made in triplicate. 
 
3.4. Real-time RT-PCR  
We used quantitative real-time reverse transcription PCR (qRT-PCR) to examine A. 
baumannii ATCC 17978, ATCC 17978 ΔmurI1, ATCC 17978 ΔmurI2 and ATCC 17978 ΔmurI1 
ΔmurI2 strains for the expression of murI1 and murI2 genes; P. aeruginosa PAO1, PAO1 
ΔmurI strains for the expression of murI gene; in turn, S. aureus 132, 132 ΔmurI, 132 Δdat 
and 132 ΔmurI Δdat strains for the expression of murI and dat genes, using the Universal 
Probe Library (UPL) TaqMan probes (Roche) or TaqMan probes specifically designed (TIB 
MOLBIOL, Germany) together with the primers listed in Table 7. Total DNase-treated RNA 
(500 ng for A. baumannii and 100 ng for P. aeruginosa and S. aureus) was obtained from 
log-phase cultures (OD600nm = 0.5 to 0.7) using the High Pure RNA Isolation Kit (Roche). For 
qRT-PCR, a LightCycler 480 RNA instrument and Master hydrolysis probes kit (both from 
Roche) were used together with the following protocol: initial incubation at 65 ºC, 3 min, 
followed by a denaturation step at 95 ºC for 30 s, 45 cycles at 95 ºC, 15 s and 60 ºC, 45 s, 
and a final elongation step at 40 ºC, 30 s. In all cases, the expression levels were normalized 
relative to the transcription levels of gyrB (A. baumannii and S. aureus) and proC (P. 
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aeruginosa) housekeeping genes, which were assigned a value of 1.0. All assays were 
performed using samples from three different RNA extractions. 
 
Table 7 | Oligonucleotides and probes used for qRT-PCR. 
 
Analysis, gene and primer Orientation Primer sequence (5’-3’) 
UPL 
probe 
A. baumannii qRT-PCR   
gyrB (A1S_0004) 
Forward tctctagtcaggaagtgggtacatt 
76 
Reverse ggttatattcttcacggccaat 
murI1 (A1S_0380) 
Forward ggcactaaaacctgccgtat 
145 
Reverse catctttaatgagttgtccacga 
murI2 (A1S_3398) 
Forward gcaatgactttgagcaagca 
87 
Reverse aactttttaagtttttgcccttc 
P. aeruginosa qRT-PCR   
proC (PA0393) 
Forward cttcgaagcactggtggag 
20 
Reverse ttattggccaagctgttcg 
murI (PA4662) 
Forward gagcggatcggtgatttc 
50 
Reverse attgcaggccagtaccagag 
S. aureus qRT-PCR     
gyrB 
Forward cggtggcggatacaaagt 
131 
Reverse gcgtttacaactgatgaacca 
murI 
Forward cagcaactgctgtagctttagaat 
118 
Reverse gcacctggttcaattacgc 
dat 
Forward tggtgtagctgaaaggaatcatagc - (*) 
Reverse accatcggatatcttcaacgga - (*) 
(*) These primers were used with D-Ala P-Taqman probe 6FAM-tcccgacacctgaagtagaaccagca-BBQ 
(6FAM, 6-carboxyfluorescein; BBQ, BlackBerry Quencher). 
 
3.5. Scanning electron microscopy (SEM)  
In order to take microphotographs by SEM, A. baumannii ATCC 17978, ATCC 17978 
ΔmurI1 ΔmurI2, P. aeruginosa PAO1 and PAO1 ΔmurI strains were cultured overnight at 37 
ºC in 5 mL LB supplemented with 10 mM D-Glu. Bacterial cultures were centrifuged (4,000 
g, 15 min) and the pellets were washed twice with 0.9% NaCl. After pellet suspension in 5 
mL LB, 1 mL was used to inoculate 100 mL of LB. The cultures were incubated at 37 ºC for 2 
hours under agitation (180 rpm) and then centrifuged and washed twice with 0.9% NaCl. 
After pellet suspension in 100 mL LB, 50 µL were used to inoculate 5 mL of LB with D-Glu at 
0, 0.1, 1.25 and 10 mM. The cultures were incubated at 37 ºC under agitation (180 rpm) for 
2 hours and were subsequently centrifuged and washed twice with PBS. S. aureus 132 and 
132 ΔmurI Δdat strains were cultured overnight at 37 ºC in 5 mL of TSB supplemented with 
20 mM D-Glu. Bacterial cultures were centrifuged (3,900 g, 20 min) and the pellets were 
washed twice with 0.9% NaCl. After pellet suspension in 1 mL TSB, 50 µL of each suspension 
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were used to inoculate 5 mL of TSB with D-Glu at 0, 0.1, 1.5 and 20 mM. Then cultures were 
incubated at 37 ºC with shaking (180 rpm) for 3 hours and were subsequently centrifuged 
and washed twice with PBS. The pellets were then fixed with 4% paraformaldehyde in 0.1 
M PBS pH 7.4 for 30 min and washed again twice with PBS. Each sample was dehydrated in 
increasing series of ethanol (50%, 70%, 90% and 100%) for 10-15 min and then dried to the 
critical point with CO2 (Bal-Tec CPD 030). One drop of each sample was placed onto a slide 
cover and fixed in aluminium supports for gold coating (Bal-Tec SCD 004 sputter coater). 
Observation was conducted and photographs were taken using a Jeol JSM-6400 electron 
microscope. 
 
3.6. Transmission electron microscopy (TEM) 
In order to take microphotographs using TEM, A. baumannii ATCC 17978, ATCC 
17978 ΔmurI1 ΔmurI2, P. aeruginosa PAO1, PAO1 ΔmurI, S. aureus 132 and 132 ΔmurI Δdat 
strains were cultured overnight at 37 ºC in LB or TSB agar supplemented with 10 mM D-Glu. 
After incubation, 2-3 colonies of each strain were plated onto MH (Mueller Hinton), LB, LB 
supplemented with MgCl2 (30 mg/L) and CaCl2 (75 mg/L) and LB supplemented with 10 mM 
D-Glu agar and incubated overnight at 37 ºC. After incubation, 2-3 colonies obtained in the 
first streak of each plate were dissolved in PBS buffer, the suspension was centrifuged and 
the resulting pellet was washed first with cacodylate buffer, and immediately after that the 
cells were fixed in ice cold 2.5% glutaraldehyde prepared in 0.2 M sodium cacodylate 
buffer, pH 7.4 for 4 hours at room temperature. The pellets were then washed with 
cacodylate buffer, dehydrated in acetone and embedded in SPURR (Spurr’s Epoxy 
Embedding Medium). Ultrathin sections (70 nm) of these samples were obtained and they 
were stained with uranyl acetate and lead citrate for observation under a JEOL JEM 1010 
(80 kV) transmission electron microscope. 
 
3.7. Animal experiments 
All mice and rats were maintained in the specific pathogen-free (SPF) facility at the 
Centro Tecnológico de Formación de la Xerencia de Xestión Integrada A Coruña (CTF-
XXIAC), Servicio Galego de Saúde. All experiments were done with the approval of and in 
accordance with regulatory guidelines and standards set by the Comité Ético de 
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Experimentación Animal of CHUAC (Complejo Hospitalario Universitario A Coruña). Male 
and female mice were used for first time procedures between the ages of 6 and 8 weeks. 
BALB/c mice were bred in our colony and used for all experiments, unless noted. C57BL/6 
mice were purchased from Harlan Sprague Dawley Inc. Female Winstar rat were bred in our 
colony and used for first time procedures at 6 months of age. Studies were not blinded.   
3.7.1. Blood samples  
Blood samples were collected from the submandibular vein of anesthetized mice, 
and sera were separated from the blood cells by centrifugation (1,500 g, 15 min) and stored 
at –80 ºC until subsequent analysis. Blood samples from rats were collected by heart 
puncture and sera were obtained as before.  
3.7.2. Bacterial burden in tissues 
To assess bacterial burden in tissues, vaccinated and control mice were euthanized 
at indicated time points for each experiment, tissues were extracted aseptically, 
homogenized in sterile NaCl 0.9% and CFU enumerated by plating ×10-2-fold serial dilutions 
in agar plates.  
3.7.3. Inocula preparation for immunizations and infections 
To prepare inocula for active immunizations and infections, bacteria were cultured 
at 37 ºC under agitation (180-210 rpm) until reaching OD600nm = 0.7 (this inoculum was 
designated 1X, unless otherwise stated). The cultures were harvested by centrifugation, 
pellets washed twice, suspended and adjusted in sterile NaCl 0.9% according to the 
previous OD600nm to different doses (0.1X meaning as bacterial inocula diluted 1:10, 2X the 
bacterial inocula 2:1 concentrated, and so on…). Prior to mice inoculation, bacterial inocula 
were quantified by CFU enumeration in agar plates (Table 8).  
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Table 8 | Equivalents of bacteria dosage and CFU used for in vivo experiments. 
 
Bacteria Purpose Dose 
Inoculum 
(CFU/mouse) 
Related item 
A. baumannii strains     
ATCC 17978 
LD 1X 8×106 
Fig. 30 
LD 2X 3×107 
LD 2.5X 4×107 
LD 3X 4×107 
Challenge 4X 7×107 Fig. 46 
Blood clearance 1X 1×107 Figs. 55, 56 
ATCC 17978 ΔmurI1 ΔmurI2 
LD 
3X 1×108 
Fig. 30 
4X 2×108 
6X 2×108 
8X 3×108 
Vaccination 
1X 4×107 Figs. 31, 34 
0.000
1X 
4×103 Fig. 33 
Vaccination 
0.01X 7×105 
Fig. 32 
0.05X 2×106 
0.1X 3×106 
0.5X 2×107 
1X 9×107 
Blood clearance 1X 1×108 Figs. 55, 56 
AbH12O-A2 Challenge 4X 4×107 Fig. 46 
Ab307-0294 Challenge 0.75X 6×106 Fig. 46 
P. aeruginosa strains     
PAO1 
LD 
 
0.1X ∼6×106 
Fig. 30 
0.4X ∼2×107 
1X ∼6×107 
4X 2×108 
Challenge 0.4X 3×107 Fig. 47 
Blood clearance 0.4X 2×107 Fig. 55 
PAO1 ΔmurI1 
LD 
1X ∼1×108 
Fig. 30 
4X ∼4×108 
10X ∼1×109 
40X ∼4×109 
Vaccination 0.4X 2×107 Fig. 31 
Vaccination 
0.1X ∼1×107 
Fig. 32 
0.4X 4×107 
1X ∼1×108 
4X ∼4×108 
10X ∼1×109 
40X ∼4×109 
Blood clearance 0.4X 2×107 Fig. 55 
PA28562 Challenge 0.5X 4×107 Fig. 47 
PA14 Challenge 0.2X 4×106 Fig. 48 
∼, estimated values.  
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Table 8 (cont.) | Equivalents of bacteria dosage and CFU used for in vivo experiments. 
 
Bacteria Purpose Dose 
Inoculum 
(CFU/mouse) 
Related item 
S. aureus strains     
132 
LD 
0.05X 3-4×106 
Fig. 30 
0.5X 3-4×107 
1X 7×107 
2.5X 1-2×108 
Challenge  
0.5-
1X 
2-7×107 Figs. 45, 49, 50, 54 
Blood clearance 0.5X 5-6×107 Fig. 55 
 
132 ΔmurI Δdat 
LD 
1X 2×107 
Fig. 30 5X 8-9×107 
10X 1-2×108 
Vaccination 1X 2-3×107 
Figs. 31, 32, 34, 45, 
49, 50 
Vaccination 
0.2X 5-7×106 Fig. 32 
5X ∼7.5×107 Fig. 32 
10X 1-2×108 Figs. 32, 54 
Blood clearance 2.5X ∼6×107 Fig. 55 
USA300LAC Challenge 0.4X ∼6×107 Fig. 50 
RF122 Challenge 0.25X 2-3×107 Fig. 50 
ED98 Challenge 0.5X ∼1×107 Fig. 50 
∼, estimated values.  
 
In detail, A. baumannii ATCC 17978, ATCC 17978 ΔmurI1, ATCC 17978 ΔmurI2, ATCC 
17978 ΔmurI1 ΔmurI2, P. aeruginosa PAO1 and PAO1 ΔmurI were cultured in LB with 10 
mM D-Glu (D-Glu auxotrophic strains) and LB (remaining strains) at 37 ºC and 180 rpm, 
harvested (4,000 g, 15 min), washed twice with LB and finally adjusted with saline as above. 
For intraperitoneal (IP) and intramuscular (IM) injections of A. baumannii and P. aeruginosa 
strains, we used a total volume of 100 and 50 µL, respectively, and insulin syringes (29G × 
1/2 in., Becton Dickinson). The manual restrain of mice and syringe insertion are shown in 
Fig. 20. For PA28562 infection, bacterial pellet was suspended in NaCl 0.9% containing 3% 
of mucin from porcine stomach, type II. Mucin stock solution was solubilized in PBS at 6% 
w/v, sterilized by autoclaving for 10 min and rapidly cooled in ice. Exceptionally for P. 
aeruginosa PA28562, we used a 250 µL volume for infection. Independently of the bacterial 
strain administrated, mice were monitored for 7 days after injections. All challenges were 
made using the IP route of administration. To prepare inocula of S. aureus 132 and 132 
ΔmurI Δdat, these strains were grown in TSB or TSB with 20 mM D-Glu at 37 ºC and 210 
rpm until OD600nm = 0.7. For 132 ΔmurI Δdat, cultures were concentrated from OD600nm = 0.7 
to 0.8 in saline prior to washing steps. Then, bacterial cultures were then centrifuged (3,900 
g, 20 min), washed twice with sterile NaCl 0.9% and suspended in the same solution. For S. 
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aureus infections, we prepared inocula with 3% mucin (as described above). Both for 
immunizations and infections, mice were administered using the IP route with a total 
volume of 250 µL and, unless otherwise stated, monitored for morbidity and mortality for 
14 days after injections. When pertinent, mice challenged with S. aureus were weighed 
daily. For active immunization assays, mice were injected with D-Glu auxotrophic strains 
ATCC 17978 ΔmurI1 ΔmurI2, PAO1 ΔmurI1 or 132 ΔmurI Δdat at a 14-day interval with a 
total of two or three injections depending on the schedule. Control mice were 
administrated saline on parallel. Mice were challenged with bacterial strains 7 days after 
the last vaccine dose, unless otherwise stated.  
 
 
 
 
 
 
 
Figure 20 | Routes of administration used for injecting mice with bacterial inocula or 
saline. A, Administration of intraperitoneal (IP) injection to lower left quadrant. B, 
Intramuscular (IM) injection into the leg muscle. From [342]. 
 
3.7.4. Sera and passive immunizations  
To generate naïve and anti-A. baumannii serum (anti-Ab) to be used in passive 
immunizations before challenging mice with A. baumannii ATCC 17978, BALB/c mice (n = 
6/group) were administered three IP injections of ATCC 17978 ΔmurI1 ΔmurI2 (1X), or 
saline, at a 14-day interval. Blood was collected on days 36, 40 and 42; serum was pooled 
and titers of total IgG were determined by indirect ELISA. IP adoptive transfer of either 250 
µL anti-Ab (1:163,840) or naïve serum (1:40) was made in naïve mice (n = 8/group) 3.5 
hours prior to the challenge. To generate naïve and anti-P. aeruginosa serum (anti-Pa) to be 
used in passive immunizations before challenging mice with P. aeruginosa PAO1, BALB/c 
mice (n = 5/group) were administered two IP injections of PAO1 ΔmurI1 (0.4X), or saline, at 
a 12-day interval. Blood was collected on day 19; serum was pooled and IP adoptive 
transfer of either 200 µL anti-Pa or naïve serum was made in naïve mice (n = 8/group) 3.5 
(B) (A) 
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hours prior to the challenge. To generate naïve and anti-S. aureus (anti-Sa) serum to be 
used in passive immunization before challenging mice with S. aureus 132, Winstar rats (n = 
1/group) were administered five IP injections (250 µL) of S. aureus 132 ΔmurI Δdat (10X), or 
saline, at a 14-day interval. Blood was collected on day 70; serum was pooled as before and 
titers of total IgG were determined by indirect ELISA using a 1:5,000 dilution of peroxidase 
conjugated goat anti-rat IgG (Life Technologies S.A.) as a detection antibody. IP adoptive 
transfer of either 200 µL anti-Sa (>1:81,920) or naïve serum (1:320) was made in naïve mice 
(n = 6/group) 3.5 hours prior to challenge. 
 
3.8. Indirect ELISA 
Quantification of IgM, total IgG, IgG1, IgG2a, IgG2b and IgG3 in mouse sera was 
performed using an indirect Enzyme-linked Immunosorbent Assay (ELISA). 96-well ELISA 
plates were “coated” with A. baumannii, P. aeruginosa and S. aureus strains, which were 
fixed to the bottom of the wells after overnight incubation at 4 ºC in 100 mM carbonate-
bicarbonate buffer, pH 9.6. For the detection of specific antibodies against S. aureus 132, a 
derived mutant strain deficient for the protein A (132 Δspa [324]) was used to avoid 
nonspecific binding between protein A and IgG or IgM antibodies. After coating, plates 
were washed five times with phosphate buffered saline (PBS) to remove any unfixed 
bacteria. The residual sites were blocked with 200 µL per well of blocking solution (5% skim 
milk in PBS) for 2 hours at room temperature. An additional blocking step was used with 
200 µL of rabbit serum diluted 1:1000 in PBS for 1 hour at 37 ºC to block protein A cell 
surface receptors, for those S. aureus strains whose derived Δspa mutants were not 
available. Plates were aspirated and washed 5 times with washing buffer (0.005% Tween 20 
in PBS) and incubated overnight at 4 ºC with mouse sera serially diluted in DMEM culture 
medium supplemented with 10% fetal bovine serum (FBS) (Gibco, Life Technologies).After 
incubation, plates were washed five times with washing buffer to remove unbound 
antibodies, and 100 µL of secondary antibody (peroxidase-labelled anti-mouse IgM, IgG, 
IgG1, IgG2a, IgG2b or IgG3) diluted 1:5000 in DMEM culture medium supplemented with 
10% FBS was added to each well and left incubating for 2 hours in the dark. Plates were 
washed five times with washing buffer to remove any unbound secondary antibodies. Then, 
100 µL of 3,3’5,5’-Tetramethylbenzidine (TMB) was added to each well. The reaction was 
stopped after 2-3 min with 50 µL of 1M H2SO4 per well, and the peroxidase reaction 
product was read at 450 nm. For endpoint assays, the endpoint titer was defined as the 
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maximum dilution having a value that exceeded the blank absorbance reading by 0.1 
values. 
 
3.9. ELISpot assay 
IFN-γ, IL-4 and IL-17-producing splenocytes were quantified by ELISpot analysis 
(R&D Systems) with splenocytes obtained from immunized (n = 6) and control (n = 6-7) 
mice, and exposed ex vivo to ATCC 17978 ΔmurI1 ΔmurI2 (4x105 CFU), PAO1 ΔmurI (8x104 
CFU) and 132 ΔmurI Δdat (3x106 CFU) during 43 hours at 37 ºC, 5% CO2. Mice spleens were 
aseptically removed after the second vaccine or saline administration, mechanically 
disrupted and washed in saline by centrifugation at 400 g for 10 min at room temperature. 
The suspension of spleen cells was enriched in lymphocytes using the Histopaque solution, 
counted in a Neubauer haemacytometer and adjusted to 4x106 or 8x106 cells/mL in RPMI 
1640 medium containing 10% FBS. Next, 100 µL were transferred to 96-well EliSpot plates, 
and restimulated with 100 µL of vaccine strain, 100 µL of 1X cell stimulation cocktail 
(positive control) or 100 µL RPMI + 10% FBS (negative control). The number of the spot-
forming units were visually determined using images obtained with a dissecting microscope 
(Nikon SMZ-745, Nikon Corporation). Spot frequency in simulated wells was corrected by 
subtracting background signal from wells with cells plus media alone.  
 
3.10. Control of phenotypic stability 
A. baumannii ATCC 17978 ΔmurI1 ΔmurI2 and P. aeruginosa PAO1 ΔmurI were 
cultured overnight at 37 ºC in 5 mL LB supplemented with 10 mM D-Glu. S. aureus 132 
ΔmurI Δdat was grown overnight at 37 ºC in 5 mL TSB supplemented with 20 mM D-Glu. 
After incubation, 1 mL of each was used to inoculate 100 mL of LB or TSB with 10 or 20 mM 
D-Glu, respectively. All the cultures were incubated at 37 ºC under agitation (180-210 rpm) 
for up to 8 days. Samples from these cultures were taken at the beginning of the incubation 
period and on days 1, 2, 3, 4 and 8, washed twice, plated in LB or TSB agar with 0 and 10 
mM D-Glu and incubated at 37 ºC for 3 days. Cultures were made in triplicate. 
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3.11. Water osmolisis assay 
To determine the viability of A. baumannii ATCC 17978, ATCC 17978 ΔmurI1 
ΔmurI2, P. aeruginosa PAO1, PAO1 ΔmurI, S. aureus 132 and 132 ΔmurI Δdat in water, 
these bacterial strains were cultured overnight at 37 ºC in LB or TSB agar with (mutant 
strains) and without (wild-type strains) 10 mM D-Glu, adjusted to 0.5 McFarland in water, 
and left incubating at 37 ºC under agitation (180 rpm) for the time necessary to observe the 
loss of viability of cells. For A. baumannii strains, daily samples of culture were taken 
initially for 2 days, next, samples were taken twice a week until day 26 and thereafter, once 
a week until day 40 for the determination of CFU counts in LB agar (wild-type strain) and LB 
agar with 10 mM D-Glu (mutant strain). For P. aeruginosa strains, daily samples of culture 
were taken initially for 3 days, next samples were taken twice a week until day 48. Finally, 
samples were taken at least once every two weeks until day 157 for the determination of 
CFU counts in LB agar (wild-type strain) and LB agar supplemented with 10 mM D-Glu 
(mutant strain). For S. aureus, daily samples of culture were taken until day 5 for the 
determination of CFU counts in TSB agar (wild-type strain) and TSB agar supplemented with 
10 mM D-Glu (mutant strain). Cultures were made in triplicate. 
 
3.12. Desiccation assay  
To determine the viability of S. aureus 132 and 132 ΔmurI Δdat after being kept in 
stressful conditions (drought tolerance), these bacterial strains were cultured at 37 ºC 
under agitation (210 rpm) in TSB and TSB with 20 mM D-Glu, respectively. Log-phase 
cultures (OD600 = 0.5-0.6) were centrifuged (3,900 g, 20 min), washed once and serially 
diluted in TSB. Drops of 5 µL from undiluted, 10-1- and 10-2-diluted cultures were then 
spotted on sterile cellulose filters (0.45 µm pore size) and sequentially placed on TSB agar 
with D-Glu 10 mM at day 0 (control) and after keeping for 4, 5, 6, 11, 18, 25 and 31 days at 
room temperature (desiccation stress). Agar plates were incubated at 37 ºC for 16 hours. 
All cultures were made in triplicate. 
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3.13. Statistics 
Means were compared by using Student’s t test for hypothesis testing to compare 
individual conditions and corresponding control groups. Mann-Whitney U test was applied 
if data set failed the Kolmogorov-Smirnov normality test. The one-way analysis of variance 
(ANOVA) was used for multiple comparisons, followed by Bonferroni’s post hoc test. 
Survival data were compared using the log-rank test. Differences were considered 
significant when P<0.05. *P<0.05 compared with control group. #P<0.05 compared with the 
preceding group represented. All statistical analyses were performed using Prism 6.0 
(GraphPad Prism, GraphPad Software, Inc.).  
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4. RESULTS 
4.1. Characterization of D-Glu auxotrophic strains 
Analysis of the genome sequence of A. baumannii strain ATCC 17978 [343] revealed 
two MurI (EC 5.1.1.3) genes: A1S_0380 (murI1) which encodes a 288 amino acid protein, 
and A1S_3398 (murI2) which encodes a 266 amino acid protein. Analysis of the genome 
sequence of P. aeruginosa strain PAO1 [344] revealed a single MurI gene: PA4662 (murI) 
which encodes a 265 amino acid protein. Analysis of the genome sequence of S. aureus 
strain 132 [324] revealed a single MurI gene (murI) which encodes a 266 amino acid 
protein, and a single Dat gene (dat) which encodes a 282 amino acid protein. All these 
genes were targeted for unmarked in-frame deletion. Figure 21 shows the phenotypic 
screening of A. baumannii, P. aeruginosa and S. aureus mutants in the final step of the 
allelic replacement method for obtaining D-Glu auxotrophic strains, whereas Figure 22 
shows the PCR screening using primers EXTfw and EXTrv for the above mentioned genes. 
94 
 
 
 
 
 
 
 
Figure 21 | Selection of D-Glu 
auxotrophic mutants in the final step 
of the allelic replacement method.  A, 
Phenotypic screening of colonies 
resulting from the second crossover 
event of pMo130_UP/DOWN_murI2 
with ATCC 17978 ΔmurI1 chromosome 
during construction of A. baumannii 
ATCC 17978 ΔmurI1 ΔmurI2. Individual 
colonies were picked from LB agar plates with 
15% sucrose and 10 mM D-Glu and inoculated in patches at comparable locations in LB agar 
plates with and without 10 mM D-Glu. Colonies with the ΔmurI1 ΔmurI2 genotype grew 
exclusively in supplemented plates; colonies with the ΔmurI1 genotype grew with and 
without D-Glu. B, Phenotypic screening of colonies resulting from the second crossover 
event of pEX18Gm_UP/DOWN_murI with PAO1 chromosome during construction of P. 
aeruginosa PAO1 ΔmurI. Individual colonies were picked from LB agar plates with 15% 
sucrose and 10 mM D-Glu and inoculated in patches at comparable locations in LB agar 
plates with and without 10 mM D-Glu. Colonies with the ΔmurI genotype grew exclusively 
in supplemented plates; colonies with the wild-type genotype grew with and without D-Glu. 
C, Phenotypic screening of colonies resulting from the second crossover event of 
pMAD_UP/DOWN_dat with 132 ΔmurI chromosome during construction of S. aureus 132 
ΔmurI Δdat. Individual colonies were picked from TSB agar plates with 10 mM D-Glu and 
inoculated in patches at comparable locations in TSB agar plates with and without 10 mM 
D-Glu. Colonies with the ΔmurI Δdat genotype grew exclusively in supplemented plates; 
colonies with the ΔmurI genotype grew with and without D-Glu. 
(A) (B) 
(C) 
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Figure 22 | PCR screening of A. baumannii MurI–, P. aeruginosa PAO1 MurI– and S. aureus 
132 MurI–Dat– mutants. A, Oligonucleotides EXTfw_murI1 and EXTrv_murI1 generated 
fragments with 1116 bp from A. baumannii ATCC 17978 colonies carrying the wild-type 
murI1 allele or fragments with 345 bp from colonies carrying the mutant ΔmurI1 allele. 
Oligonucleotides EXTfw_murI2 and EXTrv_murI2 generated fragments with 1056 bp from A. 
baumannii ATCC 17978 colonies carrying the wild-type murI2 allele or fragments with 516 
bp from colonies carrying the mutant ΔmurI2 allele. B, Oligonucleotides EXTfw_murI and 
EXTrv_murI generated fragments with 1741 bp from P. aeruginosa PAO1 colonies carrying 
the wild-type murI allele or fragments with 943 bp from colonies carrying the mutant ΔmurI 
allele. C, Oligonucleotides EXTfw_dat and EXTrv_dat generated fragments with 1892 bp 
from S. aureus 132 colonies carrying the wild-type dat allele or fragments with 1049 bp 
from colonies carrying the mutant Δdat allele. Oligonucleotides EXTfw_murI and 
EXTrv_murI generated fragments with 1481 bp from S. aureus 132 colonies carrying the 
wild-type murI allele or fragments with 739 bp from colonies carrying the mutant ΔmurI 
allele. A-C, MW, molecular weight marker.    
 
(A) 
(B) (C) 
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In A. baumannii ATCC 17978, the resulting single mutants ATCC 17978 ΔmurI1 and 
ATCC 17978 ΔmurI2 grew normally, while the ATCC 17978 ΔmurI1 ΔmurI2 double mutant 
required exogenous D-Glu for growth. In P. aeruginosa PAO1, the resulting mutant PAO1 
ΔmurI also required exogenous D-Glu. In S. aureus 132, the single mutants 132 ΔmurI and 
132 Δdat grew normally, while the 132 ΔmurI Δdat double mutant required exogenous D-
Glu (Fig. 23).  
 
 
 
Figure 23 | Characterization of A. baumannii MurI–, P. aeruginosa MurI– and S. aureus 
MurI–Dat– D-Glu auxotrophic strains. Growth and viability of A. baumannii ATCC 17978, P. 
aeruginosa PAO1, S. aureus 132 and derived mutant strains (mean ± s.e.m.). ATCC 17978 
ΔmurI1 ΔmurI2, PAO1 ΔmurI and 132 ΔmurI Δdat show normal grow in culture 
medium supplemented with D-Glu but are unable to grow without the exogenous 
supply of this compound. In contrast, the wild-type strains grow as per normal in 
medium with and without the addition of D-Glu.   
 
Using real time qRT-PCR (Fig. 24), the absence of MurI and Dat genes mRNA in 
these mutant strains was confirmed. This shows the involvement of the murI genes in the 
production of D-Glu in A. baumannii ATCC 17978 and P. aeruginosa PAO1 and both murI 
and dat genes in the case of S. aureus 132. This means that for those bacteria not 
possessing the Dat enzyme, the inactivation of a single or multiple MurI genes is requisite 
to produce an auxotrophic strain for D-Glu, as in the respective cases of P. aeruginosa PAO1 
and A. baumannii ATCC 17978 (MurI– mutants). In other cases, the inactivation of genes 
4. RESULTS 
97 
 
coding for MurI protein as well as those coding for Dat is required (MurI–Dat– mutants), as 
in the case of some Gram-positive bacteria like S. aureus. 
 
 
 
 
 
 
 
 
 
 
 
Figure 24 | qRT-PCR of MurI–, Dat–, and MurI–Dat– mutants. A, Comparative expression 
levels by qRT-PCR of murI in ATCC 17978 (normalized relative to gyrB) and derived mutant 
strains. B, Comparative expression levels by qRT-PCR of murI in PAO1 (normalized relative 
to proC) and derived mutant strain. C, Comparative expression levels by qRT-PCR of murI 
and dat in 132 (normalized relative to gyrB) and derived mutant strains (mean ± s.d.). 
*P<0.05. 
 
(A) 
(B) 
(C) 
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To assess the effects of D-Glu deprivation on cellular growth of the wild-type and D-
Glu auxotrophic strains, bacteria grown in media supplemented with different 
concentrations of D-Glu were collected and analysed by scanning electron microscopy 
(SEM) for morphology alterations (Fig. 25). The ATCC 17978 ΔmurI1 ΔmurI2, PAO1 ΔmurI 
and 132 ΔmurI Δdat strains showed significant growth impairment when the exogenous 
supply of D-Glu decreased, until complete loss of replication. Some bacteria detected on 
the culture medium without D-Glu were reminiscent of the inoculum previously grown with 
this compound. Moreover, both ATCC 17978 ΔmurI1 ΔmurI2 and 132 ΔmurI Δdat strains 
exhibited an altered pattern of cell division when D-Glu was supplied at 0.1 mM. With 1.25 
mM D-Glu for A. baumannii and 1.5 mM D-Glu for S. aureus a greater cell density was seen 
with respect to the preceding condition (reflection of a higher growth rate) but with many 
visible protoplast-like structures. Also, though lower in number, some cells had an 
appearance similar to their wild-type morphology. Finally, when D-Glu was supplemented 
at 10 or 20 mM, both morphology and cell density of the mutant strains were 
indistinguishable from the corresponding wild-type homologues.    
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Figure 25 | A. baumannii MurI– and S. aureus MurI–Dat– impaired growth in D-Glu 
deprivation conditions. SEM of A. baumannii ATCC 17978, P. aeruginosa PAO1, S. aureus 
132 and derived D-Glu auxotrophic strains in the presence of different D-Glu 
concentrations. 
 
In addition to growth impairment, both ATCC 17978 ΔmurI1 ΔmurI2 and 132 ΔmurI 
Δdat strains exhibited an altered pattern of cell division when D-Glu was supplied at 0.1 
mM (Fig. 26). The ATCC 17978 ΔmurI1 ΔmurI2 mutant strain showed filamentous 
aggregates consisting of three or more units of cells with atypical binary fission while 132 
ΔmurI Δdat displayed large clusters of irregular cells due to impaired cell separation. A mass 
of presumptive protoplasts was observed in the vicinity of the intact cell forms of the 
mutant strains.  
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Figure 26 | A. baumannii MurI– and S. aureus MurI–Dat– altered pattern of cell division. 
SEM of A. baumannii ATCC 17978, ATCC 17978 ΔmurI1 ΔmurI2, S. aureus 132 and 132 
ΔmurI Δdat in the presence of 0.1 mM D-Glu showing differences at the bacterial cell 
morphology and altered pattern of cell division. 
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Similarly, transmission electron microscopy (TEM) was performed showing that the 
cell walls of ATCC 17978 ΔmurI1 ΔmurI2 (Fig. 27A), PAO1 ΔmurI (Fig. 27B) and 132 ΔmurI 
Δdat (Fig. 27C), experience progressive destruction when kept in the absence of D-Glu as a 
result of the blockage of peptidoglycan biosynthesis. Micrographs presented show cells 
with altered conformation that lose their semi-rigid structure, cells with several ruptures 
and displacement of membranes, lysis and extrusion of the intracellular content. Thus, the 
mechanism of lysis of D-Glu auxotrophic bacteria can be represented as follows (Fig. 28). 
First, inhibition of cell wall production leaves the protoplasm surrounded only by the inner 
(gram-negative) or cell membrane (Gram-positive bacteria), which renders this cell body 
susceptible to the variations in the osmolarity of the medium. Ultimately, lysis occurs 
through osmotic pressure, leaving traces of the cytoplasmic membranes that can form 
aggregates, and internal cellular content. These phenomena may occur either 
simultaneously or sequentially. 
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Figure 27 | D-Glu auxotrophy produces cell wall degeneration and bacterial lysis. 
Different atypical morphologies, progressive degeneration of the cell wall and lysis of D-Glu 
auxotrophic strains when kept in the absence of D-Glu. Micrographs were taken with a 
transmission electron microscope at different scales. A, A. baumannii ATCC 17978 and 
ATCC 17978 ΔmurI1 ΔmurI2. B, P. aeruginosa PAO1 and PAO1 ΔmurI. C, S. aureus 132 and 
132 ΔmurI Δdat. 
 
 
(A) 
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Figure 27 | D-Glu auxotrophy produces cell wall degeneration and bacterial lysis. 
Different atypical morphologies, progressive degeneration of the cell wall and lysis of D-Glu 
auxotrophic strains when kept in the absence of D-Glu. Micrographs were taken with a 
transmission electron microscope at different scales. A, A. baumannii ATCC 17978 and 
ATCC 17978 ΔmurI1 ΔmurI2. B, P. aeruginosa PAO1 and PAO1 ΔmurI. C, S. aureus 132 and 
132 ΔmurI Δdat. 
 
(B) 
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Figure 27 | D-Glu auxotrophy produces cell wall degeneration and bacterial lysis. 
Different atypical morphologies, progressive degeneration of the cell wall and lysis of D-Glu 
auxotrophic strains when kept in the absence of D-Glu. Micrographs were taken with a 
transmission electron microscope at different scales. A, A. baumannii ATCC 17978 and 
ATCC 17978 ΔmurI1 ΔmurI2. B, P. aeruginosa PAO1 and PAO1 ΔmurI. C, S. aureus 132 and 
132 ΔmurI Δdat. 
(C) 
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Figure 28 | Proposed schematic mechanism of cell wall degeneration and bacterial lysis of 
Gram-negative and Gram-positive bacteria auxotrophic for D-Glu.  
 
4.2. Virulence attenuation of MurI– and MurI–Dat– mutants 
One of the main characteristics that makes GMOs especially suitable for use as 
vaccines is the higher level of virulence attenuation respective to parental strains [58]. To 
test the hypothesis that bacteria auxotrophic for D-Glu are attenuated, the invasive 
capacity of the different A. baumannii ATCC 17978 mutants was first evaluated in 
comparison with the parental strain. BALB/c mice were injected intraperitoneally (IP) (2X) 
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with ATCC 17978, ATCC 17978 ΔmurI1, ATCC 17978 ΔmurI2 and ATCC 17978 ΔmurI1 
ΔmurI2. After 12 hours, the following bacterial loads (Log10 CFU/g average values) in livers 
were obtained: 8.29 (mice administered ATCC 17978), 6.88 (mice administered ATCC 17978 
ΔmurI1), 8.06 (mice administered ATCC 17978 ΔmurI2) and 1.59 (mice administered ATCC 
17978 ΔmurI1 ΔmurI2) (Fig. 29). Moreover, in 4 of the 9 mice injected ATCC 17978 ΔmurI1 
ΔmurI2, bacteria were not recovered. Although significant differences were observed also 
for ATCC 17978 ΔmurI1, the most accentuated reduction in bacterial burden resulted from 
the ATCC 17978 ΔmurI1 ΔmurI2 administration. These results suggested that combined 
ΔmurI1 and ΔmurI2 mutations prevent the invasive and replicative capacities of A. 
baumannii. 
 
Figure 29 | Bacterial 
burden after infection. 
Bacterial loads in livers 
of BALB/c mice 12 hours 
after IP injection with A. 
baumannii ATCC 17978 
(n = 8), ATCC 17978 
ΔmurI1 (n = 9), ATCC 
17978 ΔmurI2 (n = 9) and 
ATCC 17978 ΔmurI1 ΔmurI2 (n = 9). Each dot represents one mouse and each horizontal 
line represents the mean for each group. *P<0.05 compared to ATCC 17978.  
 
Next, mice survival was measured after IP injection with ATCC 17978 ΔmurI1 
ΔmurI2, PAO1 ΔmurI and 132 ΔmurI Δdat. Using this acute lethal infection model, the LD100 
(the minimal lethal dose for 100% of mice) of wild-type homologues were 2.5X for A. 
baumannii ATCC 17978, 0.4X for P. aeruginosa PAO1 and 1X for S. aureus 132. In contrast, 
the observed LD100 for ATCC 17978 ΔmurI1 ΔmurI2, PAO1 ΔmurI and 132 ΔmurI Δdat were 
6X, >40X and >10X, respectively (Fig. 30). These results evidenced that D-Glu auxotrophic 
strains are attenuated in comparison with the parental strains. 
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Figure 30 | D-Glu auxotrophic strains are attenuated respective to parental strains. 
Survival of BALB/c mice inoculated IP with A. baumannii ATCC 17978 (n = 8), ATCC 17978 
ΔmurI1 ΔmurI2 (n = 6), P. aeruginosa PAO1 (n = 4), PAO1 ΔmurI (n = 4), S. aureus 132 (n = 5) 
and 132 ΔmurI Δdat (n = 4) with different bacterial doses.    
 
4.3. Generation of antibody-mediated immune responses 
To measure the antibody-mediated immune responses at different vaccination 
regimens, BALB/c mice were immunized with D-Glu auxotrophic strains or administered 
saline according to Figure 31, and antibody titers were determined by ELISA. As shown, 
significant levels of IgM, IgG, IgG1, IgG2a, IgG2b and IgG3 against A. baumannii ATCC 17978, 
P. aeruginosa PAO1 and protein A-deficient S. aureus 132 (132 Δspa [324]) were present in 
all immunized mice at the end of the immunization schedules. Antibody production after 
two immunizations was significantly higher than with one immunization, except for IgM 
with PAO1 ΔmurI. Analysis of the IgG isotype revealed that vaccination with any of the D-
Glu auxotrophic strains triggered a dominant IgG1 response, consistent with a predominant 
activation of Th2 lymphocytes [345]. Despite IgG2a, IgG2b and IgG3 levels being 
substantially lower in response to 132 ΔmurI Δdat, titers were still significant in all 
vaccinated groups. These results indicate that a Th1 differentiation was also stimulated 
upon vaccination [345]. 
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Figure 31 | Vaccination with D-Glu auxotrophic strains elicit high level of specific 
antibodies. Antibody titers against A. baumannii ATCC 17978 (n = 5-13), P. aeruginosa 
PAO1 (n = 4-7) and S. aureus 132 Δspa (n = 5-7) in vaccinated and control mice after one or 
two injections with ATCC 17978 ΔmurI1 ΔmurI2 (1X, ±107 CFU/mouse), PAO1 ΔmurI (0.4X, 
±107 CFU/mouse) and 132 ΔmurI Δdat (1X, ±107 CFU/mouse), respectively, or saline. S, 
saline; D, day. *P<0.05, compared with saline group. #P<0.05, compared with the preceding 
condition.  
 
Immune responses after administering different doses of ATCC 17978 ΔmurI1 
ΔmurI2, PAO1 ΔmurI and 132 ΔmurI Δdat were also evaluated. To that end, groups of mice 
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were immunized on days 0 and 14 with ATCC 17978 ΔmurI1 ΔmurI2: 0.01X, 0.05X, 0.1X, 
0.5X and 1X. On day 21, serum was obtained. For P. aeruginosa, groups of mice were 
immunized once with the following PAO1 ΔmurI doses: 0.1X, 0.4X, 1X, 4X, 10X and 40X. 
Serum was obtained on day 40. For S. aureus, groups of mice were immunized on days 0 
and 14 with the following 132 ΔmurI Δdat doses: 0.2X, 1X, 5X and 10X; sera were obtained 
on day 21. Control mice were administered saline (0X). As shown in Figure 32, significant 
levels of IgM and total IgG were present in all immunized mice at the end of the 
immunization schedules. All tested ATCC 17978 ΔmurI1 ΔmurI2 vaccine doses above 0.05X 
elicited significant levels of IgG1, IgG2a, IgG2b and IgG3 subtypes. Although PAO1 ΔmurI 
0.1X was sufficient to induce IgM and IgG titers significantly, total IgG titers were higher 
when using a dose of 0.4X. For 132 ΔmurI Δdat, only 5X and 10X doses raised significantly 
all IgG subtypes; using 132 ΔmurI Δdat 1X elicited IgG1 and IgG3 subtypes only. Altogether, 
these results suggest that these D-Glu auxotrophic vaccines drive the production of 
antibodies in a dose-dependent manner. 
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Figure 32 | Antibody-mediated immune response activation by D-Glu auxotrophic strains 
is dose-dependent. Antibody titers elicited in mice by administration of different doses of 
ATCC 17978 ΔmurI1 ΔmurI2 (n = 5-10), PAO1 ΔmurI (n = 2-7) and 132 ΔmurI Δdat (n = 4-7) 
on days 21 (after two immunizations), 40 (one immunization) and 21 (two immunizations), 
respectively. *P<0.05, compared with saline group (0X). #P<0.05 compared with antibody 
production of an immediate lower dose. 
 
The exposure to foreign antigen yields a biphasic response: the first phase is 
associated with production of IgM followed by production of IgG, the second phase is 
characterized by a reduction in IgM followed by an increase of IgG. Higher proportion of IgG 
and other isotypes of antibodies compared with the level of IgM also characterizes memory 
antibody responses. Indeed, using a single immunization low dose (0.0001X) of ATCC 17978 
ΔmurI1 ΔmurI2, it was possible to detect antigen-specific IgM, IgG, IgG1, IgG2a, IgG2b and 
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IgG3 in the sera of mice, 123 days and 1 year after immunization (Fig. 33). Also, IgM titers 
were higher at day 7 but markedly reduced on day 123. In contrast, IgG1, IgG2b and IgG3 
titers increased significantly between days 7 and 123; total IgG levels were maintained until 
1 year after immunization, indicating a biphasic response and a long-term antibody 
memory.  
 
 
 
 
 
Figure 33 | ATCC 17978 ΔmurI1 ΔmurI2 vaccination elicits long-term antibody memory. 
Antibody titers (n = 5-8) against ATCC 17978 on days 7, 123 and 365 after ATCC 17978 
ΔmurI1 ΔmurI2 (0.0001X) administration, or saline. S, saline; D, day. *P<0.05, compared 
with saline group. #P<0.05, compared with the preceding condition.  
 
 
A key feature of any vaccine is its ability to generate a broad immune response; it is 
crucial that vaccination with a single strain preparation induces antibodies reactive against 
heterologous strains. As shown in Figure 34, IgG antibodies elicited with ATCC 17978 
ΔmurI1 ΔmurI2 were cross-reactive with ATCC 19606, MDR-AbH12O-A2 and encapsulated-
Ab307-0294 (see Table 5). IgG titers obtained after two PAO1 ΔmurI immunizations were 
cross-reactive with PA21_ST175, PA14, PA51441321, LES431, PA28562 and PA51442390 
(see Table 5). IgG titers obtained with three PAO1 ΔmurI immunizations were cross-reactive 
with the previous strains plus PA12142 and LES400 (see Table 5). Of note, PA28562 and 
PA51442390 present the mucoid phenotype associated with chronic infections from CF 
patients [346]. IgG antibodies elicited with 132 ΔmurI Δdat were cross-reactive with 
FPR3757 strain of the high-risk clone CA-MRSA USA300, and with S. aureus strains of animal 
origin, RF122 (bovine), ED133 (ovine) and ED98 (poultry) (see Table 5). IgG titers and cross-
reactivity were significantly raised when a higher dose of 132 ΔmurI Δdat was used (10X). 
Taken together our data indicate that IgG induced by ATCC 17978 ΔmurI1 ΔmurI2, PAO1 
ΔmurI1 and 132 ΔmurI Δdat is cross-reactive to a wide variety of A. baumannii, P. 
aeruginosa and S. aureus strains, respectively. 
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Figure 34 | Vaccination with D-Glu auxotrophic strains elicit high levels of cross-reactive 
antibodies. IgG titers against different A. baumannii (n = 6), P. aeruginosa (n = 5) and S. 
aureus (n = 5-9) strains in vaccinated and control mice after two or three injections with 
ATCC 17978 ΔmurI1 ΔmurI2 (1X), PAO1 ΔmurI (0.4X) and 132 ΔmurI Δdat (1X and 10X), 
respectively, or saline. Mucoid (+) and non-mucoid (–) phenotype appearance of tested P. 
aeruginosa strains. S, saline; D, day. *P<0.05, compared with saline group. #P<0.05, 
compared with the preceding condition.  
4. RESULTS 
113 
 
4.4. Activation of cell-mediated immunity 
A successful vaccine should potentially trigger an appropriate cellular immune 
response. To explore the nature of T cell responses generated by the vaccine strains, we 
measured antigen specific IFN-γ-, IL-4-, and IL-17-secreting splenocytes after ex vivo 
restimulation with A. baumannii ATCC 17978 ΔmurI1 ΔmurI2, P. aeruginosa PAO1 ΔmurI 
and S. aureus ΔmurI Δdat, using ELISpot (Figs. 35-43). These cytokines were selected as 
markers of Th1, Th2 and Th17 T cell subsets, respectively. ATCC 17978 ΔmurI1 ΔmurI2, 
PAO1 ΔmurI and 132 ΔmurI Δdat mediated a significant increase in the number of IL-17-
secreting splenocytes and it was the predominant T cell subset triggered by 132 ΔmurI Δdat 
(Fig. 44). A significant number of IFN-γ-secreting splenocytes was triggered by 132 ΔmurI 
Δdat, while a substantial increment – although not significant – was observed with ATCC 
17978 ΔmurI1 ΔmurI2 and PAO1 ΔmurI (Fig. 44). IL-4-producing splenocytes were 
stimulated in response to ATCC 17978 ΔmurI1 ΔmurI2 and PAO1 ΔmurI, but not in response 
to 132 ΔmurI Δdat (Fig. 44). These data indicate that active immunization with ATCC 17978 
ΔmurI1 ΔmurI2 and PAO1 ΔmurI triggers a consistent Th2 immune response while 132 
ΔmurI Δdat elicits a Th1 response.  
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(A) 
Figure 35 | Vaccination with ATCC 17978 ΔmurI1 ΔmurI2 triggers IFN-γ cytokine-secreting T cells. Detection of antigen-
specific IFN-γ-secreting T cells collected at day 82 from the spleens of A, saline mice (n = 7) and B, vaccinated mice (n = 6), 
after being restimulated ex vivo for 43 hours with ATCC 17978 ΔmurI1 murI2, PMA (phorbol 12-myristate 13-
acetate)/Ionomycin, or medium alone. A-B, Each well contains 4×105 splenocytes. S, saline; V, vaccinated. 
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(B) 
Figure 35 | Vaccination with ATCC 17978 ΔmurI1 ΔmurI2 triggers IFN-γ cytokine-secreting T cells. Detection of antigen-
specific IFN-γ-secreting T cells collected at day 82 from the spleens of A, saline mice (n = 7) and B, vaccinated mice (n = 6), 
after being restimulated ex vivo for 43 hours with ATCC 17978 ΔmurI1Δ murI2, PMA (phorbol 12-myristate 13-
acetate)/Ionomycin, or medium alone. A-B, Each well contains 4×105 splenocytes. S, saline; V, vaccinated. 
4
. R
E
S
U
LT
S
 
1
16 
 
(A) 
Figure 36 | Vaccination with ATCC 17978 ΔmurI1 ΔmurI2 triggers IL-4 cytokine-secreting T cells. Detection of antigen-
specific IL-4-secreting T cells collected at day 82 from the spleens of A, saline mice (n = 7) and B, vaccinated mice (n = 6), 
after being restimulated ex vivo for 43 hours with ATCC 17978 ΔmurI1 ΔmurI2, PMA (phorbol 12-myristate 13-
acetate)/Ionomycin, or medium alone. A-B, Each well contains 4×105 splenocytes. S, saline; V, vaccinated. 
4
. R
E
S
U
LT
S
 
1
17 
 
(B) 
Figure 36 | Vaccination with ATCC 17978 ΔmurI1 ΔmurI2 triggers IL-4 cytokine-secreting T cells. Detection of antigen-
specific IL-4-secreting T cells collected at day 82 from the spleens of A, saline mice (n = 7) and B, vaccinated mice (n = 6), 
after being restimulated ex vivo for 43 hours with ATCC 17978 ΔmurI1 ΔmurI2, PMA (phorbol 12-myristate 13-
acetate)/Ionomycin, or medium alone. A-B, Each well contains 4×105 splenocytes. S, saline; V, vaccinated. 
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(A) 
Figure 37 | Vaccination with ATCC 17978 ΔmurI1 ΔmurI2 triggers IL-17 cytokine-secreting T cells. Detection of antigen-
specific IL-17-secreting T cells collected at day 82 from the spleens of A, saline mice (n = 7) and B, vaccinated mice (n = 6), 
after being restimulated ex vivo for 43 hours with ATCC 17978 ΔmurI1 ΔmurI2, PMA (phorbol 12-myristate 13-
acetate)/Ionomycin, or medium alone. A-B, Each well contains 4×105 splenocytes. S, saline; V, vaccinated. 
4
. R
E
S
U
LT
S
 
1
19 
 
(B) 
Figure 37 | Vaccination with ATCC 17978 ΔmurI1 ΔmurI2 triggers IL-17 cytokine-secreting T cells. Detection of antigen-
specific IL-17-secreting T cells collected at day 82 from the spleens of A, saline mice (n = 7) and B, vaccinated mice (n = 6), 
after being restimulated ex vivo for 43 hours with ATCC 17978 ΔmurI1 ΔmurI2, PMA (phorbol 12-myristate 13-
acetate)/Ionomycin, or medium alone. A-B, Each well contains 4×105 splenocytes. S, saline; V, vaccinated. 
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Figure 38 | Vaccination with PAO1 ΔmurI triggers IFN-γ cytokine-secreting T cells. Detection of antigen-specific IFN-γ-
secreting T cells collected at day 68 from the spleens of A, saline mice (n = 6) and B, vaccinated mice (n = 6), after being 
restimulated ex vivo for 43 hours with PAO1 ΔmurI, PMA (phorbol 12-myristate 13-acetate)/Ionomycin, or medium alone. 
A-B, Each well contains 8×105 splenocytes. S, saline; V, vaccinated. 
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Figure 38 | Vaccination with PAO1 ΔmurI triggers IFN-γ cytokine-secreting T cells. Detection of antigen-specific IFN-γ-
secreting T cells collected at day 68 from the spleens of A, saline mice (n = 6) and B, vaccinated mice (n = 6), after being 
restimulated ex vivo for 43 hours with PAO1 ΔmurI, PMA (phorbol 12-myristate 13-acetate)/Ionomycin, or medium alone. 
A-B, Each well contains 8×105 splenocytes. S, saline; V, vaccinated. 
(B) 
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Figure 39 | Vaccination with PAO1 ΔmurI triggers IL-4 cytokine-secreting T cells. Detection of antigen-specific IL-4-
secreting T cells collected at day 68 from the spleens of A, saline mice (n = 6) and B, vaccinated mice (n = 6), after being 
restimulated ex vivo for 43 hours with PAO1 ΔmurI, PMA (phorbol 12-myristate 13-acetate)/Ionomycin, or medium alone. 
A-B, Each well contains 8×105 splenocytes. S, saline; V, vaccinated. 
(A) 
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Figure 39 | Vaccination with PAO1 ΔmurI triggers IL-4 cytokine-secreting T cells. Detection of antigen-specific IL-4-
secreting T cells collected at day 68 from the spleens of A, saline mice (n = 6) and B, vaccinated mice (n = 6), after being 
restimulated ex vivo for 43 hours with PAO1 ΔmurI, PMA (phorbol 12-myristate 13-acetate)/Ionomycin, or medium alone. 
A-B, Each well contains 8×105 splenocytes. S, saline; V, vaccinated. 
(B) 
4
. R
E
S
U
LT
S
 
1
24 
                     
Figure 40 | Vaccination with PAO1 ΔmurI triggers IL-17 cytokine-secreting T cells. Detection of antigen-specific IL-17-
secreting T cells collected at day 68 from the spleens of A, saline mice (n = 6) and B, vaccinated mice (n = 6), after being 
restimulated ex vivo for 43 hours with PAO1 ΔmurI, PMA (phorbol 12-myristate 13-acetate)/Ionomycin, or medium alone. 
A-B, Each well contains 8×105 splenocytes. S, saline; V, vaccinated. 
(A) 
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Figure 40 | Vaccination with PAO1 ΔmurI triggers IL-17 cytokine-secreting T cells. Detection of antigen-specific IL-17-
secreting T cells collected at day 68 from the spleens of A, saline mice (n = 6) and B, vaccinated mice (n = 6), after being 
restimulated ex vivo for 43 hours with PAO1 ΔmurI, PMA (phorbol 12-myristate 13-acetate)/Ionomycin, or medium alone. 
A-B, Each well contains 8×105 splenocytes. S, saline; V, vaccinated. 
(B) 
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(A) 
Figure 41 | Vaccination with 132 ΔmurI Δdat  triggers IFN-γ cytokine-secreting T cells. Detection of antigen-specific IFN-γ-
secreting T cells collected at day 50 from the spleens of A, saline mice (n = 6) and B, vaccinated mice (n = 6), after being 
restimulated ex vivo for 43 hours with 132 ΔmurI Δdat, PMA (phorbol 12-myristate 13-acetate)/Ionomycin, or medium 
alone. A-B, Each well contains 8×105 splenocytes. S, saline; V, vaccinated. 
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(B) 
Figure 41 | Vaccination with 132 ΔmurI Δdat  triggers IFN-γ cytokine-secreting T cells. Detection of antigen-specific IFN-γ-
secreting T cells collected at day 50 from the spleens of A, saline mice (n = 6) and B, vaccinated mice (n = 6), after being 
restimulated ex vivo for 43 hours with 132 ΔmurI Δdat, PMA (phorbol 12-myristate 13-acetate)/Ionomycin, or medium 
alone. A-B, Each well contains 8×105 splenocytes. S, saline; V, vaccinated. 
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(A) 
Figure 42 | Vaccination with 132 ΔmurI Δdat does not trigger IL-4 cytokine-secreting T cells. Detection of antigen-specific 
IL-4-secreting T cells collected at day 50 from the spleens of A, saline mice (n = 6) and B, vaccinated mice (n = 6), after being 
restimulated ex vivo for 43 hours with 132 ΔmurI Δdat, PMA (phorbol 12-myristate 13-acetate)/Ionomycin, or medium 
alone. A-B, Each well contains 8×105 splenocytes. S, saline; V, vaccinated. 
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(B) 
Figure 42 | Vaccination with 132 ΔmurI Δdat does not trigger IL-4 cytokine-secreting T cells. Detection of antigen-specific 
IL-4-secreting T cells collected at day 50 from the spleens of A, saline mice (n = 6) and B, vaccinated mice (n = 6), after being 
restimulated ex vivo for 43 hours with 132 ΔmurI Δdat, PMA (phorbol 12-myristate 13-acetate)/Ionomycin, or medium 
alone. A-B, Each well contains 8×105 splenocytes. S, saline; V, vaccinated. 
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(A) 
Figure 43 | Vaccination with 132 ΔmurI Δdat triggers IL-17 cytokine-secreting T cells. Detection of antigen-specific IL-17-
secreting T cells collected at day 50 from the spleens of A, saline mice (n = 6) and B, vaccinated mice (n = 6), after being 
restimulated ex vivo for 43 hours with 132 ΔmurI Δdat, PMA (phorbol 12-myristate 13-acetate)/Ionomycin, or medium 
alone. A-B, Each well contains 8×105 splenocytes. S, saline; V, vaccinated. 
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(B) 
Figure 43 | Vaccination with 132 ΔmurI Δdat triggers IL-17 cytokine-secreting T cells. Detection of antigen-specific IL-17-
secreting T cells collected at day 50 from the spleens of A, saline mice (n = 6) and B, vaccinated mice (n = 6), after being 
restimulated ex vivo for 43 hours with 132 ΔmurI Δdat, PMA (phorbol 12-myristate 13-acetate)/Ionomycin, or medium 
alone. A-B, Each well contains 8×105 splenocytes. S, saline; V, vaccinated. 
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Figure 44 | Vaccination with D-Glu auxotrophic strains triggers cytokine-secreting T cells. 
A, Number of spot forming cells per 4×105 splenocytes collected at day 82 from mice 
vaccinated twice with ATCC 17978 ΔmurI1 ΔmurI2 (1X) (n = 6) and control mice (n = 7) after 
being restimulated ex vivo with ATCC 17978 ΔmurI1 ΔmurI2 for 43 hours. B, Number of spot 
forming cells per 8×105 splenocytes collected at day 68 from mice vaccinated twice with 
PAO1 ΔmurI (0.4X) (n = 6) and control mice (n = 6) after being restimulated ex vivo with 
PAO1 ΔmurI for 43 hours. C, Number of spot forming cells per 8×105 splenocytes collected 
at day 50 from mice vaccinated twice with 132 ΔmurI Δdat (1X) (n = 6) and control mice (n = 
(A) 
(B) 
(C) 
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6) after being restimulated ex vivo with 132 ΔmurI Δdat for 43 hours. A-C, S, saline; V, 
vaccinated. *P<0.05, compared with saline control mice (mean ± s.e.m.). Representative 
wells for each cytokine, obtained from saline and vaccinated mice after incubation with 
stimuli or PMA (phorbol 12-myristate 13-acetate)/Ionomycin used as positive control.  
 
4.5. Protective immunity against acute lethal infection 
While antibody and cell-mediated immunity are useful markers for protective 
immune responses, these can only be predictors. To verify whether D-Glu auxotrophic 
strains confer protection, we assessed their effectiveness using an acute lethal infection 
model in mice. Firstly, the effect of vaccination was determined by measuring bacterial 
loads in multiple tissues from vaccinated and control mice after injection with the vaccine 
wild-type homologues. As illustrated in Figure 45, vaccination with D-Glu auxotrophic 
strains resulted in all cases in a significant reduction in tissue bacterial loads of A. 
baumannii ATCC 17978, P. aeruginosa PAO1 and S. aureus 132 (104-106-fold reductions) 
compared to those observed in control mice. Moreover, 132 ΔmurI Δdat vaccinatiom 
prevented mice from severe body weight loss. 
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Figure 45 | Immunization with D-Glu auxotrophs protects against bacterial dissemination 
and prevents weight loss. Bacterial loads in tissues and percentage of body weight loss 
(mean ± s.e.m.) from vaccinated (ATCC 17978 ΔmurI1 ΔmurI2 1X, PAO1 ΔmurI 0.4X and 132 
ΔmurI Δdat 1X) and control mice after challenge with A. baumannii ATCC 17978 (4X) (n = 
10; after 12 hours), P. aeruginosa PAO1 (0.4X) (n = 8; after 10 hours) and S. aureus 132 
(0.5X) (n = 14, pooled data set form two independent experiments; after 45 hours). S, 
saline; V, vaccinated. *P<0.05, compared with control group. 
 
Further, vaccine efficacy was evaluated by determining mice survival after 
challenge with parental and heterologous strains. As illustrated in Figure 46, a two-dose 
vaccination schedule with ATCC 17978 ΔmurI1 ΔmurI2 protected mice from challenge with 
ATCC 17978, whereas all control mice died within 24 hours. Likewise, survival rates of 
vaccinated mice were 100% and 86% after challenge with A. baumannii AbH12O-A2 and 
Ab307-0294, respectively. These observations evidenced that immunization with the ATCC 
17978 ΔmurI1 ΔmurI2 provides protective immunity against epidemiologically and 
genetically unrelated A. baumannii strains. 
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Figure 46 | Immunization with A. baumannii ATCC 17978 ΔmurI1 ΔmurI2 protects against 
ATCC 17978, MDR and highly virulent strains. Mice survival after vaccination with ATCC 
17978 ΔmurI1 ΔmurI2 (1X) or saline administration, and challenge with ATCC 17978 (4X) on 
day 21 (n = 11-13), AbH120-A2 (4X) on day 21 (n = 9) and Ab307-0294 (0.75X) on day 22 (n = 
7-8). S, saline; V, vaccinated. *P<0.05, compared with control group. 
 
Also, mice challenged with P. aeruginosa PAO1 presented a 87.5% and a 100% 
survival after vaccination with 0.04X and 0.4X doses of PAO1 ΔmurI, respectively. In this 
case, all control mice died within 15 hours. Similar results were obtained when challenging 
mice with the mucoid strain PA28562: vaccinated mice registered 100% survival, whereas 
all control mice died (Fig. 47). 
 
 
 
 
 
 
Figure 47 | Immunization with P. aeruginosa PAO1 ΔmurI protects against PAO1 and the 
mucoid strain PA28562. Mice survival after vaccination with PAO1 ΔmurI (0.04X and 0.4X) 
or saline administration, and challenge with PAO1 (0.4X) on day 22 (n = 8) and PA28562 
(0.5X) on day 25 (n = 8). S, saline; V, vaccinated. *P<0.05, compared with control group. 
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When immunized through the intramuscular (IM) route, PAO1 ΔmurI conferred 
mice protection after challenge with PAO1. Similar results were obtained for the highly 
virulent strain PA14: all vaccinated mice survived whereas 71% of control mice died (Fig. 
48). These results suggest that immunization with the PAO1 ΔmurI provides protective 
immunity against diverse P. aeruginosa strains. 
 
 
 
 
 
 
 
Figure 48 | Intramuscular immunization with P. aeruginosa PAO1 ΔmurI protects against 
PAO1 and the highly virulent strain PA14. Mice survival after IM vaccination with PAO1 
ΔmurI (0.4X) or saline administration, and challenge with PAO1 (1X) (n = 8) and PA14 (0.2X) 
(n = 7-8), on day 35. S, saline; V, vaccinated. *P<0.05, compared with control group. 
 
As illustrated in Figure 49, mice vaccinated with S. aureus 132 ΔmurI Δdat were 
completely protected from challenge with strain 132, whereas 81.3% of control mice 
succumbed to infection within 11 days. All vaccinated mice recovered their initial body 
weight within 85 hours post infection; control mice still alive at this time point (37.5%) 
presented 19.2% of body weight loss. At day 53, we observed significant differences in 
bacterial loads (Log10 CFU/g) among three individuals randomly selected from saline and 
vaccinated mice (4.33, 6.66 and 6.96 on livers; 6.71 and 7.41 on kidneys for control mice vs 
0 for vaccinated mice). Apparently, these mice presented no clinical signs of disease. 
Multiple abscesses were also evident on the tissues of control mice; but not detected on 
vaccinated mice.  
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Figure 49 | Immunization with S. aureus 132 ΔmurI Δdat protects against S. aureus 132, 
infection-derived weight loss and abscess formation. Mice survival and percentage of body 
weight loss (mean ± s.e.m.) after vaccination with 132 ΔmurI Δdat (1X) or saline 
administration, and challenge with 132 (0.5X) on day 21 (n = 16-17, pooled data set from 
two independent experiments). Arrows indicate visible liver abscesses after mice necropsy 
on day 53. S, saline; V, vaccinated. *P<0.05, compared with control group.  
 
When challenging mice with FRP3757 (CA-MRSA USA300, a highly virulent and 
epidemic S. aureus clone), RF122 (bovine) and ED98 (poultry) strains, we observed 100% 
survival, whereas all control mice died within 15 hours. All these vaccinated mice 
completely recovered their initial body weight 85 hours after infection (Fig. 50). These 
results evidence that immunization with S. aureus 132 ΔmurI Δdat provides protective 
immunity against epidemic MRSA and diverse S. aureus animal S. aureus strains. 
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Figure 50 | Immunization with S. aureus 132 ΔmurI Δdat protects against diverse S. 
aureus strains. Mice survival and percentage of body weight loss (mean ± s.e.m.) after 
vaccination with 132 ΔmurI Δdat (1X) or saline administration, and challenge with FPR3757-
USA300LAC (0.4X) (n = 7), RF122 (0.25X) (n = 7) and ED98 (0.5X) (n = 7) on day 21. S, saline; 
V, vaccinated. *P<0.05, compared with control group. 
 
While BALB/c have a Th2-dominant immune response, C57BL/6 mice are prone to 
response bias Th1 [347]. To rule out any confounding effect of the immune system inherent 
to the inbred mouse strain, we vaccinated C57BL/6 mice with D-Glu auxotrophic strains. 
When challenged with ATCC 17978, PAO1 and 132, survival rates were 100% for vaccinated 
vs 0% for control mice. Also, 132 ΔmurI Δdat vaccinated mice recovered their initial body 
weight, as BALB/C mice (Fig 51). When PAO1 ΔmurI was administered IM, survival was 
100% for vaccinated vs 25% for control mice, after PAO1 infection (Fig 52). Thus, the 
protective immunity conferred by these D-Glu auxotrophs is independent of different mice 
genetic backgrounds. 
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Figure 51 | Immunization with D-Glu auxotrophs protects C57BL/6 mice against acute 
lethal infection. C57BL/6 mice survival after vaccination with ATCC 17978 ΔmurI1 ΔmurI2 
(1X) or saline administration, and challenge with ATCC 17978 (8X) on day 21 (n = 8). 
C57BL/6 mice survival after vaccination with PAO1 ΔmurI (0.4X) or saline administration, 
and challenge with PAO1 (0.8X) on day 28 (n = 4). C57BL/6 mice survival and percentage of 
body weight loss (mean ± s.e.m.) after vaccination with 132 ΔmurI Δdat (1X) or saline 
administration, and challenge with 132 (1X) on day 21 (n = 8). S, saline; V, vaccinated. 
*P<0.05, compared with control group. 
 
 
 
 
 
 
 
 
 
 
Figure 52 | Intramuscular immunization with P. aeruginosa PAO1 ΔmurI protects C57BL/6 
mice against acute lethal infection. C57BL/6 mice survival after IM vaccination with PAO1 
ΔmurI (0.4X) or saline administration, and challenge with PAO1 (0.4X) on day 35 (n = 8). S, 
saline; V, vaccinated. *P<0.05, compared with control group. 
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In situations in which the completion of a vaccination schedule is not possible, high-
risk situations after pathogen exposure, or when individuals cannot synthesize antibody, 
the use of passive immunization may be beneficial. Those antibodies formed with ATCC 
17978 ΔmurI1 ΔmurI2, PAO1 ΔmurI1 and 132 ΔmurI Δdat vaccinations (anti-Ab, anti-Pa and 
anti-Sa sera, respectively) can be obtained from the host and transferred into another 
recipient where they can provide immediate passive immunity or help fight the infectious 
disease (Fig. 53).   
Figure 53 | Active and passive 
immunization. Antibodies elicited 
by D-Glu auxotrophic strains can 
be obtained after active 
immunization and transferred to 
naïve mice where they can confer 
immediate passive protection 
against infection.  
 
In this sense, we determined if vaccine antisera could be used to therapeutically 
rescue mice from lethal infection. As shown in Figure 54, all mice treated with anti-Ab 
serum and subsequently challenged with ATCC 17978 survived, whereas all control mice 
receiving naïve serum succumbed to infection. Similarly, 100% of survival was observed for 
mice treated with anti-Pa and -Sa sera, and challenged with PAO1 and 132, respectively; 
survival for controls receiving naïve serum was 50% (P<0.05 and P=0.05, respectively). 
These results indicate that at least anti-Ab and -Pa sera can effectively prevent A. 
baumannii and P. aeruginosa acute lethal infection, respectively, whereas antibodies alone 
are sufficient to provide protective immunity. 
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Figure 54 | Immunization with D-Glu auxotrophs induces therapeutically active antisera. 
Survival of mice treated with anti-Ab, anti-Pa, anti-Sa or naïve serum and challenged with 
ATCC 17978 (5X) (n = 8), PAO1 (0.4X) (n = 8) or 132 (1X) (n = 6), 3.5 hours after treatment. S, 
saline; V, vaccinated. *P<0.05, compared with control group. 
 
 
4.6. In vivo and environmental safety of D-Glu auxotrophic bacteria as 
GMO vaccines  
The attenuation should be carried out in such a way that it permits the vaccine 
strain to be sufficiently invasive and to induce both a strong primary and long lasting 
memory immune response, but not a persistent carrier state of the vaccinee [348]. This can 
be achieved by the auxotrophic strain’s ability to colonize and multiply in the host over a 
limited period, before it lyses, being eliminated without causing the disease. This was 
observed for A. baumannii ATCC 17978, P. aeruginosa PAO1 and S. aureus 132 D-Glu 
auxotrophic strains when injected to mice, as they were eliminated from blood faster than 
the wild-type homologues (Fig 55). Unlike ATCC 17978 (1X), we could not recover ATCC 
17978 ΔmurI1 ΔmurI2 (1X) 6 hours after injection, as all blood cultures became negative 
after this time (Fig. 56). In the case of PAO1 ΔmurI (0.4X), this strain was also rapidly 
eliminated from the blood, with negative blood cultures obtained 4 hours after 
administration. Unlike S. aureus 132 (0.5X), 132 ΔmurI Δdat (2.5X) could not be recovered 
beyond 17 hours. Hence, these observations suggest that these strains present no potential 
risk for causing disease and spreading to non-target recipients.  
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Figure 55 | D-Glu auxotrophic bacteria are eliminated from the blood within hours. A. 
baumannii ATCC 17978 (n = 3), ATCC 17978 ΔmurI1 ΔmurI2 (n = 3), P. aeruginosa PAO1 (n = 
4), PAO1 ΔmurI (n = 4), S. aureus 132 (n = 4) and 132 ΔmurI Δdat (n = 4) colonies recovered 
over time from the blood of BALB/c mice upon injection (mean ± s.e.m.).  
 
 
 
Figure 56 | Blood cultures of mice injected A. baumannii ATCC 17978 (1X) or ATCC 17978 
ΔmurI1 ΔmurI2 (1X). Blood samples were collected at the indicated time points after 
bacterial injection and incubated at 37 ºC, for 3 days, in medium supplemented with 10 mM 
D-Glu. C-, negative controls: medium alone. C+, positive controls: medium inoculated with 
ATCC 17978. +, positive blood culture. -, negative blood culture.     
 
  
Also, to be safe and suitable as a genetically modified organism (GMO) vaccine, an 
inherent property of these organisms must be that the attenuation mutations are not 
reversible [58]. To check the irreversibility of the nutritional auxotrophy of ATCC 17978 
ΔmurI1 ΔmurI2, PAO1 ΔmurI and 132 ΔmurI Δdat, these strains were grown with D-Glu for 
8 days and their viability evaluated over time on agar plates with and without D-Glu. In the 
hypothetical case of a phenotype reversion, similar bacterial counts would be expected in 
supplemented and non-supplemented agar plates. Even considering that agar plates were 
incubated for 3 days to encourage phenotype reversion, higher bacterial counts were 
observed in supplemented plates at the initial stage of incubation and on subsequent days 
(Fig. 57), indicating that these strains remain auxotrophic for D-Glu over time. 
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Figure 57 | D-Glu auxotrophic strains cannot revert to the wild-type phenotype. Viable 
counts of ATCC 17978 ΔmurI1 ΔmurI2, PAO1 ΔmurI, and 132 ΔmurI Δdat obtained on agar 
plates (○) and agar supplemented with 10 mM D-Glu (●) after cultivation on media 
supplemented with 10 mM D-Glu (ATCC 17978 ΔmurI1 ΔmurI2 and PAO1 ΔmurI strains) or 
20 mM D-Glu (132 ΔmurI Δdat strain) during 8 days. 
 
Finally, any live attenuated bacterial strain constituting the active ingredient of a 
vaccine should be unable of replicating and persisting in the general environment if it 
hypothetically leaves the vaccinated individual. Spreading of live vaccines, including GMOs, 
must be compared with the wild-type pathogens from diseased individuals and the risk of 
creating epidemics [58]. Thus, persistence of D-Glu auxotrophic strains was compared with 
that of their wild-type homologues. When analysing survival in water (Fig. 58A), marked 
differences in the viability of ATCC 17978 ΔmurI1 ΔmurI2 and PAO1 ΔmurI with respect to 
wild-type strains were observed. Using the same model, no significant differences for S. 
aureus were seen, as no viable bacteria were recovered after 72 and 96 hours from 132 
ΔmurI Δdat and 132 water cultures, respectively. This may be related with the physiology of 
this bacterium. Alternatively, we compared tolerance to drought stress of both S. aureus 
strains, using a desiccation model (Fig. 58B). Indeed, a progressive reduction in the viability 
of 132 ΔmurI Δdat was observed along the time when this strains was kept under drought 
stress as no viable 132 ΔmurI Δdat were recovered from 10-1 and 10-2-spotted cultures after 
the 18th day. In contrast, the 132 strain showed resistance to desiccation and remained 
viable until day 31, even when ×10-2-diluted. 
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Figure 58 | D-Glu auxotrophic strains show lower persistence than wild-type homologues.  
A, Viable counts of ATCC 17978, ATCC 17978 ΔmurI1 ΔmurI2, PAO1, PAO1 ΔmurI, 132 and 
132 ΔmurI Δdat recovered from water during 40, 157 and 5 days (mean ± s.e.m.). B, 
Viability of spotted cultures of S. aureus 132 and 132 ΔmurI Δdat obtained on agar plates 
supplemented with 10 mM D-Glu at day 0 (control) and after being kept under desiccation 
conditions during 31 days. 
 
 
(A) 
(B) 
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5. DISCUSSION 
Having a whole-cell vaccine that contains all the antigenic determinants to induce 
protective immunity in the vaccinee, including those that are synthesized only during 
infection, without the risk of clinical disease, and with minimal possibilities of adverse 
reactions, is the paradigm for effective and safe immunizations. Live vaccines composed of 
bacteria attenuated by natural selection or genetic engineering can afford some of these 
aspects. However, these strains require particular attention regarding their safety as they 
may propagate in the host and be released into the environment by the vaccinees [58]. 
Safety issues of these strains involve changes in cell tissue and host tropism, reversion of 
virulence by acquisition of complementation genes, exchange of genetic information with 
other vaccine or wild-type strains of the carrier organism and spread of undesired genes 
such as antibiotic resistance genes, and must be considered carefully. Furthermore, 
obtaining virulence attenuation is usually impeded by the laborious identification of 
rational targets in each particular bacterium.  
D-Glu is an essential component of the bacterial cell wall. MurI, enzyme that 
converts L-glutamate (L-Glu) to D-Glu, is present in all species of bacteria and its essential 
role in peptidoglycan biosynthesis has been confirmed in species spanning the bacterial 
kingdom, including Gram-positive bacteria that encode the Dat for D-Glu production. In a 
previous study performed by our group in which different proteomic approaches were used 
to study biofilm-associated proteins of A. baumannii [349], we observed a clear up-
regulation of proteins that were directly or indirectly related to L-histidine metabolism. 
Together with L-aspartate, L-arginine and L-histidine, L-Glu was found to triggers biofilm 
formation in vitro. Moreover, the metabolic routes of these amino acids converged 
unequivocally into L-Glu. This observation prompted us to investigate the influence of A. 
baumannii ΔmurI mutants in biofilm formation, considering that L-Glu is the substrate of 
MurI. Indeed, A. baumannii ATCC 17978 ΔmurI1 and ATCC 17978 ΔmurI1 ΔmurI2 were 
found to produce less biofilm than wild-type strain (data not shown). Further, A. baumannii 
ATCC 17978 ΔmurI1 ΔmurI2 was investigated as a vaccine candidate against A. baumannii 
infections, considering its marked virulence attenuation in vivo. This observation was the 
starting point for a more broad approach to generate and validate experimental live 
vaccines based on MurI deletion mutants and D-Glu auxotrophy also in P. aeruginosa and S. 
aureus bacteria. 
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Although D-amino acids are increasingly recognized as physiologically functional 
molecules in mammals, the amounts of free D-Glu are trace substances in most cases [350]. 
Detailed distributions of D-Glu in the brain and peripheral tissues of the rat have been 
clarified and were extremely low, ranging between 1.9 to 9.0 nmol/g [351]. 
Hence, by creating MurI– (and MurI–Dat–) mutants, we took advantage of the highly 
conserved function of MurI in bacteria and the strict requirement of sufficient D-Glu pool 
levels to impair bacterial replication in the host, considering that amounts of free D-amino 
acids are trace substances in mammals. Indeed, A. baumannii, P. aeruginosa and S. aureus 
D-Glu auxotrophic strains presented here were incapable of proliferating in mice due to the 
blockage of the cell wall synthesis, overcoming the problem of in vivo bacterial growth. 
These GMOs were attenuated in comparison with the parental strains and triggered the 
appropriate cellular immune responses and the production of specific and cross-reactive 
antibodies to a wide variety of clonally unrelated epidemic, MDR and highly virulent strains 
of A. baumannii, P. aeruginosa and S. aureus. These results correlated with protection 
against acute lethal infection mainly through using a two-dose immunization schedule. In 
addition, these strains did not appear to represent a risk for causing disease and spreading 
to non-target recipients, considering their rapid elimination from the blood and their 
limited persistence in non-optimal conditions, more likely to occur in the hypothetical case 
of an accidental environmental release. These attributes constitute advantages in relation 
to attenuated and inactivated vaccines, and are summarized in Table 9.   
Table 9 | Characteristics of attenuated, inactivated and auxotrophic vaccines compared.  
 
 Attenuated Inactivated   Auxotrophic 
No. of doses One or few Several One or few 
Need for booster doses Lesser Higher Lesser 
Cross protection from unrelated strains  Present Rare Present 
Growth of bacteria in vivo Yes No No (self-limited) 
Risk of disease Yes No No 
Risk of transmission Yes No No 
Possibility of reversion Yes No No 
Humoral immune response Yes Yes Yes 
Cellular immune response Yes Scarce Yes 
 
A. baumannii is an opportunistic pathogen with notorious ability to withstand 
desiccation and disinfection processes and to persist in the hospital environment. The 
escalating number of infections involving multidrug or pandrug resistant strains of this 
bacterium necessitates the development of new options for preventing against this 
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emerging threat. Although anti-A. baumannii vaccines based on a single, highly purified 
bacterial antigens of A. baumannii (Ata, K1 polysaccharide, OmpA, PNAG, Bap, OmpW) are 
attractive on the basis that these vaccine preparations are well defined and may produce a 
more predictable immune response, this approach has some limitations. Importantly, a 
vaccine targeting a single bacterial antigen would not have activity against strains that lack 
or down regulate the expression of the target gene. Such a decrease in target antigen 
expression could occur due to adaptation to immune pressure or during the acquisition of 
antibiotic resistance, since it has been shown that the expression of certain A. baumannii 
outer membrane proteins is decreased upon the acquisition of resistance [352]. Secondly, 
the process required for antigen purification may alter the conformation of the antigen. 
Multicomponent vaccines composed of outer membrane vesicles and formalin-inactivated 
whole-cells can overcome these problems as these vaccines can elicit antibodies against 
multiple bacterial antigens and better coverage against circulating strains since the 
decreased expression of a single bacterial antigen would likely have less effect on the 
efficacy of such a vaccine. However, the high endotoxin levels present in these vaccines due 
to the presence of LPS complicates their use in human vaccination. Immunization with an 
LPS-deficient whole-cell of A. baumannii provided protective immunity in mice and could 
present a good anti-A. baumannii vaccine. But, like many Gram-negative bacteria, the LPS 
of A. baumannii is highly immunostimulatory [353] and removing this immune-activating 
molecule could impair a broader immune response. Considering the rapid elimination of A. 
baumannii ATCC 17978 MurI- from the blood of mice and in view of the absence of adverse 
effects, it seems that there is no risk for endotoxin accumulation when administering this 
vaccine. However, further studies will be needed to address this aspect.    
Although considerable progress has been made towards understanding the 
epidemiology, mechanisms of antibiotic resistance and persistence, much less is known 
regarding the pathogenesis of A. baumannii and the influence of immune responses to 
control A. baumannii disease. Considering the cellular immune responses elicited in 
response to A. baumannii ATCC 17978 MurI–, a significant increment in IL-4-producing 
splenocytes was observed, consistent with a Th2 response. However, the role of IL-4 
cytokines in host defense against this pathogen is poorly defined. Also, ATCC 17978 MurI– 
mediated a significant increase in the number of IL-17-secreting splenocytes, however IL-17 
seems not to play a major role against systemic A. baumannii infection [354]. 
The alternative complement pathway, a major bactericidal component in serum 
that limits microbial dissemination, is responsible for A. baumannii killing in human serum; 
5. DISCUSSION 
150 
 
however, clinically relevant strains can be resistant to complement activity. This pathway is 
activated leading to deposition of complement factor on the surface of bacteria and 
consequent bacterial lysis or opsonin-mediated phagocytosis. There is considerable debate 
over the mechanism behind the serum resistance of A. baumannii. Proposed models 
include bacterial-mediated inactivation of the alternative complement pathway inhibitor 
Factor H [355], A. baumannii release of LPS [356], and the modification of peptidoglycan by 
the penicillin-binding protein PBP-7/8 [357]. Furthermore, the presence of surface 
polysaccharides or capsule protects Gram-negative bacteria from host antimicrobials in 
serum, and several strains of A. baumannii, like Ab307-0294, produce a polysaccharide 
capsule [326]. Considering that A. baumannii ATCC 17978 does not produces a capsule, the 
ability of the ATCC 17978 MurI– mutant to elicit protective immunity against Ab307-0294 
was noteworthy. Cross protection observed against this strain could be derived from the 
broadly reactive antibodies elicited against whole cell antigens presented by ATCC 17978 
MurI–. 
Therefore, anti-A. baumannii vaccine composed of MurI–  mutants, auxotrophic for 
D-Glu might be a viable approach to effectively control A. baumannii infections.  
It is well established that P. aeruginosa is a frequent and virulent pulmonary 
pathogen in patients with CF and other forms of bronchiectasis [358]. After a period of 
intermittent colonization, the organism becomes permanently established and is difficult to 
eradicate. Most patients with CF become chronically infected with wild-type P. aeruginosa 
strains in early childhood and during the years following initial colonization, the wild-type 
strains uniformly mutate into mucoid variants [359]. High resistance to antibiotics, 
hypermutability, biofilm growth and alginate hyperproduction, or a customized 
pathogenicity which may include the loss of classical virulence factors and metabolic 
changes, are the traits that contribute to P. aeruginosa ability to colonize and persist in the 
lungs as chronic respiratory infections in patients suffering from CF or other chronic 
respiratory diseases [360].   
Despite considerable advances in antimicrobial therapy, effective treatment and 
control of P. aeruginosa infections remains a persistent problem, primarily because of the 
natural resistance of the organism and its remarkable ability to acquire resistance to 
multiple antimicrobial agents by various mechanisms [361]. As an alternative strategy to 
prevent P. aeruginosa infections in susceptible populations, effective immunotherapies or 
vaccines against P. aeruginosa have long been sought. A vaccine to delay or prevent initial 
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pulmonary infection in individuals with CF would have significant impact and may be 
accomplished in the future.  
As P. aeruginosa is an extracellular pathogen, humoral, mucosal or systemic 
opsonizing immunity is most effective to prevent bacterial colonization and infection. 
However, T cell responses can also mediate protective immunity in individuals with P. 
aeruginosa infections [362-364].  
P. aeruginosa PAO1 MurI– triggered a substantial increment – although not 
significant – in IFN-γ-secreting splenocytes, as marker of Th1, as well a significant increment 
in IL-4-producing splenocytes, consistent with a Th2 immune response. IL-4 is known to 
enhance pulmonary clearance of P. aeruginosa in mice [365]. However, comparing the CF 
patients with and without chronic lung infection suggested that a Th2 type response 
correlated with infection, implying that a Th1 response may be more protective [366,367]. 
More importantly, P. aeruginosa MurI– mediated a significant increase in the number of IL-
17-secreting splenocytes, essential in acute pulmonary P. aeruginosa infection [181,368].  
The most similar to MurI– experimental vaccines obtained so far against P. 
aeruginosa are those derived from P. aeruginosa ΔaroA deletion mutants. These mutants 
are unable to synthesize aromatic amino acids and cannot efficiently acquire them from the 
host and hence can survive at detectable levels only up to 3–4 days following 
administration [179]. Recently, a multivalent vaccine composed of different P. aeruginosa 
ΔaroA strains induced multifactorial immune responses against diverse bacterial antigens 
and protected against acute fatal lung infection [183]. Despite these results, residual 
virulence in these strains was observed [179,180,182,183]. In the case of P. aeruginosa 
MurI–, this strain was rapidly eliminated from the blood of BALB/c mice, with negative 
blood cultures and no viable bacterial counts 4 hours after administration. Although we did 
not evaluate the clearance of P. aeruginosa from lungs, it seems that P. aeruginosa MurI– 
can overcome the limitations presented by ΔaroA mutants.  
Considering all these aspects, an anti-P. aeruginosa vaccine composed of MurI– 
mutants, auxotrophic for D-Glu, might be a viable approach to effectively control P. 
aeruginosa infections in CF and non-CF patients. 
With the increasing propensity of S. aureus to develop resistance to essentially all 
classes of antibiotics, alternative strategies, such as prophylactic vaccination to prevent S. 
aureus infections, are actively being pursued in healthcare settings. Within the last decade, 
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the S. aureus vaccine field as witnessed two major vaccine failures in phase III clinical trials 
designed to prevent S. aureus infections in either patients undergoing cardiothoracic 
surgery or patients with end-stage renal disease undergoing haemodialysis, evidencing the 
need for an effective vaccine.  
Preclinical and clinical data indicate that immunization with intact whole S. aureus 
bacteria induces high immune titers, but does not confer protection from S. aureus disease 
[369,370]. Additionally, the S. aureus stimulated humoral immune response may not play a 
meaningful role in bacterial clearance in some models. While antibodies undoubtedly play 
some role in protection, they may not be determinative for vaccine protective efficacy 
because animals and humans already have sufficient baseline opsonins to allow for 
phagocytic uptake by neutrophils. T cells were observed to play a pivotal role in the 
prevention of S. aureus infection, as demonstrated in models of disseminated as well as 
local infection. In this study, S. aureus MurI–Dat– vaccine triggered an appropriate cellular 
immune response, with IL-17-secreting splenocytes being the predominant T cell subset 
triggered. Th17/IL-17 pathway was demonstrated to be essential in defence against S. 
aureus acute lethal infection in mice [304,371]. Also, a significant number of IFN-γ-secreting 
splenocytes was elicited. Th1 effector cytokines such as IFN-γ may play a crucial role in the 
eradication of S. aureus [372]. These data indicate that active immunization with S. aureus 
MurI–Dat– elicits a Th1 and Th17 response.  
The precise immunopathological mechanisms that predispose a given individual to 
to S. aureus disease are still unclear. Preclinical animal models have thus been developed to 
study S. aureus pathogenesis but these models are limited by the fact that S. aureus is 
exquisitely adapted to the human host. Therefore, no preclinical animal model of infection 
fully recapitulates the natural infections process in humans, due to differences in host cell 
proteins, such as haemoglobin [373], and the requirement for high bacterial challenge 
doses [374] in the non-human host. The experimental S. aureus MurI–Dat– vaccine 
presented here demonstrated to be highly effective using a preclinical model of mouse 
acute lethal infection, and perhaps, these results would apply to humans. Further studies 
need to be accomplished.   
Therefore, our D-Glu auxotrophs are promising whole-cell vaccines against the 
high-priority pathogens A. baumannii, P. aeruginosa and S. aureus. Moreover, this 
pioneering approach of bacterial attenuation can be more broadly applied to other Gram-
negative and Gram-positive pathogens of global concern, and individual vaccine 
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compositions obtained this way can be reinforced with the combination of multiple 
bacterial strains for their use as prophylactics for human or animal health in the future.  
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6. CONCLUSIONS 
6.1. Characterization of MurI– and MurI–Dat– mutants 
6.1.1. MurI– mutants of Acinetobacter baumannii ATCC 17978 and Pseudomonas 
aeruginosa PAO1 are auxotrophic for D-Glu 
6.1.2. The MurI–Dat– mutant of Staphylococcus aureus 132 is auxotrophic for D-
Glu 
6.1.3. A. baumannii MurI– and S. aureus MurI–Dat– present an altered pattern of 
cell division in the presence of low D-Glu concentrations 
6.1.4. D-Glu auxotrophy produces cell wall degeneration and bacterial lysis of 
MurI– or MurI–Dat– mutants 
6.2. Virulence attenuation of MurI– and MurI–Dat– mutants 
6.2.1. D-Glu auxotrophic strains are attenuated respective to parental strains in a 
mouse model of acute lethal infection 
6.3. Generation of antibody-mediated immune responses 
6.3.1. Vaccination with D-Glu auxotrophic strains elicits high level of specific 
antibodies in BALB/c mice 
6.3.2. Antibody-mediated immune response activation by D-Glu auxotrophic 
strains is dose-dependent 
6.3.3. The MurI– mutant of A. baumannii elicits long-term antibody memory 
6.3.4. Immunization with D-Glu auxotrophic strains elicits high levels of cross-
reactive IgG antibodies against clonally unrelated bacterial strains 
6.4. Activation of cell-mediated immunity 
6.4.1. Immunization with A. baumannii MurI– and P. aeruginosa MurI– elicits 
consistent Th2 and Th17 immune responses 
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6.4.2. Immunization with S. aureus MurI–Dat– elicits consistent Th1 and Th17 
immune responses 
6.5. Protective immunity against acute lethal infection 
6.5.1. Vaccination with A. baumannii MurI– and P. aeruginosa MurI– protects 
against bacterial dissemination after challenge 
6.5.2. Vaccination with S. aureus MurI–Dat– protects against bacterial 
dissemination and prevents weight loss after challenge 
6.5.3. Vaccination with A. baumannii MurI– protects against A. baumannii 
parental, MDR and highly virulent strains  
6.5.4. Vaccination with P. aeruginosa MurI– protects against P. aeruginosa 
parental, mucoid and highly virulent strains 
6.5.5. Vaccination with S. aureus MurI–Dat– protects against S. aureus parental, 
MRSA, highly disseminated, bovine and poultry strains 
6.5.6. The protective efficacy of vaccination with MurI– and MurI–Dat– mutants 
against parental strains is independent of different mice genetic 
backgrounds 
6.5.7. Intramuscular vaccination with P. aeruginosa MurI– confers protection 
against parental and highly virulent P. aeruginosa strains 
6.5.8. Vaccination with D-Glu auxotrophic strains induces therapeutically active 
antisera  
6.6. In vivo and environmental safety of D-Glu auxotrophic bacteria as 
GMO vaccines 
6.6.1. A. baumannii MurI–, P. aeruginosa MurI– and S. aureus MurI–Dat– are 
eliminated from the blood of mice within hours, and appear safe for 
parenteral administrations  
6.6.2. MurI– or MurI–Dat– mutants of A. baumannii, P. aeruginosa and S. aureus 
do not revert to the wild-type phenotype in vitro 
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6.1.5. MurI– mutants of A. baumannii and P. aeruginosa are more susceptible to 
osmolisis than its wild-type homologues 
6.1.6. MurI–Dat– mutant of S. aureus is more susceptible to desiccation than its 
wild-type homologue 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. CONCLUSIONS 
160 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
161 
 
 
 
 
 
 
7. REFERENCES               
 
 
 
 
 
 
 
 
 
162 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
163 
 
7. REFERENCES 
1. Vidarsson, G., Dekkers, G. & Rispens, T. IgG subclasses and allotypes: from structure 
to effector functions. Front. Immunol. 5, 520 (2014). 
 
2. Wheelock, E. F. Interferon-like virus-inhibitor induced in human leukocytes by 
phytohemagglutinin. Science 149, 310–1 (1965). 
 
3. Billiau, A. Interferon-gamma: biology and role in pathogenesis. Adv. Immunol. 62, 
61–130 (1996). 
 
4. Boehm, U., Klamp, T., Groot, M. & Howard, J. C. Cellular responses to interferon-
gamma. Annu. Rev. Immunol. 15, 749–95 (1997). 
 
5. Farrar, M. A. & Schreiber, R. D. The molecular cell biology of interferon-gamma and 
its receptor. Annu. Rev. Immunol. 11, 571–611 (1993). 
 
6. Puddu, P. et al. IL-12 induces IFN-gamma expression and secretion in mouse 
peritoneal macrophages. J. Immunol. 159, 3490–7 (1997). 
 
7. Sugaya, M., Nakamura, K. & Tamaki, K. Interleukins 18 and 12 synergistically 
upregulate interferon-gamma production by murine dendritic epidermal T cells. J. 
Invest. Dermatol. 113, 350–4 (1999). 
 
8. Ohteki, T. et al. Interleukin 12-dependent interferon gamma production by 
CD8alpha+ lymphoid dendritic cells. J. Exp. Med. 189, 1981–6 (1999). 
 
9. Gupta, A. A., Leal-Berumen, I., Croitoru, K. & Marshall, J. S. Rat peritoneal mast cells 
produce IFN-gamma following IL-12 treatment but not in response to IgE-mediated 
activation. J. Immunol. 157, 2123–8 (1996). 
 
10. Howard, M. et al. Identification of a T cell-derived b cell growth factor distinct from 
interleukin 2. J. Exp. Med. 155, 914–23 (1982). 
 
11. Brown, M. A. & Hural, J. Functions of IL-4 and control of its expression. Crit. Rev. 
Immunol. 17, 1–32 (1997). 
 
12. Noma, Y. et al. Cloning of cDNA encoding the murine IgG1 induction factor by a 
novel strategy using SP6 promoter. Nature 319, 640–6 
 
13. Yokota, T. et al. Isolation and characterization of a human interleukin cDNA clone, 
homologous to mouse B-cell stimulatory factor 1, that expresses B-cell- and T-cell-
164 
 
stimulating activities. Proc. Natl. Acad. Sci. U. S. A. 83, 5894–8 (1986). 
 
14. Arai, N. et al. Complete nucleotide sequence of the chromosomal gene for human IL-
4 and its expression. J. Immunol. 142, 274–82 (1989). 
 
15. McKnight, A. J., Barclay, A. N. & Mason, D. W. Molecular cloning of rat interleukin 4 
cDNA and analysis of the cytokine repertoire of subsets of CD4+ T cells. Eur. J. 
Immunol. 21, 1187–94 (1991). 
 
16. Mosmann, T. R. et al. Species-specificity of T cell stimulating activities of IL 2 and 
BSF-1 (IL 4): comparison of normal and recombinant, mouse and human IL 2 and 
BSF-1 (IL 4). J. Immunol. 138, 1813–6 (1987). 
 
17. Ramírez, F., Stumbles, P., Puklavec, M. & Mason, D. Rat interleukin-4 assays. J. 
Immunol. Methods 221, 141–50 (1998). 
 
18. Ho, I. C., Hodge, M. R., Rooney, J. W. & Glimcher, L. H. The proto-oncogene c-maf is 
responsible for tissue-specific expression of interleukin-4. Cell 85, 973–83 (1996). 
 
19. Nakamura, E. et al. Involvement of NK1+ CD4- CD8- alphabeta T cells and 
endogenous IL-4 in non-MHC-restricted rejection of embryonal carcinoma in 
genetically resistant mice. J. Immunol. 158, 5338–48 (1997). 
 
20. Launois, P., Ohteki, T., Swihart, K., MacDonald, H. R. & Louis, J. A. In susceptible 
mice, Leishmania major induce very rapid interleukin-4 production by CD4+ T cells 
which are NK1.1-. Eur. J. Immunol. 25, 3298–307 (1995). 
 
21. Kelleher, P., Maroof, A. & Knight, S. C. Retrovirally induced switch from production 
of IL-12 to IL-4 in dendritic cells. Eur. J. Immunol. 29, 2309–18 (1999). 
 
22. Adachi, Y., Kindzelskii, A. L., Ohno, N., Yadomae, T. & Petty, H. R. Amplitude and 
frequency modulation of metabolic signals in leukocytes: synergistic role of IFN-
gamma in IL-6- and IL-2-mediated cell activation. J. Immunol. 163, 4367–74 (1999). 
 
23. Rumbley, C. A. et al. Activated eosinophils are the major source of Th2-associated 
cytokines in the schistosome granuloma. J. Immunol. 162, 1003–9 (1999). 
 
24. Seder, R. A. et al. Mouse splenic and bone marrow cell populations that express 
high-affinity Fc epsilon receptors and produce interleukin 4 are highly enriched in 
basophils. Proc. Natl. Acad. Sci. U. S. A. 88, 2835–9 (1991). 
 
25. Pan, P. Y. & Rothman, P. IL-4 receptor mutations. Curr. Opin. Immunol. 11, 615–20 
(1999). 
7. REFERENCES 
165 
 
 
26. Faquim-Mauro, E. L., Coffman, R. L., Abrahamsohn, I. A. & Macedo, M. S. Cutting 
edge: mouse IgG1 antibodies comprise two functionally distinct types that are 
differentially regulated by IL-4 and IL-12. J. Immunol. 163, 3572–6 (1999). 
 
27. Hart, P. H. et al. Differential responses of human monocytes and macrophages to IL-
4 and IL-13. J. Leukoc. Biol. 66, 575–8 (1999). 
 
28. O’Garra, A. Cytokines induce the development of functionally heterogeneous T 
helper cell subsets. Immunity 8, 275–83 (1998). 
 
29. Korn, T., Bettelli, E., Oukka, M. & Kuchroo, V. K. IL-17 and Th17 Cells. Annu. Rev. 
Immunol. 27, 485–517 (2009). 
 
30. Kolls, J. K. & Lindén, A. Interleukin-17 family members and inflammation. Immunity 
21, 467–76 (2004). 
 
31. Witowski, J., Ksiazek, K. & Jörres, A. Interleukin-17: a mediator of inflammatory 
responses. Cell. Mol. Life Sci. 61, 567–79 (2004). 
 
32. Schwarzenberger, P. et al. Requirement of endogenous stem cell factor and 
granulocyte-colony-stimulating factor for IL-17-mediated granulopoiesis. J. Immunol. 
164, 4783–9 (2000). 
 
33. Jovanovic, D. V et al. IL-17 stimulates the production and expression of 
proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J. 
Immunol. 160, 3513–21 (1998). 
 
34. Numasaki, M., Takahashi, H., Tomioka, Y. & Sasaki, H. Regulatory roles of IL-17 and 
IL-17F in G-CSF production by lung microvascular endothelial cells stimulated with 
IL-1β and/or TNF-α. Immunol. Lett. 95, 97–104 (2004). 
 
35. Miljkovic, D. et al. The role of interleukin-17 in inducible nitric oxide synthase-
mediated nitric oxide production in endothelial cells. Cell. Mol. Life Sci. 60, 518–25 
(2003). 
 
36. Chen, K. et al. Th17 Cells Mediate Clade-Specific, Serotype-Independent Mucosal 
Immunity. Immunity 35, 997–1009 (2011). 
 
37. Khader, S. A. et al. IL-23 and IL-17 in the establishment of protective pulmonary 
CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis 
challenge. Nat. Immunol. 8, 369–77 (2007). 
 
7. REFERENCES 
166 
 
38. Lindenstrøm, T. et al. Vaccine-induced th17 cells are maintained long-term 
postvaccination as a distinct and phenotypically stable memory subset. Infect. 
Immun. 80, 3533–44 (2012). 
 
39. Aggarwal, S. & Gurney, A. L. IL-17: prototype member of an emerging cytokine 
family. J. Leukoc. Biol. 71, 1–8 (2002). 
 
40. Moseley, T. A., Haudenschild, D. R., Rose, L. & Reddi, A. H. Interleukin-17 family and 
IL-17 receptors. Cytokine Growth Factor Rev. 14, 155–74 (2003). 
 
41. Yao, Z. et al. Human IL-17: a novel cytokine derived from T cells. J. Immunol. 155, 
5483–6 (1995). 
 
42. Rouvier, E., Luciani, M. F., Mattéi, M. G., Denizot, F. & Golstein, P. CTLA-8, cloned 
from an activated T cell, bearing AU-rich messenger RNA instability sequences, and 
homologous to a herpesvirus saimiri gene. J. Immunol. 150, 5445–56 (1993). 
 
43. Kennedy, J. et al. Mouse IL-17: a cytokine preferentially expressed by alpha beta TCR 
+ CD4-CD8-T cells. J. Interferon Cytokine Res. 16, 611–7 (1996). 
 
44. Liang, S. C. et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and 
cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. 203, 2271–
9 (2006). 
 
45. Mitsdoerffer, M. et al. Proinflammatory T helper type 17 cells are effective B-cell 
helpers. Proc. Natl. Acad. Sci. U. S. A. 107, 14292–7 (2010). 
 
46. Leo, O., Cunningham, A. & Stern, P. L. Understanding modern vaccines: perspectives 
in vaccinology. 25–59 (Elsevier B.V., 2011).  
 
47. Levine, M. M. et al. Safety, immunogenicity, and efficacy of recombinant live oral 
cholera vaccines, CVD 103 and CVD 103-HgR. Lancet (London, England) 2, 467–70 
(1988). 
 
48. Simanjuntak, C. H. et al. Oral immunisation against typhoid fever in Indonesia with 
Ty21a vaccine. Lancet 338, 1055–9 (1991). 
 
49. Liu, J., Tran, V., Leung, A. S., Alexander, D. C. & Zhu, B. BCG vaccines: their 
mechanisms of attenuation and impact on safety and protective efficacy. Hum. 
Vaccin. 5, 70–8 (2009). 
 
50. Michael, A., Geier, E., Konshtok, R., Hertman, I. & Markenson, J. Attenutated live 
fowl cholera vaccine. III. Laboratory and field vaccination trials in turkeys and 
7. REFERENCES 
167 
 
chickens. Avian Dis. 23, 878–85 (1979). 
 
51. Panciera, R. J., Corstvet, R. E., Confer, A. W. & Gresham, C. N. Bovine pneumonic 
pasteurellosis: effect of vaccination with live Pasteurella species. Am. J. Vet. Res. 45, 
2538–42 (1984). 
 
52. Sakano, T., Sakurai, K., Furutani, T. & Shimizu, T. Immunogenicity and safety of an 
attenuated Bordetella bronchiseptica vaccine in pigs. Am. J. Vet. Res. 45, 1814–7 
(1984). 
 
53. Turnbull, P. C. B. Review Anthrax vaccines : past , present and future. 9, 533–9 
(1991). 
 
54. Thiaucourt, F. et al. Contagious bovine pleuropneumonia. A reassessment of the 
efficacy of vaccines used in Africa. Ann. N. Y. Acad. Sci. 916, 71–80 (2000). 
 
55. Schurig, G. G., Sriranganathan, N. & Corbel, M. J. Brucellosis vaccines : past , present 
and future. 90, 479–96 (2002). 
 
56. Begg, D. J. & Griffin, J. F. T. Vaccination of sheep against M. paratuberculosis: 
Immune parameters and protective efficacy. Vaccine 23, 4999–5008 (2005). 
 
57. Lee, Y. J., Mo, I. P. & Kang, M. S. Safety and efficacy of Salmonella gallinarum 9R 
vaccine in young laying chickens. Avian Pathol. 34, 362–6 (2005). 
 
58. Frey, J. Biological safety concepts of genetically modified live bacterial vaccines. 
Vaccine 25, 5598–605 (2007). 
 
59. Crump, J. A. & Mintz, E. D. Global trends in typhoid and paratyphoid Fever. Clin. 
Infect. Dis. 50, 241–6 (2010). 
 
60. Engels, E. A., Falagas, M. E., Lau, J. & Bennish, M. L. Typhoid fever vaccines: a meta-
analysis of studies on efficacy and toxicity. BMJ 316, 110–6 (1998). 
 
61. Fraser, A., Paul, M., Goldberg, E., Acosta, C. J. & Leibovici, L. Typhoid fever vaccines: 
systematic review and meta-analysis of randomised controlled trials. Vaccine 25, 
7848–57 (2007). 
 
62. Guzman, C. A. et al. Vaccines against typhoid fever. Vaccine 24, 3804–11 (2006). 
 
63. Germanier, R. & Füer, E. Isolation and characterization of Gal E mutant Ty 21a of 
Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J. Infect. Dis. 131, 
7. REFERENCES 
168 
 
553–8 (1975). 
 
64. Kopecko, D. J. et al. Genetic stability of vaccine strain Salmonella Typhi Ty21a over 
25 years. Int. J. Med. Microbiol. 299, 233–46 (2009). 
 
65. Germanier, R. & Fürer, E. Characteristics of the attenuated oral vaccine strain ‘S. 
typhi’ Ty 21a. Dev. Biol. Stand. 53, 3–7 (1983). 
 
66. Gentschev, I. et al. Vivotif--a ‘magic shield’ for protection against typhoid fever and 
delivery of heterologous antigens. Chemotherapy 53, 177–80 (2007). 
 
67. Anwar, E. et al. Vaccines for preventing typhoid fever. Cochrane database Syst. Rev. 
1, CD001261 (2014). 
 
68. Raffatellu, M., Wilson, R. P., Winter, S. E. & Bäumler, A. J. Clinical pathogenesis of 
typhoid fever. J. Infect. Dev. Ctries. 2, 260–6 (2008). 
 
69. Breen, J. F. & Apicella, M. A. Immunogenicity of gonococcal Gc2 polysaccharide: 
comparative studies with pneumococcal type III polysaccharide and Salmonella 
typhosa Vi antigen. Infect. Immun. 22, 195–9 (1978). 
 
70. Lake, J. P., Reed, N. D., Ulrich, J. T. & Varitek, V. A. Development of a localized 
hemolysis-in-gel assay for Vi antigen: characterization of the Vi-specific PFC 
response of nude and normal mice. Immunol. Commun. 6, 149–65 (1977). 
 
71. Ryan, E. T. & Calderwood, S. B. Cholera vaccines. Clin. Infect. Dis. 31, 561–5 (2000). 
 
72. Ketley, J. M., Michalski, J., Galen, J., Levine, M. M. & Kaper, J. B. Construction of 
genetically marked Vibrio cholerae O1 vaccine strains. FEMS Microbiol. Lett. 111, 15–
21 (1993). 
 
73. Kotloff, K. L. et al. Safety and immunogenicity in North Americans of a single dose of 
live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, 
double-blind crossover trial. Infect. Immun. 60, 4430–2 (1992). 
 
74. Tacket, C. O. et al. Onset and duration of protective immunity in challenged 
volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J. Infect. 
Dis. 166, 837–41 (1992). 
 
75. Tacket, C. O. et al. Randomized, double-blind, placebo-controlled, multicentered 
trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in 
preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three 
months after vaccination. Infect. Immun. 67, 6341–5 (1999). 
7. REFERENCES 
169 
 
 
76. Kenner, J. R. et al. Peru-15, an improved live attenuated oral vaccine candidate for 
Vibrio cholerae O1. J. Infect. Dis. 172, 1126–9 (1995). 
 
77. Sack, D. A. et al. Evaluation of Peru-15, a new live oral vaccine for cholera, in 
volunteers. J. Infect. Dis. 176, 201–5 (1997). 
 
78. Qadri, F. et al. Randomized, controlled study of the safety and immunogenicity of 
Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in 
Bangladesh. J. Infect. Dis. 192, 573–9 (2005). 
 
79. Qadri, F. et al. Peru-15, a live attenuated oral cholera vaccine, is safe and 
immunogenic in Bangladeshi toddlers and infants. Vaccine 25, 231–8 (2007). 
 
80. Benítez, J. A. et al. Preliminary assessment of the safety and immunogenicity of a 
new CTXPhi-negative, hemagglutinin/protease-defective El Tor strain as a cholera 
vaccine candidate. Infect. Immun. 67, 539–45 (1999). 
 
81. García, L. et al. The vaccine candidate Vibrio cholerae 638 is protective against 
cholera in healthy volunteers. Infect. Immun. 73, 3018–24 (2005). 
 
82. Thungapathra, M. et al. Construction of a recombinant live oral vaccine from a non-
toxigenic strain of Vibrio cholerae O1 serotype inaba biotype E1 Tor and assessment 
of its reactogenicity and immunogenicity in the rabbit model. Immunol. Lett. 68, 
219–27 (1999). 
 
83. Liang, W. et al. Construction and evaluation of a safe, live, oral Vibrio cholerae 
vaccine candidate, IEM108. Infect. Immun. 71, 5498–504 (2003). 
 
84. Ryan, E. T., Calderwood, S. B. & Qadri, F. Live attenuated oral cholera vaccines. 
Expert Rev. Vaccines 5, 483–94 (2006). 
 
85. Weekly epidemiological record Relevé épidémiologique hebdomadaire. World 
Health Organization. 79, 25–40 (2004). 
 
86. Leung, A. S. et al. Novel genome polymorphisms in BCG vaccine strains and impact 
on efficacy. BMC Genomics 9, 413 (2008). 
 
87. Chen, J. M., Islam, S. T., Ren, H. & Liu, J. Differential productions of lipid virulence 
factors among BCG vaccine strains and implications on BCG safety. Vaccine 25, 
8114–22 (2007). 
 
7. REFERENCES 
170 
 
88. Bonah, C. The ‘experimental stable’ of the BCG vaccine: safety, efficacy, proof, and 
standards, 1921-1933. Stud. Hist. Philos. Biol. Biomed. Sci. 36, 696–721 (2005). 
 
89. Mahairas, G. G., Sabo, P. J., Hickey, M. J., Singh, D. C. & Stover, C. K. Molecular 
analysis of genetic differences between Mycobacterium bovis BCG and virulent M. 
bovis. J. Bacteriol. 178, 1274–82 (1996). 
 
90. Behr, M. A. et al. Comparative genomics of BCG vaccines by whole-genome DNA 
microarray. Science 284, 1520–3 (1999). 
 
91. Abdallah, A. M. et al. Type VII secretion--mycobacteria show the way. Nat. Rev. 
Microbiol. 5, 883–91 (2007). 
 
92. Pym, A. S. et al. Recombinant BCG exporting ESAT-6 confers enhanced protection 
against tuberculosis. Nat. Med. 9, 533–9 (2003). 
 
93. Sherman, D. R. et al. Mycobacterium tuberculosis H37Rv: Delta RD1 is more virulent 
than M. bovis bacille Calmette-Guérin in long-term murine infection. J. Infect. Dis. 
190, 123–6 (2004). 
 
94. Brosch, R. et al. Genome plasticity of BCG and impact on vaccine efficacy. Proc. Natl. 
Acad. Sci. U. S. A. 104, 5596–601 (2007). 
 
95. Onwueme, K. C., Vos, C. J., Zurita, J., Ferreras, J. A. & Quadri, L. E. N. The 
dimycocerosate ester polyketide virulence factors of mycobacteria. Prog. Lipid Res. 
44, 259–302 (2005). 
 
96. Frigui, W. et al. Control of M. tuberculosis ESAT-6 secretion and specific T cell 
recognition by PhoP. PLoS Pathog. 4, (2008). 
 
97. Lee, J. S. et al. Mutation in the transcriptional regulator PhoP contributes to 
avirulence of Mycobacterium tuberculosis H37Ra strain. Cell Host Microbe 3, 97–103 
(2008). 
 
98. Martin, C. et al. The live Mycobacterium tuberculosis phoP mutant strain is more 
attenuated than BCG and confers protective immunity against tuberculosis in mice 
and guinea pigs. Vaccine 24, 3408–19 (2006). 
 
99. Chesne-Seck, M.-L. et al. A point mutation in the two-component regulator PhoP-
PhoR accounts for the absence of polyketide-derived acyltrehaloses but not that of 
phthiocerol dimycocerosates in Mycobacterium tuberculosis H37Ra. J. Bacteriol. 190, 
1329–34 (2008). 
 
7. REFERENCES 
171 
 
100. Cole, S. T. et al. Deciphering the biology of Mycobacterium tuberculosis from the 
complete genome sequence. Nature 393, 537–44 (1998). 
 
101. Burian, J. et al. The mycobacterial antibiotic resistance determinant WhiB7 acts as a 
transcriptional activator by binding the primary sigma factor SigA (RpoV). Nucleic 
Acids Res. 41, 10062–76 (2013). 
 
102. Ramón-García, S. et al. WhiB7, an Fe-S-dependent transcription factor that activates 
species-specific repertoires of drug resistance determinants in actinobacteria. J. Biol. 
Chem. 288, 34514–28 (2013). 
 
103. Larsson, C. et al. Gene expression of Mycobacterium tuberculosis putative 
transcription factors whiB1-7 in redox environments. PLoS One 7, e37516 (2012). 
 
104. Steyn, A. J. C. et al. Mycobacterium tuberculosis WhiB3 interacts with RpoV to affect 
host survival but is dispensable for in vivo growth. Proc. Natl. Acad. Sci. U. S. A. 99, 
3147–52 (2002). 
 
105. Singh, A. et al. Mycobacterium tuberculosis WhiB3 maintains redox homeostasis by 
regulating virulence lipid anabolism to modulate macrophage response. PLoS 
Pathog. 5, e1000545 (2009). 
 
106. Parish, T. et al. Deletion of two-component regulatory systems increases the 
virulence of Mycobacterium tuberculosis. Infect. Immun. 71, 1134–40 (2003). 
 
107. Casali, N. & Riley, L. W. A phylogenomic analysis of the Actinomycetales mce 
operons. BMC Genomics 8, 60 (2007). 
 
108. Mostowy, S., Tsolaki, A. G., Small, P. M. & Behr, M. A. The in vitro evolution of BCG 
vaccines. Vaccine 21, 4270–4 (2003). 
 
109. Pandey, A. K. & Sassetti, C. M. Mycobacterial persistence requires the utilization of 
host cholesterol. Proc. Natl. Acad. Sci. U. S. A. 105, 4376–80 (2008). 
 
110. Rathor, N. et al. An insight into the regulation of mce4 operon of Mycobacterium 
tuberculosis. Tuberculosis (Edinb). 93, 389–97 (2013). 
 
111. WHO Information sheet: observed rate of vaccine reactions bacilli Calmette-Guérin 
(BCG) vaccine. Global Vaccine Safety, Immunizations and Biologicals (2012).   
 
112. Malaga, W., Perez, E. & Guilhot, C. Production of unmarked mutations in 
mycobacteria using site-specific recombination. FEMS Microbiol. Lett. 219, 261–8 
(2003). 
7. REFERENCES 
172 
 
 
113. Arbues, A. et al. Construction, characterization and preclinical evaluation of 
MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical 
trials. Vaccine 31, 4867–73 (2013). 
 
114. Roberts, M., Maskell, D., Novotny, P. & Dougan, G. Construction and 
characterization in vivo of Bordetella pertussis aroA mutants. Infect. Immun. 58, 
732–9 (1990). 
 
115. Mielcarek, N. et al. Live attenuated B. pertussis as a single-dose nasal vaccine against 
whooping cough. PLoS Pathog. 2, 0662–70 (2006). 
 
116. Mielcarek, N., Debrie, A.-S., Mahieux, S. & Locht, C. Dose response of attenuated 
Bordetella pertussis BPZE1-induced protection in mice. Clin. Vaccine Immunol. 17, 
317–24 (2010). 
 
117. Feunou, P., Kammoun, H. & Debrie, A. Long-term immunity against pertussis 
induced by a single nasal administration of live attenuated B . pertussis BPZE1. 
Vaccine 28, 7047–53 (2010). 
 
118. Kammoun, H. et al. Dual mechanism of protection by live attenuated Bordetella 
pertussis BPZE1 against Bordetella bronchiseptica in mice. Vaccine 30, 5864–70 
(2012). 
 
119. Thorstensson, R. et al. A phase I clinical study of a live attenuated Bordetella 
pertussis vaccine--BPZE1; a single centre, double-blind, placebo-controlled, dose-
escalating study of BPZE1 given intranasally to healthy adult male volunteers. PLoS 
One 9, e83449 (2014). 
 
120. Locht, C. A common vaccination strategy to solve unsolved problems of tuberculosis 
and pertussis? Microbes Infect. 10, 1051–6 (2008). 
 
121. Boucher, H. W. et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious 
Diseases Society of America. Clin. Infect. Dis. 48, 1–12 (2009). 
 
122. Spellberg, B. et al. The epidemic of antibiotic-resistant infections: a call to action for 
the medical community from the Infectious Diseases Society of America. Clin. Infect. 
Dis. 46, 155–64 (2008). 
 
123. Peleg, A. Y., Seifert, H. & Paterson, D. L. Acinetobacter baumannii: Emergence of a 
successful pathogen. Clin. Microbiol. Rev. 21, 538–82 (2008). 
 
124. Kempf, M. & Rolain, J.-M. Emergence of resistance to carbapenems in Acinetobacter 
7. REFERENCES 
173 
 
baumannii in Europe: clinical impact and therapeutic options. Int. J. Antimicrob. 
Agents 39, 105–14 (2012). 
 
125. Lin, M.-F. & Lan, C.-Y. Antimicrobial resistance in Acinetobacter baumannii: From 
bench to bedside. World J. Clin. cases 2, 787–814 (2014). 
 
126. Wright, M. S. et al. New insights into dissemination and variation of the health care-
associated pathogen Acinetobacter baumannii from genomic analysis. MBio 5, 
e00963–13 (2014). 
 
127. Peleg, A. Y. et al. The success of acinetobacter species; genetic, metabolic and 
virulence attributes. PLoS One 7, e46984 (2012). 
 
128. Pachón, J. & McConnell, M. J. Considerations for the development of a prophylactic 
vaccine for Acinetobacter baumannii. Vaccine 32, 2534–6 (2014). 
 
129. Xiao, W. et al. A genomic storm in critically injured humans. J. Exp. Med. 208, 2581–
90 (2011). 
 
130. Marik, P. E. & Flemmer, M. The immune response to surgery and trauma: 
Implications for treatment. J. Trauma Acute Care Surg. 73, 801–8 (2012). 
 
131. van Faassen, H. et al. Neutrophils play an important role in host resistance to 
respiratory infection with Acinetobacter baumannii in mice. Infect. Immun. 75, 
5597–608 (2007). 
 
132. Qiu, H. et al. Role of macrophages in early host resistance to respiratory 
Acinetobacter baumannii infection. PLoS One 7, e40019 (2012). 
 
133. Weinberger, B., Herndler-Brandstetter, D., Schwanninger, A., Weiskopf, D. & 
Grubeck-Loebenstein, B. Biology of immune responses to vaccines in elderly 
persons. Clin. Infect. Dis. 46, 1078–84 (2008). 
 
134. Bentancor, L. V., O’malley, J. M., Bozkurt-Guzel, C., Pier, G. B. & Maira-Litrán, T. Poly-
n-acetyl-β-(1-6)-glucosamine is a target for protective immunity against 
Acinetobacter baumannii infections. Infect. Immun. 80, 651–6 (2012). 
 
135. Bentancor, L. V. et al. Evaluation of the trimeric autotransporter ata as a vaccine 
candidate against Acinetobacter baumannii infections. Infect. Immun. 80, 3381–8 
(2012). 
 
136. McConnell, M. J. & Pachón, J. Active and passive immunization against Acinetobacter 
baumannii using an inactivated whole cell vaccine. Vaccine 29, 1–5 (2010). 
7. REFERENCES 
174 
 
 
137. Huang, W. et al. Immunization against multidrug-resistant Acinetobacter baumannii 
effectively protects mice in both pneumonia and sepsis models. PLoS One 9, 16–9 
(2014). 
 
138. Russo, T. a. et al. The K1 capsular polysaccharide from Acinetobacter baumannii is a 
potential therapeutic target via passive immunization. Infect. Immun. 81, 915–22 
(2013). 
 
139. McConnell, M. J. et al. Vaccination with outer membrane complexes elicits rapid 
protective immunity to multidrug-resistant Acinetobacter baumannii. Infect. Immun. 
79, 518–26 (2011). 
 
140. Luo, G. et al. Active and passive immunization protects against lethal, extreme drug 
resistant-Acinetobacter baumannii infection. PLoS One 7, (2012). 
 
141. Fattahian, Y. et al. Protection against Acinetobacter baumannii infection via its 
functional deprivation of biofilm associated protein (Bap). Microb. Pathog. 51, 402–
6 (2011). 
 
142. Huang, W. et al. OmpW is a potential target for eliciting protective immunity against 
Acinetobacter baumannii infections. Vaccine 33, 4479–85 (2015). 
 
143. McConnell, M. J., Rumbo, C., Bou, G. & Pachón, J. Outer membrane vesicles as an 
acellular vaccine against Acinetobacter baumannii. Vaccine 29, 5705–10 (2011). 
 
144. Harris, G. et al. A mouse model of Acinetobacter baumannii-associated pneumonia 
using a clinically isolated hypervirulent strain. Antimicrob. Agents Chemother. 57, 
3601–13 (2013). 
 
145. KuoLee, R. et al. Intranasal immunization protects against Acinetobacter baumannii-
associated pneumonia in mice. Vaccine 33, 260–7 (2015). 
 
146. García-Quintanilla, M., Pulido, M. R., Pachón, J. & McConnell, M. J. Immunization 
with lipopolysaccharide-deficient whole cells provides protective immunity in an 
experimental mouse model of Acinetobacter baumannii infection. PLoS One 9, 
e114410 (2014). 
 
147. Adams, M. D. et al. Comparative genome sequence analysis of multidrug-resistant 
Acinetobacter baumannii. J. Bacteriol. 190, 8053–64 (2008). 
 
148. Perez, F. & Bonomo, R. a. Vaccines for Acinetobacter baumannii: Thinking ‘out of the 
box’. Vaccine 32, 2537–9 (2014). 
7. REFERENCES 
175 
 
 
149. Zhang, S., McCormack, F. X., Levesque, R. C., O’Toole, G. A. & Lau, G. W. The 
flagellum of Pseudomonas aeruginosa is required for resistance to clearance by 
surfactant protein A. PLoS One 2, e564 (2007). 
 
150. Gaynes, R. & Edwards, J. R. Overview of nosocomial infections caused by gram-
negative bacilli. Clin. Infect. Dis. 41, 848–54 (2005). 
 
151. Thirumala, R., Ramaswamy, M. & Chawla, S. Diagnosis and management of 
infectious complications in critically ill patients with cancer. Crit. Care Clin. 26, 59–91 
(2010). 
 
152. Carratalà, J., Rosón, B., Fernández-Sevilla, A., Alcaide, F. & Gudiol, F. Bacteremic 
pneumonia in neutropenic patients with cancer: causes, empirical antibiotic therapy, 
and outcome. Arch. Intern. Med. 158, 868–72 (1998). 
 
153. Murray, C. K. et al. Infections complicating the care of combat casualties during 
operations Iraqi Freedom and Enduring Freedom. J. Trauma 71, S62–73 (2011). 
 
154. Petersen, K. et al. Trauma-related infections in battlefield casualties from Iraq. Ann. 
Surg. 245, 803–11 (2007). 
 
155. Folkesson, A. et al. Adaptation of Pseudomonas aeruginosa to the cystic fibrosis 
airway: an evolutionary perspective. Nat. Rev. Microbiol. 10, 841–51 (2012). 
 
156. Driebe, W. T. Present status of contact lens-induced corneal infections. Ophthalmol. 
Clin. North Am. 16, 485–94, viii (2003). 
 
157. Parkins, M. D., Gregson, D. B., Pitout, J. D. D., Ross, T. & Laupland, K. B. Population-
based study of the epidemiology and the risk factors for Pseudomonas aeruginosa 
bloodstream infection. Infection 38, 25–32 (2010). 
 
158. Dantes, R. et al. National burden of invasive methicillin-resistant Staphylococcus 
aureus infections, United States, 2011. JAMA Intern. Med. 173, 1970–8 (2013). 
 
159. Sievert, D. M. et al. Antimicrobial-resistant pathogens associated with healthcare-
associated infections: summary of data reported to the National Healthcare Safety 
Network at the Centers for Disease Control and Prevention, 2009-2010. Infect. 
Control Hosp. Epidemiol. 34, 1–14 (2013). 
 
160. Rello, J. et al. Survival in patients with nosocomial pneumonia: impact of the severity 
of illness and the etiologic agent. Crit. Care Med. 25, 1862–7 (1997). 
 
7. REFERENCES 
176 
 
161. Gibson, R. L., Burns, J. L. & Ramsey, B. W. Pathophysiology and management of 
pulmonary infections in cystic fibrosis. Am. J. Respir. Crit. Care Med. 168, 918–51 
(2003). 
 
162. Lam, J. S., Taylor, V. L., Islam, S. T., Hao, Y. & Kocíncová, D. Genetic and functional 
diversity of Pseudomonas aeruginosa lipopolysaccharide. Front. Microbiol. 2, 118 
(2011). 
 
163. Fisher, M. W., Devlin, H. B. & Gnabasik, F. J. New immunotype schema for 
Pseudomonas aeruginosa based on protective antigens. J. Bacteriol. 98, 835–6 
(1969). 
 
164. Pier, G. B. Promises and pitfalls of Pseudomonas aeruginosa lipopolysaccharide as a 
vaccine antigen. Carbohydr. Res. 338, 2549–56 (2003). 
 
165. Alexander, J. W., Fisher, M. W. & MacMillan, B. G. Immunological control of 
Pseudomonas infection in burn patients: a clinical evaluation. Arch. Surg. 102, 31–5 
(1971). 
 
166. Young, L. S., Meyer, R. D. & Armstrong, D. Pseudomonas aeruginosa vaccine in 
cancer patients. Ann. Intern. Med. 79, 518–27 (1973). 
 
167. Haghbin, M., Armstrong, D. & Murphy, M. L. Controlled prospective trial of 
Pseudomonas aeruginosa vaccine in children with acute leukemia. Cancer 32, 761–6 
(1973). 
 
168. Pennington, J. E., Reynolds, H. Y., Wood, R. E., Robinson, R. A. & Levine, A. S. Use of 
a Pseudomonas aeruginosa vaccine in pateints with acute leukemia and cystic 
fibrosis. Am. J. Med. 58, 629–36 (1975). 
 
169. MacIntyre, S., McVeigh, T. & Owen, P. Immunochemical and biochemical analysis of 
the polyvalent Pseudomonas aeruginosa vaccine PEV. Infect. Immun. 51, 675–86 
(1986). 
 
170. Langford, D. T. & Hiller, J. Prospective, controlled study of a polyvalent 
pseudomonas vaccine in cystic fibrosis--three year results. Arch. Dis. Child. 59, 1131–
4 (1984). 
 
171. Hatano, K. et al. Immunogenic and antigenic properties of a heptavalent high-
molecular-weight O-polysaccharide vaccine derived from Pseudomonas aeruginosa. 
Infect. Immun. 62, 3608–16 (1994). 
 
172. Hatano, K. & Pier, G. B. Complex serology and immune response of mice to variant 
high-molecular-weight O polysaccharides isolated from Pseudomonas aeruginosa 
7. REFERENCES 
177 
 
serogroup O2 strains. Infect. Immun. 66, 3719–26 (1998). 
 
173. Hancock, R. E. et al. Pseudomonas aeruginosa isolates from patients with cystic 
fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide 
O side chains. Infect. Immun. 42, 170–7 (1983). 
 
174. Pier, G. B. et al. Opsonophagocytic killing antibody to Pseudomonas aeruginosa 
mucoid exopolysaccharide in older noncolonized patients with cystic fibrosis. N. 
Engl. J. Med. 317, 793–8 (1987). 
 
175. Cryz, S. J., Fürer, E. & Que, J. U. Synthesis and characterization of a Pseudomonas 
aeruginosa alginate-toxin A conjugate vaccine. Infect. Immun. 59, 45–50 (1991). 
 
176. Kashef, N. et al. Synthesis and characterization of Pseudomonas aeruginosa alginate-
tetanus toxoid conjugate. J. Med. Microbiol. 55, 1441–6 (2006). 
 
177. Theilacker, C. et al. Construction and characterization of a Pseudomonas aeruginosa 
mucoid exopolysaccharide-alginate conjugate vaccine. Infect. Immun. 71, 3875–84 
(2003). 
 
178. Pier, G. B. et al. Human monoclonal antibodies to Pseudomonas aeruginosa alginate 
that protect against infection by both mucoid and nonmucoid strains. J. Immunol. 
173, 5671–8 (2004). 
 
179. Priebe, G. P. et al. Construction and characterization of a live, attenuated aroA 
deletion mutant of Pseudomonas aeruginosa as a candidate intranasal vaccine. 
Infect. Immun. 70, 1507–17 (2002). 
 
180. Priebe, G. P., Meluleni, G. J., Coleman, F. T., Goldberg, J. B. & Pier, G. B. Protection 
against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization 
with a live, attenuated aroA deletion mutant. Infect. Immun. 71, 1453–61 (2003). 
 
181. Priebe, G. P. et al. IL-17 is a critical component of vaccine-induced protection against 
lung infection by lipopolysaccharide-heterologous strains of Pseudomonas 
aeruginosa. J. Immunol. 181, 4965–75 (2008). 
 
182. Zaidi, T. S., Priebe, G. P. & Pier, G. B. A live-attenuated Pseudomonas aeruginosa 
vaccine elicits outer membrane protein-specific active and passive protection 
against corneal infection. Infect. Immun. 74, 975–83 (2006). 
 
183. Kamei, A., Coutinho-Sledge, Y. S., Goldberg, J. B., Priebe, G. P. & Pier, G. B. Mucosal 
vaccination with a multivalent, live-attenuated vaccine induces multifactorial 
immunity against Pseudomonas aeruginosa acute lung infection. Infect. Immun. 79, 
1289–99 (2011). 
7. REFERENCES 
178 
 
 
184. DiGiandomenico, A., Rao, J. & Goldberg, J. B. Oral vaccination of BALB/c mice with 
Salmonella enterica serovar Typhimurium expressing Pseudomonas aeruginosa O 
antigen promotes increased survival in an acute fatal pneumonia model. Infect. 
Immun. 72, 7012–21 (2004). 
 
185. DiGiandomenico, A. et al. Intranasal immunization with heterologously expressed 
polysaccharide protects against multiple Pseudomonas aeruginosa infections. Proc. 
Natl. Acad. Sci. U. S. A. 104, 4624–9 (2007). 
 
186. Scarff, J. M. & Goldberg, J. B. Vaccination against Pseudomonas aeruginosa 
pneumonia in immunocompromised mice. Clin. Vaccine Immunol. 15, 367–75 
(2008). 
 
187. Faure, K. et al. O-antigen serotypes and type III secretory toxins in clinical isolates of 
Pseudomonas aeruginosa. J. Clin. Microbiol. 41, 2158–60 (2003). 
 
188. Arnold, H. et al. Enhanced immunogenicity in the murine airway mucosa with an 
attenuated Salmonella live vaccine expressing OprF-OprI from Pseudomonas 
aeruginosa. Infect. Immun. 72, 6546–53 (2004). 
 
189. Bumann, D. et al. Systemic, nasal and oral live vaccines against Pseudomonas 
aeruginosa: a clinical trial of immunogenicity in lower airways of human volunteers. 
Vaccine 28, 707–13 (2010). 
 
190. Finke, M., Duchêne, M., Eckhardt, A., Domdey, H. & von Specht, B. U. Protection 
against experimental Pseudomonas aeruginosa infection by recombinant P. 
aeruginosa lipoprotein I expressed in Escherichia coli. Infect. Immun. 58, 2241–4 
(1990). 
 
191. von Specht, B. U. et al. Safety and immunogenicity of a Pseudomonas aeruginosa 
outer membrane protein I vaccine in human volunteers. Vaccine 14, 1111–7 (1996). 
 
192. Mansouri, E. et al. Safety and immunogenicity of a Pseudomonas aeruginosa hybrid 
outer membrane protein F-I vaccine in human volunteers. Infect. Immun. 67, 1461–
70 (1999). 
 
193. Westritschnig, K. et al. A randomized, placebo-controlled phase I study assessing the 
safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane 
protein OprF/I vaccine (IC43) in healthy volunteers. Hum. Vaccin. Immunother. 10, 
170–83 (2014). 
 
194. Ding, B., von Specht, B.-U. & Li, Y. OprF/I-vaccinated sera inhibit binding of human 
interferon-gamma to Pseudomonas aeruginosa. Vaccine 28, 4119–22 (2010). 
7. REFERENCES 
179 
 
 
195. Döring, G., Meisner, C. & Stern, M. A double-blind randomized placebo-controlled 
phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis 
patients. Proc. Natl. Acad. Sci. U. S. A. 104, 11020–5 (2007). 
 
196. Arora, S. K., Ritchings, B. W., Almira, E. C., Lory, S. & Ramphal, R. The Pseudomonas 
aeruginosa flagellar cap protein, FliD, is responsible for mucin adhesion. Infect. 
Immun. 66, 1000–7 (1998). 
 
197. Cobb, L. M., Mychaleckyj, J. C., Wozniak, D. J. & López-Boado, Y. S. Pseudomonas 
aeruginosa flagellin and alginate elicit very distinct gene expression patterns in 
airway epithelial cells: implications for cystic fibrosis disease. J. Immunol. 173, 5659–
70 (2004). 
 
198. Ramphal, R., Guay, C. & Pier, G. B. Pseudomonas aeruginosa adhesins for 
tracheobronchial mucin. Infect. Immun. 55, 600–3 (1987). 
 
199. Döring, G. & Pier, G. B. Vaccines and immunotherapy against Pseudomonas 
aeruginosa. Vaccine 26, 1011–24 (2008). 
 
200. Campodónico, V. L., Llosa, N. J., Bentancor, L. V, Maira-Litran, T. & Pier, G. B. Efficacy 
of a conjugate vaccine containing polymannuronic acid and flagellin against 
experimental Pseudomonas aeruginosa lung infection in mice. Infect. Immun. 79, 
3455–64 (2011). 
 
201. Castric, P. A. & Deal, C. D. Differentiation of Pseudomonas aeruginosa pili based on 
sequence and B-cell epitope analyses. Infect. Immun. 62, 371–6 (1994). 
 
202. Kus, J. V, Tullis, E., Cvitkovitch, D. G. & Burrows, L. L. Significant differences in type IV 
pilin allele distribution among Pseudomonas aeruginosa isolates from cystic fibrosis 
(CF) versus non-CF patients. Microbiology 150, 1315–26 (2004). 
 
203. Sawa, T. et al. Active and passive immunization with the Pseudomonas V antigen 
protects against type III intoxication and lung injury. Nat. Med. 5, 392–8 (1999). 
 
204. Holder, I. A., Neely, A. N. & Frank, D. W. PcrV immunization enhances survival of 
burned Pseudomonas aeruginosa-infected mice. Infect. Immun. 69, 5908–10 (2001). 
 
205. Markham, A. P. et al. Formulation and immunogenicity of a potential multivalent 
type III secretion system-based protein vaccine. J. Pharm. Sci. 99, 4497–509 (2010). 
 
206. Chen, T. Y. et al. A nontoxic Pseudomonas exotoxin A induces active immunity and 
passive protective antibody against Pseudomonas exotoxin A intoxication. J. Biomed. 
7. REFERENCES 
180 
 
Sci. 6, 357–63 
 
207. Denis-Mize, K. S., Price, B. M., Baker, N. R. & Galloway, D. R. Analysis of 
immunization with DNA encoding Pseudomonas aeruginosa exotoxin A. FEMS 
Immunol. Med. Microbiol. 27, 147–54 (2000). 
 
208. Shiau, J. W. et al. Mice immunized with DNA encoding a modified Pseudomonas 
aeruginosa exotoxin A develop protective immunity against exotoxin intoxication. 
Vaccine 19, 1106–12 (2000). 
 
209. Döring, G. et al. In vivo activity of proteases of Pseudomonas aeruginosa in a rat 
model. J. Infect. Dis. 149, 532–7 (1984). 
 
210. Fick, R. B., Baltimore, R. S., Squier, S. U. & Reynolds, H. Y. IgG proteolytic activity of 
Pseudomonas aeruginosa in cystic fibrosis. J. Infect. Dis. 151, 589–98 (1985). 
 
211. Parmely, M., Gale, A., Clabaugh, M., Horvat, R. & Zhou, W. W. Proteolytic 
inactivation of cytokines by Pseudomonas aeruginosa. Infect. Immun. 58, 3009–14 
(1990). 
 
212. Horvat, R. T. & Parmely, M. J. Pseudomonas aeruginosa alkaline protease degrades 
human gamma interferon and inhibits its bioactivity. Infect. Immun. 56, 2925–32 
(1988). 
 
213. Kharazmi, A., Eriksen, H. O., Döring, G., Goldstein, W. & Høiby, N. Effect of 
Pseudomonas aeruginosa proteases on human leukocyte phagocytosis and 
bactericidal activity. Acta Pathol. Microbiol. Immunol. Scand. C. 94, 175–9 (1986). 
 
214. Theander, T. G. et al. Inhibition of human lymphocyte proliferation and cleavage of 
interleukin-2 by Pseudomonas aeruginosa proteases. Infect. Immun. 56, 1673–7 
(1988). 
 
215. Pedersen, B. K. & Kharazmi, A. Inhibition of human natural killer cell activity by 
Pseudomonas aeruginosa alkaline protease and elastase. Infect. Immun. 55, 986–9 
(1987). 
 
216. Homma, J. Y. et al. Effectiveness of immunization with single and multi-component 
vaccines prepared from a common antigen (OEP), protease and elastase toxoids of 
Pseudomonas aeruginosa on protection against hemorrhagic pneumonia in mink 
due to P. aeruginosa. Jpn. J. Exp. Med. 48, 111–33 (1978). 
 
217. Hirao, Y. & Homma, J. Y. Therapeutic effect of immunization with OEP, protease 
toxoid and elastase toxoid on corneal ulcers in mice due to Pseudomonas 
aeruginosa infection. Jpn. J. Exp. Med. 48, 41–51 (1978). 
7. REFERENCES 
181 
 
 
218. Kawaharajo, K. & Homma, J. Y. Effects of elastase, protease and common antigen 
(OEP) from Pseudomonas aeruginosa on protection against burns in mice. Jpn. J. 
Exp. Med. 47, 495–500 (1977). 
 
219. Matsumoto, T. et al. Efficacies of alkaline protease, elastase and exotoxin A toxoid 
vaccines against gut-derived Pseudomonas aeruginosa sepsis in mice. J. Med. 
Microbiol. 47, 303–8 (1998). 
 
220. Priebe, G. P. & Goldberg, J. B. Vaccines for Pseudomonas aeruginosa: a long and 
winding road. Expert Rev. Vaccines 13, 507–19 (2014). 
 
221. Sharma, A., Krause, A. & Worgall, S. Recent developments for Pseudomonas 
vaccines. Hum. Vaccin. 7, 999–1011 (2011). 
 
222. DiGiandomenico, A. et al. A multifunctional bispecific antibody protects against 
Pseudomonas aeruginosa. Sci. Transl. Med. 6, 262ra155 (2014). 
 
223. Cohen, M. L. Staphylococcus aureus: biology, mechanisms of virulence, 
epidemiology. J. Pediatr. 108, 796–9 (1986). 
 
224. Klevens, R. M., Edwards, J. R. & Gaynes, R. P. The impact of antimicrobial-resistant, 
health care-associated infections on mortality in the United States. Clin. Infect. Dis. 
47, 927–30 (2008). 
 
225. Klevens, R. M. et al. Invasive methicillin-resistant Staphylococcus aureus infections in 
the United States. JAMA 298, 1763–71 (2007). 
 
226. Forstner, C. et al. Predictors of clinical and microbiological treatment failure in 
patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: a 
retrospective cohort study in a region with low MRSA prevalence. Clin. Microbiol. 
Infect. 19, E291–7 (2013). 
 
227. Peyrani, P. et al. Severity of disease and clinical outcomes in patients with hospital-
acquired pneumonia due to methicillin-resistant Staphylococcus aureus strains not 
influenced by the presence of the Panton-Valentine leukocidin gene. Clin. Infect. Dis. 
53, 766–71 (2011). 
 
228. de Kraker, M. E. A., Davey, P. G. & Grundmann, H. Mortality and hospital stay 
associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: 
estimating the burden of antibiotic resistance in Europe. PLoS Med. 8, e1001104 
(2011). 
 
7. REFERENCES 
182 
 
229. Lambert, M.-L. et al. Clinical outcomes of health-care-associated infections and 
antimicrobial resistance in patients admitted to European intensive-care units: a 
cohort study. Lancet. Infect. Dis. 11, 30–8 (2011). 
 
230. Fowler, V. G. et al. Effect of an investigational vaccine for preventing Staphylococcus 
aureus infections after cardiothoracic surgery: a randomized trial. JAMA 309, 1368–
78 (2013). 
 
231. Koch, K., Nørgaard, M., Schønheyder, H. C., Thomsen, R. W. & Søgaard, M. Effect of 
socioeconomic status on mortality after bacteremia in working-age patients. A 
Danish population-based cohort study. PLoS One 8, e70082 (2013). 
 
232. Jung, W. J. et al. Prediction of methicillin-resistant Staphylococcus aureus in patients 
with non-nosocomial pneumonia. BMC Infect. Dis. 13, 370 (2013). 
 
233. Su, C.-H. et al. Excess mortality and long-term disability from healthcare-associated 
staphylococcus aureus infections: a population-based matched cohort study. PLoS 
One 8, e71055 (2013). 
 
234. Cosgrove, S. E. et al. Comparison of mortality associated with methicillin-resistant 
and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin. 
Infect. Dis. 36, 53–9 (2003). 
 
235. David, M. Z. & Daum, R. S. Community-associated methicillin-resistant 
Staphylococcus aureus: epidemiology and clinical consequences of an emerging 
epidemic. Clin. Microbiol. Rev. 23, 616–87 (2010). 
 
236. Klevens, R. M. et al. Invasive methicillin-resistant Staphylococcus aureus infections in 
the United States. JAMA 298, 1763–71 (2007). 
 
237. Botelho-Nevers, E. et al. Staphylococcal vaccine development: review of past failures 
and plea for a future evaluation of vaccine efficacy not only on staphylococcal 
infections but also on mucosal carriage. Expert Rev. Vaccines 12, 1249–59 (2013). 
 
238. Wertheim, H. F. L. et al. The role of nasal carriage in Staphylococcus aureus 
infections. Lancet. Infect. Dis. 5, 751–62 (2005). 
 
239. Liu, G. Y. Molecular pathogenesis of Staphylococcus aureus infection. Pediatr. Res. 
65, 71R–77R (2009). 
 
240. Kim, H. K., Thammavongsa, V., Schneewind, O. & Missiakas, D. Recurrent infections 
and immune evasion strategies of Staphylococcus aureus. Curr. Opin. Microbiol. 15, 
92–9 (2012). 
 
7. REFERENCES 
183 
 
241. Jönsson, K., Signäs, C., Müller, H. P. & Lindberg, M. Two different genes encode 
fibronectin binding proteins in Staphylococcus aureus. The complete nucleotide 
sequence and characterization of the second gene. Eur. J. Biochem. 202, 1041–8 
(1991). 
 
242. Massey, R. C. et al. Fibronectin-binding protein A of Staphylococcus aureus has 
multiple, substituting, binding regions that mediate adherence to fibronectin and 
invasion of endothelial cells. Cell. Microbiol. 3, 839–51 (2001). 
 
243. McDevitt, D. et al. Characterization of the interaction between the Staphylococcus 
aureus clumping factor (ClfA) and fibrinogen. Eur. J. Biochem. 247, 416–24 (1997). 
 
244. Ní Eidhin, D. et al. Clumping factor B (ClfB), a new surface-located fibrinogen-binding 
adhesin of Staphylococcus aureus. Mol. Microbiol. 30, 245–57 (1998). 
 
245. Patti, J. M. et al. Molecular characterization and expression of a gene encoding a 
Staphylococcus aureus collagen adhesin. J. Biol. Chem. 267, 4766–72 (1992). 
 
246. Wertheim, H. F. L. et al. Key role for clumping factor B in Staphylococcus aureus 
nasal colonization of humans. PLoS Med. 5, e17 (2008). 
 
247. Weidenmaier, C. et al. Role of teichoic acids in Staphylococcus aureus nasal 
colonization, a major risk factor in nosocomial infections. Nat. Med. 10, 243–5 
(2004). 
 
248. Torres, V. J., Pishchany, G., Humayun, M., Schneewind, O. & Skaar, E. P. 
Staphylococcus aureus IsdB is a hemoglobin receptor required for heme iron 
utilization. J. Bacteriol. 188, 8421–9 (2006). 
 
249. Horsburgh, M. J. et al. MntR modulates expression of the PerR regulon and 
superoxide resistance in Staphylococcus aureus through control of manganese 
uptake. Mol. Microbiol. 44, 1269–86 (2002). 
 
250. Nanra, J. S. et al. Capsular polysaccharides are an important immune evasion 
mechanism for Staphylococcus aureus. Hum. Vaccin. Immunother. 9, 480–7 (2013). 
 
251. Hair, P. S., Ward, M. D., Semmes, O. J., Foster, T. J. & Cunnion, K. M. Staphylococcus 
aureus clumping factor A binds to complement regulator factor I and increases 
factor I cleavage of C3b. J. Infect. Dis. 198, 125–33 (2008). 
 
252. Forsgren, A. & Sjöquist, J. ‘Protein A’ from S. aureus. I. Pseudo-immune reaction with 
human gamma-globulin. J. Immunol. 97, 822–7 (1966). 
 
7. REFERENCES 
184 
 
253. Foster, T. J. Immune evasion by staphylococci. Nat. Rev. Microbiol. 3, 948–58 (2005). 
 
254. Smith, E. J., Visai, L., Kerrigan, S. W., Speziale, P. & Foster, T. J. The Sbi protein is a 
multifunctional immune evasion factor of Staphylococcus aureus. Infect. Immun. 79, 
3801–9 (2011). 
 
255. Rooijakkers, S. H. M. et al. Immune evasion by a staphylococcal complement 
inhibitor that acts on C3 convertases. Nat. Immunol. 6, 920–7 (2005). 
 
256. Kubica, M. et al. A potential new pathway for Staphylococcus aureus dissemination: 
the silent survival of S. aureus phagocytosed by human monocyte-derived 
macrophages. PLoS One 3, e1409 (2008). 
 
257. de Haas, C. J. C. et al. Chemotaxis inhibitory protein of Staphylococcus aureus, a 
bacterial antiinflammatory agent. J. Exp. Med. 199, 687–95 (2004). 
 
258. Chavakis, T. et al. Staphylococcus aureus extracellular adherence protein serves as 
anti-inflammatory factor by inhibiting the recruitment of host leukocytes. Nat. Med. 
8, 687–93 (2002). 
 
259. Sieprawska-Lupa, M. et al. Degradation of human antimicrobial peptide LL-37 by 
Staphylococcus aureus-derived proteinases. Antimicrob. Agents Chemother. 48, 
4673–9 (2004). 
 
260. Jin, T. et al. Staphylococcus aureus resists human defensins by production of 
staphylokinase, a novel bacterial evasion mechanism. J. Immunol. 172, 1169–76 
(2004). 
 
261. Tomita, T. & Kamio, Y. Molecular biology of the pore-forming cytolysins from 
Staphylococcus aureus, alpha- and gamma-hemolysins and leukocidin. Biosci. 
Biotechnol. Biochem. 61, 565–72 (1997). 
 
262. Wang, R. et al. Identification of novel cytolytic peptides as key virulence 
determinants for community-associated MRSA. Nat. Med. 13, 1510–4 (2007). 
 
263. Bhakdi, S. & Tranum-Jensen, J. Alpha-toxin of Staphylococcus aureus. Microbiol. Rev. 
55, 733–51 (1991). 
 
264. Choi, Y. W. et al. Interaction of Staphylococcus aureus toxin ‘superantigens’ with 
human T cells. Proc. Natl. Acad. Sci. U. S. A. 86, 8941–5 (1989). 
 
265. Genestier, A.-L. et al. Staphylococcus aureus Panton-Valentine leukocidin directly 
targets mitochondria and induces Bax-independent apoptosis of human neutrophils. 
7. REFERENCES 
185 
 
J. Clin. Invest. 115, 3117–27 (2005). 
 
266. Lee, L. Y. et al. The Staphylococcus aureus Map protein is an immunomodulator that 
interferes with T cell-mediated responses. J. Clin. Invest. 110, 1461–71 (2002). 
 
267. Llewelyn, M. & Cohen, J. Superantigens: microbial agents that corrupt immunity. 
Lancet. Infect. Dis. 2, 156–62 (2002). 
 
268. Goodyear, C. S. & Silverman, G. J. Staphylococcal toxin induced preferential and 
prolonged in vivo deletion of innate-like B lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 
101, 11392–7 (2004). 
 
269. Shinefield, H. et al. Use of a Staphylococcus aureus conjugate vaccine in patients 
receiving hemodialysis. N. Engl. J. Med. 346, 491–6 (2002). 
 
270. Weems, J. J. et al. Phase II, randomized, double-blind, multicenter study comparing 
the safety and pharmacokinetics of tefibazumab to placebo for treatment of 
Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 50, 2751–5 
(2006). 
 
271. Rupp, M. E. et al. Phase II, randomized, multicenter, double-blind, placebo-
controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide 
immune globulin in treatment of Staphylococcus aureus bacteremia. Antimicrob. 
Agents Chemother. 51, 4249–54 (2007). 
 
272. Hua, L. et al. MEDI4893* Promotes survival and extends the antibiotic treatment 
window in a Staphylococcus aureus immunocompromised pneumonia model. 
Antimicrob. Agents Chemother. 59, 4526–32 (2015). 
 
273. Benjamin, D. K. et al. A blinded, randomized, multicenter study of an intravenous 
Staphylococcus aureus immune globulin. J. Perinatol. 26, 290–5 (2006). 
 
274. DeJonge, M. et al. Clinical trial of safety and efficacy of INH-A21 for the prevention 
of nosocomial staphylococcal bloodstream infection in premature infants. J. Pediatr. 
151, 260–5, 265.e1 (2007). 
 
275. Weisman, L. E. et al. A randomized study of a monoclonal antibody (pagibaximab) to 
prevent staphylococcal sepsis. Pediatrics 128, 271–9 (2011). 
 
276. Nethercott, C. et al. Molecular characterization of endocarditis-associated 
Staphylococcus aureus. J. Clin. Microbiol. 51, 2131–8 (2013). 
 
277. Peacock, S. J. et al. Virulent combinations of adhesin and toxin genes in natural 
7. REFERENCES 
186 
 
populations of Staphylococcus aureus. Infect. Immun. 70, 4987–96 (2002). 
 
278. Bonventre, P. F. et al. Antibody responses to toxic-shock-syndrome (TSS) toxin by 
patients with TSS and by healthy staphylococcal carriers. J. Infect. Dis. 150, 662–6 
(1984). 
 
279. Christensson, B. & Hedström, S. A. Serological response to toxic shock syndrome 
toxin in Staphylococcus aureus infected patients and healthy controls. Acta Pathol. 
Microbiol. Immunol. Scand. B. 93, 87–90 (1985). 
 
280. Johnson, H. M., Russell, J. K. & Pontzer, C. H. Staphylococcal enterotoxin microbial 
superantigens. FASEB J. 5, 2706–12 (1991). 
 
281. Novick, R. P. Mobile genetic elements and bacterial toxinoses: the superantigen-
encoding pathogenicity islands of Staphylococcus aureus. Plasmid 49, 93–105 
(2003). 
 
282. Golubchik, T. et al. Within-host evolution of Staphylococcus aureus during 
asymptomatic carriage. PLoS One 8, e61319 (2013). 
 
283. Dreisbach, A. et al. Profiling the surfacome of Staphylococcus aureus. Proteomics 10, 
3082–96 (2010). 
 
284. Dreisbach, A. et al. Surface shaving as a versatile tool to profile global interactions 
between human serum proteins and the Staphylococcus aureus cell surface. 
Proteomics 11, 2921–30 (2011). 
 
285. Scully, I. L., Liberator, P. A., Jansen, K. U. & Anderson, A. S. Covering all the bases: 
preclinical development of an effective Staphylococcus aureus vaccine. Front. 
Immunol. 5, 109 (2014). 
 
286. Fowler, V. G. & Proctor, R. A. Where does a Staphylococcus aureus vaccine stand? 
Clin. Microbiol. Infect. 20 Suppl 5, 66–75 (2014). 
 
287. Brown, A. F., Leech, J. M., Rogers, T. R. & McLoughlin, R. M. Staphylococcus aureus 
colonization: modulation of host immune response and impact on human vaccine 
design. Front. Immunol. 4, 507 (2014). 
 
288. Proctor, R. A. Challenges for a universal Staphylococcus aureus vaccine. Clin. Infect. 
Dis. 54, 1179–86 (2012). 
 
289. Bagnoli, F., Bertholet, S. & Grandi, G. Inferring reasons for the failure of 
Staphylococcus aureus vaccines in clinical trials. Front. Cell. Infect. Microbiol. 2, 16 
7. REFERENCES 
187 
 
(2012). 
 
290. Daum, R. S. & Spellberg, B. Progress toward a Staphylococcus aureus vaccine. Clin. 
Infect. Dis. 54, 560–7 (2012). 
 
291. Avery, T. R., Kleinman, K. P., Klompas, M., Aschengrau, A. & Huang, S. S. Inclusion of 
30-day postdischarge detection triples the incidence of hospital-onset methicillin-
resistant Staphylococcus aureus. Infect. Control Hosp. Epidemiol. 33, 114–21 (2012). 
 
292. Huang, S. S. & Platt, R. Risk of methicillin-resistant Staphylococcus aureus infection 
after previous infection or colonization. Clin. Infect. Dis. 36, 281–5 (2003). 
 
293. Duffy, J. et al. Community-onset invasive methicillin-resistant Staphylococcus aureus 
infections following hospital discharge. Am. J. Infect. Control 41, 782–6 (2013). 
 
294. Skurnik, D. et al. Natural antibodies in normal human serum inhibit Staphylococcus 
aureus capsular polysaccharide vaccine efficacy. Clin. Infect. Dis. 55, 1188–97 (2012). 
 
295. Skurnik, D. et al. Animal and human antibodies to distinct Staphylococcus aureus 
antigens mutually neutralize opsonic killing and protection in mice. J. Clin. Invest. 
120, 3220–33 (2010). 
 
296. Kim, H. K., Cheng, A. G., Kim, H.-Y., Missiakas, D. M. & Schneewind, O. Nontoxigenic 
protein A vaccine for methicillin-resistant Staphylococcus aureus infections in mice. 
J. Exp. Med. 207, 1863–70 (2010). 
 
297. Kim, H. K., Thammavongsa, V., Schneewind, O. & Missiakas, D. Recurrent infections 
and immune evasion strategies of Staphylococcus aureus. Curr. Opin. Microbiol. 15, 
92–9 (2012). 
 
298. Salgado-Pabón, W. & Schlievert, P. M. Models matter: the search for an effective 
Staphylococcus aureus vaccine. Nat. Rev. Microbiol. 12, 585–91 (2014). 
 
299. Weisman, L. E. et al. Phase 1/2 double-blind, placebo-controlled, dose escalation, 
safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an 
antistaphylococcal monoclonal antibody for the prevention of staphylococcal 
bloodstream infections, in very-low-birth-weight neon. Antimicrob. Agents 
Chemother. 53, 2879–86 (2009). 
 
300. Shinefield, H. R. Use of a conjugate polysaccharide vaccine in the prevention of 
invasive staphylococcal disease: is an additional vaccine needed or possible? Vaccine 
24 Suppl 2, S2–65–9 (2006). 
 
7. REFERENCES 
188 
 
301. Vernachio, J. et al. Anti-clumping factor A immunoglobulin reduces the duration of 
methicillin-resistant Staphylococcus aureus bacteremia in an experimental model of 
infective endocarditis. Antimicrob. Agents Chemother. 47, 3400–6 (2003). 
 
302. Josefsson, E., Hartford, O., O’Brien, L., Patti, J. M. & Foster, T. Protection against 
experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, 
a novel virulence determinant. J. Infect. Dis. 184, 1572–80 (2001). 
 
303. Fattom, A. I., Sarwar, J., Ortiz, A. & Naso, R. A Staphylococcus aureus capsular 
polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial 
challenge. Infect. Immun. 64, 1659–65 (1996). 
 
304. Joshi, A. et al. Immunization with Staphylococcus aureus iron regulated surface 
determinant B (IsdB) confers protection via Th17/IL17 pathway in a murine sepsis 
model. Hum. Vaccin. Immunother. 8, 336–46 (2012). 
 
305. Kim, H. K. et al. IsdA and IsdB antibodies protect mice against Staphylococcus aureus 
abscess formation and lethal challenge. Vaccine 28, 6382–92 (2010). 
 
306. Hall, A. E. et al. Characterization of a protective monoclonal antibody recognizing 
Staphylococcus aureus MSCRAMM protein clumping factor A. Infect. Immun. 71, 
6864–70 (2003). 
 
307. Pier, G. B. Will there ever be a universal Staphylococcus aureus vaccine? Hum. 
Vaccin. Immunother. 9, 1865–76 (2013). 
 
308. van Heijenoort, J. Formation of the glycan chains in the synthesis of bacterial 
peptidoglycan. Glycobiology 11, 25R–36R (2001). 
 
309. Hoffmann, B., Messer, W. & Schwarz, U. Regulation of polar cap formation in the life 
cycle of Escherichia coli. J. Supramol. Struct. 1, 29–37 (1972). 
 
310. Doublet, P., van Heijenoort, J. & Mengin-Lecreulx, D. Identification of the Escherichia 
coli murI gene, which is required for the biosynthesis of D-glutamic acid, a specific 
component of bacterial peptidoglycan. J. Bacteriol. 174, 5772–9 (1992). 
 
311. Doublet, P., van Heijenoort, J., Bohin, J. P. & Mengin-Lecreulx, D. The murI gene of 
Escherichia coli is an essential gene that encodes a glutamate racemase activity. J. 
Bacteriol. 175, 2970–9 (1993). 
 
312. Dougherty, T. J., Thanassi, J. A. & Pucci, M. J. The Escherichia coli mutant requiring D-
glutamic acid is the result of mutations in two distinct genetic loci. J. Bacteriol. 175, 
111–6 (1993). 
 
7. REFERENCES 
189 
 
313. Fotheringham, I. G., Bledig, S. A. & Taylor, P. P. Characterization of the genes 
encoding D-amino acid transaminase and glutamate racemase, two D-glutamate 
biosynthetic enzymes of Bacillus sphaericus ATCC 10208. J. Bacteriol. 180, 4319–23 
(1998). 
 
314. Tanizawa, K., Masu, Y., Asano, S., Tanaka, H. & Soda, K. Thermostable D-amino acid 
aminotransferase from a thermophilic Bacillus species. Purification, characterization, 
and active site sequence determination. J. Biol. Chem. 264, 2445–9 (1989). 
 
315. Taylor, P. P. & Fotheringham, I. G. Nucleotide sequence of the Bacillus licheniformis 
ATCC 10716 dat gene and comparison of the predicted amino acid sequence with 
those of other bacterial species. Biochim. Biophys. Acta 1350, 38–40 (1997). 
 
316. Pucci, M. J., Thanassi, J. A., Ho, H. T., Falk, P. J. & Dougherty, T. J. Staphylococcus 
haemolyticus contains two D-glutamic acid biosynthetic activities, a glutamate 
racemase and a D-amino acid transaminase. J. Bacteriol. 177, 336–42 (1995). 
 
317. Thompson, R. J., Bouwer, H. G., Portnoy, D. A. & Frankel, F. R. Pathogenicity and 
immunogenicity of a Listeria monocytogenes strain that requires D-alanine for 
growth. Infect. Immun. 66, 3552–61 (1998). 
 
318. Bae, T. et al. Staphylococcus aureus virulence genes identified by bursa aurealis 
mutagenesis and nematode killing. Proc. Natl. Acad. Sci. U. S. A. 101, 12312–7 
(2004). 
 
319. Kada, S., Nanamiya, H., Kawamura, F. & Horinouchi, S. Glr, a glutamate racemase, 
supplies D-glutamate to both peptidoglycan synthesis and poly-gamma-glutamate 
production in gamma-PGA-producing Bacillus subtilis. FEMS Microbiol. Lett. 236, 13–
20 (2004). 
 
320. Kimura, K., Tran, L.-S. P. & Itoh, Y. Roles and regulation of the glutamate racemase 
isogenes, racE and yrpC, in Bacillus subtilis. Microbiology 150, 2911–20 (2004). 
 
321. Song, J.-H. et al. Identification of essential genes in Streptococcus pneumoniae by 
allelic replacement mutagenesis. Mol. Cells 19, 365–74 (2005). 
 
322. Fisher, S. L. Glutamate racemase as a target for drug discovery. Microb. Biotechnol. 
1, 345–60 (2008). 
 
323. Oh, S.-Y., Richter, S. G., Missiakas, D. M. & Schneewind, O. Glutamate racemase 
mutants of Bacillus anthracis. J. Bacteriol. 197, 1854–61 (2015). 
 
324. Vergara-Irigaray, M. et al. Relevant role of fibronectin-binding proteins in 
Staphylococcus aureus biofilm-associated foreign-body infections. Infect. Immun. 77, 
7. REFERENCES 
190 
 
3978–91 (2009). 
 
325. Acosta, J. et al. Multidrug-resistant Acinetobacter baumannii harboring OXA-24 
carbapenemase, Spain. Emerg. Infect. Dis. 17, 1064–67 (2011). 
 
326. Russo, T. a. et al. The K1 capsular polysaccharide of Acinetobacter baumannii strain 
307-0294 is a major virulence factor. Infect. Immun. 78, 3993–4000 (2010). 
 
327. Lee, D. G. et al. Genomic analysis reveals that Pseudomonas aeruginosa virulence is 
combinatorial. Genome Biol. 7, R90 (2006). 
 
328. Viedma, E., Juan, C., Otero, J. R., Oliver, A. & Chaves, F. Draft genome sequence of 
VIM-2-producing multidrug-resistant Pseudomonas aeruginosa ST175, an epidemic 
high-risk clone. Genome Announc. 1, e0011213 
 
329. Tomás, M. et al. Efflux pumps, OprD porin, AmpC β-lactamase, and multiresistance 
in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob. Agents 
Chemother. 54, 2219–24 (2010). 
 
330. Salunkhe, P. et al. A Cystic Fibrosis Epidemic Strain of. J. Bacteriol. 187, 4908–20 
(2005). 
 
331. Simon, R., Priefer, U. & Pühler, A. A broad host range mobilization system for in vivo 
genetic engineering: transposon mutagenesis in Gram negative bacteria. 
Bio/Technology 1, 784–91 (1983). 
 
332. Sambrook, J., Fritsch, E. F. & Maniatis, T. Molecular cloning: a laboratory manual, 
2nd ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989). 
 
333. Monk, I. R., Shah, I. M., Xu, M., Tan, M.-W. & Foster, T. J. Transforming the 
untransformable: application of direct transformation to manipulate genetically 
Staphylococcus aureus and Staphylococcus epidermidis. MBio 3, (2012). 
 
334. Kreiswirth, B. N. et al. The toxic shock syndrome exotoxin structural gene is not 
detectably transmitted by a prophage. Nature 305, 709–12 
 
335. Diep, B. A. et al. Complete genome sequence of USA300, an epidemic clone of 
community-acquired meticillin-resistant Staphylococcus aureus. Lancet (London, 
England) 367, 731–9 (2006). 
 
336. Fitzgerald, J. R. et al. Characterization of a putative pathogenicity island from bovine 
Staphylococcus aureus encoding multiple superantigens. J. Bacteriol. 183, 63–70 
(2001). 
7. REFERENCES 
191 
 
 
337. Ben Zakour, N. L. et al. Genome-wide analysis of ruminant Staphylococcus aureus 
reveals diversification of the core genome. J. Bacteriol. 190, 6302–17 (2008). 
 
338. Lowder, B. V et al. Recent human-to-poultry host jump, adaptation, and pandemic 
spread of Staphylococcus aureus. Proc. Natl. Acad. Sci. U. S. A. 106, 19545–50 
(2009). 
 
339. Hamad, M. A., Zajdowicz, S. L., Holmes, R. K. & Voskuil, M. I. An allelic exchange 
system for compliant genetic manipulation of the select agents Burkholderia 
pseudomallei and Burkholderia mallei. Gene 430, 123–31 (2009). 
 
340. Hoang, T. T., Karkhoff-Schweizer, R. R., Kutchma, A. J. & Schweizer, H. P. A broad-
host-range F1p-FRT recombination system for site-specific excision of 
chromosomally-located DNA sequences: Application for isolation of unmarked 
Pseudomonas aeruginosa mutants. Gene 212, 77–86 (1998). 
 
341. Arnaud, M., Chastanet, A. & De, M. New vector for efficient allelic replacement in 
naturally Gram-positive bacteria. Appl. Enviromental Microbiol. 70, 6887–91 (2004). 
 
342. Shimizu, S. The Laboratory Mouse (Elsevier Ltd, 2004). 
 
343. Smith, M. G. et al. New insights into Acinetobacter baumannii pathogenesis revealed 
by high-density pyrosequencing and transposon mutagenesis. Genes Dev. 21, 601–
14 (2007). 
 
344. Stover, C. K. et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, 
an opportunistic pathogen. Nature 406, 959–64 (2000). 
 
345. Lefeber, D. J. et al. Th1-directing adjuvants increase the immunogenicity of 
oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae 
type 3. Infect. Immun. 71, 6915–20 (2003). 
 
346. Pritt, B., O’Brien, L. & Winn, W. Mucoid Pseudomonas in cystic fibrosis. Am. J. Clin. 
Pathol. 128, 32–34 (2007). 
 
347. Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J. & Hill,  a M. M-1/M-2 macrophages 
and the Th1/Th2 paradigm. J. Immunol. 164, 6166–73 (2000). 
 
348. Curtiss, R. Bacterial infectious disease control by vaccine development. J. Clin. Invest. 
110, 1061–66 (2002). 
 
7. REFERENCES 
192 
 
349. Cabral, M. P. et al. Proteomic and functional analyses reveal a unique lifestyle for 
Acinetobacter baumannii biofilms and a key role for histidine metabolism. J. 
Proteome Res. 10, 3399–417 (2011). 
 
350. Miyoshi, Y., Oyama, T., Itoh, Y. & Hamase, K. Enantioselective two-dimensional high-
performance liquid chromatographic determination of amino acids ; analysis and 
physiological significance of D-amino acids in mammals. Chromatography 35, 49–57 
(2014). 
 
351. Han, H. et al. Simultaneous determination of D-aspartic acid and D-glutamic acid in 
rat tissues and physiological fluids using a multi-loop two-dimensional HPLC 
procedure. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 879, 3196-202 (2011). 
 
352. Vila, J., Martí, S. & Sánchez-Céspedes, J. Porins, efflux pumps and multidrug 
resistance in Acinetobacter baumannii. J. Antimicrob. Chemother. 59, 1210–5 (2007). 
 
353. García, A. et al. Some immunological properties of lipopolysaccharide from 
Acinetobacter baumannii. J. Med. Microbiol. 48, 479–83 (1999). 
 
354. Breslow, J. M. et al. Innate immune responses to systemic Acinetobacter baumannii 
infection in mice: neutrophils, but not interleukin-17, mediate host resistance. 
Infect. Immun. 79, 3317–27 (2011). 
 
355. Kim, S. W. et al. Serum resistance of Acinetobacter baumannii through the binding 
of factor H to outer membrane proteins. FEMS Microbiol. Lett. 301, 224–31 (2009). 
 
356. García, A., Solar, H., González, C. & Zemelman, R. Effect of EDTA on the resistance of 
clinical isolates of Acinetobacter baumannii to the bactericidal activity of normal 
human serum. J. Med. Microbiol. 49, 1047–50 (2000). 
 
357. Russo, T. A. et al. Penicillin-binding protein 7/8 contributes to the survival of 
Acinetobacter baumannii in vitro and in vivo. J. Infect. Dis. 199, 513–21 (2009). 
 
358. Govan, J. R. & Deretic, V. Microbial pathogenesis in cystic fibrosis: mucoid 
Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol. Rev. 60, 539–74 
(1996). 
 
359. Li, Z. et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection 
and lung disease progression in children with cystic fibrosis. JAMA 293, 581–8 
(2005). 
 
360. Rodríguez-Rojas, A., Oliver, A. & Blázquez, J. Intrinsic and environmental 
mutagenesis drive diversification and persistence of Pseudomonas aeruginosa in 
chronic lung infections. J. Infect. Dis. 205, 121–7 (2012). 
7. REFERENCES 
193 
 
 
361. Tenover, F. C. Mechanisms of antimicrobial resistance in bacteria. Am. J. Infect. 
Control 34, S3–10; discussion S64–73 (2006). 
 
362. Dunkley, M. L., Clancy, R. L. & Cripps, A. W. A role for CD4+ T cells from orally 
immunized rats in enhanced clearance of Pseudomonas aeruginosa from the lung. 
Immunology 83, 362–9 (1994). 
 
363. Dunkley, M. L., Cripps, A. W., Reinbott, P. W. & Clancy, R. L. Immunity to respiratory 
Pseudomonas aeruginosa infection: the role of gut-derived T helper cells and 
immune serum. Adv. Exp. Med. Biol. 371B, 771–5 (1995). 
 
364. Stevenson, M. M., Kondratieva, T. K., Apt, A. S., Tam, M. F. & Skamene, E. In vitro 
and in vivo T cell responses in mice during bronchopulmonary infection with mucoid 
Pseudomonas aeruginosa. Clin. Exp. Immunol. 99, 98–105 (1995). 
 
365. Jain-Vora, S. et al. Interleukin-4 enhances pulmonary clearance of Pseudomonas 
aeruginosa. Infect. Immun. 66, 4229–36 (1998). 
 
366. Jensen, P. Ø., Givskov, M., Bjarnsholt, T. & Moser, C. The immune system vs. 
Pseudomonas aeruginosa biofilms. FEMS Immunol. Med. Microbiol. 59, 292–305 
(2010). 
 
367. Moser, C. et al. The immune response to chronic Pseudomonas aeruginosa lung 
infection in cystic fibrosis patients is predominantly of the Th2 type. APMIS 108, 
329–35 (2000). 
 
368. Liu, J. et al. Early production of IL-17 protects against acute pulmonary Pseudomonas 
aeruginosa infection in mice. FEMS Immunol. Med. Microbiol. 61, 179–88 (2011). 
 
369. Lee, J. C. The prospects for developing a vaccine against Staphylococcus aureus. 
Trends Microbiol. 4, 162–6 (1996). 
 
370. Schaffer, A. C. & Lee, J. C. Vaccination and passive immunisation against 
Staphylococcus aureus. Int. J. Antimicrob. Agents 32 Suppl 1, S71–8 (2008). 
 
371. Lin, L. et al. Th1-Th17 cells mediate protective adaptive immunity against 
Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog. 5, 
(2009). 
 
372. Zhao, Y. X., Nilsson, I. M. & Tarkowski,  A. The dual role of interferon-gamma in 
experimental Staphylococcus aureus septicaemia versus arthritis. Immunology 93, 
80–5 (1998). 
7. REFERENCES 
194 
 
 
373. Pishchany, G. et al. Specificity for human hemoglobin enhances Staphylococcus 
aureus infection. Cell Host Microbe 8, 544–50 (2010). 
 
374. Veloso, T. R. et al. Use of a human-like low-grade bacteremia model of experimental 
endocarditis to study the role of Staphylococcus aureus adhesins and platelet 
aggregation in early endocarditis. Infect. Immun. 81, 697–703 (2013). 
 
7. REFERENCES 
195 
 
 
 
 
 
 
ATTACHMENTS               
 
 
 
 
 
 
 
 
 
196 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
197 
 
A. Resumo 
Las vacunas bacterianas vivas son muy eficaces debido a que se tratan de versiones 
atenuadas de bacterias patógenas que “mimetizan” la infección real pero sin causar la 
enfermedad. Estas vacunas inducen respuestas inmunitarias de tipo humoral y celular y su 
empleo suele resultar en una profilaxis muy eficiente, sin necesidad de refuerzos. Vienen 
siendo utilizadas desde hace muchas décadas para prevenir enfermedades respiratorias, 
entéricas y con carácter epidémico, tanto en humanos como en animales. Además, suelen 
ser vacunas de bajo coste de producción y distribución. Para lograr la atenuación de la 
virulencia bacteriana se realizan pases sucesivos en cultivo hasta obtener una selección 
natural de microorganismos atenuados, se realiza una mutagenesis aleatoria o, más 
recientemente, se recurre directamente a la manipulación genética de genes asociados a 
mecanismos de virulencia. Sin embargo, la utilización de organismos vivos atenuados en 
vacunas no es libre de riesgos, ya que estos microrganismos mantienen su capacidad de 
multiplicación en el individuo vacunado y pueden ser liberados en el ambiente 
accidentalmente. Con lo cual, una vacuna ideal debería contener preferentemente todos 
los determinantes antigénicos para mantener su capacidad inmunológica intacta, pero sin 
conllevar a un riesgo de enfermedad. La alternativa que proponemos es la utilización de 
organismos genéticamente modificados incapaces de sintetizar peptidoglicano, cuya 
función es esencial para la supervivencia bacteriana ya que es el principal componente de la 
pared celular. Estos microorganismos genéticamente modificados se ven afectados en la 
correcta formación de pared bacteriana en el individuo vacunado, de tal forma que no 
pueden replicarse, minimizando cualquier riesgo de reacción adversa y permitiendo la 
presentación de todos sus determinantes antigénicos.   
El compuesto D-glutamato (D-Glu) es un componente esencial del peptidoglicano 
de la pared bacteriana. La enzima glutamato racemasa (MurI) es la responsable de 
transformar L-glutamato en D-Glu, que es enseguida introducido en el peptidoglicano. 
Aunque varios estudios señalan esta enzima como una diana para nuevos antibióticos, 
ninguno de los trabajos publicados hasta la fecha demuestra la posibilidad de utilizar 
mutantes defectivos MurI– como vacunas bacterianas vivas atenuadas, y la evaluación de su 
eficacia en modelos animales. Estos microorganismos genéticamente modificados, 
auxótrofos para el compuesto D-Glu, pueden obtenerse mediante la inactivación de los 
genes codificantes de la enzima MurI y de la enzima D-aminoacido trasaminasa (Dat), 
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cuando corresponda, responsable por la transformación de la D-alanina en D-Glu, 
exclusivamente en algunas bacterias Gram-positivas.  
Aunque los D-aminoacidos vienen siendo últimamente reconocidos como 
moléculas funcionales en los mamíferos, estos compuestos suelen presentarse en 
concentraciones extremadamente bajas, entre los 1.9 y 9.0 nmol/g.  
Por otra parte, la emergencia de bacterias multirresistentes tales como 
Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus resistente a 
meticilina (SARM) y la inexistencia de vacunas licenciadas para prevenir las infecciones 
causadas por estos patógenos resultan en elevados índices de mortalidad y opciones de 
tratamiento muy limitadas, especialmente en el caso de infecciones causadas por 
organismos Gram-negativos. Como respuesta a este desafío, recurrimos a la manipulación 
genética de estas bacterias para obtener cepas auxótrofas para D-Glu, a través de la 
creación de mutantes con los genes codificantes de MurI o MurI y Dat deleccionados, en las 
cepas A. baumannii ATCC 17978, P. aeruginosa PAO1 y S. aureus 132. Una vez obtenidas, se 
evaluó la utilización de estas cepas como vacunas en un modelo de infección aguda letal 
aguda en ratón.   
En el genoma de A. baumannii ATCC 17978 se identificaron dos genes MurI: 
A1S_0380 (murI1) y A1S_3398 (murI2). En el genoma de P. aeruginosa PAO1 encontramos 
un único gen MurI: PA4662 (murI). En el genoma de S. aureus se identificó un gen MurI 
(murI) y un gen Dat (dat). Una vez identificados, recurrimos a la mutación de estos genes 
por delección total. Se observó un crecimiento normal en medio de cultivo LB de los 
mutantes A. baumannii ATCC 17978 ΔmurI1 y A. baumannii ATCC 17978 ΔmurI2; sin 
embargo se observó que el mutante doble A. baumannii ATCC 17978 ΔmurI1 ΔmurI2 
requiere la adicción exógena de D-Glu para crecer. Igualmente, el mutante P. aeruginosa 
PAO1 ΔmurI requiere también la adicción de este compuesto para su crecimiento. Respecto 
a S. aureus, se observó un crecimiento normal de los mutantes 132 ΔmurI y 132 Δdat; sin 
embargo el mutante doble S. aureus 132 ΔmurI Δdat requiere la adicción exógena de este 
compuesto. Mediante qRT-PCR se confirmó la ausencia del mRNA codificante para MurI y 
Dat en estas cepas mutantes. Estos resultados demuestran la implicación de los genes murI 
en la producción de D-Glu en A. baumannii ATCC 17978 y P. aeruginosa PAO1, pero 
también la implicación conjunta de los genes murI y dat en el caso de la cepa S. aureus 132. 
Esto significa que se pueden obtener microorganismos auxótrofos para D-Glu en el caso de 
bacterias que no poseen la enzima Dat, mediante la inactivación de uno o de múltiples 
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genes murI (mutantes MurI–), como es el caso de P. aeruginosa PAO1 y A. baumannii ATCC 
17978, respectivamente. En el caso de bacterias que poseen la enzima Dat, como S. aureus 
132, es necesaria la inactivación conjunta de genes murI y dat (mutantes MurI– Dat–). 
Para evaluar los efectos de la ausencia de D-Glu en el crecimiento bacteriano de las 
cepas de A. baumannii ATCC 17978, P. aeruginosa PAO1 y S. aureus 132 salvajes, y sus 
mutantes derivados, se cultivaron las bacterias en medio suplementado con diferentes 
concentraciones de D-Glu y se evaluaron las morfologías correspondientes por microscopia 
electrónica de barrido (SEM). Se observó una crecimiento sucesivamente menos evidente 
de las tres cepas mutantes ATCC 17978 ΔmurI1 ΔmurI2, PAO1 ΔmurI y 132 ΔmurI Δdat con 
concentraciones decrecientes de D-Glu, hasta su cese total. Algunas de las bacterias que se 
observaron en el medio de cultivo sin D-Glu parecen ser remanentes del inoculo bacteriano 
previamente crecido con el compuesto. En el medio de cultivo con una concentración de 
0.1 mM D-Glu, se observó un crecimiento anormal de las cepas ATCC 17978 ΔmurI1 ΔmurI2 
y 132 ΔmurI Δdat. La cepa ATCC 17978 ΔmurI1 ΔmurI2 presentó agregados filamentosos 
con tres o más unidades celulares, con una división celular atípica, mientras que la cepa 132 
ΔmurI Δdat presentó largos “clusters” de células irregulares debido a una división celular 
aberrante. Se detectaron masas de presuntos protoplastos, en las proximidades de células 
intactas correspondientes a las cepas mutantes. A la concentración de 1.25 mM D-Glu para 
A. baumannii y 1.5 mM D-Glu para S. aureus se observó una más elevada densidad celular, 
respecto a la condición anterior, reflejo de un crecimiento microbiano más abundante, pero 
con mas estructuras similares a protoplastos. También se observaron más células con un 
aspecto similar a las células salvajes. Finalmente, a la concentración de 10 ó 20 mM, las 
cepas mutantes son indistinguibles de las cepas salvajes correspondientes, tanto a nivel de 
la morfología como de densidad celular.  
De igual forma, se procedió a la evaluación de los efectos de la ausencia de D-Glu 
en la morfología bacteriana utilizando para ello la microscopia de transmisión electrónica 
(TEM). Mediante esta técnica, observamos que los mutantes ATCC 17978 ΔmurI1 ΔmurI2, 
PAO1 ΔmurI y 132 ΔmurI Δdat sufren una degeneración progresiva en la ausencia de este 
compuesto como resultado del bloqueo de la síntesis del peptidoglicano. Se aprecian 
células con una conformación alterada que pierden su estructura semirrígida, células con 
varias rupturas y desplazamiento de las membranas, lisis celular y pérdida del contenido 
intracelular. Por lo tanto, el mecanismo de la lisis en las bacterias auxótrofas para D-Glu se 
puede resumir de la siguiente forma: primeramente, la inhibición de la formación de pared 
celular conlleva a que el protoplasma quede recubierto únicamente por la membrana 
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interna (caso de las bacterias Gram-negativas) o por la única membrana (caso de las 
bacterias Gram-positivas), dejándolo totalmente expuesto a las variaciones de tonicidad del 
medio. A continuación, ocurre la lisis celular por presión osmótica, dejándose vestigios de 
membranas citoplasmáticas que pueden formar agregados, o material intracelular. Estos 
fenómenos pueden ocurrir secuencialmente u en simultaneo.   
Una de las características que hace con que los organismos genéticamente 
modificados sean especialmente útiles como vacunas es su grado de atenuación de la 
virulencia. Para testar la hipótesis de que las bacterias auxótrofas para D-Glu están 
atenuadas, medimos la supervivencia de ratones de la línea BALB/c después de la inyección 
intraperitoneal de estas cepas mimetizando una infección aguda letal. Con este modelo, 
pudimos determinar la DL100 (mínima dosis letal para el 100% de los ratones) tanto de los 
mutantes como de las cepas salvajes: A. baumannii ATCC 17978, DL100 = 2.5X; ATCC 17978 
ΔmurI1 ΔmurI2, DL100 = 6X; P. aeruginosa PAO1, DL100 = 0.4X; PAO1 ΔmurI, DL100 > 40X; S. 
aureus 132, DL100 = 1X; 132 ΔmurI Δdat, DL100>10X. Estos resultados indicaron que las cepas 
auxótrofas para D-Glu están atenuadas frente a sus homólogos salvajes.  
Para evaluar la respuesta humoral generada con las cepas auxótrofas para D-Glu, 
cuantificamos la producción de anticuerpos en ratones inmunizados con estas cepas por 
ELISA. Efectivamente, los ratones inmunizados mostraron niveles significativos de las 
inmunoglobulinas IgM, IgG, IgG1, IgG2a, IgG2b y IgG3 específicos contra A. baumannii ATCC 
17978, P. aeruginosa PAO1 y S. aureus 132 Δspa al terminar los calendarios de vacunación. 
La producción de anticuerpos después de dos administraciones de vacuna fue 
significativamente superior que después de una sola toma, exceptuando el caso de las 
inmunoglobulinas IgM inducidas por PAO1 ΔmurI. IgG1 fue el subtipo de IgG dominante en 
la respuesta humoral inducida por las tres cepas auxótrofas para D-Glu, consistente con una 
activación predominante de linfocitos de tipo Th2. Los títulos de IgG2a, IgG2b y IgG3 
inducidos en respuesta a 132 ΔmurI Δdat fueron sustancialmente inferiores que en el caso 
de A. baumannii y P. aeruginosa, sin embargo, fueron significativos. Esto indica que las tres 
cepas mutantes estimulan también la diferenciación de linfocitos de tipo Th1. 
Se observaron niveles significativos de IgM y IgG en ratones vacunados con 
diferentes dosis de las tres cepas mutantes, una vez terminados los calendarios de 
vacunación. Una dosis 0.05X de ATCC 17978 ΔmurI1 ΔmurI2 fue suficiente para estimular 
significativamente las inmunoglobulinas de los subtipos IgG1, IgG2a, IgG2b y IgG3. Los 
títulos más elevados de IgG se obtuvieron con una dosis 0.4X de PAO1 ΔmurI. Con S. aureus 
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132 ΔmurI Δdat, fue necesaria una dosis de 5X o 10X para elevar significativamente todos 
los subtipos de IgG. En su conjunto, estos datos sugieren que las cepas bacterianas 
auxótrofas para D-Glu estimulan los anticuerpos de forma dosis- dependiente. 
Se observó que la vacunación con una dosis 0.0001X de A. baumannii ATCC 17978 
ΔmurI1 ΔmurI2 es suficiente para estimular significativamente la producción de anticuerpos 
IgM, IgG, IgG1, IgG2a, IgG2b y IgG3 en ratón, y que estos se mantienen por lo menos hasta 
1 año después de la inmunización. 
Una de las principales características de una vacuna es su capacidad para generar 
una respuesta inmune amplia; en el caso concreto de las vacunas bacterianas vivas 
atenuadas, esto significa que una preparación que contenga una única cepa debe ser 
suficiente para estimular una respuesta inmunológica que reconozca patrones comunes en 
otras cepas no incluidas en la composición de la vacuna. Los anticuerpos IgG generados por 
la cepa ATCC 17978 ΔmurI1 ΔmurI2 presentan un alto nivel de reactividad cruzada frente a 
otras cepas de A. baumannii, tales como ATCC 19606, AbH12O-A2 (MDR) y Ab307-0294 
(posee capsula). Los anticuerpos IgG generados por la cepa PAO1 ΔmurI presentan 
reactividad cruzada frente a otras cepas de P. aeruginosa, tales como PA21_ST175, PA14, 
PA51441321, LES400, LES431, PA28562, PA12142 y PA51442390. Destacar que las cepas 
PA28562 y PA51442390 presentan el fenotipo mucoide asociado a las infecciones crónicas 
en pacientes con CF y que la cepa PA14 se trata de un clon más virulento que la PAO1. A su 
vez, los anticuerpos IgG generados por la cepa 132 ΔmurI Δdat presentan un alto nivel de 
reactividad cruzada frente a otras cepas de S. aureus, tales como: CA-MRSA USA300 (clone 
de alto riesgo), RF122 (origen bovino), ED133 (origen ovino) y ED98 (pollos). En su conjunto, 
estos datos indican que las cepas ATCC 17978 ΔmurI1 ΔmurI2, PAO1 ΔmurI1 y 132 ΔmurI 
Δdat inducen una respuesta inmunitaria amplia frente a una gran diversidad de cepas de A. 
baumannii, P. aeruginosa y S. aureus, respectivamente.  
Para que una vacuna sea eficaz debe estimular también una respuesta inmunitaria 
de tipo celular. Para explorar la naturaleza de la respuesta de tipo T estimulada por la 
vacunación con A. baumannii ATCC 17978 ΔmurI1 ΔmurI2, P. aeruginosa PAO1 ΔmurI y S. 
aureus 132 ΔmurI Δdat, cuantificamos el número de linfocitos productores de las 
interleucinas IFN-γ, IL-4 y IL-17, estimulados después de un contacto ex vivo con las cepas 
ATCC 17978 ΔmurI1 ΔmurI2, PAO1 ΔmurI y 132 ΔmurI Δdat, en ratones previamente 
vacunados, con la técnica de ELISpot. Tanto la cepa A. baumannii ATCC 17978 ΔmurI1 
ΔmurI2, como P. aeruginosa PAO1 ΔmurI y S. aureus 132 ΔmurI Δdat fueron capaces de 
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estimular significativamente linfocitos de tipo Th17, productores de IL-17. De hecho, los 
linfocitos Th17 fueron la población mayoritaria de linfocitos T activada en respuesta a la 
vacunación con 132 ΔmurI Δdat. S. aureus 132 ΔmurI Δdat estimulo significativamente 
también la población de linfocitos Th1 (productores de IFN-γ). Se observó un incremento 
sustancial, aunque no significativo, de los linfocitos Th1 también con ATCC 17978 ΔmurI1 
ΔmurI2 y PAO1 ΔmurI. Se observó una población de linfocitos Th2 (productores de IL-4) 
activados en respuesta a la inmunización con ATCC 17978 ΔmurI1 ΔmurI2 y PAO1 ΔmurI, 
pero no en respuesta a la inmunización con 132 ΔmurI Δdat. Estos datos indican que la 
inmunización activa con ATCC 17978 ΔmurI1 ΔmurI2 y PAO1 ΔmurI desencadena una 
respuesta consistentemente de tipo Th2, mientras que 132 ΔmurI Δdat induce una 
respuesta de tipo Th1. 
Para averiguar si tanto las respuestas inmunitarias de tipo humoral y celular se 
corresponden a un efecto protector de estas vacunas, evaluamos su eficacia en ratón 
efectuando un desafío experimental con una infección aguda letal. Aplicando un calendario 
de vacunación de 2 tomas separadas por 14 días, la vacunación con las tres cepas 
auxótrofas resultó en un efecto protector frente a la carga bacteriana de la cepa utilizada 
en el desafío, en los tejidos de los ratones vacunados. Además, la vacunación con la cepa 
132 ΔmurI Δdat evitó la pérdida de peso de los ratones después del desafío con S. aureus 
132. A. baumannii ATCC 17978 ΔmurI1 ΔmurI2 tuvo un efector protector frente al desafío 
con las cepas ATCC 17978, AbH12O-A2 y Ab307-0294. P. aeruginosa ΔmurI fue eficaz en 
proteger a los ratones frente a las cepas PAO1, PA28562 y PA14, para esta última se aplicó 
un calendario de vacunación con 3 tomas intramusculares separadas por 14 días. S. aureus 
132 ΔmurI Δdat tuvo un efecto protector frente a las cepas S. aureus 132, CA-MRSA 
USA300, RF122 y ED98. Estos resultados ponen de manifiesto que A. baumannii ATCC 
17978 ΔmurI1 ΔmurI2, P. aeruginosa PAO1 ΔmurI y S. aureus 132 ΔmurI Δdat son vacunas 
eficaces contra cepas multirresistentes, virulentas y epidémicas, algunas incluso de origen 
animal. Además, verificamos que este efecto protector no es exclusivo del fondo genético 
de los ratones BALB/c, considerando que observamos que estas vacunas son eficaces 
también en ratones de la línea C57BL/6. 
Se observó también que los anticuerpos generados por A. baumannii ATCC 17978 
ΔmurI1 ΔmurI2, P. aeruginosa PAO1 ΔmurI y S. aureus 132 ΔmurI Δdat se pueden transferir 
a un recipiente en riesgo de contraer la enfermedad causada por cualquier uno de estos 
microrganismos, para conferirles una inmunidad pasiva protectora. 
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El grado de atenuación de una bacteria debe ser suficiente para minimizar su 
patogenicidad pero no debe debilitar su capacidad invasiva, por el riesgo de dificultar la 
generación de una respuesta inmune fuerte y de larga duración, y tampoco debe conducir 
al individuo vacunado a un estado de portador crónico. La solución a este problema puede 
derivar de la capacidad de las cepas auxótrofas para colonizar y replicarse en el individuo 
vacunado durante un periodo limitado de tiempo, antes de sufrir una lisis, o ser eliminadas 
del organismo sin llegar a causar la enfermedad. Esta eliminación rápida de la sangre fue 
observada después de administradas las cepas A. baumannii ATCC 17978 ΔmurI1 ΔmurI2, P. 
aeruginosa PAO1 ΔmurI y S. aureus 132 ΔmurI Δdat al ratón, lo cual sugiere que estas cepas 
no presentan un riesgo potencial de causar enfermedad o dispersarse descontroladamente 
en el ambiente. 
Para que un organismo genéticamente modificado sea seguro como un 
componente de una vacuna sus mutaciones y sus características derivadas deberán ser 
irreversibles. Para evaluar la irreversibilidad de la auxotrofia nutricional de A. baumannii 
ATCC 17978 ΔmurI1 ΔmurI2, P. aeruginosa PAO1 ΔmurI y S. aureus 132 ΔmurI Δdat, se 
crecieron estas cepas con D-Glu durante 8 días y se evaluó su viabilidad en placas con y sin 
D-Glu. En el caso hipotético de una reversión de fenotipo, observaríamos el mismo número 
de colonias bacterianas en las placas con y sin D-Glu, a partir del cultivo con D-Glu. Sin 
embargo, observamos recuentos sustancialmente superiores en las placas suplementadas 
con D-Glu, tanto al inicio de la incubación, como en los días posteriores, lo que indica que 
estas cepas mantienen la auxotrofia nutricional a lo largo del tiempo.  
Además, una cepa bacteriana viva atenuada que constituya un ingrediente activo 
de una vacuna debe ser incapaz de replicar y persistir en el medio ambiente si 
hipotéticamente se dispersa a través del individuo vacunado. Así que evaluamos la 
persistencia de las cepas auxótrofas para D-Glu en comparación con sus homólogos 
salvajes. De hecho, observamos que las cepas ATCC 17978 ΔmurI1 ΔmurI2 y PAO1 ΔmurI 
presentan una capacidad de resistir a la osmolisis sustancialmente inferior a la de sus 
homólogos salvajes, cuando mantenidas en agua durante varios días. Observamos también 
una reducción sustancial en la capacidad de la cepa S. aureus 132 ΔmurI Δdat para resistir a 
la desecación frente a su homologo salvaje S. aureus 132.  
En conclusión, en el presente trabajo presentamos tres microorganismos 
genéticamente modificados, denominados MurI– y/o MurI–Dat–, incapaces de replicarse en 
el húesped debido a la inexistencia de concentraciones suficientes de D-Glu para la correcta 
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formación del peptidoglicano. Estas cepas bacterianas, auxótrofas para D-Glu, son vacunas 
prometedoras frente a los patógenos A. baumannii, P. aeruginosa y S. aureus, ya que 
presentan un nivel de eficacia y seguridad muy elevado en ratón. Más importante, esta 
estrategia para la atenuación es una plataforma que puede ser ampliamente aplicada a 
otras bacterias Gram-negativas y Gram-positivas de interés, y las composiciones vacunales 
individuales pueden ser reforzadas con la introducción de múltiples cepas para la profilaxis 
tanto de humanos como de animales en el futuro. 
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Abstract
Background: Acinetobacter baumannii is a nosocomial pathogen that has been associated with
outbreak infections in hospitals. Despite increasing awareness about this bacterium, its proteome
remains poorly characterised, however recently the complete genome of A. baumannii reference
strain ATCC 17978 has been sequenced. Here, we have used 2-DE and MALDI-TOF/TOF
approach to characterise the proteome of this strain.
Results: The membrane and cytoplasmatic protein extracts were analysed separately, these
analyses revealed the reproducible presence of 239 and 511 membrane and cytoplamatic protein
spots, respectively. MALDI-TOF/TOF characterisation identified a total of 192 protein spots (37
membrane and 155 cytoplasmatic) and revealed that the identified membrane proteins were mainly
transport-related proteins, whereas the cytoplasmatic proteins were of diverse nature, although
mainly related to metabolic processes.
Conclusion: This work indicates that A. baumannii has a versatile and robust metabolism and also
reveal a number of proteins that may play a key role in the mechanism of drug resistance and
virulence. The data obtained complements earlier reports of A. baumannii proteome and provides
new tools to increase our knowledge on the protein expression profile of this pathogen.
Background
Acinetobacter baumannii is a Gram-negative, nonmotile,
aerobic coccobacillus that is often found in health care
settings. There is increasing concern as regarding the prev-
alence of this bacterium in hospital environments, espe-
cially in intensive care units, where it has been associated
with different types of infections such as pneumonia,
meningitis, bacteraemia, urinary tract infections and oth-
ers [1-3]. In addition, A. baumannii has a remarkable
capacity to acquire resistance to most antibiotics used in
clinical practice and to cause outbreaks throughout cities,
countries and even continents [4-6]. Despite the emerging
awareness of the potential hazards of this bacterium, little
is known about the mechanisms that operate during anti-
biotic resistance, virulence, or persistence strategies of A.
baumannii.
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Genomic approaches have recently been successfully
applied for A. baumannii. For instance, genomic compari-
son between SDF and AYE strains with the soil-living A.
baylyi strain ADP1 revealed important exclusive features of
each strain, which may partly explain their existence in
different ecological niches [7,8]. The recently described
sequence of A. baumannii ATCC 17978 isolate revealed
that its genome is composed by 3,976,746 base pairs (bp)
and that it has 3,830 open reading frames (ORFs), of
which nearly 17% are situated in 28 putative alien islands
[9], which suggests that the genome has acquired a signif-
icant amount of foreign DNA.
Nevertheless, it is widely accepted that most ORFs are
expressed under different conditions and/or states of
growth and environmental stress [10]. Moreover, the
identification of proteins via MS/MS analyses validate pre-
dicted genes, correct erroneous gene annotation and
reveal some completely missed genes [10,11]. Therefore
as pointed out by Brötz-Oesterhelt et al. (2005) [12], the
application of further techniques such as proteomics is
required in order to establish the protein composition of
a given cell under certain conditions, independently of its
linear gene sequence.
Proteomics analysis has been applied to fractions
enriched with A. baumannii cell membranes, and a group
of 22 proteins, composed by ribosomal proteins, chaper-
ones elongation factors and outer membrane proteins
identified [13]. A total of 135 proteins (inner and outer
membrane) and 23 periplasmic proteins were identified
in A. baumannii in another study [14]. More recently, it
was characterise the proteome of outer membrane vesicles
from a clinical A. baumannii isolate [15]. These studies
provide important data regarding the proteome of Aci-
nectobacter, nevertheless as far as we are aware, the cyto-
plasmatic proteome of A. baumannii remains to be
characterised. In the current study, we used 2-DE and
MALDI-TOF/TOF to analyse the membrane and cytoplas-
matic proteome of A. baumannii, and the data obtained
confirms the results of previous genomic studies showing
that A. baumannii displays a robust and versatile metabo-
lism capable of exploiting a variety of carbon sources and
energy.
Materials and methods
Bacterial strain and growth conditions
A. baumannii ATCC 17978 was grown overnight in Muel-
ler Hinton broth (Fluka, Madrid, Spain) at 37°C under
constant shaking. Fresh nutrient media (500 mL) was
inoculated with a 1:100 dilution of the overnight culture
and grown to OD600 = 0.4-0.6, at 37°C with vigorous
shaking.
Protein extraction
The cell were harvested by centrifugation at 3,500 g for 15
min at 4°C and washed twice with 10 mL 0.9% (w/v)
NaCl. The resultant pellet was resuspended in 3 or 5 mL
of disintegration buffer [13] (7.8 g/L NaH2PO4, 7.1 g/L
Na2HPO4, 0.247 g/L MgSO4 7.H2O + protease inhibitor
mix (GE Healthcare, USA) + nuclease mix (GE Healthcare,
USA)) and sonicated on ice for 3 periods of 5 min. The
unbroken cells were separated by centrifugation at 1,500
g. The supernatant was centrifuged for 30 min at 4°C at
4,500 rpm and was then clarified through a 0.45 μM filter
(Milipore, USA) to remove the cell debris. Finally, the
extract was processed with a 2-DE Cleanup Kit (GE
Healthcare, USA).
The same extraction method was used to extract cell sur-
face membrane. However, after the separation of unbro-
ken cells, the lysate was treated as described by Molly et al.
(2000) [16]. Briefly, an equal volume of ice-cold 0.1 M
sodium carbonate (pH 11) was added to the resulting
supernatant and the mixture was stirred slowly overnight,
on ice. The carbonate treated membranes were then col-
lected by ultracentrifugation at 100,000 g for 45 min at
4°C, and the membranes were then re-suspended in 500
μl H2O. Finally, as with the soluble fraction, the extract
was processed with a 2-DE Cleanup Kit (GE Healthcare,
USA).
Two-dimensional gel electrophoresis (2-DE)
Protein concentration in the extracts was determined with
a Biorad protein assay kit (Biorad, Germany), by a modi-
fied Bradford assay [17] as suggested by Ramagli et al.
(1999) [18].
For isoelectric focusing (IEF), the IPGphor III system was
used (GE Healthcare, USA) with 3-10 non-linear (NL), 4-
7 (L) or 6-11(L) pH gradient strips (IPG strips, GE Health-
care, Sweden). Proteins were solubilised in 8 M urea, 2%
(w/v) CHAPS, 40 mM DTT and 0.5% (v/v) corresponding
IPG buffer (GE Healthcare, Sweden). IEF was carried out
at 30 V for 12 h, followed by 250 V for 1 h, 500 V for 1.5
h, 1,000 V for 1.5 h, a gradient to 8,000 V over 1.5 h and
maintenance at 8,000 V for a further 4 h, all at 20°C.
Note, for 6-11 (L) pH gradient strips, IEF was carried out
at 30 V for 12 h, followed by 500 V for 1 h, 1,000 V for 1
h, a gradient to 8,000 V for 2.5 h and maintenance at
8,000 V for 0.5 h. Prior to the second dimension (SDS-
PAGE), the focused IPG strips were equilibrated for 2 × 15
min in buffer containing 50 mM Tris-HCl (pH 8.8), 6 M
urea, 30% (v/v) glycerol, 2% (w/v) SDS and a trace of
Bromophenol Blue. DTT at 1% (w/v) was added to the
first equilibration step and 2.5% (w/v) iodoacetamide to
the second. SDS-PAGE was performed on 12% or 15%
polyacrylamide gels [19]. For analytical 2-DE gels, silver
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staining was performed according to Blum et al. (1987)
[20] and gels were loaded with 25 to 40 μg of total pro-
tein. For preparative gels, MS-compatible silver staining
[21] was used and the gels were loaded with at least 350
μg of total protein.
Image acquisition and 2-DE analyses
Gels were scanned with an Image Scanner v3.3 densitom-
eter (GE Healthcare) and analysed with Image Master
Platinum software, V.6.0, as described by the manufac-
turer (GE Healthcare). Briefly, a matched set consisting of
three images was created. In order to confirm reproduci-
bility, at least three biological replicates were processed.
For spot detection, the parameters were adjusted in the
following order: smooth 2; MinArea 5; Saliency 1.00000,
and only spots observed on all three gels of a replicated
group were considered for further analyses. Numerical
data for individual spots were generated automatically
and expressed as % of spot volume.
Trypsin digestion of proteins and characterisation by 
MALDI-TOF/TOF
Selected spots were manual excised from the gels and
transferred to microcentrifuge tubes. Samples were then
destained with a solution containing 20% (w/v) sodium
thiosulphate and 1% (w/v) potassium ferricyanide for 5
min. Destained spots were then in-gel reduced, alkylated
and digested with trypsin as suggested be Sechi and Chait
1998 [22]. Briefly, spots were washed twice with 25 mM
ammonium bicarbonate in 50% (v/v) acetonitrile (ACN)
for 20 min. The gel spots were then shrunk with 100% (v/
v) in acetonitrile and dried in a speed-vac (Savant, USA).
The samples were reduced with DTT and subsequently
alkylated with iodoacetamide. Samples were digested
with 20 ng/μl sequencing grade trypsin (Roche Applied
Science, USA), overnight at 37°C. After digestion the
supernatant was collected and 1 μl was spotted onto a
MALDI target plate (384-spot Teflon®-coated plates) and
allowed to air dry at room temperature. Where necessary,
tryptic peptides were passed through C18 Zip-Tips (Milli-
pore, USA) and mixed with 3 mg/ml of an α-cyano-4-
hydroxycinnamic acid in 0.1% (v/v) TFA and 50% (v/v)
ACN was added to the dried peptide digest spots and
allowed to air dry. The samples were analyzed using a
MALDI-TOF/TOF mass spectrometer 4800 Proteomics
Analyzer (Applied Biosystems). MALDI-TOF spectra were
acquired in reflector positive ion mode using 1000 laser
shots per spectrum. Data Explorer version 4.2 (Applied
Biosystems) was used for spectra analyses and generating
peak picking list. All mass spectra were internally cali-
brated using autoproteolytic trypsin fragments and exter-
nally calibrate using standard peptide mixture (Sigma-
Aldrich). TOF/TOF fragmentation spectra were acquired
by selecting the 10 most abundant ions of each MALDI-
TOF peptide mass map (excluding trypsin autolytic pep-
tides and other background ions) and averaging 2,000
laser shots per fragmentation spectrum. The parameters
used to analyze the data were a signal to noise threshold
of 20, minimum area of 100 and a resolution higher than
10,000 with a mass accuracy of 20 ppm.
Database queries and protein identification
The monoisotopic peptide mass fingerprinting data
obtained from MS and the amino acid sequence tag
obtained from each peptide fragmentation in MS/MS
analyses were used to search for protein candidates using
Mascot version 1.9 from Matrix Science http://
www.matrixscience.com. Peak intensity was used to select
up to 50 peaks per spot for peptide mass fingerprinting
and 50 peaks per precursor for MS/MS identification.
Tryptic autolytic fragment-, keratin-, and matrix-derived
peaks were removed from the data set utilised for data-
based search. The search for peptides mass fingerprints
and tandem MS spectra were performed in NCBInr data-
base without any taxonomy restriction. Fixed and variable
modifications were considered (Cys as S-carbadiomethyl
and Met as oxidised methionine, respectively), allowing
one trypsin missed cleavage. MS/MS ions search were con-
ducted with a mass tolerance of ± 1.2 Da on the parent
and 0.3-0.8 Da on fragments, in all cases the peptide
charge was +1. Decoy search was done automatically by
Mascot on randomized database of equal composition
and size. Mascot scores for all protein identifications were
higher than the accepted threshold for significance (at the
p < 0.050 level, positive rate measured to be 0.047). For
protein subcellular localisation prediction it was utilised
PSORTb v.2.0.4, available free online at http://
www.psort.org/psortb/index.html.
Results and Discussion
Bimodal distribution of Acinetobacter baumannii 
proteome
In the current study, a 2-DE based proteomic analyses of
A. baumannii ATCC 17978, grown under rich medium
conditions and harvested during exponential phase were
performed. The study was based on the analysis of two
distinct protein fractions, a fraction enriched in mem-
brane proteins and a fraction enriched in cytoplasmatic
proteins; for convenience, these are referred in the text as
membrane and cytoplasmatic fractions respectively. Anal-
ysis of three biological replicates revealed that at least 239
spots were reproducibly detected in the membrane frac-
tion, whereas the cytoplasmatic fraction contained a total
of 511 reproducible spots.
As a first approach, both the membrane and the cytoplas-
matic protein fractions were analysed by use of 2-DE gels
with immobilized pH gradient (IPG) strips (pH 3-10) (see
Fig. 1A and 1B, respectively). However, for the cytoplas-
matic fraction, these analyses revealed a clear predomi-
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nance of acidic proteins, although a number of highly
basic proteins remained unresolved close to the cathode
(pI > 9) (see Fig. 1B). Therefore, in an attempt to over-
come the intrinsic under-representation of the alkaline
proteins [12,23], the acidic and basic cytoplasmatic sub-
proteomes were analysed using immobilized pH gradient
strips of various pH range (see Fig. 2 and 3). Use of 2-DE
12% polyacrylamide (pI ranges of 4-7) silver stained gels
revealed 390 spots that could be reproducibly detected on
the acidic range (Fig. 2A). Additionally, complementary
analyses using 15% polyacrylamide silver stain gels in the
range pH 3-10 revealed the presence of further 30 protein
spots of low molecular weight (between 9 and 12 kDa)
(Fig. 2B). Use of 2-DE gels 12% polyacrylamide (pI ranges
of 6-11) added a further 91 reproducible alkaline protein
spots (nearly 21% of the total soluble protein spots)
(Fig. 3).
In concordance with previous reports referring other bac-
teria species [23], the 2-DE gels analysis revealed that the
spot pattern of this pathogen is characterised by clear pre-
dominance of high molecular protein spots and in terms
of pI there is visible a bimodal distribution of protein
spots, where the most crowded regions is found between
pI 4-7 and 9-11 (Fig. 4).
2-DE gels showing A. baumannii proteinsFigure 1
2-DE gels showing A. baumannii proteins. (A) mem-
brane proteins, (B) cytoplasmatic proteins. Numbered spots 
(in A) indicate membrane proteins identified by MALDI-TOF/
TOF. All gels (12% SDS) were silver stained and loaded with 
25 μg total protein.
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Characterisation of the Acinetobacter baumannii 
proteome
In the current study we wished to identify the most abun-
dant proteins spots, since these are likely to play a relevant
role in bacterial biology. A total of 192 protein spots were
identified 37 and 155 from membrane and cytoplasmatic
protein fractions respectively. The list included proteins
within a pI range of 4.3-10.5 and a Mw from 9.2 - 73.8
kDa (table S1, Additional file 1 and table S2, Additional
file 2), indicating that the 2-DE analyses provided a repre-
sentative view of the A. baumannii proteome. Most of the
identifications were based on multiple peptide matches
(table S3, Additional file 3), although in some cases pro-
tein identification was based on a single peptide sequence
(namely spot # 36, 110, 134, 172, 242, 248, 459 - see
table S1, Additional file 1 and table S2, Additional file 2,
table S3, Additional file 3,). However, the scores for all
proteins identified here were higher than the significance
threshold (determined at the 95% confidence level) calcu-
lated by Mascot (table S1, Additional file 1 and table S2,
Additional file 2) and in all cases the data was search
against an Mascot decoy database in order to check for
false positive (additional identification data for all spots is
provided as supplementary material). Furthermore, all the
proteins identified belong to A. baumannii proteome, and
from the 192 spots, 172 were in fact matched with pro-
teins belonging to A. baumannii ATCC 17978 proteome.
This criterion, together with the fact that in most of the
cases the theoretical molecular weights and/or pI of the
identified proteins were very close to that observed in gel
(table S1, Additional file 1 and table S2, Additional file 2)
provided additional confidence in the identification.
Occasionally, protein spots with only small shifts in
molecular weight and/or pI were identified with the same
sequence in the data base (e.g. spots; 34, 35 & 36, 64 & 67;
spots 94 & 95, spots 271 & 273, 469 & 472; 473 & 474
among others, see also table S1, Additional file 1 and table
S2, Additional file 2). These observations are a common
feature of 2-DE gels [14,24], and possibly arise from the
heterogeneity in post-translation modifications. There-
fore within this context, membrane and cytoplasmatic
fractions together contained 153 unique proteins. Other
spots shared homology with the same protein families
(e.g. spot # 1, spot # 2 and spot # 35), but with different
corresponding gene sequences, indicating the presence of
multi-gene families in the A. baumannii proteome.
The results demonstrate that the A. baumannii proteome is
diverse in nature, and can be conveniently divided into at
least 16 distinct functional groups, namely: amino acid
transport and metabolism; carbohydrate transport and
metabolism; cell division and chromosome partitioning;
coenzyme metabolism; cell envelope and outer mem-
brane biogenesis (transport); defence; energy production
and conversion; general function predicted only; multi-
functional; nucleotide transport and metabolism; pos-
translation modification, protein turnover, chaperones;
redox reactions; RNA and protein synthesis; signalling;
translation, ribosomal structure and biogenesis and tran-
scription (see Fig. 5), in addition there was further 4 hypo-
thetical proteins with unknown function. Whenever
possible the proteins were classified according to the clus-
ters of orthologous groups (COG) [25].
2-DE (12% SDS) gel containing basic proteins within a pH range of 6-11Figure 3
2-DE (12% SDS) gel containing basic proteins within 
a pH range of 6-11. Gel was loaded with 40 μg, total pro-
tein. Numbered spots indicate proteins identified by MALDI-
TOF/TOF.
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Membrane extract
MALDI-TOF/TOF analyses of 37 selected membrane spots
revealed that 12 were identified as outer membrane pro-
teins (Omps) (e.g. spot # 459, 465, 466, 467, 468, 469,
470, 471, 472, 473, 474, and 496) and 7 proteins spots
(spot # 462, 483, 484, 485, 488, 490 and 499) were iden-
tified as subunits of membrane-bound complex F(1)F(0)-
ATP synthase (see table S2, Additional file 2). In addition,
further analyses using PSORTb v.0.4 (a program for bacte-
rial protein subcellular localisation prediction) [26] indi-
cated that there are several other proteins which could be
located in the membrane, for instance: spot # 460 (local-
isation (L): outer membrane; localisation score (LS):
9.49), spot # 461 (L: outer membrane; LS: 9.52), spot #
463, 464, 487 and 488 (L: outer membrane, LS: 9.49),
spot # 478 (L: periplasmic, LS: 4.48), spot # 481 (L: Cyto-
plasmic membrane; LS: 0.51), spot # 493 (L: Cytoplasmic
membrane; LS: 0.51), spot # 494 (L: Cytoplasmic mem-
brane; LS: 0.51), spot # 495 (L: Cytoplasmic membrane;
LS: 0.51).
Curiously, when comparing the data here presented with
previous reports, it become visible that several proteins
here identified are also present in the membrane pro-
teome of other A. baumannii strains, including clinical iso-
lates [13-15] (see table S2, Additional file 2). It is therefore
tempting to propose that these proteins are constitutively
present in the membrane of A. baumannii and if that so,
then this valuable information can be utilised for devel-
opment of new drugs, vaccines and/or diagnostic.
A number of Omps associated with the transport across
the membrane of several compounds were identified in
the present study. Including proteins such as putative cop-
per receptor (OprC, spot # 459), which allows the pene-
tration of small cations, a putative Omp (OprD, spot #
465) that in Pseudomonas aeruginosa has been demon-
strated to be involved in the uptake of basic amino acids,
small peptides and of imipenem [27]; putative glucose-
sensitive porin (OprB-like spot # 466), this porin is often
referred to as carbohydrate selective porin, since it acts as
a central component of glucose, mannitol, glycerol, and
fructose transport across the outer membrane [28]; Omp
38 precursor (spot # 467) belonging to the OmpA family,
which has been suggested to be involved with the trans-
port of β-lactams and saccharides up to approximately
800 Da [29,30]; an Omp (with homology with Omp 33-
36 kDa, spot # 468) involved in the transport of water and
carbapenems [31]; Omp CarO (spot # 469 & spot # 472),
which is essential for the uptake of L-ornithine and partic-
ipates in the selective uptake of carbapenems and other
basic amino acids in A. baumannii [32].
Hence, the results indicate that the most abundant mem-
brane proteins were those involved in the transport of dif-
A functional classification of the 37 most abundant protein spots in the membrane fraction (A) and of the 155 m st abundan  prot in spo s in the cytopl smatic fraction (B)Figure 5
A functional classification of the 37 most abundant 
protein spots in the membrane fraction (A) and of 
the 155 most abundant protein spots in the cytoplas-
matic fraction (B). The protein class was abbreviated as 
follows: ATM, amino acid transport and metabolism; CDCP, 
cell division and chromosome partitioning; CTM, carbohy-
drate transport and metabolism; CEOM, cell envelope bio-
genesis and outer membrane; CoE, coenzyme metabolism; 
D, Defence; EPC, energy production and conversion; GF, 
general function predicted only; Mult., multifunctional; NTM, 
nucleotide transport and metabolism; PTC, postranslation 
modification, protein turnover, chaperones; RPS, RNA and 
protein synthesis; RR, proteins involved in redox reactions; 
S, signalling; TRB, translation, ribosomal structure and bio-
genesis; Trans., transcription; T, transport. Note: Hypotheti-
cal proteins (3) with unknown function are not included in 
this classification.
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ferent components (amino acid, sugars, and fatty acids),
which suggests that A. baumannii have an adaptable
metabolism that utilises a wide range of carbon sources.
Cytoplasmatic extract
MALDI-TOF/TOF analyses of cytoplasmatic extract
revealed that of the 155 identified spots, 12 were identi-
fied as hypothetical proteins (see table S1, Additional file
1) and of those 9 could be functionally classified accord-
ing COG (information obtained by MASCOT analyses).
The three most representative groups are those related to
amino acid and transport metabolism (29), translation,
ribosomal structure and biogenesis (28) and energy pro-
duction and conversion (14). Also there are other impor-
tant groups (see table S1, Additional file 1 and Fig. 5).
Analyses of the cytoplasmatic proteins revealed that much
of the A. baumannii proteome is dedicated to the metabo-
lism of a wide range of components. One of the most
highly represented classes of proteins was that involved in
amino acid transport and metabolism. This comprised
proteins involved in the metabolism of amino acid such
as glutamine (spot # 8), serine (spot # 64 & 67), aspartate
(spot # 103), methionine (spot # 104), cysteine (spot #
182 & 186), trypthophan (spot # 233), lysine (spot # 95;
176 & 211), glutamate (spot # 85), proline (spot # 75),
threonine (spot # 108), and histidine (spot # 120; 182 &
234). In addition, the multifunctional proteins included
proteins such as branched-chain amino acid transferase,
which catalyses the transamination of the branched-chain
amino acids (spot # 132) leucine, isoleucine and valine to
their respective alpha-keto acids [33]. Taking into consid-
eration the number, level of expression (in a population
with an average of % spot volume of 0.21 there was: spot
# 67 0.6 ± 0.04; spot # 123 0.55 ± 0.03; spot # 285 1.13 ±
0.36; see also Fig. 2) and the diversity of proteins within
this group, it is reasonable to conclude that the amino
acid metabolism is in fact a major pillar of the overall A.
baumannii metabolism.
Interestingly, a phospho-2-dehydro-3-heoxyheptonate
aldolase (spot # 123) was identified; in E. coli this type of
synthetase catalyses the first step in aromatic amino acid
biosynthesis from chorismate [34]. Earlier studies have
demonstrated that species of the genus Acinetobacter are
capable of degrading aromatic compounds [24,35-37].
The capacity of Acinetobacter spp. to degrade aromatic
compounds is of particular interest for bioremediation
studies [38] and also for the development of new antibi-
otics [24]. Therefore, the protein here identified and its
possible involvement in aromatic compound degradation
may be subject of further investigation.
As mentioned above, a low molecular weight protein
named nitrogen assimilation regulatory protein P-II 2
(spot # 352) was identified. In E. coli this protein regulates
the assimilation of nitrogen by modulating the activity of
glutamase synthase [39], this regulatory mechanism
allows the cell to adjust the glutamase synthase activity
quickly - in response to alterations in the abundance of
the preferred nitrogen source, ammonia [39]. Although
further investigation is required, this suggests that nitro-
gen is another source of energy utilised by this microor-
ganism.
In concordance with previous genomic studies [8,9,40]
that indicated the inability of A. baumannii to catabolise
glucose, the current proteomic analysis did not detect any
enzymes such as hexokinase, glucosekinase or proteins of
the phosphotransferase transport system essential for gly-
colysis. However, it has to be referred the already men-
tioned presence of the putative glucose porin sensitive
outer membrane (OprB-like) suggests the uptake of glu-
cose from A. baumannii. Hence, this information supports
the existence of a route passing through the Entner-Dou-
doroff pathway [41], in which the oxidation of glucose in
the periplasm leads to pyruvate formation. Moreover, the
presence of both fructose-1,6-bisphosphatase (spot #
138) and fructose-1,6-bisphosphate aldolase (spot #
156), shows that the bacterium in question is capable of
catabolising fructose. Hence, it would be interesting to
investigate further the capability of these and other sugars
to support growth of this bacterium.
Identification of the selected alkaline spots revealed that
most were ribosomal proteins (see table S1, Additional
file 1) as previously described in other microbe studies
[42]. In addition, to ribosome-associated proteins, several
other proteins of the translational machinery were also
detected. For instance, translation elongation factors EF-G
(spot # 5), EF-Tu (spot # 100), EF-Ts (spot # 178), EF-P
(spot # 235) and ribosome releasing factor (spot # 248).
Ribosomes, ribosome-associated proteins and proteins
associated with translation are targets for many antibiot-
ics, which interfere with translation through different
molecular mechanisms of action [12]. As far as we know,
this is the first proteomic study that has identified such a
large number of ribosomes and ribosome-associated pro-
teins in the A. baumannii proteome, and we believe that
the data provided here can serve as preliminary data for
further studies on this bacterium, including studies of
antibiotic drug action.
Proteins with potential role in drug resistance, stress 
response and in virulence
A recent description of the A. baumannii ATCC 17978
genome revealed that this strain has acquired several
genes from its environment, these foreign genes are clus-
tered in small (>10 kb) regions called putative alien
islands (pAs) [9]. In addition, it was reported that ATCC
17978 genome have a total of 28 pAs and some of these
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are associated with drug resistance, virulence, iron uptake,
metabolism and others [9]. Of the identified proteins,
only 26 out of 192 were encoded by genes mapped in
these pAs (see table S1, Additional file 1 and table S2,
Additional file 2). This led us to conclude that most of the
expressed proteins correspond to genes located in the
native A. baumannii chromosome. Hence, it is tempting to
speculate that those pAs are mainly expressed under spe-
cific conditions, e.g. stress.
Although for the most cases it was not clear the associa-
tion between the protein and its respective pAs function,
there were a few examples where it was possible to estab-
lish a more direct association. For instance, heat-shock
proteins (Hsps) namely chaperone Hsp60 (spot # 35),
and Co-chaperonin GroES (spot # 347), are encoded by
genes situated in drug resistance pA 23 [9]. Many of the
Hsps are chaperones and are important for protection
against environmental stress and provide tolerance to
high temperature [43,44], nutrient deprivation [45],
salinity and osmotic stress [46]. Moreover, taking into
account that Hsp60 chaperones were by far one of the
most abundant protein spot (spot # 35 1.13 ± 0.8); and
considering the presence of other Hsps (spot # 1, 2 and
393), it appears reasonable to suggest that these Hsps play
a relevant role in the responses of A. baumannii to environ-
mental changes and in the survival and adaptation to
stress conditions. At this respect, a recent report have
shown downregulation of Hsp60 proteins associated with
resistance to colistin concomitantly to a decrease in bacte-
rial fitness in an A. baumannii isolate [47]. In addition to
Hsps, the Universal stress proteins (Usps) here identified
(spot # 332, 333 and 498) are encoded by genes located
in pA 18, which is associated with drug resistance [9]. In
E. coli the expression level of these small cytoplasmatic
proteins increase when cells are exposed to stress includ-
ing CdCl2, H2O2, DNP, CCCP and osmotic stress [48],
moreover Usp enhances the rate of cell survival during
prolonged exposure to stress conditions [48]. In A. bau-
mannii, the function of Usps remain elusive, recently we
have observed that the expression of these proteins
increase at late phases of in vitro growth (data not pub-
lished), therefore Usps can be an attractive target for fur-
ther studies concerning drug resistance.
Within the stress response context it is worthy to refer the
presence of proteins known to play a relevant role in
response to oxidative stress such as alkyl hydroperoxide
reductase (spot # 271 and 273), superoxide dismutase
(spot # 247), and glutathione peroxidase (478).
Here we have identified several proteins encoded by genes
situated in pAs with a predicted role in virulence, however
again it is not straightforward the association of those pro-
teins with virulence. Nevertheless, amongst the proteins
identified in this report, a few may be more directly
related to virulence. For example, a protein blast align-
ment (data not shown) of the here identified OmpW
revealed that this protein shares a high homology with
putative virulence-related OmpW (gi|188591914) from
Cupriavidus taiwanensis. Also, it has been suggested that
Omp 38 (spot # 467) may act as a potential virulence fac-
tor inducing apoptosis of epithelial cells in the early stage
of A. baumannii infection [[49], Choi, 2008 #392]. In
addition, a recently publication describing the proteome
of OMVs of a clinical A. baumannii presented evidence
that virulence-associated proteins such as Omp38
(gi|126642864), OmpW (gi|126640380) and bacteriofer-
ritin (gi|126640856) are transported in OMVs, where they
have been suggested to play an important role during in
vivo infection [15]. It is of interest that whereas Kwon et al.
(2009) [15] identified proteins such as 30S ribosomal
protein S1 (spot # 3), Glutamine synthetase (spot # 8),
Malic enzyme (spot # 21), Chaperone Hsp60 (spot # 35)
and others (see table S1, Additional file 1) associated to
the OMVs, we find these proteins exclusively in the cyto-
plasmatic fraction. In the referred study, the authors do
not rule out the possibility of the entrapment of these pro-
teins by unknown mechanism. If this is the case, then the
data gathered here, together with that presented in the
referred study provide a list of potential candidate cyto-
plasmatic proteins that can be transported in OMVs.
Furthermore, in the current study a putative type III effec-
tor (spot # 353) was identified, and the interactions
between Pseudomonas synringae-host interaction is medi-
ated in great part by effector proteins, which are injected
into plant cells by type III secretion [50]. In A. baumannii
the function of type III effector has yet to be elucidated,
although it probably participates in bacterium-host inter-
actions.
The specific virulence factors or pathogenic mechanisms
of this bacterium remain elusive [51]. In light of the
present results, it would be interesting to use a proteomic
approach to investigate the expression of these and other
proteins with a potential role in virulence, in the presence
of virulence-induced stimuli or in the process of host-bac-
teria interactions (experiments are currently in progress).
Conclusion
Here we report for the first time a 2-DE based analysis, of
both membrane and cytoplasmatic fraction of the oppor-
tunistic pathogen A. baumannii. Analysis of the most
abundant proteins of this microorganism indicates that A.
baumannii has a versatile and robust metabolism capable
of utilising a wide range of nutrient sources. In addition,
this study revealed the presence of highly expressed pro-
teins such as porins (membrane fraction) and chaperones
or heat-shock proteins and others, which are likely to play
Proteome Science 2009, 7:37 http://www.proteomesci.com/content/7/1/37
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a crucial role not only in mechanisms of virulence and
drug resistance, but also in adaptive environmental
responses, which are probably related to the persistence in
hospital settings, one of the hallmark of this microorgan-
ism. Thus, this proteomic approach provides us with new
molecular tools to investigate the complexity of mecha-
nisms operating during virulence and adaptive responses
of this pathogen, which has been recently outlined by the
Infectious Diseases Society of America as one of six impor-
tant highly dangerous drug resistant microbes in hospitals
worldwide.
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Acinetobacter baumannii is an opportunistic pathogen that has been associated with severe infections
and outbreaks in hospitals. At present, very little is known about the biology of this bacterium,
particularly as regards mechanisms of adaptation, persistence and virulence. To investigate the growth
phase-dependent regulation of proteins in this microorganism, we analyzed the proteomic pattern of
A. baumannii ATCC 17978 at different stages of in vitro growth. In this study, proteomics analyses
were conducted using 2-DE and MALDI-TOF/TOF complemented by iTRAQ LC-MS/MS. Here we have
identified 107 differentially expressed proteins. We highlight the induction of proteins associated with
signaling, putative virulence factors and response to stress (including oxidative stress). We also present
evidence that ROS (O2
- and OH-) and RNI (ONOO-) accumulate during late stages of growth. Further
assays demonstrated that stationary cells survive at high concentrations of H2O2 (30 mM), the O2
- donor
menadione (500 µM) or the NO donor sodium nitroprusside (1 mM), and showed a higher survival rate
against several bactericidal antibiotics. The growth phase-dependent changes observed in the A.
baumannii proteome are discussed within a context of adaptive biological responses, including those
related to ROS and RNI stress.
Keywords: Proteomics • Growth curve • Acinetobacter baumannii • Oxidative stress • Antibiotic
resistance • 2-DE • iTRAQ • MALDI-TOF/TOF
Introduction
Acinetobacter baumannii is a Gram-negative, nonmotile,
aerobic coccobacillus that is often found in health care settings,
where it has been associated with several types of infections
that mostly affect debilitated hospitalized patients in the
ICUs.1,2 Recently, this pathogen has been related with fatal
cases of necrotizing fasciitis.3 A. baumannii is often referred
as a successful pathogen, not only due to its epidemiological
characteristics, but also due to its outstanding ability to acquire
resistance to most antibiotics used in clinical practice.1,4,5
Despite the attention given to this bacterium over the last 10
years,2 so far little is known about the mechanisms operating
during adaptation, virulence and persistence of A. baumannii.
Hence, as pointed out by Dijkshoorn et al.,1 the employment
of further approaches such as genomics, proteomics and fitness
studies might contribute insights into the mechanisms behind
the remarkable adaptability of this pathogen to variable condi-
tions and selective pressures.
Recent studies have revealed some pertinent aspects of the
A. baumannii proteome.6-8 For instance, a 2-DE -based
analysis demonstrated that this microorganism has a robust
and versatile metabolism8 and a comparative study between a
drug-susceptible and multidrug-resistant strains revealed that
the latter showed significant differences in the membrane
protein pattern.7 In addition, a comparison between a colistin-
resistant and a susceptible strain demonstrated that the
induced resistance was associated with the down-regulation
of several proteins.9 However, with the exception of the latter
study, changes in the A. baumannii proteome in response to
changes in environmental conditions and/or in response to
stress have not been investigated in any detail. Analysis of the
changes that occur during in vitro growth culture is a suitable
mean for obtaining useful information regarding bacterial
adaptation. Throughout in vitro growth, bacteria are exposed
to several different conditions in the surrounding medium. For
instance, during the exponential phase, all nutrients are present
in excess and there is scarce accumulation of waste products;
these nearly optimal conditions favor bacterial growth and this
stage is characterized by doubling of the population.10 There
then follows a period during which the growth rate of bacteria
slows down owing to nutrient limitation and/or accumulation
of an end product, and the organisms must respond accord-
ingly to such limitations. During the stationary phase of growth,
the bacteria are exposed to a much more hostile environment
as the culture reaches its maximum cell density, so that
individuals face strong competition and a lack of nutrients,
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changes in pH, induction of several virulence factors, oxygen
depletion and accumulation of toxic products.11 Thus, as
mentioned by Lee et al.,12 proteins that undergo significant
changes in the level of expression throughout the growth curve
are likely to play a relevant role in central intermediary
metabolism, amino acid synthesis, nucleotide, and fatty acid
metabolism, cell wall synthesis, protein degradation and stress
responses.
Reactive oxygen species (ROS) and reactive nitrogen inter-
mediates (RNI) are potentially highly reactive molecules that
are continuously produced in organisms as byproduct of
aerobic respiration metabolism and under hypoxic conditions,
respectively. Previous reports have demonstrated that late
phases of growth are often associated with the induction of
stress responsive proteins, including those specifically associ-
ated with oxidative stress.12-15 Moreover, in other bacterial
species, it has been demonstrated that late stationary cells
support higher concentrations of ROS.13,16,17 Similarly, it has
been demonstrated that during stationary phase there is an
increase in the expression of proteins associated with responses
to nitric oxide (NO) and RNI stress.18,19
Understanding bacterial adaptation to oxidative and nitro-
sative stress is of particular interest, as during infection
microbial pathogens are literally engulfed by phagocytic cells,
such as macrophages, and are then exposed to lethal levels of
both ROS and RNI.20,21 Moreover, further interest has been
recently focused in bacterial resistance to oxidative stress
following the demonstration that the production of ROS is in
fact a common mechanism of cell death initiated by bacteri-
cidal antibiotics.22,23 Furthermore, it has been recently dem-
onstrated that, in Escherichia coli, this mode of action of ROS
can be extended to include other bacteriostatic antibiotics.24
Herein, we present a report that for the first time provides a
dynamic view of the A. baumannii proteome during adaptation
to different environmental conditions. In addition, changes
observed are discussed within the context of adaptive biological
responses, including those related to ROS and RNI stress.
Materials and Methods
Bacterial Strain and Growth Conditions. A. baumannii
ATCC 17978 was grown overnight in Mueller Hinton (MH)
broth (Fluka, St. Louis, MO) at 37 °C with constant shaking.
Fresh nutrient medium (500 mL) was inoculated with a 1:100
dilution of the overnight culture and grown at 37 °C with
vigorous shaking. Cells were harvested at exponential
(OD600 nm ) 0.4), early stationary (OD600 nm ) 1.4) and late
stationary phases of growth, approximately 48 h after inocula-
tion (OD600 nm ) 2.0).
Protein Extraction. Cytoplasmatic Protein Fraction. The
cells were harvested by centrifugation at 3500g for 15 min and
washed twice with 10 mL of 0.9% (w/v) NaCl. The resultant
pellet was resuspended in 3-5 mL of disintegration buffer6 (7.8
g/L NaH2PO4, 7.1 g/L Na2HPO4, 0.247 g/L MgSO4 ·7H2O +
protease inhibitor mix (GE Healthcare, Piscataway, NJ)) +
nuclease mix (GE Healthcare) and sonicated on ice for 3 periods
of 5 min. Unbroken cells were separated by centrifugation at
1500g. The supernatant was centrifuged for 30 min at 4 °C at
3395g and then clarified through a 0.45 µm filter (Millipore,
Billerica, MA) to remove cell debris. Finally, the extract was
processed with a 2-DE Cleanup Kit (GE Healthcare).
Membrane Protein Fraction. The same extraction method
was used to extract the cell surface membrane. However, after
separation of unbroken cells, the lysate was treated as described
by Molloy et al.25 Briefly, an equal volume of ice-cold 0.1 M
sodium carbonate (pH 11) was added to the resulting super-
natant and the mixture was stirred slowly overnight, on ice.
The carbonate-treated membranes were then collected by
ultracentrifugation at 100 000g for 45 min at 4 °C, and then
resuspended in 500 µL of H2O. The extract was processed with
a 2-DE Cleanup Kit.
Two-Dimensional Gel Electrophoresis (2-DE). In this study,
cell extracts were harvested at three time points of the in vitro
growth curve (see above), and the membrane and cytoplas-
matic fractions were analyzed separately. In addition, for
cytoplasmatic protein, fractions were subject to isoelectric
focusing (IEF) using IPG strips of pH 4-7 and pH 6-11 to
obtain further resolution of acidic and basic proteins, respec-
tively. The protein concentration in the extracts was determined
with a Biorad protein assay kit (Biorad, Munich, Germany), by
a modified Bradford assay26 as suggested by Ramagli.27
For IEF, an IPGphor III system was used (GE Healthcare),
with 3-10 nonlinear (NL), 4-7 linear (L) pH or 6-11 (L) pH
gradient strips (13 cm IPG strips, GE Healthcare, Uppsala,
Sweden). Proteins were solubilized in 8 M urea, 2% (w/v)
CHAPS, 40 mM DTT and 0.5% (v/v) corresponding IPG buffer
(GE Healthcare, Sweden) and 3 µL of DeStreak solution (GE
Healthcare, Sweden). For 3-10 (NL) and 4-7 (L) pH gradient
strips, IEF was carried out at 30 V for 12 h, followed by 250 V
for 1 h, 500 V for 1.5 h, 1000 V for 1.5 h, a gradient to 8000 V
for 1.5 h and maintenance at 8000 V for a further 4 h, all at 20
°C. For 6-11 (L) pH gradient strips, IEF was carried out at 30
V for 12 h, followed by 500 V for 1 h, 1000 V for 1 h, a gradient
to 8000 V for 2.5 h and maintenance at 8000 V for 0.5 h. Prior
to the second-dimension (SDS-PAGE), the focused IPG strips
were equilibrated for 2 × 15 min in buffer containing 50 mM
Tris-HCl (pH 8.8), 6 M urea, 30% (v/v) glycerol, 2% (w/v) SDS
and a trace of bromophenol blue. One percent (w/v) DTT was
added to the first equilibration step and 2.5% (w/v) iodoac-
etamide to the second. SDS-PAGE was performed on 12% or
15% polyacrylamide gels.28 For analytical 2-DE gels, silver
staining was performed according to Blum et al.,29 and gels
were loaded with 25-40 µg of total protein. For preparative
gels, MS-compatible silver staining30 was used and the gels
were loaded with at least 250 µg of total protein.
Image Acquisition and 2-DE Analyses. Gels of at least three
biological replicates were scanned with an Image Scanner
version (v).3.3 densitometer (GE Healthcare, Sweden) and
analyzed with Image Master Platinum software, v.6.0, as
described by the manufacturer (GE Healthcare, Sweden).
Briefly, a matched set consisting of three images was created
for each time point on the curve, which allowed intercom-
parative analyses between three matched sets consisting of nine
images. For spot detection, the parameters were adjusted in
the following order: smooth 2; MinArea 5; Saliency 1.00000, and
only spots observed on all three gels of a replicated group were
considered for further analyses. Numerical data for individual
spots were generated automatically and expressed as % of spot
volume. A minimum fold-change of two and Student t-test
(p < 0.050) was used to select for significant changes in protein
levels between growth phases.
Trypsin Digestion of Proteins and Characterization by
MALDI-TOF/TOF. Selected spots were excised from the gels
and destained in 20% (w/v) sodium thiosulphate and 1%
(w/v) potassium ferricyanide for 5 min. Destained spots were
then in-gel reduced, alkylated and digested with trypsin as
suggested by Sechi and Chait.31 Briefly, spots were washed
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twice with 25 mM ammonium bicarbonate in 50% (v/v)
acetonitrile (ACN) for 20 min. The gel spots were then
incubated with 100% (v/v) ACN and dried in a Speed-Vac
(Savant, Ramsey, MN). The samples were reduced with DTT
and subsequently alkylated with iodoacetamide. Samples were
digested overnight with 20 ng/µL sequencing grade trypsin
(Roche Applied Science, Mannheim, Germany) at 37 °C. After
digestion, the supernatant was collected and 1 µL was spotted
onto a MALDI target plate (384-spot Teflon-coated plates) and
allowed to air-dry at room temperature. Where necessary,
tryptic peptides were passed through C18 Zip-Tips (Millipore)
prior to spotting. The dried peptide digests were mixed with 3
mg/mL of an R-cyano-4-hydroxycinnamic acid in 0.1% (v/v)
TFA and 50% (v/v) ACN and allowed to air-dry. The samples
were analyzed using a MALDI-TOF/TOF mass spectrometer
4800 Proteomics Analyzer (Applied Biosystems, Farmingham,
MA) and 4000 Series explorer software (Applied Biosystems).
MALDI-TOF spectra were acquired in reflector positive ion
mode using 1000 laser shots per spectrum. Data Explorer v.4.2
(Applied Biosystems) was used for spectra analyses and gen-
erating peak picking list. All mass spectra were internally
calibrated using autoproteolytic trypsin fragments and exter-
nally calibrate using standard peptide mixture (Sigma-Aldrich,
St. Louis, MO). TOF/TOF fragmentation spectra were acquired
by selecting the 10 most abundant ions of each MALDI-TOF
peptide mass map (excluding trypsin autolytic peptides and
other background ions) and averaging 2000 laser shots per
fragmentation spectrum. The parameters used to analyze the
data were a signal-to-noise threshold of 20, minimum area of
100 and a resolution higher than 10 000 with a mass accuracy
of 20 ppm. For database queries and protein identification, the
monoisotopic peptide mass fingerprinting data obtained from
MS and the amino acid sequence tag obtained from each
peptide fragmentation in MS/MS analyses were used to search
for protein candidates using Mascot v.1.9 from Matrix Science
(www.matrixscience.com). Peak intensity was used to select up
to 50 peaks per spot for peptide mass fingerprinting and 50
peaks per precursor for MS/MS identification. Tryptic autolytic
fragment-, keratin-, and matrix-derived peaks were removed
from the data set utilized for database search. The search for
peptides mass fingerprints and tandem MS spectra were
performed in NCBInr database without any taxonomy restric-
tion. Fixed and variable modifications were considered (Cys
as S-carbamidomethyl and Met as oxidized methionine, re-
spectively), allowing one trypsin missed cleavage. MS/MS ions
search were conducted with a mass tolerance of (1.2 Da on
the parent and 0.3-0.8 Da on fragments. Decoy search was
done automatically by Mascot on randomized database of
equal composition and size. Mascot scores for all protein
identifications were higher than the accepted threshold for
significance (at the p < 0.050 level, positive rate measured to
be 0.047).
iTRAQ Analysis. Protein Label. Total proteins samples were
submitted to W.M. Keck Foundation Biotechnology resource
laboratory at Yale University (New Haven, CT). To accurately
determine the protein concentration, each sample was subject
to AAA (amino acid analysis). Sample labeling with isobaric
tagging reagents was carried out according to the manufac-
turer’s instructions (Applied Biosystems). Briefly, 50 µg was
dissolved in 20 µL of dissolution buffer and 2 µL of denaturant
(2% SDS) from iTRAQ kit. Two microliters of reducing reagent
(50 mM TCEP) was added followed by incubation at 60 °C for
1 h. After centrifugation, 1 µL of cysteine-blocking (200 mM
MMTS) agent was added and incubated at room temperature
for 10 min. This was followed by addition of 5 µL of Lys C which
was incubated for 5 h at 37 °C and then 5 µL of Trypsin
(Promega grade, Madison, WI) incubated overnight at 37 °C.
Digested samples were labeled with eight different iTRAQ
reagents dissolved in 50 µL of isopropanol and left at room
temperature for 2 h. The samples were labeled with iTRAQ tag
as follows: exponential1, iTRAQ 113; exponential2, iTRAQ 114;
Late stationary1, iTRAQ 115; Late stationary2, iTRAQ 116. The
differentially labeled digests were mixed and analyzed by LC-
MS/MS.
Cation-Exchange Chromatography and LC-MS/MS
Analyses. After digestion, 180 µL of the combine peptide
mixture was loaded onto an off-line strong cation exchange
chromatography (SCX) using an Applied Biosystems Vision
Workstation with a 2.1 mm × 200 mm PolySulfethyl A column
(5 µm 300 Å bead, from PolyLC, Inc., 2.1 × 200 mm, PN
202SE0503). The PolySulfethyl A column is equilibrated with
Buffer A (10 mM KH2PO4, 25% ACN, pH 3.0). Peptides are then
separated into 20 fractions using a 90 min linear salt gradient
from 0-98% Buffer B (10 mM KH2PO4, 25% ACN, 1 M KCl, pH
3.0). All 20 collected fractions from the SCX chromatography
were dried and reconstituted with 5 µL of 70% Formic acid and
15 µL of 0.1% TFA. LC-MS/MS was performed on a QSTAR Elite
mass spectrometer interfaced with a Waters nanoAcquity UPLC
system running Analyst QS 2.0 software. Peptides were resolved
for LC-MS/MS by loading 5 µL of sample onto a Symmetry C18
nanoAcquity trapping column (180 µm × 20 mm, 5 µm) with
2% ACN/0.1% FA at 15 µL/min for 3 min. After trapping,
peptides were resolved on a BEH130 C18 nanoAcquity column
(75 µm × 250 mm, 1.7 µm) with a 60 min, 2-40% ACN/0.1%
FA linear gradient (0.3 µL/min flow rate).
Electrospray ionization was performed using a Nanospray
II interface (Applied Biosystems) equipped with the Microion-
spray source and FS360-75-15-D-20 PicoTip Emitter (New
Objective, Inc., Woburn, MA). Data dependent acquisition with
each cycle consisted of 0.2 s MS spectrum and MS/MS
acquisition using Smart CE and Smart Exit functionality on
three highest peptide peaks.
Data Analysis and Statistics. Each of the QSTAR Elite mass
spectrometer spectra files (*.wiff) was processed with MASCOT
Distiller v.2.3.1 and the resulting peak lists were combined and
database searched using MASCOT Server 2.2.06 and Swiss-Prot
57.0 (released March 24, 2009 and contained 428 650 se-
quences). The search parameters included trypsin with one
miscleavage, static modifications carbamidomethyl (cys) and
iTRAQ reagents (N-term, K), and variable modifications for
oxidation (met). iTRAQ Quantiation and secondary protein
identification was performed using the Paragon search algo-
rithm32 in ProteinPilot v.3.0 software using Swiss-Prot 57.0
database with “thorough search”. The “iTRAQ 8plex peptide
labeled” sample type and a “biological modification ID focus”
were selected in the analysis method. Trypsin was selected as
the digestion enzyme with cysteine alkylation by methyl
methane thiosulfonate as a modification. Raw data that in-
cluded, but was not limited to, reporter ion peak areas, reporter
ion peak area error, and peptide assignment, and confidence
was exported from ProteinPilot (tab-delimited) without Pro-
teinPilot’s auto bias correction applied (non-normalized data)
so we could perform quantile normalization as described
below. The tab delimited ProteinPilot results was then uploaded
into our Yale Protein Expression Database (YPED). For second-
ary protein identification, each protein had to have also been
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identified by Paragon and had two or more identified peptides
and a ProteinPilot Confidence Score >2 (99% confidence level).
To ensure that we only compared data that ProteinPilot
includes in its quantitation analysis, peptides had to be
classified as “used”, which requires the presence of an iTRAQ
label and at least one valid iTRAQ reporter ion ratio. Addition-
ally, ProteinPilot only uses high-quality reporter ions for the
peak area measurements to calculate iTRAQ peptide ratios. To
remove low-intensity reporter ion ratios from the exported raw
data sets, we used ProteinPilot’s nonmodifiable criterion, which
requires that valid iTRAQ reporter ion ratios must contain two
iTRAQ reporter ions with a summed S/N ratio >9 to be included
in the analysis. The data was then merged and loaded onto
the Yale Protein expression database (YEPD, http://yped.
med.yale.edu), which allows the view data online and perform
downstream data analysis.
Real Time Reverse Transcription (QRT-PCR) Analysis. The
samples were collected as described above. Total RNA was
isolated from harvested bacteria with the RNeasy Mini Kit
(Qiagen, Huntsville, AL), according to the manufacturer’s
instructions. Each preparation was incubated with RNase-free
DNase (Promega) at room temperature for 45 min, extracted
with phenol/chloroform (1:1 v/v) and precipitated with ethanol.
Purified RNA was resolved on an ethidium bromide-containing
agarose gel to check integrity. Reverse transcription (RT) was
carried out according to the instructions for Transcriptor First
strand cDNA synthesis kit (Roche).
The RNA in each sample (at exponential, early stationary and
late stationary phases of growth) was analyzed independently,
three times by QRT-PCR. For each pair of primers (designed
to amplify 90-100 pb and described in Table 3 of Supporting
Information), different amounts of cDNA were used as template
with a constant cycle number of 20.
Briefly, the following QRT-PCR conditions were set: denatur-
ing step of 5 min at 94 °C, followed by 45 amplification cycles
of 94 °C for 10 s, 60 °C for 10 s, and 72 °C for 10 s using the kit
LightCycler 480SYBR Green I Master (Roche). PCR products
were tested for melting temperature with a temperature ramp
of 2.2 °C/s from 65 to 95 °C and shown to correspond to the
expected amplicons. Overexpression was considered for genes
whose expression was 2-fold that of the control (in this case,
expression values obtained at exponential phase). Similarly, the
value 0.5-fold was used to identify underexpression.
Detection of ROS and RNI. For the detection of exogenous
ROS, growth medium was harvested at the above-mentioned
three time points on the curve and the supernatant was then
centrifuged for 5 min at 27 000g. For detection of O2-, 250 µL
of each supernatant was incubated with 6 mM nitroblue
tetrazolium (NBT; Fluka) for 4 h. Note that in all cases the
results presented are mean values of 3 replicates. For detection
of H2O2, 500 µL of 500 µM ferrous ammonium sulfate; 50 mM
H2SO4, 200 µM xylenol and 200 mM sorbitol was added to 500
µL of culture medium after removing the bacteria. After 45 min
incubation, the respective absorbance was measured at 560 nm
in a UV/Visible Nicolete Evolution (Thermo) spectrophotom-
eter.33
To measure the endogenous production of ROS and RNI, a
series of reactive fluorescent dyes were used for the detection
of specific ROS and RNI produced during A. baumanni growth:
dihydrorhodamine 123 (DHR) (Sigma-Aldrich) for detection of
peroxynitrite (ONOO-); 5-(and-6)carboxy-2′,7′-dichlorodihy-
drofluorescein diacetate (H2DCF-DA) (Fluka) for detection of
hydrogen peroxide (H2O2); hydroethidine (HEt) (Sigma-Aldrich)
for detection of superoxide radicals (O2-) and 3′-(p-hydroxy-
phenyl) fluorescein (HPF) (Invitrogen, Molecular Probes, Eu-
gene, OR) for detection of hydroxyl radical (OH-). Procedures
were followed as indicated by the manufacturers for each
fluorophore. All data were collected using a Becton Dickinson
FACSCalibur flow cytometer with a 488 nm argon laser and a
515-545 nm emission filter (FL1) at low flow rate. At least
50 000 cells were collected for each sample.
Antioxidant Activity Assay. To remove small molecules that
could interfere with the measurement of protein antioxidant
activity, all samples were in advance subject to gel-filtration
with PD-10 columns (GE Healthcare, Buckinghamshire, U.K.).
To measure the total antioxidant capacity (TAA) of the protein
extracts, the Antioxidant Assay Kit (Sigma-Aldrich) was utilized
according to the manufacturer’s instructions. Briefly, we used
the manual spectrophotometric assay to determine the TAA
of experimental samples, and a reference antioxidant, the water
cytoplasmatic analogue of vitamin E, Trolox (6-hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylic acid). The kinetics of the
quenching of the 2,2-azino-bis-(3-ethylbezothiazoline-6-sul-
fonic acid; ABTS) radical cation was followed at 405 nm, using
a visible spectrophotometer. TAA values were calculated from
a Trolox standard curve that showed a linear relationship (r2
) 0.99) between concentration (0-0.42 mM). Here we have
measured the TAA from protein extract (containing a total
protein concentration of 4 µg) obtained from both exponential
and late stationary phases of growth. Note: this was based in
three biological replicates and the protein extracts were
obtained as described for cytoplasmatic protein fraction (see
above).
Survival Studies of A. baumannii in the Presence of
H2O2, O2
-, and ONOO- and Antibiotics. Bacterial cells collected
at exponential phase of growth (OD600 nm ) 0.4) or late
stationary phases of growth (approximately 48 h after inocula-
tion; OD600 nm ) 2.0) were incubated in either 30 mM hydrogen
peroxide (H2O2, Sigma-Aldrich), 500 µM menadione (Sigma-
Aldrich) as a supply of O2-, 1 mM of the NO donor sodium
nitroprusside (SNP, Sigma-Aldrich) or several bactericidal
antibiotics such as -lactams (ceftazidime, imipenem), quino-
lones (levofloxacin) and colistin.
After addition of hydrogen peroxide/menadione/SNP, ali-
quots of bacteria at both exponential and stationary phases of
growth were removed and the viability analyzed after 15, 30,
45, and 60 min. Cells were collected at the indicated time
points, diluted accordingly and plated onto MH agar plates.
After 24 h incubation at 37 °C, colonies were counted. The data
correspond to three independent biological experiments. Each
biological experiment is the result of three independent
measurements.
The bactericidal effect of ceftazidime, imipenem, levofloxacin
and colistin with cells at two different phases of growth curve
was measured by counting colonies or CFU (colony-forming
unit). Briefly, cells were obtained from both growth phases and
washed twice with 0.9% NaCl. After centrifugation at 3500g for
10 min, cell pellets were then resuspended in 5 mL of fresh
MH broth, adjusted to 0.4 (exponential cells) and 1.0 (late
stationary cells) Mc Farland units and inoculated into 15 mL
of MH broth with adjusted volume of antibiotic stock solutions.
After 0, 2, and 4 h of incubation at 37 °C with shaking, aliquots
of cells were taken, diluted in 0.9% NaCl and plated onto
McConkey agar plates. After 24 h incubation at 37 °C, cells were
counted and CFU was determined according to each dilution
factor. Each experiment was repeated at least three times.
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A Student’s t-test was used for two-group comparisons and
ANOVA followed by an unpaired Student’s t-test with Bonfer-
roni’s correction was used for multiple group comparisons.
Results and Discussion
Proteome Profiles of A. baumannii in Different Growth
Phases. Characterization of the Growth Phase Dependent
Proteins. In the present study, a 2-DE and MALDI-TOF/TOF
coupled with iTRAQ approach was used to establish a proteome
profile for in vitro cultured A. baumannii strain ATCC 17978.
To obtain an overview of the temporal regulation of protein
expression, cells were harvested at exponential, early stationary
and late stationary phases of growth (Figure 1) and analyzed
using 2-DE based approach. Time-dependent changes in the
proteome of A. baumannii strain ATCC 17978 during in vitro
culture are summarized in Table 1 and 2 (see also Figure 2).
2-DE analyses of three biological replicates and Student’s
paired t test (95% confidence interval) was performed and a
minimum fold-change of 2 was used to select protein spots
which suffered significant changes in intensity during in vitro
growth. Using this gel-based proteomic approach, we have
identified a total of 76 proteins that were differentially ex-
pressed during in vitro growth. The differentially expressed
proteins consisted of 13 membrane and 63 cytosolic proteins
(Table 1 and Supporting Information).
To further increase confidence of assigning protein expres-
sion level, we also performed an iTRAQ coupled with LC-MS/
MS analyses. In this case, we have analyzed protein extracts
from both cells harvested during exponential and late stationary
phases of growth (Figure 1). iTRAQ analyses of the two
biological replicates were performed. To be considered with
significant altered expression, its representative peptides must
have met the following criteria: (i) protein score should be more
than 2 (99% confidence); (ii) the protein had to be represented
by at least two peptides of differing amino acid sequence; and
(iii) to be considered a differentially regulated protein the
protein ratio should be greater than 1.2 or less than 0.8.
Through iTRAQ analyses we have identified 31 differentially
expressed proteins (Table 2) and of these, there are a number
of proteins identified by both iTRAQ and 2-DE gel approach
which show the same tendency of change throughout the in
vitro growth (e.g., spots nos. 178 and i16; 432 and i62; 437 and
i49; E23 and i5; 54 and i14; L10 and i158, and IL11 and i242, see
Tables 1 and 2). Therefore, our results support the concept that
these two techniques complement each other34 and that in this
case combining the two methods not only allowed a validation
of some results, but also to obtain a wider view of the proteome
changes occurring during in vitro growth of A. baumannii.
The results regarding the pattern of protein expression through-
out the growth phases (resumed in Tables 1 and 2) revealed a
clear tendency for the down-regulation of proteins functionally
related with cell division, such as trigger factor septum formation
molecular chaperones (spot no. 33, Figure 2A) and cell division
protein FtsZ (spot no. 88, Figure 2B). Similarly, there was a
reduced expression of several proteins associated with translation,
ribosomal structure and biogenesis (Tables 1 and 2).
As stated earlier in the text, during the stationary phase,
bacteria are exposed to a rather hostile environment, and
therefore, survival of bacteria at this stage will largely rely on
the promptness and suitability of the bacterial response to
external stimuli. Many of such adaptive responses are mediated
by the activation of complex signal transduction systems, that
are sensitive to changes in the external environment and that
coordinate cellular events accordingly. Within this context, the
present results revealed the de novo appearance of a lipoprotein
(spot no. L17, Figure 2C) in the late stationary phase. This
lipoprotein, which belongs to the NlpE superfamily, is appar-
ently required for signaling by the Cpx pathway. The Cpx two-
component signal transduction pathway responds specifically
to stress caused by envelope disturbances, and increases the
expression of periplasmic protein folding and degradation
factors.35 Thus, NlpE together with the other sensing and
signaling proteins identified here (e.g., spot nos. L22, Figure
2D; BL2, Figure 2E; IL6, IL7, Figure 2F; IL17 and protein no.
i280, see Tables 1 and 2) are attractive targets for future studies
aimed at a better understanding of signal transduction systems
mediating environmental adaptation in A. baumannii.
Furthermore, previous studies in other species have dem-
onstrated a correlation between the entry into stationary phase
and the induction of virulence factors.36,37 The present results
revealed that proteins with adhesive surface properties, which
are probably involved in biofilm formation, were up-regulated
at late stages of growth, for example, the lipoprotein NlpE (spot
no. L17, Figure 2C)35 and putative peptidoglycan-binding LysM
(spot nos. IL6 and IL7, Figure 2F).38,39 These type of proteins
may be considered to be virulence factors, since preliminary
observations indicate that A. baumannii biofilm-forming strains
could be associated with catheter-related urinary and blood-
stream infections.40,41 Regarding virulence factors, it is worth
mentioning the presence of Omp38, as it has been demon-
strated that this outer membrane protein may act as a potential
virulence factor inducing apoptosis of epithelial cells in the
early stage of A. baumannii infection.42 Moreover, another
known virulence mechanism is the ability of some pathogens,
including A. baumannii, to acquire iron from their hosts.43,44
Here, the present report indicate the induction of two proteins,
namely, bacteroferritin (spot no. IL11, Figure 2G) and a heme
containing protein flavohemoprotein (spot no. 172, Figure 2H),
which may be involved in iron uptake and storage, respectively.
Finally, it is worth mentioning that a putative protein belonging
to the glyoxalase I family is greatly increased with the entry
into the stationary phase (spot no. L23, Figure 2I); this is of
particular interest considering that this type of protein may play
a relevant role in the pathogenicity of Mycobacterium tuber-
culosis.45
Figure 1. In vitro growth of A. baumannii ATCC 17978 in MH
broth. The figure shows the (SD of values obtained from three
independent cultures. The arrows indicate time points at which
the cells were collected for proteomic analysis. (A) Exponential
phase (OD600 nm ) 0.4); (B) early stationary phase (OD600 nm ) 1.4);
(C) late stationary phase (OD600 nm ≈ 2.0 at 48 h).
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Table 1. Functional Classification of Identified Differentially Expressed 2-DE Gels Protein Spots during A. baumannii in vitro
Culturea
average % spot volume (MSD) MALDI-TOF/TOF
protein description
spot
no.b
NCBlnr
accession no. exp.c earlyc latec score
matched
peptides
(%)
cov.
Post-translation Modification, Protein Turnover, Chaperones
Trigger factor septum formation molecular chaperone 33 gi|126640548 0.54 (0.08) 0.32 (0.12) 0.01 (0.01) 313 4 18
Chaperone Hsp60 35 gi|126642698 1.14 (0.28) 1.15 (0.49) 0.73 (0.15) 585 5 21
ATP-dependent protease Hsp 100 E20 gi|126641234 ND 0.25 (0.18) ND 251 4 7
ATP-dependent protease Hsp 100 L2 gi|126641234 ND ND 0.45 (0.05) 172 3 5
Translation, Ribosomal Structure and Biogenesis
30S ribosomal protein S1 3 gi|126641617 0.71 (0.29) 0.19 (0.11) 0.02 (0.01) 167 3 7
Elongation factor Ts 178 gi|126642362 1.14 (0.42) 0.82 (0.29) 0.14 (0.13) 794 10 33
30S ribosomal protein S2 406 gi|126642363 2.15 (0.22) 0.66 (0.04) ND 60 1 28
50S ribosomal protein L3 428 gi|126643095 0.77 (0.09) 0.09 (0.09) ND 491 7 41
50S ribosomal protein L6 432 gi|169632365 3.50 (0.24) 2.46 (0.57) ND 306 5 28
50S ribosomal protein L5 437 gi|126643084 1.78 (0.11) 1.06 (0.40) ND 156 3 32
50S ribosomal protein L13 439 gi|126643019 2.13 (0.06) ND ND 161 4 42
30S ribosomal protein S8 443 gi|169632364 1.54 (0.21) ND ND 301 4 38
50S ribosomal protein L23 450 gi|126643093 2.58 (0.02) ND ND 139 2 35
30S ribosomal protein L25 451 gi|126643096 2.86 (0.31) ND ND 474 5 44
50S ribosomal protein L25 452 gi|126640884 1.94 (0.31) 0.53 (0.12) ND 305 2 36
Elongation factor G E23 gi|126640918 0.20 (0.01) 0.16 (0.01) ND 72 2 4
Elongation factor Tu L12 gi|162286746 0.05 (0.02) 0.04 (0.00) 0.62 (0.12) 255 4 10
Elongation factor Tu L14 gi|162286746 0.05 (0.02) 0.04 (0.01) 0.62 (0.18) 189 4 10
Elongation factor G L39 gi|126640918 0.09 (0.04) ND 0.42 (0.02) 145 4 9
Elongation factor Tu L44 gi|162286746 ND 0.41 (0.10) 0.30 (0.08) 288 7 24
Energy Production and Conversion
F0F1 ATP synthase subunit  54 gi|162286755 0.50 (0.14) 0.32 (0.07) 0.13 (0.02) 213 4 15
Phosphoglycerate kinase 135 gi|126641588 0.38 (0.03) 0.06 (0.08) 0.05 (0.07) 81 2 10
Putative flavohemoprotein 172 gi|126643100 0.20 (0.02) 0.52 (0.13) 0.47 (0.03) 57 1 7
Electron transferase flavoprotein R-subunit L9 gi|169632682 ND ND 0.64 (0.15) 575 7 48
Cell Division and Chromosome Partioning
Cell division protein FtsZ 88 gi|126643338 0.32 (0.12) 0.21 (0.01) ND 107 2 12
Amino Acid Transport and Metabolism
Methionine adenosyltranferase 104 gi|126641564 0.28 (0.12) 0.16 (0.02) 0.01 (0.01) 184 4 16
Succinylornithine transaminase 110 gi|126643147 0.08 (0.01) 0.11 (0.03) 0.03 (0.03) 61 1 6
Xanthine phosphoribosyltransferase 259 gi|126643050 0.33 (0.05) 0.17 (0.01) 0.11 (0.02) 88 3 22
2,3,4,5-tetrahydropyridine-2-carboxylate
N-succinyltransferase
300 gi|126642574 0.37 (0.05) 0.17 (0.01) 0.09 (0.02) 195 4 20
Aconitate hydratase 1 E21 gi|193076354 ND 0.18 (0.02) ND 147 4 5
Putative intracellular/amidase L3 gi|193078218 0.06 (0.01) 0.53 (0.06) 0.59 (0.01) 192 4 18
Putative protease L15 gi|193078237 0.27 (0.15) 1.09 (0.40) 0.93 (0.30) 218 3 16
2,3,4,5-tetrahydropyridine-2-carboxylate
N-succinyltransferase
L48 gi|126642574 0.32 (0.09) 0.17 (0.08) 0.83 (0.05) 201 4 19
Dihydrodipicolinate synthase L49 gi|126642699 ND ND 0.20 (0.06) 431 7 32
Coenzyme Metabolism
Succinyl-CoA synthetase R chain 137 gi|126642750 0.36 (0.01) 0.19 (0.01) 0.13 (0.01) 64 2 14
Putative acetyl-CoA carboxylase,  subunit 194 gi|126642893 0.27 (0.05) 0.27 (0.08) 0.03 (0.01) 101 2 8
Acetoacetyl-CoA transferase R subunit L5 gi|126641777 0.04 (0.03) 0.24 (0.05) 0.25 (0.07) 242 7 47
Putative enoyl-CoA hydratase II L13 gi|193077017 ND ND 0.39 (0.23) 576 11 48
Transcription
DNA-directed RNA polymerase subunit R 145 gi|158513671 0.40 (0.06) 0.32 (0.05) 0.03 (0.07) 379 8 27
Carbohydrate Transport and Metabolism
Inorganic pyrophosphatase 268 gi|126640295 0.79(0.08) 0.77(0.07) 0.76 (0.08) 181 3 23
Lipid Transport and Metabolism
Biotin carboxyl carrier protein of acetyl-CoA
carboxylase (BCCP)
310 gi|126642055 1.07 (0.23) 0.94 (0.45) 0.06 (0.03) 108 2 29
Multifunctional
Putative lipoprotein L17 gi|169633901 ND ND 0.34 (0.05) 251 5 20
Putative lipoprotein L41 gi|126641128 ND ND 0.39 (0.05) 394 6 37
Possible Role in Signaling
Putative signal peptide BL2 gi|193077163 0.12 (0.02) 0.05 (0.00) 1.67 (0.31) 238 4 31
Putative signal peptide IL17* gi|126643195 ND ND 2.33 (0.10) 435 7 43
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Interestingly, the results revealed that A. baumannii contains
several proteins that may be directly associated with ROS
metabolism (see Tables 1 and 2). In addition, it was seen that
entry into stationary phase is associated with the induction of
a number of oxidative stress responsive proteins, such as alkyl
hydroperoxidase reductase (spot no. L10, Figure 2J), glutatione
peroxidase (spot no. IL1, Figure 2K), catalase-peroxidase (pro-
tein no. i26), catalase HPII (protein no. i287) and antioxidant
proteins (spot nos. L16 and L19, Figure 2L,M). In addition to
these, there was the induction of proteins known to play an
important role in the detoxification processes, such as bacte-
roferritin46 (spot no. IL11, Figure 2G), putative glyoxalase I
family protein (spot no. L23, Figure 2I)47,48 and universal stress
proteins (USPs) (spot no. L25, L26, Figure 2N and L27).49
Moreover, a growth phase-dependent induction of proteins
involved in DNA repair (e.g., integration host factor (IHF)
(protein no. i96) and protein recA (protein no. i80), Table 2)
was observed, as well as the induction of proteins implicated
in protein repair (e.g., chaperone protein dnaK, 10 kDa and 60
kDa chaperonins (protein nos. i7, i8 and i270, respectively),
Table 2).
Spot Pattern Indicating Oxidative Modification of the
Late Stationary Proteome. Occasionally, protein-spots were
identified as the same protein included in the database. Some
Table 1 Continued
average % spot volume (MSD) MALDI-TOF/TOF
protein description
spot
no.b
NCBlnr
accession no. exp.c earlyc latec score
matched
peptides
(%)
cov.
Cell Envelope Biogenesis, Outer Membrane
Outer membrane protein (Omp)38 precursor 140 gi|75438841 0.54 (0.11) 0.52 (0.09) ND 364 6 17
Omp38 precursor 149 gi|75438841 1.40 (0.64) 1.34 (0.48) ND 256 4 11
Putative outer membrane protein 202 gi|126643304 0.18 (0.03) 0.10 (0.08) 0.03 (0.01) 91 3 24
Putative peptidoglycan-binding LysM 298 gi|126640876 0.79 (0.27) 1.03 (0.28) 0.15 (0.07) 189 5 59
Putative outer membrane protein W 299 gi|126640380 0.88 (0.20) 0.91 (0.21) 1.02 (0.19) 97 2 15
Omp38 L8 gi|126642864 ND ND 1.56 (0.23) 719 8 23
Putative peptidoglycan-binding LysM L22 gi|126640876 ND ND 1.19 (0.20) 183 3 24
Omp38 BL5 gi|126642864 ND ND 4.2 (1.60) 306 6 16
Putative outer membrane protein BL9 gi|126640934 0.42 (0.07) ND 1.24 (0.09) 73 2 11
Omp38 467* gi|126642864 2.45 (0.17) 5.8 (0.31) 5.9 (0.00) 690 9 30
Omp 33-36 kDa 468* gi|193078641 3.56 (0.29) 1.25 (0.56) 0.56 (0.26) 465 5 28
Omp CarO precursor 469* gi|126642573 0.38 (0.04) 0.85 (0.14) 0.79 (0.13) 145 3 20
Omp CarO precursor 472* gi|126642573 1.60 (0.06) 4.05 (0.90) 4.10 (0.02) 308 4 35
Putative Omp W 474* gi|126640380 3.01 (0.52) 4.26 (1.19) 3.6 (1.38) 356 6 44
Omp 38 IL3* gi|126642864 ND ND 1.03 (0.26) 112 2 10
Omp 38 IL4* gi|126642864 ND ND 0.32 (0.00) 108 2 6
Omp 38 IL5* gi|126642864 ND ND 0.44 (0.06) 98 2 6
Putative peptidoglycan-binding LysM IL6* gi|126640876 ND 2.83 (0.54) 2.27 (0.48) 120 3 24
Putative peptidoglycan-binding LysM IL7* gi|193076594 0.87 (0.13) 2.10 (0.11) 2.12 (0.03) 163 4 32
Outer membrane protein CarO precursor IL18* gi|126642573 0.48 (0.04) 0.61 (0.18) 0.95 (0.42) 187 2 13
Function Unknown
Conserved hypothetical protein 204 gi|169797441 0.17 (0.02) 0.11 (0.06) 0.03 (0.01) 64 2 11
Hypothetical protein A1S_2728 L4 gi|126642759 ND ND 0.39 (0.05) 149 4 29
Hypothetical protein A1S_2406 L45 gi|126642443 0.24 (0.03) 0.53 (0.16) 0.59 (0.10) 435 7 30
Proteins Involved in Redox Reactions
Thioredoxin reductase 171 gi|193076628 0.22 (0.10) 0.16 (0.05) 0.15 (0.01) 174 2 7
Superoxide dismutase [Mn/Fe] 247 gi|126642383 0.47 (0.21) 0.31 (0.12) 0.49 (0.05) 138 2 9
Alkyl hydroperoxide reductase C22 subunit 271 gi|126641253 0.30 (0.03) 0.39 (0.05) 0.10 (0.03) 127 2 16
Alkyl hydroperoxide reductase C22 subunit 273 gi|126641253 1.37 (0.03) 1.05 (0.09) 0.57 (0.10) 197 3 26
NADH-dependent enoyl-ACP reductase E6 gi|126640605 0.24 (0.19) 0.36 (0.08) 0.08 (0.06) 115 3 14
Alkyl hydroperoxide reductase C22 subunit L10 gi|126641253 0.06 (0.04) ND 1.05 (0.06) 433 6 38
Putative oxidoreductase L16 gi|126641974 0.05 (0.01) 0.40 (0.11) 0.49 (0.06) 245 3 20
Putative antioxidant protein L19 gi|126642887 ND ND 0.46 (0.05) 75 2 18
Glyoxalase I super family protein (Hypothetical protein
A1S_2863)
L23 gi|193078285 0.06 (0.02) 0.70 (0.19) 0.71 (0.11) 112 4 27
Glutathione peroxidase IL1* gi|126640260 ND 0.24 (0.07) 0.37 (0.01) 98 2 14
Bacterioferritin IL11* gi|126640856 0.23 (0.05) 1.39 (0.28) 1.40 (0.18) 150 4 26
Defense
Universal stress protein L25 gi|169795610 0.08 (0.02) 0.56 (0.26) 0.40 (0.07) 410 5 57
Universal stress protein L26 gi|169795610 0.21 (0.03) 1.23 (0.08) 1.43 (0.18) 443 6 58
Universal stress protein L27 gi|126642117 ND 0.45 (0.04) 0.32 (0.07) 388 4 49
a Some constitutive proteins (spots nos. 35, 171, 247, 268, 299, and 474*) are shown for comparison. b (*) Protein spots isolated by the method used to
extract cell surface membranes. c Exp., early and late refer to exponential, early stationary and late stationary stages of growth, respectively. Student’s test
statistical significance of changes in percentage of spot volume. Levels p e 0.05 were considered significant. ND, protein spot not detected. MSD, the
square root of the average difference of each sample value to the center location is calculated. Note: all the identifications were based on multiple peptide
matches, although in three specific cases protein identification was based on a single peptide sequence (spot nos. 110, 172, and 406). However, the scores
for all proteins identified here were higher than the significance threshold (determined at the 95% confidence level) calculated by Mascot and in all cases
the data was searched against an Mascot decoy database in order to check for false positive (additional identification data for all spots is provided as
supplementary material).
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of these spots in which small shifts in spot pI were verified are
probably isoforms of the same protein (e.g., spot nos. 34 and
35, see Figure 2A and Supporting Information). There were,
however, several examples of protein isoforms in which the
molecular weights of spots and/or the pI substantially differed,
and which demonstrated differing regulation with growth phase
progression (e.g., spot nos. 273 and L10 Figure 2J; L26 and L25
Figure 2N; 298 and L22, Figure 2D and also 149 and L8, BL5,
Figure 2O, P and Q). For instance, during stationary phase,
Omp38 (spot nos. L8 and BL5) and elongation factor G (EF-G)
(spot no. L39, Figure 2R) migrated at masses much lower than
expected. In fact, Omp38 peptides from one isoform (spot no.
L8, Figure 2P) were found only from the N-terminal part of
the protein, whereas peptides from a further isoform (spot no.
BL5, Figure 2Q) were found only from the C-terminal (data not
shown), suggesting cleavage of Omp38 into two halves (spot
nos. L8 and BL5). In addition, the iTRAQ analysis revealed that
Omp38 (protein no. i17, Table 2) in fact suffered a slight
decreased in expression level during late stationary phase,
which suggests that the de novo appearance of both spot nos.
L8 and BL5 can only be explained by the proteolysis of this
protein. Oxidation damage has been found to be a major
limiting factor for bacterial cells in stationary-phase.11 In
addition, a recent study of protein oxidative damage in E. coli
revealed that proteins such as Omp38, EF-G and F0F1 suffered
major modification in their structure.50 Therefore, it is possible
Table 2. Functional Classification of Differentially Expressed Proteins Identified by iTRAQ
protein description
protein
no.a
NCBlnr
accession no. (%) cov. no. peptides E2:E1a L1:E1b L2:E1c
Post-translation Modification, Protein Turnover, Chaperones
Chaperone protein dnaK i7 gi|226738224 80.03 40 1.10 (0.12)d 2.38 (0.00) 2.13 (0.00)
60 kDa chaperonin i8 gi|226704107 82.35 33 0.99 (0.99) 2.38 (0.00) 1.75 (0.00)
10 kDa chaperonin i270 gi|166233974 54.17 2 1.12 (0.75) 2.50 (0.28) 3.10 (0.21)
Protein grpE i144 gi|226737248 55.40 4 0.95 (0.61) 2.14 (0.02) 1.50 (0.01)
Trigger factor i21 gi|226703990 72.97 24 0.85 (0.07) 0.46 (0.00) 0.52 (0.00)
Translation, Ribosomal Structure and Biogenesis
Elongation factor G i5 gi|238685496 81.88 39 0.93 (0.40) 0.51 (0.00) 0.78 (0.00)
Elongation factor Ts i16 gi|166221178 89.00 18 0.83 (0.05) 0.58 (0.07) 0.52 (0.00)
50S ribosomal protein L2 i35 gi|160419217 71.17 15 0.89 (0.33) 0.46 (0.00) 0.54 (0.00)
50S ribosomal protein L21 i168 gi|226730509 48.54 4 0.82 (0.03) 0.51 (0.12) 0.54 (0.01)
50s ribosomal protein L5 i49 gi|226731478 78.09 13 0.72 (0.21) 0.31 (0.00) 0.44 (0.01)
50s ribosomal protein L10 i74 gi|226700243 70.24 6 0.80 (0.33) 0.50 (0.26) 0.51 (0.20)
50S ribosomal protein L6 i62 gi|226731363 62.7 6 0.67 (0.05) 0.31 (0.00) 0.48 (0.03)
Energy Production and Conversion
ATP synthase -subunit i14 gi|226694415 69.4 19 0.87 (0.33) 0.33 (0.00) 0.58 (0.00)
Isocitrate lyase i147 gi|76364071 23.7 2 1.46 (0.26) 2.76 (0.35) 4.06 (0.18)
Amino Acid Transport and Metabolism
2,3,4,5- tetrahydropyridine-2-carboxylate
N-succinyltransferase
i64 gi|166224190 56.78 10 0.94 (0.63) 1.36 (0.07) 1.14 (0.43)
Aconitate hydratase 1 i51 gi|81622450 25.8 6 1.59 (0.07) 3.60 (0.01) 3.89 (0.02)
Lipid Transport and Metabolism
Fatty acid oxidation complex R-subunit i10 gi|254788553 72.94 32 1.74 (0.00) 3.30 (0.00) 3.20 (0.00)
D-amino acid dehydrogenase small subunit i76 gi|226722637 32.07 8 1.61 (0.07) 3.00 (0.00) 4.54 (0.00)
Possible Role in Signaling
Carbon storage regulator homologue i280 gi|226711125 57.1 2 0.86 (0.60) 2.68 (0.12) 1.25 (0.27)
Replication, Recombination and Repair
Protein recA i80 gi|238685519 40.4 8 1.30 (0.01) 2.08 (0.00) 2.05 (0.00)
Integration host factor R-subunit i96 gi|226707551 62.2 4 1.38 (0.07) 4.43 (0.03) 4.26 (0.02)
Transcription
DNA-directed RNA polymerase -subunit i6 gi|212288355 62.78 46 0.87 (0.08) 0.49 (0.00) 0.65 (0.00)
DNA-directed RNA polymerase R-subunit i38 gi|158513671 68.66 18 0.83 (0.04) 0.65 (0.00) 0.59 (0.00)
Cell Envelope Biogenesis, Outer Membrane
Omp38 i17 gi|148839593 69.9 14 1.60 (0.00) 0.68 (0.12) 0.93 (0.63)
Dihydroorotate dehydrogenase i185 gi|226711019 33.53 6 0.86 (0.50) 2.46 (0.15) 1.69 (0.04)
Alanine racemase i221 gi|226711023 19.3 2 1.20 (0.42) 3.40 (0.22) 2.73 (0.26)
Proteins Involved in Redox Reactions
Catalase-peroxidase i26 gi|215275637 52.2 15 1.50 (0.10) 3.02 (0.00) 3.34 (0.00)
Alkyl hydroperoxide reductase C22 subunite i158 gi|83286947 21 1 1.87 (-) 7.59 (-) 2.98 (-)
Bacterioferrtin i242 gi|74599304 80.0 2 1.24 (0.65) 3.50 (0.41) 2.72 (0.33)
Superoxide dismutase [Fe]e i263 gi|34098495 23.2 1 0.80 (-) 3.93 (-) 1.76 ( (-)
Catalase HPII i287 gi|81541033 12.0 2 0.86 (0.68) 2.59 (0.17) 2.92 (0.38)
a E2:E1, the ratio of different expression level between biological replicates of exponential cell. b L1:E1, the ratio of different expression level between
exponential cell control (E1) and late stationary cell (L1). c L2:E1, the ratio of different expression level between exponential cell control (E1) and late
stationary cell (L2). d p-value obtained from Protein pilot analyses. e Protein ID based on one peptide; however, these are shown for comparison with
respective 2-DE generated data.
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that, in the present study, late-stationary phase isoforms of
Omp38 and EF-G are a consequence of oxidative damage.
Moreover, the analysis of 12 genes involved in ROS metabo-
lism and stress response by real time reverse transcription
(QRT-PCR) showed a poor correlation between the mRNA
transcript and the protein pattern (Figure 3). These discrep-
ancies are consistent with the suspicion that a considerable
number of protein spot changes observed during the late
stationary phase are due to possible post-translational modi-
fication and/or post-transcriptional regulation as pointed out
by Choi et al. who made similar observations in Helicobacter
pylori.51
Figure 2. Representative protein spot images of differentially expressed proteins at each growth phases (exponential, early stationary and
late-stationary panels). There are examples of spots that in terms of it intensity remained nearly unchanged throughout the growth curve,
these are shown for comparison (e.g., spot nos. 34 and 35 {panel A}; spot no. 135 {panel B}; spot no. 285 {panel M} spot no. 268 {panel P};
for additional information concerning the protein identification of these type of spots please see Supporting Information). The figure shows
examples of protein spots that suffered a visible decrease in spot intensity at the late stage of the growth curve (e.g., spot no. 33 {panel A};
spot no. 88 {panel B}, spot no. 437 {panel E}; spot# no. 259 {panel L} and spot no. 149 {panel O}). There are also several examples in which
spot intensity increased clearly during early and stationary phases (e.g.; spot no. BL2 {panel E}; spot no. IL6 and IL7 {panel F}; IL11 {panel G};
spot no. 172 {panel H}; spot no. L23 {panel I}; spot no. IL1 and IL18 {panel K}; spot no. L15, L16 {panel L} and spot no. L25, L26 {panel N}). It
is also indicated cases of the appearance of de novo spots at late stationary phase (e.g., spot no. L17 {panel C}; spot no. L22 {panel D} spot
no. L10 {panel J}; L14 and L44 {panel L}; spot no. L19 {panel M}; spot no. L8, L9 {panel P}; spot no. BL5 {panel Q} and spot no. L39 {panel R}).
Note that panel F, G and K represent areas from gels obtained from membrane protein fractions.
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ROS and RNI Production during in Vitro Growth of A.
baumannii. Our proteomic data strongly suggests that through-
out in vitro growth, the ability of A. baumannii to respond to
oxidative stress undergoes adaptive changes. To test for any
correlation between late stationary phase and the accumulation
of ROS in the medium, ROS production was measured during
the three growth phases, as described in Material and Methods
(Figure 4).
In a first approach, colorimetric assays were used to verify
qualitative changes in exogenous ROS production. The incuba-
tion of samples of medium from exponential and early station-
ary phases with NBT indicated that there was no detectable
production of O2- during these phases. However, a strong
reaction with NBT was observed with medium from the late
stationary phase (Figure 4.1), indicating production and ac-
cumulation of O2- in the late stationary phases of in vitro
growth of A. baumannii. Xylenol orange was used to monitor
production of H2O2, but no reaction was with medium from
any phase of growth (data not shown).
On the basis of these results, we then proceeded to evaluate
quantitative changes of endogenous ROS production. For this
purpose, we used several fluorescent report dyes, 5-(and-
6)carboxy-2′,7′-dichlorodihydrofluorescein diacetate (H2DCF-
DA), hydroethidine (HEt), and 3′-(p-hydroxyphenyl) fluorescein
(HPF), which detect H2O2, O2-, and OH-, respectively (see
Material and Methods). Consistent with the colorimetric assays,
flow cytometry/report dye analysis revealed that O2- ac-
cumulated during late stationary phase (Figure 4.2 (A) (data
not shown)) and that the levels of H2O2 did not change
throughout growth. Furthermore, as regards OH- detection, it
was verified that the level remained the same during exponen-
tial and early stationary phases and increased at the late
stationary phase (Figure 4.2 (B)).
The apparent discrepancy between O2- and H2O2 accumula-
tion was somewhat surprising, since that it is known that
detoxification of O2- via scavenging enzymes, namely, super-
oxide dismutase and superoxide reductase (SOR) (in prokary-
otic cells only),52 results in the formation of H2O2. However, a
recent study in Pseudomonas aeruginosa, which is closely
related to A. baumannii, revealed that O2-, but not H2O2
accumulated during biofilm formation.53 The authors justified
this by the existence of high levels of catalases, enzymes that
disproportionate and neutralize H2O2. An analogous explana-
tion may be applied to the current results, since in later stages
of the growth curve catalase-peroxidase and alkyl hydroper-
oxidase reductase increased (Tables 1 and 2), and both of these
proteins have been referred to as major scavengers of H2O2.
54
It is known that NO reacts with O2- to form a potential
peroxynitrite (ONOO-), which may damage cellular compo-
nents in a similar way to other chemical oxidants.55,56 Here it
was demonstrated that O2- accumulated during growth. To
determine whether O2- accumulation during growth was
accompanied by NO formation and consequently ONOO-
accumulation, we have used fluorescence DHR, which mea-
sures the accumulation of both ONOO- and H2O2. However,
as mentioned earlier, we were unable to detect exogenous or
endogenous production of H2O2 and we can therefore reason-
ably assume that assays involving DHR detected the accumula-
tion of ONOO- alone. The results confirmed that as for O2-,
ONOO- accumulates at the late stationary phase of growth
(Figure 4.2 (C)).
A recent study in Staphylococcus aureus revealed that the
addition of different oxidative stresses to exponentially growing
cells resulted in complex changes in protein expression, includ-
ing the induction of many proteins with a role in protection
against oxidative stress.57 Here, we also observe that ROS
accumulation occurs in late stationary phase of in vitro growth
and that this occurs with the induction of several proteins with
a role in protection against oxidative stress. It is conceivable
that throughout the growth curve, ROS act as signaling
molecules activating pathways that regulate the induction of
these proteins.
A. baumannii Stationary Cells Show a Constitutive
Protection against ROS and RNI Related Stress. To test the
susceptibility of A. baumannii to ROS throughout in vitro
growth, cells from exponential and late stationary phases were
incubated with menadione (500 µM) as a source of O2- or H2O2
(30 mM).13,57,58 As referred to above, O2- can be dismutated
into H2O2, which in its turn decomposes into hydroxyl radicals
(OH-) through catalysis by low-valence-transition metal ions
in a Fenton-Haber-Weiss reaction. These oxidizing agents react
strongly with macromolecules, resulting in a variety of types
of base damage.59 The results obtained here revealed that when
challenged with H2O2 the cell survival rates increased from 0%
Figure 3. Real time RT-PCR (QRT-PCR) of genes involved in ROS metabolism and stress response. Expression was calculated by the
∆∆Ct method with gyrB as internal control. Names refer to the identified protein spots as well genes in the annotated A. baumannii
ATCC 17978 genome.
research articles Soares et al.
1960 Journal of Proteome Research • Vol. 9, No. 4, 2010
(exponential cells) to approximately 25% (late stationary)
(Figure 5A). Similarly, when incubated with menadione, the cell
survival rates increased from approximately 5% (exponential
cells) nearly to 40-85% (late stationary) (Figure 5B).
To determine if the increased resistance of late stationary
cell to ROS could be associated with the induction of antioxi-
dant proteins, we have compared the antioxidant capacities
of cell lysates obtained from the exponential and late stationary
phases of growth (see Materials and Methods). According to
total antioxidant activity assay, the antioxidant capacity in-
creased from 0 (exponential cells) to 80 240 ( 8300 µM/mg of
protein extract of late stationary cells.
This report clearly indicates that late stationary cells are in
fact more protected against oxidative stress and this can be
associated with the induction of several enzymes that scavenge
ROS, such as catalases (protein nos. i26 and i287), alkyl
hydroperoxidase reductase (spot no. L10, Figure 2J), glutatione
peroxidase (spot no. IL1, Figure 2K), antioxidant proteins (spot
nos. L16 and L19, Figure 2L and 2M), but also with increased
in the expression level of proteins related with protein repair,
such as dnaK that minimize protein oxidative damage. In
addition, the induction of DNA repair proteins, such as IHF,
has been shown to play an important role against DNA OH-
cleavage.60
As referred to above, ONOO- accumulates at late stages of
growth (Figure 4.2 (C)). On the basis of this, we wished to test
the susceptibility of A. baumannii to RNI during in vitro growth.
Figure 4. Accumulation of ROS during growth phases. (4.1)
Detection of exogenous O2
- accumulation with NBT. A change
in color indicates accumulation of O2
-. No color change was
observed in the control wells (A), at exponential phase (B), and
early stationary phase (C). The well corresponding to stationary
phase medium was the only one in which incubation with NBT
resulted in a change in color to deep red (D). The same result
was obtained in three independent experiments. (4.2) Production
of endogenous ROS and RNI at different phases of growth; (A)
O2
-, (B) OH- and (C) ONOO-. In each panel, black line represents
the negative control, yellow line represents exponential cells,
blue line represents the early stationary cells, and red represents
the late stationary cells.
Figure 5. Effects of different oxidant stress on cells at different
stages of growth. Exponential growing cells and late stationary
cells were treated with 30 mM of H2O2. (A) Exponential growing
cells and late stationary cells were treated with 500 µM of
menadione (supply of O2
-). (B) Exponential growing cells and
late stationary cells were treated with 1 mM of a sodium
nitroprusside (NO donor), (C). Error bars indicate the standard
deviations for replicate samples. At least three replicate experi-
ments were performed and each had results similar to those
shown. Error bars indicate the standard deviations for replicate
samples. At least three replicate experiments were performed
and each had results similar to those shown (p < 0.001 in all
cases).
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Here the cells from both exponential and late stationary phase
were incubated with 1 mM of a NO donor sodium nitroprusside
(SNP).53 Similar to the ROS assays, it was found that survival rates
were higher among the late stationary cells when compared with
exponential cells (Figure 5C). Interestingly, entry to stationary
phase was associated with the induction of a flavohemoprotein
(spot no. 172, Figure 2H). This correlation is of particular interest,
since it was recently demonstrated that NO-inducible flavohe-
moproteins play an important role in protecting bacterial cells
from nitrosative stress.19,21,61 Hence, it is very likely that the up-
regulation of this protein is part of an adaptive response of A.
baumannii to the accumulation of RNI accumulation.
Several reports have shown evidence suggesting that an
efficient defense mechanism against ROS and RNI damage
enhances the ability of bacteria to survive macrophage
attack.62-65 We suggest that comparative analyses of the
different phases of in vitro cultures can provide a convenient
means of gaining new insights into the bacterial mechanism
underlying during host interaction.
Stationary Cells Present a Higher Survival Rate to
Antibiotics. It was recently demonstrated that the production
of ROS is a common mechanism of cell death induced by
bactericidal antibiotics.22 As referred above, our observations
indicate that late stationary cells are more protected against
oxidative stress, which prompted us to investigate whether the
susceptibility of A. baumannii to this type of antibiotics
changed during the different growth phases of in vitro culture.
Three major classes of bactericidal antibiotics were utilized,
namely, -lactams (ceftazidime and imipenem), quinolones
(levofloxacin) and colistin.
Figure 6. Survival rate of exponential growing A. baumannii cells and late stationary cells after treatment with different antibiotics:
Ceftazidime (1); Levofloxacin (2); Imipenem (3); Colistin (4). In all cases the upper panel indicates the CFU of exponential cells (A) and
lower panel indicates the cfu of cells at stationary phase of growth (B), after treatment with the respective antibiotics at the indicated
minimal inhibitory concentrations (MIC). Error bars indicate the standard deviations for replicate samples. At least three replicate
experiments were performed and each had results similar to those shown and statistical significant differences are indicated by *p <
0.050 and **p < 0.010.
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The assays clearly showed that in all cases late stationary
cells show higher survival rates to the action of bactericidal
antibiotics (Figure 6). Whereas, in case of colistin, this is the
first time that have been reported, in case of -lactams and
levofloxacin, this was some how expected, since that is widely
accepted that the mode of action interferes with cell wall
biosynthesis and DNA replication, respectively. However, it has
to be mentioned that, for both -lactams and quinolones, other
toxicity mechanisms are implicated; for instance, it has been
demonstrated that these types of antibiotics cause cell death
by inducing ROS.22,24,66
Recent studies have demonstrated that ROS detoxifying en-
zymes such as catalases, superoxide dismutase and alkyl hydro-
peroxide reductase play an important role during response to
antimicrobial stress.24,67 Consistent with the concept that bacteria
protection to ROS confers cross-protection against antibiotics,
here we propose that throughout in vitro growth A. baumannii
is exposed to adaptive doses of ROS, which in its turn leads to
the induction of several oxidative stress responsive proteins and
these are implicated in the protection not only against oxidative
stress, but also against antibiotic stress.
Concluding Remarks
Herein, for first time, it was demonstrated that ROS and RNI
accumulate during in vitro growth. This study indicates that
A. baumannii contains a dynamic proteome, which responds
accordingly to changes in the surrounding environment. Within
this context, we highlight the induction of several oxidative-
stress responsive proteins during the late stationary phase of
growth, which may function in ROS and RNI detoxification,
DNA repair and protein repair processes. Hence, it can be
concluded that the A. baumannii proteome possesses robust
machinery against oxidative stress. Moreover, it can be con-
cluded that, throughout in vitro growth, A. baumannii under-
goes important adaptive changes (including at the proteome
level), that permitted late stationary phase cells to withstand
levels of ROS, RNI and antibiotics considered to be lethal in
other culture systems.
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’ INTRODUCTION
Acinetobacter baumannii is a human pathogen that is often
found in health care settings and is associated with a wide
spectrum of infectious diseases, including pneumonia and blood-
stream infections.1,2
Bioﬁlms are assemblages of microorganisms characterized by
cells that are irreversibly attached to a substratum and em-
bedded in a matrix of self-produced extracellular polymeric
substances, such as exopolysaccharides (EPS), proteins, nucleic
acids and other substances; this type of sessile community
based existence is a critical characteristic for bacterial
persistence.3 Bioﬁlm formation is frequent in clinical strains
of A. baumannii,4 and it is an important requirement for chronic
colonization of human tissues and persistence in implanted
medical devices. In addition, these structures are associated
with multiple drug resistance,5,6 being the microorganisms
contained in the bioﬁlm more resistant to desiccation, environ-
mental stress (nutritional or oxidative stress), and UV light
exposure. Although bioﬁlm formation on abiotic surfaces con-
tributes to the unique survival pattern of this pathogen in the
hospital settings, little is known about this phenomenon. There-
fore, the main goal of this study is to contribute insight into
mechanisms behind the remarkable capacity of A. baumannii to
form this type of structures.
Bacterial bioﬁlm formation involves several complex molecular
mechanisms in which some proteins are thought to play a major
role during important events such as cell adhesion, maturation,
signaling and others.710 Bioﬁlm initiation is mainly characterized
by adhesion of cells to biotic or abiotic surfaces. Cell surface-
attachment is mediated by proteins; some of which have already
been described inA. baumannii. For instance, formation of bioﬁlms
on abiotic surfaces appears to depend on the expression of aCsuA/
BABCDE chaperone-usher pili assembly system,11 whereas the
expression of the CsuA/BABCDE polycistronic operon is appar-
ently not required for adhesion to biotic surfaces.12,13 Instead, it is
known that an outer membrane protein (OmpA) plays a crucial
role during interaction with eukaryotic cells.13
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Another example is a surface adhesin called Bap,14 which is
able to mediate primary attachment to both abiotic and biotic
surfaces.15 A Bap homologue has recently been described in A.
baumannii,16 and has been found to be directly involved in
intercellular adhesion within mature bioﬁlms, and to be con-
served among a panel of 98 Acinetobacter strains.
The processes of cell surface attachment and subsequent
bioﬁlm formation/maturation involve complex regulatory net-
works, which coordinate the temporal expression of several
mobility, adhesion, and exopolysaccharide genes.17 Recently,
the phosphoproteome was mapped over the course of bioﬁlm
development in Pseudomonas aeruginosa, and three novel two-
component regulatory systems that are required for the devel-
opment and maturation of bioﬁlms were identiﬁed.18 It has been
suggested that in A. baumannii, an analogous two-component
regulatory system comprising a sensor kinase encoded by bfmS
and a response regulator encoded by bfmR, is involved in
regulation of the CsuA/BABCDE chaperone-usher pili assembly
system.19
Bioﬁlm-associated microorganisms may grow in two diﬀer-
ent ways involving bioﬁlms or planktonic (free-moving) life-
styles. The mechanism of bioﬁlm development involves
transition from planktonic cells to bioﬁlm sessile cells, and
the bacterium undergoes considerable changes during the
transition. Comparison between these two states is therefore
essential for obtaining further information about the bioﬁlm
lifestyle. At present, most of the available information regarding
transition from planktonic lifestyle to bioﬁlms is based on
transcriptomic analyses. However, researchers have recently
raised some concerns about the limitations of this technique for
the identiﬁcation of bioﬁlm-regulated genes and, as pointed out
by Sauer et al.,9 proteomics is an essential complement to
transcriptomic analyses. Taking this into account and that
information concerning the transition of A. baumannii from
planktonic to bioﬁlms remains incomplete,20 we propose a
proteomic overview of this transition.
Recently, Shin et al.21 used gels stained with Coomassie blue
to compare the A. baumannii bioﬁlm proteome with planktonic
cells, and 17 diﬀerentially regulated proteins were detected of
which 11 were up-regulated and 6 down-regulated in bioﬁlms.
In the above study, the bioﬁlm protein extracts were recovered
from 24 h-bioﬁlm cultures grown in polystyrene Petri dishes for
comparison with those obtained from a planktonic culture.
However, as pointed out by Sauer et al.,9 bioﬁlms grown in
beakers or microtiter plates are considered somewhat limited
since mature bioﬁlms cannot be studied under such experi-
mental conditions. In the current study, we have attempted to
complement this earlier work by comparing the proteome of
bioﬁlms obtained under ﬂow conditions22 with that of plank-
tonic populations (at exponential and late stationary phases of
growth). The respective protein extracts were subject to two-
dimensional (2D) DIGE MALDI-TOF/TOF and iTRAQ
analyses. We believe that the present study provides a more
extensive and detailed description of the characteristics of the
two bacterial lifestyles.
Several studies have indicated that salicylate (SA) aﬀects the
formation of bioﬁlms in diﬀerent bacterial species.23,24 This
compound is one member of a large group of pharmaceuticals
referred to as nonsteroidal anti-inﬂammatories and it is the
active component of the analgesic aspirin.25 Moreover, salicylic
acid produced by plants aﬀects bioﬁlm formation in a number of
pathogenic bacteria, including P. aeruginosa,26 Staphylococcus
aureus,27 Staphylococcus epidermidis,28 and Escherichia coli.29 In
the present study, we show that SA eﬀectively inhibits A.
baumannii bioﬁlm formation and that SA it is a useful tool for
ﬁnding proteins that are directly or indirectly related to bioﬁlm
forming ability and even for obtaining further information
about the mechanisms involved in bioﬁlm formation.
A transcriptomic study comparing bioﬁlm and planktonic
cells in E. coli reported that bioﬁlm development leads to up-
regulation of amino acid metabolism30 and in Salmonella
typhimurium, a combination of transcriptomic and proteomic
approaches revealed that genes involved in tryptophan bio-
synthesis and transport were up-regulated in the mature
bioﬁlm.31 More recently, it has been reported that continu-
ous-ﬂow bioﬁlms formed bymany E. coli strains and other gram-
negative bacteria accumulate high levels of valine, which
inhibits the growth of E. coli K-12 and other isolates.32 In a
further report it was demonstrated that the presence of D-amino
acids prevents bioﬁlm formation in S. aureus and P. aeruginosa.33
Overall, these studies illustrate the importance of amino
acid metabolism during bioﬁlm development. Moreover, evi-
dence is provided here to support the idea that amino acid
metabolism plays a pivotal role during bioﬁlm formation
in A. baumannii.
’MATERIALS AND METHODS
Bacterial Strains and Plasmids
Bacterial strains and plasmids used in this study are listed in
Table 1; see also refs 3436. All strains were stored at80 C in
LuriaBertani broth (LB) containing 10% (v/v) glycerol.
Kanamycin (50 μg/mL) and rifampicin (50 μg/mL; Sigma-
Aldrich, St. Louis, MO) were used to select E. coli TG1 and A.
baumannii mutant and complemented strains.
Growth Conditions for Obtaining A. baumannii Planktonic
Cells and Biofilms
A. baumannii strain ATCC 17978 was grown overnight in
Mueller-Hinton (MH) broth (Sigma-Aldrich) at 37 C with
constant shaking. To obtain SA-treated and nontreated cells,
the resulting culture was diluted 100-fold in 500 mL of MH
broth prepared with or without 16 mM SA (Sigma-Aldrich),
respectively, and was incubated with shaking at 37 C. Cells
were harvested at exponential (OD600 nm = 0.4) and late
stationary (OD600 nm = 2.0) phases of growth. The A. baumannii
bioﬁlm was obtained under a continuous ﬂow culture system,
consisting of 60-mL microfermentors (Pasteur Institute, Labora-
tory of Fermentation) with a continuous ﬂow (40 mL/h) of MH
broth and high constant aeration with sterile compressed air.
Submerged Pyrex slides served as the growth substratum. A sample
(with equivalent of OD600 nm = 10) from an overnight culture of A.
baumannii grown in MH broth was used to inoculate the micro-
fermentors, which were then maintained at 37 C for 24 h. Bioﬁlms
formed on the Pyrex slides were then removed with a cell scraper
and frozen in liquid nitrogen.
Protein Extraction of Planktonic and Biofilm Cells
A. baumannii ATCC 17978 planktonic cells were harvested by
centrifugation (3500g, 10 min, 4 C) and washed twice with 0.9%
(w/v) NaCl. The protein lysates of planktonic/bioﬁlm cells were
obtained bymechanical disruption. Brieﬂy, total protein fractions
were obtained from pellets were thawed in 3 or 5 mL lysis buﬀer
[65 mMNaH2PO4, 50 mMNa2HPO4, 1 mMMgSO4 3 7H2O, 30
or 50 μL of protease inhibitor mix (GE Healthcare) and 30 or
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50 μL of nuclease mix (GE Healthcare), depending on pellet
mass] and sonicated for 3 5min (0.5 cycle, 60 amplitude, 4 C).
Unbroken cells and cell debris were removed by centrifugation
(1500g for 10 min and 3600g for 30 min, at 4 C) and the
supernatants were clariﬁed through a 0.45 μm ﬁlter (Millipore,
Billerica, MA). For gel-based analyses, the protein extracts were
processed with a 2D Clean-up Kit (GE Healthcare), following the
manufacturer’s instructions and resuspended in rehydration buﬀer
[8Murea, 2% (w/v)CHAPS, 0.5% (v/v) IPGbuﬀer pH3.010.0
(GE Healthcare), 40 mM DTT]. The concentration of protein
was measured by a modiﬁed Bradford assay37 by use of a
commercial kit (BioRad, Munich, Germany). In order to obtain
the membrane-enriched protein fraction, the lysate was treated as
described in Molloy et al.38 and was modiﬁed as in Soares et al.39
Brieﬂy, an equal volume of 0.1MNa2CO3 pH 11was added to the
A. baumannii protein lysate and was gently shaken overnight at
4 C. The membrane-enriched fraction was obtained by ultracen-
trifugation (100 000g, 45 min, 4 C) and the pellet was resus-
pended in 500 μL of double distilled water. The protein content
was measured as above.
Table 1. Bacterial Strains and Plasmids Used in This Work
strain or plasmid strain or plasmid strain or plasmid
Strains
Acinetobacter baumannii
ATCC 17978 wild-type strain 34
AbH12O-A2 clinical strain 35
CE1 clinical strain laboratory stock
CE2 clinical strain laboratory stock
CE3 clinical strain laboratory stock
CE4 clinical strain laboratory stock
urocanase protein
mutant (Δhut)
derived from ATCC 17978. A1S_3407 locus mutant
obtained by plasmid insertion. KanR, ZeoR
this work
outer membrane protein CarO precursor
mutant (ΔcarO)
derived from ATCC 17978. A1S_2538 locus mutant
obtained by plasmid insertion. KanR, ZeoR
this work
putative outer membrane protein
mutant (ΔoprD-like)
derived from ATCC 17978. A1S_0201 locus mutant
obtained by plasmid insertion. KanR, ZeoR
this work
putative protein DcaP-like
mutant (ΔdcaP-like)
derived from ATCC 17978. A1S_2753 locus mutant
obtained by plasmid insertion. KanR, ZeoR
this work
putative phosphate transporter
protein mutant (ΔpstS)
derived from ATCC 17978. A1S_2448 locus mutant
obtained by plasmid insertion. KanR, ZeoR
this work
putative peptidoglycan-binding LysM
protein mutant (ΔlysM)
derived from ATCC 17978. A1S_0820 locus mutant
obtained by plasmid insertion. KanR, ZeoR
this work
outer membrane protein OmpA
mutant (ΔompA)
derived from ATCC 17978. A1S_2840 locus mutant
obtained by plasmid insertion. KanR, ZeoR
this work
outer membrane protein Omp33
mutant (Δomp33)
derived from ATCC 17978. A1S_3297 locus mutant
obtained by gene replacement with an antibiotic resistance
cassette ﬂanked by regions homologous to the target locus. KanR
36
urocanase protein complemented
mutant (Δhut-c)
derived from Δhut. Complemented with A1S_3407 locus gene
cloned in pET-RA. KanR, ZeoR, Rif R
this work
outer membrane protein CarO
precursor complemented
mutant (ΔcarO-c)
derived from ΔcarO. Complemented with A1S_2538 locus gene
cloned in pET-RA. KanR, ZeoR, Rif R
this work
putative outer membrane
protein complemented
mutant (ΔoprD-like-c)
derived from ΔoprD-like. Complemented with A1S_0201 locus
gene cloned in pET-RA. KanR, ZeoR, Rif R
this work
putative protein DcaP-like complemented
mutant (ΔdcaP-like-c)
derived from ΔdcaP-like. Complemented with A1S_2753 locus
gene cloned in pET-RA. KanR, ZeoR, Rif R
this work
Escherichia coli
TG1 supE thi-1 Δ(lac-proAB) Δ(mcrB-hsdSM)5(rK mK)
[F traD36 proAB lacIqZΔM15]
laboratory stock
Plasmids
pCR-BluntII-TOPO suicide plasmid for A. baumannii. KanR, ZeoR Invitrogen
pET-RA A. baumannii replication origin. CTX-M14 β-lactamase gene promoter. Rif R HM219006a
aGenBank Accession Number.
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DIGE Experimental Design and Protein Labeling
The comparison of exponential cells, late stationary cells, and
bioﬁlms was performed across six DIGE gels (see Supporting
Information Table S1.1), using 50 μg of total protein fraction per
CyDye gel and two biological replicates for each condition (see
Supporting Information Table S1.2). Cyanine dyes were recon-
stituted in 99.8% (v/v) anhydrous DMF and added to labeling
reactions at a ratio of 400 Fmol CyDye/50 μg protein. To ensure
that there were no dye-speciﬁc labeling artifacts, sample repli-
cates in diﬀerent gels were labeled with either Cy3 or Cy5,
whereas the pooled standard sample was labeled with Cy2. The
standard sample was prepared by pooling 50 μg of protein from
each cell sample prior to labeling. Two samples of diﬀerent
replicates (Cy3 andCy5) and an aliquot of internal standard pool
(Cy2) were separated by two-dimensional gel electrophoresis
(2DE) in each of the six gels (see Supporting Information Tables
S1.1 and S1.2).
2DE and 2D DIGE
For DIGE analyses, total protein extracts from bioﬁlm and
planktonic cells were applied to 24 cm, nonlinear (NL) pH
3.011.0 IPG strips and treated as described in Ruiz-Romero
et al.40 For 2DE analysis of SA-treated and nontreated cells,
solubilized protein extracts from planktonic cells (total and
membrane-enriched fractions) were applied to 13 cm NL pH
3.010.0 IPG strips and treated as described in Soares et al.,41
with some exceptions (described next). The 2DE experiments
were performed with protein extracts obtained from three
biological replicates of each condition. Standard continuous
SDS-PAGE was performed on 15% (w/v) polyacrylamide gels.
Analytical gels containing 25 μg of protein were stained with
silver and used for image acquisition and gel analysis. Pre-
parative gels were loaded with 500 μg of protein, stained
with colloidal Coomassie staining,42 and used for picking
protein spots.
Image Acquisition and 2DE and 2D DIGE Gel Analyses
For DIGE, semiautomated image analysis was performed with
Progenesis SameSpots V3.2 software (Nonlinear Dynamics).
Image quality control was ﬁrst performed to identify saturated
spots. Multiplexed analysis was selected for DIGE experiments
and a representative reference gel image was selected. The spots
were detected in the subsequent segmentation. The normalized
spot volumes were then ranked on the basis of ANOVA p-values,
as well as fold changes.
Comparative analyses of 2DE silver-stained gels of SA-
treated and nontreated cells were as described in Soares et al.39
Images were acquired with an Image Scanner v3.3 densitometer
(GE Healthcare). The 2DE gels were analyzed with Image
Master Platinum 6.0 Software (GE Healthcare), according to
the manufacturer’s instructions. Spot detection parameters
were adjusted to the following: smooth 2; MinArea 34, Saliency
10. For each protein fraction and growth phase, six image gels,
three image gels for each growth condition (SA-treated cells
compared with nontreated cells), were matched and combined
to form a master gel, so that the same spot in diﬀerent gels had
the same identiﬁcation number. Each matched spot was num-
bered, and the spot volumes were normalized by total spot
volume. Intercomparative analyses between gels corresponding
to SA-treated and nontreated cells were carried out for each
growth phase and protein fraction. Diﬀerences between
matched spots in both conditions were analyzed by Student’s
t-test, and considered signiﬁcant at p-values <0.05. Results were
expressed as change (n-fold) calculated using the ratio between
the highest and lowest average spot volume between SA-treated
and nontreated cells.
Trypsin Digestion of Proteins and Characterization by MAL-
DI-TOF/TOF
Selected spots were excised from the gels, then treated and
digested with trypsin (Roche Applied Science, Mannheim,
Germany), as suggested in Sechi et al.43 and detailed in Soares
et al.39 After digestion, the supernatant was collected and 1 μL
was spotted onto a MALDI target plate (384-spot Teﬂon-
coated plates) and allowed to air-dry at room temperature. The
dried peptide digests were mixed with 3 mg/mL of an R-cyano-
4-hydroxycinnamic acid in 0.1% (v/v) TFA and 50% (v/v)
ACN and allowed to air-dry. The samples were analyzed using a
MALDI-TOF/TOF mass spectrometer 4800 Proteomics
Analyzer (Applied Biosystems, Framinghan, MA) and 4000 Series
Explorer software (Applied Biosystems). MALDI-TOF spectra
were acquired in reﬂector positive ion mode using 1000 laser
shots per spectrum. Data Explorer version 4.2 (Applied
Biosystems) was used for spectra analyses and generating peak
picking list. All mass spectra were internally calibrated using
autoproteolytic trypsin fragments and externally calibrate using
standard peptide mixture (Sigma-Aldrich). TOF/TOF fragmen-
tation spectra were acquired by selecting the 10 most abundant
ions of each MALDI-TOF peptide mass map (excluding
trypsin autolytic peptides and other background ions) and
averaging 2000 laser shots per fragmentation spectrum. The
parameters used to analyze the data were a signal-to-noise
threshold of 20, minimum area of 100 and a resolution higher
than 10000 with a mass accuracy of 20 ppm. For database
queries and protein identiﬁcation, the monoisotopic peptide
mass ﬁngerprinting data obtained fromMS and the amino acid
sequence tag obtained from each peptide fragmentation in
MS/MS analyses were used to search for protein candi-
dates using Mascot version 1.9 from Matrix Science (www.
matrixscience.com). Peak intensity was used to select up to
50 peaks per spot for peptide mass ﬁngerprinting and
50 peaks per precursor for MS/MS identiﬁcation. Tryptic
autolytic fragment-, keratin-, and matrix-derived peaks were
removed from the data set utilized for database search. The
search for peptides mass ﬁngerprints and tandem MS spectra
were performed in NCBInr database without any taxonomy
restriction. Fixed and variable modiﬁcations were considered
(Cys as S-carbamidomethyl and Met as oxidized methionine,
respectively), allowing one trypsin missed cleavage. MS/MS
ions searches were conducted with a mass tolerance of(1.2 Da
on the parent and 0.30.8 Da on fragments. Decoy search was
done automatically by Mascot on randomized database of
equal composition and size. Proteins and peptides scores were
set up to maintain the false positive peptide ratio below 1%.
Mascot scores for all protein identiﬁcations were higher than
the accepted threshold for signiﬁcance (at the p < 0.05 level,
positive rate measured to be 0.047).
iTRAQ Analysis and Protein Label
The total protein fractions obtained from A. baumanniiATCC
17978 planktonic cells (exponential phase, late stationary phase,
and SA-treated cells) and bioﬁlms were submitted to the W.M.
Keck Foundation Biotechnology resource laboratory at Yale
University, U.S.A. Two biological replicates were obtained for
each protein fraction and used in this analysis, based on the
experimental design developed by Gan et al.44 For accurate
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determination of the protein concentration, each sample was
subject to AAA (amino acid analysis). On the basis of the results
of the AAA, 50 μg of each sample was digested with trypsin
(Promega, Madison, WI) and subjected to 8plex iTRAQ labeling
and strong Cation Exchange chromatography on the Yale Uni-
versity Vision workstation. Sample labeling with isobaric tagging
reagents was carried out according to the manufacturer’s instruc-
tions (Applied Biosystems). Brieﬂy, 50 μg was dissolved in 20 μL
of dissolution buﬀer and 2 μL of denaturant [2% (w/v) SDS]
from iTRAQ kit. Two microliters of reducing reagent (50 mM
TCEP) were added followed by incubation at 60 C for 1 h. After
centrifugation, 1 μL of cysteine-blocking (200 mM MMTS)
agent was added and incubated at room temperature for 10 min.
This was followed by addition of 5 μL of Lys C that was incubated
for 5 h at 37 C and then 5 μL of trypsin (Promega), followed by
overnight incubation at 37 C. Digested samples were labeled
with eight diﬀerent iTRAQ reagents dissolved in 50 μL of
isopropanol and left at room temperature for 2 h. The samples
were labeled with iTRAQ tags as follows: E1 (exponential
phase), iTRAQ113; E2, iTRAQ114; L1 (late stationary phase),
iTRAQ115; L2, iTRAQ116; Bio1 (bioﬁlms), iTRAQ117;
Bio2, iTRAQ118; SAexp (SA-treated samples, exponential
phase), iTRAQ119; SAlate (SA-treated samples, late stationary
phase), iTRAQ121.
StrongCationExchangeChromatography (SCX) andLCMS/MS
Analysis
After digestion, 180 μL of the combined peptide mixture was
subjected to oﬀ-line SCX chromatography using an Applied
Biosystems Vision Workstation with a 2.1 mm  200 mm
PolySulfethyl A column (5 μm 300 Å bead from PolyLC, Inc.,
2.1  200 mm, PN 202SE0503). The column was equilibrated
with Buﬀer A [10 mM KH2PO4, 25% (v/v) ACN, pH 3.0].
Peptides were then separated into 20 fractions using a 90 min
linear salt gradient from 098% (v/v) Buﬀer B [Buﬀer Aþ 1M
KCl]. All 20 collected fractions from the SCX chromatography
were dried and reconstituted with 5 μL of 70% (v/v) FA and
15 μL of 0.1% (v/v) TFA. LCMS/MS was performed on a
QSTAR Elite mass spectrometer interfaced with a Waters
nanoAcquity UPLC system running Analyst QS 2.0 software.
Peptides were resolved for LCMS/MS by loading 5 μL of
sample onto a Symmetry C18 nanoAcquity trapping column
(180 μm 20 mm, 5 μm) with 2% (v/v) ACN/0.1% (v/v) FA
at 15 μL/min for 3 min. After trapping, peptides were resolved
on a BEH130 C18 nanoAcquity column (75 μm tme250 mm,
1.7 μm) with a 60 min, 240% (v/v) ACN/0.1% (v/v) FA
linear gradient (0.3 μL/min ﬂow rate).
Electrospray ionization was performed using a Nanospray II
interface (Applied Biosystems) equipped with the Microion-
spray source and FS360-75-15-D-20 PicoTip Emitter (New
Objective Inc., Woburn, MA). Data dependent acquisition with
each cycle consisted of 0.2 s MS spectrum and MS/MS acquisi-
tion using Smart CE and Smart Exit functionality on three
highest peptide peaks.
Data Analysis and Statistics
Each of the QSTAR Elite mass spectrometer spectra ﬁles
(*.wiﬀ) was processed with MASCOT Distiller version 2.3.1
and the resulting peak lists were combined and database
searched using MASCOT Server 2.2.06 and Swissprot 57.0
(released on March 24, 2009, containing 428 650 sequences).
The search parameters included trypsin with one missed
cleavage, static modiﬁcations carbamidomethyl (cys) and
iTRAQ reagents (N-term, K), and variable modiﬁcations for
oxidation (met). For the MS/MS acceptance criteria, protein
identiﬁcations were accepted if they contained at least two
peptide matches above identity threshold with a FRD of 0.28%
and expectation >0.05. iTRAQ quantitation and secondary
protein identiﬁcation was performed using the Paragon search
algorithm in ProteinPilot v.3.0 software using Swiss-Prot 57.0
database with “thorough search”. The “iTRAQ 8plex peptide
labeled” sample type and a ‘‘biological modiﬁcation ID focus’’
were selected in the analysis method. Trypsin was selected as
the digestion enzyme with cysteine alkylation by methyl
methane thiosulfonate as a modiﬁcation. Raw data that in-
cluded, but was not limited to, reporter ion peak areas, reporter
ion peak area error, peptide assignment, and conﬁdence was
exported from ProteinPilot (tab-delimited) without Protein-
Pilot’s auto bias correction applied (non-normalized data) so
we could perform quantile normalization as described below.
The tab delimited ProteinPilot results were then uploaded into
our Yale Protein Expression Database (YPED). For secondary
protein identiﬁcation, each protein had to have also been
identiﬁed by Paragon and had two or more identiﬁed peptides
and a ProteinPilot Conﬁdence Score >2 (99% conﬁdence
level). To ensure that we only compared data that ProteinPilot
includes in its quantitation analysis, peptides had to be
classiﬁed as “used”, which requires the presence of an iTRAQ
label and at least one valid iTRAQ reporter ion ratio. Addi-
tionally, ProteinPilot only uses high-quality reporter ions for
the peak area measurements to calculate iTRAQ peptide ratios.
To remove low-intensity reporter ion ratios from the exported
raw data sets, we used ProteinPilot’s nonmodiﬁable criterion,
which requires that valid iTRAQ reporter ion ratios must
contain two iTRAQ reporter ions with a summed S/N ratio
>9 to be included in the analysis. The data was then merged
and loaded onto the Yale Protein expression database (YPED-
http://yped.med.yale.edu), which allows viewing data online
and performing downstream data analysis.
Quantitative Biofilm Assay
Bioﬁlm formation was quantiﬁed using a protocol described
previously45 with some modiﬁcations. One colony of each
strain of A. baumannii grown on agar media (37 C, 18 h)
was inoculated into 25 mL liquid media and incubated over-
night (37 C, shaking). Cells were harvested by centrifugation
(3500g, 10 min, 4 C) and the cell pellet was resuspended in
fresh liquid media and adjusted to 0.7 McFarland units. From
the adjusted culture, 200 μL were dispensed into each well of a
96 well ﬂat-bottom polystyrene microtiter plate (excepting for
the experiment presented in Figure 2, where U-bottom plates
were used) and was incubated (37 C, 48 h). The planktonic
cells were then aspirated, and the wells were washed three times
with sterile 0.9% (w/v) NaCl. The plate was then inverted and
allowed to air-dry (room temperature, 1 h). Bioﬁlms were
stained with 0.2% (w/v) crystal violet solution (room tempera-
ture, 15 min), washed thrice as above, and quantiﬁed at 570 nm
after solubilization with 200 μL of a 4:1 (v/v) mixture of
absolute ethanol and acetone. All bioﬁlm assays were per-
formed with at least six replicates for each strain/condition
(although the number of replicates was increased in some
experiments, the absorbance values from six replicates are
enough to determine an average and standard deviation for
each strain or condition, providing a measure of the extent of
bioﬁlm formation).
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Confocal Laser Scanning Microscopy (CLSM)
Bacterial bioﬁlms were grown in chambered glass slides with
polystyrene vessels (BD Falcon 8-well CultureSlides) for 48 h in
MH broth containing diﬀerent amounts of SA (0, 2, 4, 8, and
16 mM). The bacterial inoculum of A. baumannii ATCC 17978
was prepared and normalized as mentioned above for bioﬁlm
assay, and from the adjusted culture 500 μL was dispensed into
each slide chamber. For imaging, the cell culture supernatant and
planktonic cells were removed by aspiration with a pipet tip and
the bioﬁlms were washed thrice with sterile 0.9% (w/v) NaCl.
The bioﬁlms were stained with 200 μL of 1% (w/v) acridine
orange solution (10 min) and subsequently washed twice with
sterile 0.9% (w/v) NaCl. Confocal images were obtained in a
Nikon A1R inverted microscope, and an argon laser (488 nm)
was used for sample excitation. The images were viewed withNIS
Elements (Nikon) software.
Scanning Electron Microscopy (SEM)
Bioﬁlms formed byA. baumannii strains ATCC17978, speciﬁc
gene deletion mutants (ΔcarO, ΔdcaP-like, ΔoprD-like) and
complemented (ΔcarO-c, ΔdcaP-like-c, ΔoprD-like-c) strains
were analyzed by SEM. One colony of each strain grown on
MH agar media (37 C, 18 h) was inoculated into 2 mL of MH
broth (supplemented with rifampicin in the case of complemen-
ted strains), dispensed into each well of a six-well polystyrene
plate containing sterile coverslips, and incubated at 37 C for
48 h. The coverslips were washed twice with 2 mL of PBS, ﬁxed
with 4% (v/v) paraformaldehyde in 0.1 M phosphate buﬀer
pH 7.4 (30 min), and then washed twice with 2 mL of PBS. The
coverslips were sequentially dehydrated for 10 min in 50, 70, 90,
and 100% (v/v) ethanol and critical-point dried with CO2
(Bal-Tec CPD 030). Finally, the coverslips were ﬁxed to alumi-
num stubs with carbon tape and then coated with a layer of gold
(Bal-Tec SCD 004 sputter coater) and examined with a Jeol JSM-
6400 scanning electron microscope.
Construction of Specific Gene Mutants of A. baumannii and
Gene Complementation
Gene inactivation was carried out as previously described in
Heritier et al.46 and Aranda et al.36 with slight modiﬁcations.
Brieﬂy, kanamycin- and zeocin-resistant plasmid pCR-BluntII-
TOPO (Invitrogen), unable to replicate in A. baumannii, was
used as a suicide vector. An internal fragment (approximately 500
bp) of the target gene was ampliﬁed by PCR with the primers
listed in Supporting Information Table S2, and genomic DNA
from A. baumannii ATCC 17978 as template. The PCR product
obtained was cloned into the pCR-BluntII-TOPO vector and the
resulting plasmid was used to transform E. coli strain TG1.
Recombinant plasmid (0.1 μg) was then introduced in the
kanamycin- and zeocin-susceptible A. baumannii ATCC 17978
strain by electroporation. Mutants were selected on kanamycin-
containing plates. Inactivation of the target gene by insertion of
the plasmid via single crossover recombination was checked by
sequencing the ampliﬁed PCR products with the primer pairs
listed in Table S2.
In order to complement A. baumannii mutants, the wild-type
gene was ampliﬁed from A. baumannii strain ATCC 17978 with
the primers listed in Supporting Information Table S2 and
cloned into the XbaI restriction site of the rifampicin-resistant
pET-RA vector under the control of the β-lactamase CXT-M-14
gene promoter. A. baumanniimutants were transformed with the
corresponding recombinant plasmid. Selection of transformants
was made on rifampicin- and kanamycin-containing plates and
conﬁrmed by PCR.
Growth ofA. baumannii Biofilmswith Different AminoAcids
and Isomers Supplied As the Only Carbon Source
To test the eﬀect of given amino acids and speciﬁc L-His and
D-His isomers on the bioﬁlm formation process, A. baumannii
strain ATCC 17978 was grown on MH agar and MH broth as
made for the quantitative bioﬁlm assay (see above). After
harvesting, cells were washed thrice with sterile 0.9% (w/v)
NaCl and resuspended in a solution of M9 minimal salts
(42 mM Na2HPO4, 24 mM KH2PO4, 9 mM NaCl, and
19 mM NH4Cl) supplemented with 0.1 mM CaCl2, 2 mM
MgSO4 (M9 minimal media), and M9 minimal media contain-
ing 20 mM of diﬀerent amino acids (L-His, L-Arg, L-Val, L-Asp,
L-Glu, L-Ser, L-Thr, L-Cys, Gly), 20 mM D-His, and a combina-
tion of 20 mM L-Hisþ (5, 10, and 20 mM) D-His. Adjusted cell
suspensions were cultivated on polystyrene plates and conco-
mitant bioﬁlm formation was quantiﬁed as above. To test the
speciﬁc eﬀect of L-His, A. baumannii strains Δhut, ΔcarO,
ΔoprD-like, ΔdcaP-like, ΔompA, and Δomp33 were also
grown in M9 minimal media alone and supplemented with
20 mM of this amino acid. The bioﬁlms formed were quantiﬁed
as above. All L-amino acids and D-His were obtained from
Sigma-Aldrich, excepting L-Glu, which was obtained from
MerckCalbiochem.
’RESULTS AND DISCUSSION
Proteomics Evidence Showing That Biofilms Have a Unique
Phenotype
There is an increasing controversy about whether bioﬁlms
are basically a mass of bacteria coexisting at various stages or if
they present a speciﬁc phenotype. A transcriptome study of the
bioﬁlm and planktonic cells of P. aeruginosa revealed a diﬀer-
ence of less than 1% in gene expression.47 It can be argued that
in such cases the bioﬁlm phenotype appears to be regulated at
translational and post-translational levels. In the present study,
diﬀerent proteomic approaches were used to verify whether A.
baumannii bioﬁlm cells have a unique protein pattern or are a
mixture of exponential and stationary phase planktonic cells.
Protein extracts were subjected to comparative DIGE-Same-
Spots analyses. Almost 1200 protein spots were detected across
the three conditions. Gel images were analyzed, independent
pair comparison was performed and a minimum fold change of
1.4 (p-value <0.05) was used to select protein spots, which
suﬀered signiﬁcant changes in intensity. Principal component
analysis (PCA) was used to interpret variations in the mean
quantity of spots in the context of the following question:
Are bioﬁlms composed of a mixture of cells at various phases
of growth or do they display an exclusive proteome and there-
fore unique phenotype? The results of the analyses clearly
indicate the presence of three diﬀerent protein populations
(Figure 1): bioﬁlms, exponential phase, and stationary phase
planktonic cells.
The comparison between bioﬁlms and planktonic cells re-
vealed 392 diﬀerential abundant protein spots [summarized in
Table 2 as follows: 54 spots were exclusively up-regulated in the
bioﬁlm proteome (e.g., spots 369, 836, 860, and 1123), whereas
50 spots were exclusively down-regulated in bioﬁlms cells]. Also,
129 of the protein spots were almost equally expressed both in
exponential as well as in bioﬁlms cells (e.g., spot 560) and 40 of
the protein spots presented almost the same level of expression in
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both the bioﬁlm and in late stationary phase cells (e.g., spots 463
and 605). Finally, 119 spots were exclusively up-regulated in late
stationary phase cells.
Further gel-free analyses using SCX-LCMS/MS 8plex
iTRAQ labeling revealed that a total of 248 proteins were
quantiﬁed with two or more peptides and with a protein
score (PS) >2, and further 312 proteins were detected with
single peptide and/or PS <2. The quantitative results of each
sample are resumed in Table 3. Details as protein score, protein
ratios, p-values, unique peptides, and percentage coverage are
available at the Yale Protein expression database (YPED,
http://yped.med.yale.edu). An acceptable biological variation
level was found between the replicates; for example, replicates
obtained from protein extracts of bioﬁlms showed a correlation
of R2 = 0.778, a similar value to that found by Gan et al.44 when
comparing experimental replicates. Proteins with a ratio >1.2 or
<0.8 (p-value <0.05) in two of the replicates were considered to
be diﬀerentially expressed. The diﬀerences based on these
criteria are summarized in Table 3. Of the 248 identiﬁed
proteins, 41 were diﬀerentially regulated, for example, Orotate
phosphoribosyltransferase (i134) and 29 kDa outer membrane
protein (i213).
Although the three subproteomes share a constitutive ex-
pression of the majority of the proteins, iTRAQ and DIGE
analyses provided here are consistent with the concept that the
bacteria within bioﬁlms display a diﬀerent phenotype from their
planktonic counterparts. Combining these proteomic ap-
proaches allowed us not only to validate results obtained by
either techniques but also to gain information about unique
features from each method. Hence, similar expression patterns
were observed for F0F1 ATP synthase β-subunit (spot 605,
Table 2; protein i14, Table 3), fatty acid oxidation complex
R-subunit (spot 766, Table 2; protein i10, Table 3) and 29 kDa
Omp (CarO) (spot 1071, Table 2; protein i213, Table 3), when
comparing both techniques. Additionally, other proteins were
found to be diﬀerentially expressed with only one of the
referred methods. The number of speciﬁc bioﬁlm proteins
identiﬁed here is to some extent consistent with the proposed
developmental model of bioﬁlm formation, in which the
transition from free-swimming lifestyle to bioﬁlm involves a
hierarchical network of genetic pathways leading to the diﬀer-
ential regulation of bioﬁlm-associated proteins.48 Interestingly,
the proteome of bioﬁlm cells proteome is more similar to that of
exponential cells rather than stationary cells, given the number
of proteins that present similar expression patterns (see
Tables 2 and 3). This was somewhat unexpected, since the
results of previous transcriptomic studies in other bacterial
species suggest that bioﬁlm cells were more similar to a
stationary phase mode of growth.30,31 In the present study,
the proteins that presented similar expression patterns in
exponential phase and bioﬁlms are related to bacterial growth
and cell division, fo example, ribosomal subunits (e.g., spots 917
and 1181, Table 2; proteins i35 and i49, Table 3), elongation
factors (spot 340, Table 2) and trigger factors (spot 560,
Table 2; protein i19, Table 3). According to Stoodley et al.,49
the bioﬁlm developmental model is a temporal cycle comprised
of ﬁve stages: planktonic, attachment, macrocolony formation,
maturation, and dispersal. During the process of bioﬁlm aging,
nutrients become limiting, byproducts accumulate, and it may
therefore be advantageous for bioﬁlm-associated bacteria to
dissemble and revert to initial planktonic existence.49,50 One
possible interpretation for these unexpected ﬁndings is that in
order to ensure such versatility in lifestyle bioﬁlm cells may
conserve part of the required cell division machinery to behave
promptly as exponential cells in case of reversion of bioﬁlms to
planktonic mode. Here, bioﬁlms and late stationary proteomes
showed distinct expression pattern for some proteins related to
stress response and redox reactions. In the ﬁrst case, a universal
stress protein were found to be up-regulated in stationary phase
but not in bioﬁlm cells (spot 1196, Table 2, FC:3.3). In the last
case, the expression pattern of some proteins involved in redox
reactions indicates that late stationary cells could be more pro-
tected against oxidative stress, than bioﬁlm cells. Examples are
catalase-peroxidase (protein i26, Table 3), alkyl hydroperoxide
reductase C22 subunit (spot 1017,Table 2), superoxide dismutase
(spot 1027, Table 2) and a putative oxidoreductase (spot 1037,
Table 2). These ﬁndings suggest that stationary phase planktonic
and bioﬁlms cells are subjected to diﬀerent environmental pres-
sures, which may result in diﬀerent proteome patterns.
SA Inhibits Biofilm Formation and down-Regulates Biofilm-
Related Proteins
As alreadymentioned, it has been reported that in species closely
related to A. baumannii, such as P. aeruginosa, SA signiﬁcantly
Figure 1. Principal component analysis provided by Samespots analyses, comparing the level of variance among biological replicates within the same
sample and the level of variance among the three subproteomes (obtained from cells at exponential, late stationary phase, and bioﬁlms).
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Table 2. Functional Classiﬁcation of Identiﬁed and Diﬀerentially Expressed DIGE Protein Spots between A. baumannii
Planktonic and Bioﬁlm Culture
average spot volume
protein description spot no. Anova (p) folda NCBInr acession no. expb latec bioﬁlmd
Post-translation Modiﬁcation, Protein Turnover, Chaperones
chaperon Hsp 70 403 9.344 105 1.6 gi|126642981 0.810 1.312 0.886
trigger factor 560 5.133 107 2.1 gi|169797268 1.254 0.591 1.044
Translation, Ribosomal Structure, and Biogenesis
elongation factor G 340 3.729 104 1.6 gi|50084094 1.131 0.690 1.022
30S ribosomal protein S1 447 9.201  106 2.1 gi|50085438 1.376 0.670 1.115
30S ribosomal protein S1 463 7.837  105 1.8 gi|126641617 1.249 0.712 0.886
50S ribosomal protein L1 892 8.237  106 3.2 gi|126640372 2.117 0.812 2.582
30S ribosomal protein S2 917 2.082  104 2.0 gi|50085372 1.540 0.772 1.391
50S ribosomal protein L6 1059 1.732  105 2.5 gi|169632365 1.765 0.839 2.098
50S ribosomal protein L9 1181 0.003 1.7 gi|126642218 1.151 0.690 1.134
Energy Production and Conversion
F0F1 ATP synthase β-subunit 605 0.006 1.7 gi|50083469 1.345 0.801 0.928
acetyl-coenzyme A carboxylase carboxyl
transferase
944 6.227 105 2 gi|126640675 1.432 0.703 0.706
Amino Acid Transport and Metabolism
fumarate hydratase 619 9.018 104 1.5 gi|169795668 0.748 1.097 1.072
Lipid Transport and Metabolism
fatty acid oxidation complex R-subunit 766 1.074 105 1.9 gi|150382987 0.745 1.438 0.954
Carbohydrate Transport and Metabolism
quinoprotein glucose dehydrogenase B 630 3.980 106 4.7 gi|118560 0.341 1.588 1.185
UTP-glucose-1-phosphate uridylyltransferase 805 2.460 104 1.4 gi|169632096 0.900 0.945 1.255
mutarotase precursor 732 8.000  103 1.6 gi|126641015 0.944 1.504 1.217
mutarotase precursor 749 1.580  107 2.9 gi|126641015 0.529 1.305 1.543
Cell Envelope Biogenesis, Outer Membrane
putative RND type eﬄux pump 860 4.052  104 3.3 gi|126640124 0.840 0.829 2.755
outer membrane receptor FepA 369 2.740 104 3.7 gi|169633929 0.645 0.705 2.392
putative protein (DcaP-like) 538 3.324 104 2.6 gi|126642784 0.738 1.064 1.903
putative protein (DcaP-like) 702 0.003 1.6 gi|126642784 1.162 0.746 1.117
OmpA 760 2.500 105 2.1 gi|126642864 0.699 0.961 1.475
OmpA 762 5.550 105 1.6 gi|126642864 0.920 0.969 1.431
Cell Envelope Biogenesis, Outer Membrane
OmpA 764 0.031 1.5 gi|126642864 1.021 0.986 1.468
putative phosphate transporter 836 2.831 107 10.7 gi|126642484 0.526 0.461 4.926
Omp 33 876 9.043 107 7.7 gi|193078641 1.632 0.284 2.180
Omp CarO precursor 984 3.426 106 4.1 gi|126642573 0.454 1.136 1.870
putative peptidoglycan-binding LysM 1063 1.990 104 1.7 gi|126640876 0.868 1.247 1.472
29 kDa Omp (CarO) 1071 2.529 106 3.8 gi|55583803 0.495 1.063 1.901
CsuA/B 1123 6.231 105 25.3 gi|126642263 0.160 0.288 4.045
Signaling
two-component regulatory system 947 0.010 1.8 gi|50083946 1.245 0.744 1.321
putative signal peptide 1054 1.143 107 6.5 gi|126641568 0.288 1.870 0.619
Transcription
host factor I for bacteriophage Q beta replication 1156 2.455 107 3.8 gi|169633286 1.360 0.415 1.579
transcription elongation factor GreA 1103 0.003 1.7 gi|126642719 0.837 0.975 1.412
Multifunctional
2-keto-D-gluconate reductase 768 4.781 105 1.5 gi|193077799 1.177 0.841 1.289
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compromises the ability of the bacteria to attach and form
bioﬁlms on abiotic surfaces.26 In the present study, in order to
evaluate the eﬀects of SA on A. baumannii bioﬁlm formation, we
carried out an in vitro experiment in which several multiresistant
epidemic A. baumannii strains were incubated in liquid media
supplemented with or without SA. The impact of SA on bioﬁlm
formation was assessed by the crystal violet assay. In all cases,
the presence of SA signiﬁcantly reduced bioﬁlm formation over
a period of 48 h, relative to untreated cells (see Figure 2).
Further microscopic confocal assays of treated and untreated
cells, conﬁrmed that SA signiﬁcantly reduced bioﬁlm formation
(Supporting Information Figure S1). Taking into account that
SA inhibits bioﬁlm formation, we performed proteome analysis
under SA treatment to obtain further information about pro-
teins that are down-regulated in the presence of this compound.
A total protein extract and membrane-enriched protein frac-
tions of reference strain ATCC 17978 were analyzed by 2DE
and MS/MS at two points of in vitro growth, exponential and
late stationary phases, in the presence and absence of 16 mM
SA. The 2DE maps and diﬀerentially expressed spots of A.
baumannii under SA treatment relative to the control (no SA)
for both protein fractions and growth phases are shown in
Supporting Information Figure S2. Expression of a protein was
considered to have changed if the percentage volume of its spot
in the gels between bacteria cultured with and without SA
showed a 2-fold or greater diﬀerence (p-value <0.05). For the
exponential phase, this analysis resulted in identiﬁcation of 34
and 21 nonunique proteins out of 55 and 45 gels spots
diﬀerentially expressed in total and membrane-enriched frac-
tions, respectively. Similarly, for the stationary phase, a total of
36 and 19 nonunique proteins were identiﬁed out of 81 and
61 gels spots investigated, respectively, in the same protein
fractions. Altogether, 110 nonunique proteins were identiﬁed
(corresponding to 109 spots) from the 242 diﬀerentially
expressed spots obtained with SA treatment (see Supporting
Information Tables S3 and S4).
Given the inhibitory eﬀect of SA over A. baumannii bioﬁlms,
special attention was dedicated to those proteins that either
suﬀered signiﬁcant down-regulation in the presence of this
compound and/or were induced in bioﬁlm proteome, as a mean
of identifying a clear association with inhibition of bioﬁlms.
Cell Surface Proteins Play an Important Role in Biofilms
Among the proteins identiﬁed in this study, some of those
previously described as A. baumannii bioﬁlm-associated proteins
were found to be up-regulated in bioﬁlms, for example, CsuA/
B11 [spot 1123, Table 2, maximum fold change (FC) in bioﬁlms:
25.3], OmpA13 (spots 760/762/764, Table 2, maximum FC in
bioﬁlms: 2.1 for spot 760), outer membrane receptor FepA21
(spot 369, Table 2, maximum FC in bioﬁlms: 3.7) and putative
DcaP-like protein21 (spot 538, Table 2, maximum FC in bio-
ﬁlms: 2.6). DcaP-like protein was also negatively aﬀected by
SA treatment (spot 194, Table S3). We also suggest novel
associations between some of the identiﬁed proteins and bio-
ﬁlms. This is the case of Omp33 (spot 876, Table 2, maximum
FC in bioﬁlms, 7.7), CarO (spots 984/1071, Table 2, maximum
FC in bioﬁlms, 4.1/3.8; protein i213, Table 3, ratio Bio2/E1
3.30), LysM (spot 1063, Table 2, maximum FC in bioﬁlms, 1.7),
putative phosphate transporter (PstS) (spot 836, Table 2, max-
imum FC in bioﬁlms, 10.7) and others. In addition, we found a
novel down-regulated protein in SA-treated cells (spot 190,
Supporting Information Table S3, FC, 2.29) that contains an
OprD domain. As this protein is predicted to interact with a
ﬁmbrial protein (STRING 8.3 interaction network, http://
string-db.org; score 0.612) FimA, which is involved in cell
adhesion, we considered this OprD-like protein for further
analyses.
In order to conﬁrm the relevance of some of the above
proteins, molecular targets were selected for direct inactivation
and evaluated for bioﬁlm-forming ability. Selected mutants were
constructed for OmpA (ΔompA), Omp33 (Δomp33), CarO
(ΔcarO), OprD-like (ΔoprD-like) and DcaP-like (ΔdcaP-like)
proteins. Also, complemented A. baumannii strains for some of
these loci were constructed in order to conﬁrm whether the
results were caused by the speciﬁed locus mutation (ΔcarO-c,
ΔoprD-like-c, and ΔdcaP-like-c strains). We compared bioﬁlm
formation between wild-type, mutant, and complemented A.
baumannii strains by use of the quantitative crystal-violet assay
and in some cases SEM. Signiﬁcant diﬀerences in the pattern of
bioﬁlm formation between wild-type and the referred mutant
strains were observed with crystal violet assay, as mutant strains
showed reduced bioﬁlm forming ability (Figure 3A). In contrast,
complemented strains showed increased bioﬁlm production
Table 2. Continued
average spot volume
protein description spot no. Anova (p) folda NCBInr acession no. expb latec bioﬁlmd
Protein Involved in Redox Reactions
catalase hydroperoxidase II 321 3.349 104 2.0 gi|169796319 0.668 1.319 1.176
electron transfer ﬂavoprotein R-subunit 859 2.867 105 1.5 gi|169632682 0.827 1.264 0.971
electron transfer ﬂavoprotein β-subunit 972 2.170 104 1.8 gi|169632681 0.706 0.904 1.281
alkyl hyroperoxide reductase C22 subunit 1017 4.772 105 2.1 gi|126641253 0.695 1.455 0.905
superoxide dismutase [Fe] 1027 1.063 105 3.3 gi|169632935 0.460 1.511 0.678
alkyl hyroperoxide reductase C22 subunit 1031 5.380 104 1.7 gi|126641253 0.832 1.375 0.897
putative oxidoreductase 1037 8.820 107 4.8 gi|126641974 0.327 1.580 0.356
Defense
universal stress protein 1196 9.315  109 3.3 gi|169795610 0.515 1.606 0.484
a Fold indicates the ratio between the highest and lowest average spot volume detected among exponential, late stationary and bioﬁlm proteomes. b Exp
refers to the average spot volume determined for exponential proteomes. cLate refers to the average spot volume determined for exponential proteomes.
dBioﬁlm refers to the average spot volume determined for bioﬁlm proteomes.
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Table 3. iTRAQ Identiﬁcation of Diﬀerentially Expressed Proteins
ratio of diﬀerent expression level between samplesa
protein description protein no. NCBInr acession no (%) cov. no. peptides E2/E1b L1/E1c L2/E1d Bio1/E1e Bio2/E1f SAexp/E1g SAlate/E1h
Post-translation Modiﬁcation, Protein Turnover, Chaperones
chaperone protein dnaK i7 gi|226738075 80.03 40 1.11(0.123) 2.38(0.000) 2.13(0.000) 1.06(0.632) 1.24(0.030) 1.46(0.000) 1.44(0.000)
60 kDa chaperonin i8 gi|226704107 82.35 33 0.99(0.994) 2.38(0.000) 1.76(0.000) 1.14(0.319) 1.12(0.430) 1.15(0.180) 1.62(0.000)
trigger factor i19 gi|226703990 72.97 24 0.85(0.075) 0.46(0.000) 0.52(0.000) 0.73(0.116) 0.68(0.141) 0.89(0.373) 0.68(0.000)
protein grpE i141 gi|226737248 55.43 4 0.96(0.619) 2.14(0.023) 1.50(0.012) 1.34(0.058) 1.19(0.560) 1.52(0.013) 1.24(0.033)
Translation, Ribosomal Structure and Biogenesis
elongation factor G i5 gi|238685496 81.88 39 0.93(0.385) 0.52(0.000) 0.78(0.015) 0.69(0.005) 0.76(0.035) 0.79(0.075) 0.58(0.000)
elongation factor Ts i15 gi|166221178 89.00 18 0.83(0.057) 0.58(0.072) 0.52(0.000) 0.64(0.004) 0.56(0.002) 0.79(0.061) 0.78(0.168)
ribosome-recycling factor i65 gi|226703249 73.91 12 0.98(0.832) 1.83(0.000) 1.25(0.014) 1.35(0.019) 1.23(0.180) 1.45(0.000) 1.51(0.000)
50S ribosomal protein L2 i35 gi|22669930 71.17 15 0.87(0.338) 0.46(0.000) 0.54(0.001) 0.86(0.477) 0.69(0.085) 0.88(0.437) 0.47(0.000)
50S ribosomal protein L1 i47 gi|226724854 61.90 10 0.62(0.003) 0.66(0.070) 0.50(0.002) 0.68(0.032) 0.63(0.019) 0.66(0.08) 0.53(0.005)
50S ribosomal protein L5 i49 gi|226731453 78.09 13 0.72(0.215) 0.31(0.000) 0.44(0.031) 0.76(0.511) 0.65(0.312) 0.83(0.412) 0.38(0.008)
50S ribosomal protein L6 i61 gi|226731363 72.88 9 0.59(0.004) 0.38(0.010) 0.43(0.001) 0.55(0.076) 0.46(0.06) 0.68(0.013) 0.41(0.000)
50S ribosomal protein L14 i70 gi|226705065 76.23 9 0.69(0.118) 0.46(0.007) 0.47(0.017) 0.78(0.625) 0.62(0.203) 0.72(0.243) 0.28(0.001)
50S ribosomal protein L19 i78 gi|226723408 68.85 6 0.64(0.037) 0.43(0.041) 0.43(0.011) 0.52(0.098) 0.45(0.021) 0.69(0.285) 0.34(0.000)
50S ribosomal protein L15 i87 gi|226705097 70.55 9 0.73(0.099) 0.48(0.000) 0.54(0.002) 0.68(0.088) 0.53(0.012) 0.89(0.359) 0.49(0.000)
50S ribosomal protein L16 i90 gi|226710438 66.42 4 0.90(0.818) 0.45(0.037) 0.53(0.017) 0.50(0.118) 0.57(0.536) 0.73(0.497) 0.42(0.0.03)
50S ribosomal protein L18 i128 gi|266723574 74.14 6 0.78(0.114) 0.52(0.001) 0.56(0.026) 0.69(0.062) 0.67(0.029) 0.88(0.195) 0.49(0.009)
50S ribosomal protein L28 i190 gi|49529717 62.82 4 0.76(0.040) 0.35(0.013) 0.55(0.021) 0.52(0.001) 0.34(0.014) 0.82(0.457) 0.38(0.004)
30S ribosomal protein S3 i59 gi|226697655 80.00 14 0.93(0.682) 0.20(0.000) 0.31(0.000) 0.66(0.083) 0.63(0.067) 0.67(0.07) 0.51(0.000)
30S ribosomal protein S7 i64 gi|226705656 86.54 9 0.71(0.149) 0.53(0.038) 0.61(0.05) 0.46(0.032) 0.39(0.005) 0.85(0.565) 0.47(0.000)
30S ribosomal protein S12 i93 gi|226708443 48.39 4 0.53(0.029) 0.22(0.000) 0.38(0.012) 0.78(0.075) 0.71(0.058) 0.83(0.392) 0.27(0.004)
Energy Production and Conversion
ATP synthase β-subunit i14 gi|226739964 69.40 19 0.87(0.338) 0.35(0.000) 0.55(0.002) 0.79(0.290) 0.75(0.264) 0.58(0.030) 0.46(0.003)
ATP synthase R-subunit i17 gi|226739833 57.98 18 0.76(0.007) 0.41(0.000) 0.51(0.000) 0.91(0.661) 0.73(0.020) 0.67(0.006) 0.46(0.000)
Amino Acid Transport and Metabolism
urocanase hydratase i11 gi|226707252 63.44 22 0.93(0.450) 1.03(0.820) 1.41(0.001) 1.56(0.014) 1.48(0.033) 0.80(0.025) 0.71(0.006)
GMP synthase i41 gi|81393985 46.00 7 0.94(0.502) 0.56(0.000) 0.69(0.031) 0.55(0.026) 0.52(0.025) 0.91(0.576) 0.86(0.361)
gamma-glutamyl phosphate reductase i43 gi|22671050 57.24 10 1.66(0.010) 1.78(0.012) 1.67(0.009) 1.23(0.401) 1.06(0.745) 1.34(0.275) 1.85(0.000)
leucyl-tRNA synthetase i50 gi|226731222 34.44 11 0.95(0.685) 0.61(0.002) 0.67(0.016) 0.89(0.591) 0.84(0.392) 0.84(0.488) 0.89(0.246)
3-ketoacyl-CoA thiolase i68 gi|150382987 47.18 10 1.47(0.022) 1.91(0.010) 2.44(0.003) 1.72(0.001) 1.80(0.001) 1.49(0.028) 1.92(0.013)
arginyl-tRNA synthetase i74 gi|226701511 41.11 9 0.84(0.213) 0.62(0.041) 0.70(0.04) 0.79(0.183) 0.75(0.135) 0.85(0.386) 0.80(0.136)
D-amino acid dehydrogenase
small subunit
i75 gi|226722637 32.07 8 1.61(0.08) 3.00(0.001) 4.54(0.000) 1.87(0.127) 2.34(0.022) 1.23(0.111) 0.81(0.125)
phosphoribosylglycinamide
formyltransferase
i154 gi|172044080 24.63 6 1.43(0.085) 1.89(0.008) 2.03(0.000) 1.67(0.123) 1.5(0.213) 1.76(0.003) 1.73(0.003)
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Table 3. Continued
ratio of diﬀerent expression level between samplesa
protein description protein no. NCBInr acession no (%) cov. no. peptides E2/E1b L1/E1c L2/E1d Bio1/E1e Bio2/E1f SAexp/E1g SAlate/E1h
Lipid Transport and Metabolism
fatty acid oxidation complex R-subunit i10 gi|254788553 72.94 32 1.75(0.000) 3.29(0.000) 3.19(0.000) 2.08(0.000) 2.22(0.000) 1.59(0.000) 2.80(0.000)
Replication, Recombination, and Repair
protein recA i79 gi|238685519 40.40 8 1.30(0.011) 2.08(0.001) 2.05(0.000) 1.40(0.019) 1.59(0.081) 1.18(0.170) 1.27(0.105)
8 1.30(0.011) 2.08(0.001) 2.05(0.000) 1.40(0.019) 1.59(0.081) 1.18(0.170) 1.27(0.105)
IHF integration host factor R-subunit i95 gi|226707551 62.24 4 1.39(0.071) 4.43(0.031) 4.26(0.024) 1.39(0.344) 2.02(0.082) 1.95(0.155) 2.20(0.017)
Carbohydrate Transport and Metabolism
phosphoenolpyruvate carboxykinase [GTP] i21 gi|226739700 57.12 16 0.93(0.502) 0.39(0.001) 0.40(0.000) 0.56(0.070) 0.57(0.020) 0.69(0.188) 0.37(0.000)
Nucleotide Transport and Metabolism
adenylate kinase i46 gi|226722871 82.95 12 1.25(0.023) 1.77(0.005) 1.37(0.053) 1.45(0.009) 1.41(0.002) 1.45(0.033) 1.55(0.004)
putative nucleotide-binding protein i104 gi|169632416 75.31 8 1.25(0.243) 1.61(0.031) 1.46(0.029) 1.24(0.071) 1.30(0.139) 1.21(0.390) 1.36(0.156)
orotate phosphoribosyltransferase i134 gi|167011977 57.87 6 0.89(0.205) 0.85(0.167) 0.84(0.358) 0.51(0.023) 0.58(0.044) 0.80(0.468) 0.79(0.109)
Cell Envelope Biogenesis, Outer Membrane
29 kDa outer membrane protein i213 gi|55583803 91.67 2 2.05(0.189) 1.72(0.07) 2.32(0.125) 2.76(0.012) 3.30(0.029) 1.81(0.30) 3.89(0.127)
Transcription
DNA-directed RNA polymerase ss-subunit i3 gi|212288355 65.78 49 0.93(0.297) 0.76(0.009) 0.73(0.000) 0.95 (0.600) 0.97(0.767) 0.87(0.204) 0.68(0.000)
DNA-directed RNA polymerase R-subunit i38 gi|226699358 68.66 18 0.83(0.047) 0.65(0.007) 0.59(0.000) 0.74(0.155) 0.83(0.439) 0.76(0.032) 0.81(0.019)
Protein Involved in Redox Reactions
catalase-peroxidase i26 gi|215275637 52.23 15 1.50(0.100) 3.02(0.028) 3.34(0.003) 1.32(0.194) 1.78(0.022) 1.29(0.210) 1.96(0.065)
a p-values obtained from Protein pilot analyses are shown between (); Protein ratios >1.2 or <0.8 (p-value <0.05) observed in two replicates are shown in bold. b E2/E1, the ratio of diﬀerent expression level
between biological replicates of exponential cells. c L1/E1, the ratio of the diﬀerent expression level between late stationary cells (L1) and exponential cells control (E1). d L2/E1, the ratio of the diﬀerent
expression level between late stationary cells (L2) and exponential cells control (E1). eBio1/E1, the ratio of the diﬀerent expression level between bioﬁlm cells (Bio1) and exponential cells control (E1).
fBio2/E1, the ratio of the diﬀerent expression level between bioﬁlm cells (Bio2) and exponential cells control (E1). g SAexp/E1, the ratio of diﬀerent expression level between biological replicates of
exponential SA-treated cells (SAexp) and exponential cells control (E1). h SAlate/E1, the ratio of diﬀerent expression level between biological replicates of late stationary SA-treated cells (SAlate) and
exponential cells control (E1).
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when compared with mutant strains (Figure 3B). Using SEM, we
also found that mutant strains formed simpler and smaller cell
aggregates in contrast with wild-type strain, which formed a
denser bioﬁlm (Figure 4). Complemented strains formed bio-
ﬁlms with a structure similar to that displayed by wild-type strain,
and all tested strains showed increased bioﬁlm production
relative to mutant strains.
Within the bioﬁlm, bacterial cells are embedded in a self-
produced extracellular matrix, and although this matrix protects
bacteria against a number of environmental insults, it also limits
bacterial access to fresh nutrients. Thus, the veriﬁed increase in
expression of transmembrane channels appears to be an essen-
tial prerequisite for the entrance of important nutrient-contain-
ing ﬂuid,51 including amino acids, as discussed below. In
addition, apart from acting as channels, porins may act as
potential targets for adhesion to other cells and may mediate
cell attachment through binding to the proteins released for
bioﬁlm formation.52
Figure 2. Quantitative bioﬁlm formation in polystyrene wells by A.
baumannii wild-type strain and AbH12O-A2, CE1, CE2, CE3, and CE4
clinical strains showing a general inhibitory eﬀect of SA. Bioﬁlms
cultivated in MH (no SA) and MH supplemented with 16 mM of SA
at 37 C for 48 h were compared by use of the crystal violet assay. The
bars indicate the means for six wells. Asterisks indicate signiﬁcant
diﬀerences (*p-valuee0.05; **p-valuee0.0001, t test) between supple-
mented and nonsupplemented MH broth.
Figure 3. Quantiﬁcation (crystal violet assay) of bioﬁlm formation in polystyrene wells bymultipleA. baumannii strains grown inMHbroth at 37 C for
48 h. (A) Bioﬁlms formed by A. baumanniiwild-type strain were compared withΔompA,Δomp33,ΔcarO,ΔoprD-like,ΔdcaP-like,ΔlysM,ΔpstS, and
Δhutmutant strains. (A) Bioﬁlms formed byA. baumanniiwild-type strain were compared with (a)Δhut strain; (b)ΔcarO strain; (c)ΔoprD-like strain;
and (d) ΔdcaP-like strain. Comparisons were also made between mutant and complemented strains: (a) Δhut with Δhut-c strain, (b) ΔcarO with
ΔcarO-c strain, (c)ΔoprD-like withΔoprD-like-c strain, and (d)ΔdcaP-like withΔdcaP-like-c strain. The bars indicate the means for at least 40 wells.
Asterisks indicate signiﬁcant diﬀerences (*p-value e0.05; **p-value e0.0001, t test) between means.
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We were also interested in evaluating the impact of the gene
mutation of other surface proteins with increased expression in
bioﬁlms, namely putative peptidoglycan-binding LysM (ΔlysM)
and phosphate transporter (ΔpstS). These mutant strains also
showed a reduced bioﬁlm forming ability when compared with
the wild-type strain (Figure 3A). Recently, a novel class of
staphylococcal adhesins containing three N-terminal repetitive
sequences that comprised features of a peptidoglycan-binding
(the LysM domain) was proposed.53,54 Apparently, autolysin/
adhesins in S. epidermidis play an important role during bioﬁlm
Figure 4. SEM images showing bacterial bioﬁlms of A. baumannii formed on plastic coverslips. The morphology of bioﬁlms was viewed at 3000
magniﬁcation. Bioﬁlms formed by (A) wild-type strain; (B) ΔcarO strain; (C) ΔcarO-c strain; (D) ΔdcaP-like strain; (E) ΔdcaP-like-c strain;
(F) ΔoprD-like strain; and (G) ΔoprD-like-c strain. The scale magniﬁcation bar indicates 20 μm.
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formation on polymer surfaces, being potentially involved in
colonization. Although further investigation is necessary, it is
likely that LysM protein here identiﬁed plays a similar role during
cell attachment of A. baumannii to abiotic surfaces.
Interestingly, our results show for the ﬁrst time that a
phosphate transporter plays an important role in A. baumannii
bioﬁlm formation. Current research suggests that for many
bacterial species, the concentration of external phosphate ion
(Pi) is an important signal that regulates bioﬁlm formation.
Indeed, the activation of Pho regulon expression in the response
of Pseudomonas aureofaciens to limiting concentrations of Pi
resulted in inhibition of bioﬁlm formation.55 Furthermore, a
recent study in Pseudomonas ﬂuorescens has demonstrated that
secretion of a large adhesin LapA (a critical component for
bioﬁlm formation) is inhibited by Pi limiting conditions.
56 Thus,
it would be interesting to establish whether there is any relation
with the concentration of external Pi and bioﬁlm formation in A.
baumannii.
Additionally, since speciﬁc gene mutations on individual
membrane proteins reduced but did not abolish bioﬁlm produc-
tion completely, we can suggest that there are compensatory
eﬀects among these proteins during cell adhesion and bioﬁlm
formation, although further studies will be necessary to abrogate
this hypothesis.
Biofilm Proteome Indicates the Induction of Proteins Re-
lated with Drug Resistance and the Response to Stress
Bacterial bioﬁlms have been reported to be up to 1000 times
more tolerant to speciﬁc antibiotics than their planktonic
counterparts.57 Here, we identiﬁed a putative resistance-nodula-
tion-cell Division type eﬄux pump (RND pump), that increased
in bioﬁlms (spot 860, Table 2). Overexpression of this type of
eﬄux pump in A. baumannii confers resistance to aminoglyco-
sides, but also to other drugs, including ﬂuoroquinolones, tetra-
cyclines, chloramphenicol, erythromycin, trimethoprim, and
ethidium bromide in A. baumannii.58,59 The extent to which
the inherent resistance of bioﬁlms to antibiotics is due to the
extracellular matrix or external inﬂuences such as low diﬀusion of
compounds is not known. Here, the results indicate that changes
in the A. baumannii proteome during bioﬁlm formation may play
an important role in the formation of acquired resistance to
antibiotics. In addition, studies with planktonicA. baumannii cells
showed a wide range of mechanisms of antibiotic resistance, for
example, the down-regulation of porins.60 In this study, however,
we observed up-regulation of several membrane channels (as
discussed above). Although many other antimicrobial resistance
mechanisms operate in A. baumannii, it is tempting to suggest
that the up-regulation of eﬄux pumps is a primary mechanism of
antibiotic resistance operating inmature bioﬁlms of A. baumannii.
Bioﬁlm formation is also associated with antioxidative
activity.61 We previously demonstrated that defense against
reactive oxygen species (ROS) is an important mechanism in
the biology of A. baumannii.39 As suggested by the up-regulation
of Alkyl hydroperoxide reductase C22 subunit (spot 1017,
Table 2) and catalase-hydroperoxidase II (KatE) (spot 321,
Table 2), A. baumannii bioﬁlm cells are more protected against
the lethal eﬀect of ROS than exponential phase planktonic cells.
It is also worth noting that a Host factor I for bacteriophage Q
beta replication protein (Hfq) appears to be involved in bioﬁlm
formation, according to the results presented here (spot 632,
Supporting Information Table S4). This protein was shown to be
negatively aﬀected by SA, presenting an impressive fold change
of 12.8 in the presence of this compound. In contrast, it was
found to be up-regulated in bioﬁlms relatively to stationary phase
planktonic cells (spot 1156, Table 2). This bacterial RNA
chaperone is involved in post-transcriptional regulation of many
stress-inducible genes, via sRNAs. Although available informa-
tion is scarce, there is evidence to indicate the possible eﬀect of
Hfq on bioﬁlms. In one of these studies, an E. coli hfq mutant was
found to be less prone to form bioﬁlms.62Therefore, it is possible
that bioﬁlm formation depends to some extent on the regulatory
activity of noncoding RNAs that adjust mRNA levels of target
genes according to the environmental signals. Investigation into
these speciﬁcally regulated mRNAs inA. baumannii appears to be
an attractive future project.
Biofilm Proteome of A. baumannii Indicates That EPSMatrix
Formation May Occur via the Leloir Pathway
It is widely accepted that bioﬁlm formation is accompanied by
the production of EPS production; however in A. baumannii, the
underlying mechanisms of EPS formation remains yet to be
elucidated. Recently, EPS precursors in Acidithiobacillus ferroox-
idans were found to be formed via the Leloir pathway.63 Another
study in Vibrio cholerae shows that EPS constitutes the major
bulk of bioﬁlms and that galU and galE are essential for bioﬁlm
formation.64 In the present study, we found two proteins that are
up-regulated in bioﬁlms that participate in this pathway, namely
mutarotase (GalM) (spot 749, Table 2) (EC 5.1.3.3) and UTP-
glucose1-phosphate uridylyltransferase (GalU) (spot 805,
Table 2) (EC 2.7.7.9). Additionally, Shin et al.21 reported
another bioﬁlm associated protein that in the Leloir pathway
converts UDP-galactose to UDP-glucose (GalE). We suggest
that EPS production in A. baumannii resembles the A. ferroox-
idans Leloir pathway. According to this, interconversion between
R- and β-galactose, and the formation of glucose-1-phosphate
constitute intermediate steps for the biosynthesis of UDP-
glucose, UDP-galactose and dTDP-rhamnose, the precursors
of EPS,63 which culminate in matrix formation via glycosyltrans-
ferases (GTs).
In addition, we found a putative phosphate transporter (PstS)
that is up-regulated in bioﬁlms (as mentioned above) and that
may be indirectly involved in this pathway. This protein is a high-
aﬃnity phosphate-binding protein, part of the ABC transporter
pstSACB complex involved in Pi transport. Because the Leloir
pathway comprises a step in galactose phosphorylation
(galactose-1P), we consider that this mechanism may function
as a Pi-supplier for bioﬁlm formation, as more EPS production
will require more free Pi in the cell. In this sense, data here
provided may represent initial steps to further understanding of
the mechanism of EPS formation in A. baumannii.
Histidine Metabolism Plays an Important Role in Biofilm
Formation
Further analysis of our results indicated that in the bioﬁlm
proteome there was a clear up-regulation of proteins that are
directly or indirectly related to histidine metabolism, e.g. Uroca-
nate hydratase (HutU) [(protein i11 Table 3), which was also
down-regulated with the presence of SA (Hut) (spots 65/75 
Table S3; spot 142  Table S4)] and CarO (see above).
Although this porin is not directly involved in histidine metabo-
lism, it has been associated with L-His transport.65 Taken
together, these observations prompted us to investigate further
the inﬂuence of L-His metabolism in the formation of bioﬁlms. In
order to clarify the importance of L-His, we ﬁrst searched for
diﬀerences in the pattern of bioﬁlm formation in the presence of
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diﬀerent amino acids provided as the only carbon source. For
this, the A. baumannii wild-type strain was cultivated in minimal
media andminimal media supplemented with 20mMof diﬀerent
L-amino acids, including positively charged (L-His and L-Arg),
negatively charged (L-Asp and L-Glu) and ﬁnally neutral amino
acids (L-Val, L-Ser, L-Thr, L-Cys and Gly). We found that L-His
had the greatest eﬀect on bioﬁlm induction when compared with
other amino acids (Figure 5A). These ﬁndings support the
hypothesis that the eﬀect on bioﬁlm formation is somehow
speciﬁc rather than due to a structural or charge eﬀect.
A recent study has demonstrated that D-amino acids inhibit
bioﬁlm formation by S. aureus and P. aeruginosa.33 Considering
this and the above results, we were prompted to establish
whether D-His had similar inhibitory eﬀect on A. baumannii
bioﬁlm production, as well as to determine if D- and L-His isomers
compete each other for the degradation pathway leading to
bioﬁlm formation. For instance, theA. baumanniiwild-type strain
was grown in the presence of L-His, D-His and a combination of
L-His and various concentrations of D-His (Figure 5B). While L-His
eﬀectively induced bioﬁlm formation, D-His was found to inhibit
this process. Notably, bioﬁlm induction by L-His was progres-
sively impaired in the presence of increasing concentrations of
D-His, showing that D-His eﬀectively weakened the eﬀect of
bioﬁlm induction by L-His. These observations not only support
the importance of histidine for bioﬁlm formation, but also
conﬁrm that the D-isomer conformation inhibits bioﬁlm forma-
tion and prevents the L-isomer eﬀect.
We then wished to evaluate the importance of some bioﬁlm-
associated proteins with a hypothetical role in L-His metabolism.
For this purpose, molecular targets were selected for direct
inactivation, for further evaluation of their bioﬁlm forming
ability, as above. As Urocanase plays a central functional role in
metabolism of histidine, both a mutant with target locus inactiva-
tion of this protein (Δhut) and a complemented strain (Δhut-c)
of A. baumannii were constructed. Signiﬁcant diﬀerences were
observed with crystal violet assay, with the mutant strain showing
reduced bioﬁlm formation when compared with the wild-type
strain (Figure 3A,B). Conversely, the complemented strain
showed increased bioﬁlm production when compared with the
mutant strain (Figure 3B). In addition, we wished to investigate
possible candidates at themembrane level for the uptake of L-His.
In this case, ΔcarO, ΔoprD-like, ΔdcaP-like, ΔompA, and
Δomp33 mutant strains were tested for their eﬀect on bioﬁlm
forming ability in the presence and absence of this amino acid
(for their possible implication as channels). TheΔhut strain was
also tested in this way due to its direct involvement in L-His
metabolism; see Figure 6. The bioﬁlm quantiﬁcation assay clearly
revealed that the presence of L-His had no eﬀect on the
production of bioﬁlms by the Δhut and ΔompA strains. While
the presence of L-His led to an increase in bioﬁlm production by
ΔoprD-like, ΔdcaP-like, and Δomp33 strains, only a slight
increase in bioﬁlm formation was observed the ΔcarO strain.
These ﬁndings lead us to conclude that the Urocanase protein
plays a crucial role in L-His degradation pathway, leading to
bioﬁlm formation and that, although not exclusively, OmpA may
be one of the preferential (major) channels for L-His uptake by
the cell, while CarO can be used as an alternative (minor)
channel.
Although the mechanism whereby a signaling molecule such
as an amino acid increases bioﬁlm formation is rather complex,
we can establish a comparison between our observations and
those reported in a recent study in Pseudomonas putida.66 The
latter study describes a two-component global regulatory system
Figure 6. Quantitative bioﬁlm formation in polystyrene wells by A.
baumannii wild-type, Δhut, ΔcarO, ΔoprD-like, ΔdcaP-like, ΔompA,
and Δomp33 strains in M9 minimal media (no aa) and M9 supple-
mented with 20 mM of L-His. The bars indicate the means for at least
30 wells. Asterisks indicate signiﬁcant diﬀerences (*p-value e0.05;
**p-value e0.0001, t-test) between supplemented and nonsupplemen-
ted M9 media.
Figure 5. Quantiﬁcation (crystal violet assay) of bioﬁlm formation byA.
baumannii in polystyrene wells. (A) Comparison between bioﬁlms
formed by A. baumannii wild-type strain in M9 minimal media (no
aa) and M9 supplemented with 20 mM of diﬀerent L-amino acids.
Asterisks indicate signiﬁcant diﬀerences (*p-value e0.05; **p-value
e0.0001, t-test) between supplemented and nonsupplemented M9
media. The bars indicate the means for at least 30 wells. (B) Comparison
between bioﬁlms formed by A. baumannii wild-type strain in M9
minimal media (no aa) and M9 supplemented with D-His (20 mM),
L-His (20 mM), and L-His (20 mM) plus D-His (5, 10, and 20 mM).
Asterisks indicate signiﬁcant diﬀerences (**p-value e0.0001, t-test)
between supplemented and non supplemented M9 media and between
L-His and L-Hisþ D-His supplemented M9media. The bars indicate the
means for at least 50 wells.
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required for assimilation of several amino acids including histi-
dine as carbon or carbon and nitrogen sources. The authors
observed that cbrB mutant was unable to use ornithine or
tyrosine nitrogen and/or carbon sources, although it may use
histidine when it is the only carbon and nitrogen source present
in the medium. In addition (and more relevant to the present
discussion), the transcriptomic proﬁle of cbrB mutant showed
signiﬁcant changes in the expression levels of several genes
encoding functions potentially involved in bioﬁlm formation,
such as signal transduction proteins, exopolysaccharide biosynth-
esis or transport and the adhesion protein LapF. Considering
these observations together, it is reasonable to suggest that A.
baumannii uses certain amino acids like L-His, thus reprogram-
ming bacterial gene expression leading to bioﬁlm formation, as in
the model suggested for P. putida.
In several bacterial species, the histidine degradation pathway
occurs via urocanase and leads to the production of purines and
pyrimidines.67 As extracellular DNA (eDNA) is also an im-
portant constituent of the bioﬁlm matrix (along with EPS and
proteins)68 it is likely that histidine degradation may contribute
to purine and pyrimidine synthesis for eDNA production. Also,
as already mentioned, D-amino acids prevent bioﬁlm formation
via their incorporation into the cell wall in several bacteria
species.33 Similarly, we found that the inducible eﬀect of L-His
on bioﬁlm formation was prevented by the presence of its
D-isomer. Apparently, D-His interferes with the L-His degrada-
tion pathway leading to bioﬁlm formation (rather than incor-
poration into the cell wall) and the two isomers may compete
with each other for cell uptake and/or amino acid degradation.
’CONCLUDING REMARKS
A. baumannii bioﬁlm formation on abiotic surfaces is considered
a major pathogenicity factor in foreign-body-associated infection.
Through a multiapproach model superimposing proteomics and
genetics analyses of cells exposed to SA and bioﬁlms cultivated in
vitro, we provide evidence about new mechanisms operating in A.
baumannii bioﬁlm formation (see Figure 7). Giving special
emphasis to those proteins found to be down-regulated in SA-
treated cells, and/or up-regulated in bioﬁlms, we suggest a model
in which membrane proteins and also intracellular pathways are
involved and are often interconnected. The current report sug-
gested that bioﬁlms present a unique phenotype and allowed the
identiﬁcation of novel surface proteins with possible roles in
bioﬁlm formation and maintenance. Although further research is
needed, the antibioﬁlm activity of D-His and/or the use of an
urocanase inhibitor represent realistical tools for prevention/
eradication of A. baumannii bioﬁlms on abiotic surfaces.
Finally, although we have focused on cell surface proteins and
histidine metabolism speciﬁcally, experiments are currently in
Figure 7. Schematic representation of SA eﬀects on A. baumannii proteome, and type of protein expression occurring in bioﬁlms, at the cellular level.
The proteins identiﬁed in this study are shown in bold. Proposed pathways and potential genes intervening in bioﬁlm formation are also shown. The
model indicates possible connections between the Leloir pathway, EPS formation and Pi transport, and between histidine metabolism and uptake.
Suggested interactions are also represented. GTs, glycosyltransferases; OM, outer membrane; IM, inner membrane; atb, antibiotics; Pi, phosphate ion.
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progress to demonstrate the implication of the remaining
proteins identiﬁed here, such as like RND pump, KatE, Hfq,
GalM/GalU, and the role of concomitant cellular processes
including resistance to antibiotics, antioxidative activity, post-
transcriptional regulation and the Leloir pathway in the physiol-
ogy of A. baumannii bioﬁlms.
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